{"b2503aa9036bf546348aace94f0375026ae5f379": [["IntroductionPeramivir (PRV, Rapivab \u00e2 , BioCryst Pharmaceutical, Inc, Durham, NC, U.S.A.) was the first intravenous neuraminidase (NA) inhibitor to obtain United States Food and Drug Administration approval and possesses antiviral activity against both influenza A and B viruses.", [["intravenous", "ANATOMY", 104, 115], ["IntroductionPeramivir", "CHEMICAL", 0, 21], ["NA", "CHEMICAL", 131, 133], ["influenza A and B viruses", "DISEASE", 253, 278], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 115], ["neuraminidase", "SIMPLE_CHEMICAL", 116, 129], ["NA", "SIMPLE_CHEMICAL", 131, 133], ["influenza A", "ORGANISM", 253, 264], ["B viruses", "ORGANISM", 269, 278], ["PRV", "SPECIES", 23, 26], ["B viruses", "SPECIES", 269, 278], ["IntroductionPeramivir (PRV", "TREATMENT", 0, 26], ["Rapivab", "TREATMENT", 28, 35], ["BioCryst Pharmaceutical", "TREATMENT", 40, 63], ["the first intravenous neuraminidase (NA) inhibitor", "TREATMENT", 94, 144], ["Drug Administration approval", "TREATMENT", 178, 206], ["antiviral activity", "TREATMENT", 221, 239], ["both influenza A and B viruses", "PROBLEM", 248, 278]]], ["1 The optimal pharmacodynamic target for NA inhibitors has not yet been determined.", [["NA", "SIMPLE_CHEMICAL", 41, 43], ["NA inhibitors", "TREATMENT", 41, 54]]], ["2 A single multicenter, open-label, uncontrolled study assessed the efficacy, safety, and pharmacokinetics of PRV in pediatric patients during the 2009 pandemic H1N1 influenza A epidemic.", [["influenza A", "DISEASE", 166, 177], ["PRV", "ORGANISM", 110, 113], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["pandemic H1N1 influenza", "SPECIES", 152, 175], ["PRV", "SPECIES", 110, 113], ["uncontrolled study", "TEST", 36, 54]]], ["3 The authors concluded that a standardized, weight-based dosing regimen in pediatric patients had similar efficacy and safety outcomes when compared with adult patients.", [["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 161, 169], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 161, 169], ["a standardized, weight-based dosing regimen", "TREATMENT", 29, 72]]], ["3, 4 However, this investigation appears to have excluded pediatric patients with a disease severity necessitating admission to the intensive care unit.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["this investigation", "TEST", 14, 32], ["a disease severity", "PROBLEM", 82, 100]]], ["5 Commonly anti-infective drugs are not widely evaluated in the population in which they are intended to be used.", [["Commonly anti-infective drugs", "TREATMENT", 2, 31], ["anti-infective drugs", "OBSERVATION", 11, 31]]], ["This is especially true in the setting of critical illness even though critical illness is a known risk factor for alterations to drug pharmacokinetics and pharmacodynamics in adult and pediatric patients.", [["illness", "DISEASE", 80, 87], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["critical illness", "PROBLEM", 42, 58], ["drug pharmacokinetics", "TREATMENT", 130, 151], ["illness", "OBSERVATION", 51, 58]]], ["[6] [7] [8] [9] [10] [11] [12] [13] [14] [15] As such, there is a lack of information regarding the pharmacokinetics and pharmacodynamics of PRV in a pediatric intensive care unit (PICU) population and the degree of these alterations in comparison to healthy volunteers.", [["[6] [7] [8] [9] [10] [11", "CHEMICAL", 0, 24], ["[6] [7] [8] [9] [10] [11] [12] [13] [14] [15] As", "CHEMICAL", 0, 48], ["[6] [7] [8] [9] [10] [11] [12] [13] [14] [15", "SIMPLE_CHEMICAL", 0, 44], ["volunteers", "ORGANISM", 259, 269], ["PRV", "SPECIES", 141, 144], ["these alterations", "PROBLEM", 216, 233], ["alterations", "OBSERVATION", 222, 233]]], ["Therefore, the purpose of this investigation is to report a pharmacokinetic case series of PRV in PICU patients treated for an influenza A or B viral infection.Patient Population and Study DesignAt St. Christopher's Hospital for Children (Philadelphia, PA), critically ill patients who are prescribed anti-infectives normally receive therapeutic drug management (TDM), as has been described previously.", [["influenza A or B viral infection", "DISEASE", 127, 159], ["critically ill", "DISEASE", 258, 272], ["PRV", "ORGANISM", 91, 94], ["patients", "ORGANISM", 103, 111], ["B viral", "ORGANISM", 142, 149], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 103, 111], ["Patient", "SPECIES", 160, 167], ["Children", "SPECIES", 229, 237], ["patients", "SPECIES", 273, 281], ["PRV", "SPECIES", 91, 94], ["an influenza A", "PROBLEM", 124, 138], ["B viral infection", "PROBLEM", 142, 159], ["anti-infectives", "TREATMENT", 301, 316], ["therapeutic drug management", "TREATMENT", 334, 361], ["influenza", "OBSERVATION", 127, 136], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["infection", "OBSERVATION", 150, 159]]], ["11, 12 Therefore, in an effort to attain pharmacokinetic and pharmacodynamic targets, dosing regimens are adjusted based on concentrations.", [["pharmacokinetic and pharmacodynamic targets", "TREATMENT", 41, 84], ["dosing regimens", "TREATMENT", 86, 101]]], ["An electronic medical record review was conducted of patients undergoing PRV TDM for clinical management between January 1, 2016, and March 31, 2018.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["PRV", "SPECIES", 73, 76], ["PRV TDM", "TREATMENT", 73, 80], ["clinical management", "TREATMENT", 85, 104]]], ["Patients admitted to the PICU who received PRV for empiric or definitive therapy with an expected duration of \u2265 48 hours were eligible for inclusion.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["PRV", "SPECIES", 43, 46], ["PRV", "TREATMENT", 43, 46], ["empiric", "TREATMENT", 51, 58], ["definitive therapy", "TREATMENT", 62, 80]]], ["Patients who had cystic fibrosis, those with acute or chronic renal failure with an estimated creatinine clearance of < 60 ml/min/1.73 m 2 using the modified Schwartz 16 equation, and those receiving extracorporeal therapies with continuous renal replacement therapy and extracorporeal membrane oxygenation were excluded from this analysis.", [["cystic", "ANATOMY", 17, 23], ["renal", "ANATOMY", 62, 67], ["renal", "ANATOMY", 241, 246], ["extracorporeal membrane", "ANATOMY", 271, 294], ["fibrosis", "DISEASE", 24, 32], ["chronic renal failure", "DISEASE", 54, 75], ["creatinine", "CHEMICAL", 94, 104], ["creatinine", "CHEMICAL", 94, 104], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 62, 67], ["creatinine", "SIMPLE_CHEMICAL", 94, 104], ["renal", "ORGAN", 241, 246], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 271, 294], ["Patients", "SPECIES", 0, 8], ["cystic fibrosis", "PROBLEM", 17, 32], ["acute or chronic renal failure", "PROBLEM", 45, 75], ["an estimated creatinine clearance", "TEST", 81, 114], ["extracorporeal therapies", "TREATMENT", 200, 224], ["continuous renal replacement therapy", "TREATMENT", 230, 266], ["extracorporeal membrane oxygenation", "TREATMENT", 271, 306], ["this analysis", "TEST", 326, 339], ["cystic", "OBSERVATION_MODIFIER", 17, 23], ["fibrosis", "OBSERVATION", 24, 32], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["renal", "ANATOMY", 62, 67], ["failure", "OBSERVATION", 68, 75], ["renal", "ANATOMY", 241, 246], ["replacement", "OBSERVATION", 247, 258], ["extracorporeal membrane oxygenation", "OBSERVATION", 271, 306]]], ["The study was conducted in agreement with the Declaration of Helsinki, current amendment, the guideline for Good Clinical Practice, and approval of the Drexel University College of Medicine Institutional Review Board.Patient Population and Study DesignDemographic, clinical, and microbiological-viral data were collected.", [["Patient", "SPECIES", 217, 224], ["The study", "TEST", 0, 9], ["Study DesignDemographic", "TEST", 240, 263], ["microbiological-viral data", "TEST", 279, 305]]], ["The BioFire \u00e2 FilmArray \u00e2 Multiplex polymerase chain reaction (PCR) respiratory panel (bioM erieux Clinical Diagnostics, Salt Lake City, UT) technique was utilized for influenza A and B detection.Blood Sampling and Pharmacokinetic-Pharmacodynamic AnalysisOur methodology has been previously described 11, 12 but briefly, usually a minimum of two blood samples are collected per patient to facilitate determination of patient-specific pharmacokinetic parameters for subsequent dose alteration.", [["Blood", "ANATOMY", 196, 201], ["blood samples", "ANATOMY", 346, 359], ["Blood", "ORGANISM_SUBSTANCE", 196, 201], ["blood samples", "ORGANISM_SUBSTANCE", 346, 359], ["patient", "ORGANISM", 378, 385], ["patient", "ORGANISM", 417, 424], ["patient", "SPECIES", 378, 385], ["patient", "SPECIES", 417, 424], ["The BioFire \u00e2 FilmArray", "TEST", 0, 23], ["Multiplex polymerase chain reaction", "PROBLEM", 26, 61], ["PCR", "TEST", 63, 66], ["respiratory panel", "TEST", 68, 85], ["influenza", "PROBLEM", 168, 177], ["Blood Sampling", "TEST", 196, 210], ["blood samples", "TEST", 346, 359], ["subsequent dose alteration", "TREATMENT", 465, 491]]], ["Penetration ratios are also considered when designing dosing regimens for sites including epithelial lining fluid, for example, when available to achieve the target pharmacodynamic exposure, which primarily was an AUC of \u2265 100 lg/hr/ml for PRV while also attempting to maintain a trough level of approximately 10 lg/ ml.", [["sites", "ANATOMY", 74, 79], ["epithelial lining fluid", "ANATOMY", 90, 113], ["epithelial lining fluid", "TISSUE", 90, 113], ["PRV", "SPECIES", 240, 243], ["Penetration ratios", "PROBLEM", 0, 18], ["designing dosing regimens", "TREATMENT", 44, 69], ["epithelial lining fluid", "PROBLEM", 90, 113], ["an AUC", "TEST", 211, 217], ["PRV", "TREATMENT", 240, 243], ["a trough level", "TEST", 278, 292], ["epithelial", "ANATOMY_MODIFIER", 90, 100], ["lining", "OBSERVATION_MODIFIER", 101, 107], ["fluid", "OBSERVATION", 108, 113]]], ["17 Peramivir samples were collected in regular red top tubes and subsequently centrifuged within 30 minutes of collection at 2000 g for \u2265 15 minutes to separate the plasma, which was then transferred to a cryovial and stored at \u00c080\u00b0C. Samples were transported on dry ice to the reference laboratory and upon receipt, samples were thawed and analyzed.", [["samples", "ANATOMY", 13, 20], ["plasma", "ANATOMY", 165, 171], ["Samples", "ANATOMY", 235, 242], ["samples", "ANATOMY", 317, 324], ["Peramivir samples", "CANCER", 3, 20], ["plasma", "ORGANISM_SUBSTANCE", 165, 171], ["Peramivir samples", "TREATMENT", 3, 20], ["regular red top tubes", "TREATMENT", 39, 60], ["samples", "TEST", 317, 324], ["top tubes", "OBSERVATION", 51, 60]]], ["Peramivir concentrations were determined by validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) (U.S. Food and Drug Administration guidelines: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guida nces/UCM070107.pdf) at Atlantic Diagnostic Laboratories (Bensalem, PA).", [["Peramivir", "CHEMICAL", 0, 9], ["Peramivir", "CHEMICAL", 0, 9], ["Peramivir", "SIMPLE_CHEMICAL", 0, 9], ["Peramivir concentrations", "TREATMENT", 0, 24], ["validated liquid chromatography", "TEST", 44, 75], ["tandem mass spectrometry", "TEST", 76, 100]]], ["The LC-MS/MS method was accurate and precise at a linearity range of 1-60,000 ng/ml with a correlation coefficient (r) of \u2265 0.99 and an interday assay variability that was < 4% across all control samples.Blood Sampling and Pharmacokinetic-Pharmacodynamic AnalysisAdditionally, our pharmacokinetic analysis technique has been previously described 11, 12 for using a noncompartmental pharmacokinetic approach for each patient's concentrations to determine their respective pharmacokinetic parameters.", [["Blood", "ANATOMY", 204, 209], ["Blood", "ORGANISM_SUBSTANCE", 204, 209], ["patient", "ORGANISM", 416, 423], ["patient", "SPECIES", 416, 423], ["The LC", "TEST", 0, 6], ["MS method", "TEST", 10, 19], ["a linearity range", "TEST", 48, 65], ["an interday assay variability", "TEST", 133, 162], ["Blood Sampling", "TEST", 204, 218], ["our pharmacokinetic analysis technique", "TEST", 277, 315], ["a noncompartmental pharmacokinetic approach", "TREATMENT", 363, 406]]], ["To calculate PRV free drug concentrations, the protein binding estimate of 20% was utilized since the package insert (PI) states the protein binding estimate to be < 30%.", [["PRV", "SPECIES", 13, 16], ["PRV free drug concentrations", "TREATMENT", 13, 41], ["the protein binding estimate", "TEST", 43, 71], ["the package insert (PI", "TREATMENT", 98, 120], ["the protein binding", "TEST", 129, 148]]], ["1 Patient's medical records were reviewed to assess for adverse events specifically related to PRV administration, with emphasis on the adverse events reported in the previous investigation of PRV in pediatric patients with an incidence of \u2265 2%.", [["PRV", "ORGANISM", 193, 196], ["patients", "ORGANISM", 210, 218], ["Patient", "SPECIES", 2, 9], ["patients", "SPECIES", 210, 218], ["PRV", "SPECIES", 95, 98], ["PRV", "SPECIES", 193, 196], ["adverse events", "PROBLEM", 56, 70], ["PRV administration", "TREATMENT", 95, 113], ["the adverse events", "PROBLEM", 132, 150]]], ["3ResultsA total of 11 patients, two females (18%) and nine males (82%), were included in this investigation and accounted for 24 PRV samples for TDM.", [["samples", "ANATOMY", 133, 140], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["PRV", "SPECIES", 129, 132], ["this investigation", "TEST", 89, 107], ["TDM", "PROBLEM", 145, 148]]], ["All patients met inclusion criteria, and no patients received any form of extracorporeal therapy.", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 44, 52], ["extracorporeal therapy", "TREATMENT", 74, 96], ["extracorporeal therapy", "OBSERVATION", 74, 96]]], ["No patients were excluded based on a creatinine clearance estimate of < 60 ml/min/ 1.73 m 2 .", [["creatinine", "CHEMICAL", 37, 47], ["creatinine", "CHEMICAL", 37, 47], ["patients", "ORGANISM", 3, 11], ["creatinine", "SIMPLE_CHEMICAL", 37, 47], ["patients", "SPECIES", 3, 11], ["a creatinine clearance", "TEST", 35, 57]]], ["A median of two samples for TDM was collected per patient (range 2-3 samples).", [["samples", "ANATOMY", 16, 23], ["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["TDM", "TEST", 28, 31]]], ["The median age was 5 years (interquartile range (IQR) 1.5-6.5 years) with a median weight of 16.4 kg (IQR 14-24 kg).", [["a median weight", "TEST", 74, 89], ["IQR", "TEST", 102, 105]]], ["Patient demographics and PRV dosing information are presented in Table 1 .", [["Patient", "SPECIES", 0, 7], ["PRV", "SPECIES", 25, 28], ["PRV dosing", "TREATMENT", 25, 35]]], ["The individual patient pharmacokinetic parameter estimates are presented in Table 2 .", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22]]], ["The initial PRV doses ranged between 9.8 and 12.7 mg/kg/dose, and all patients were initiated on an every-24-hour dosing interval with doses infused over 30 minutes.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["PRV", "SPECIES", 12, 15], ["The initial PRV doses", "TREATMENT", 0, 21]]], ["Ten of 11 (91%) patients demonstrated a larger volume of distribution (V d ) as compared with the data from the PI and the previous pediatric PRV trial.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["PRV", "SPECIES", 142, 145], ["the data", "TEST", 94, 102], ["larger", "OBSERVATION_MODIFIER", 40, 46], ["volume", "OBSERVATION_MODIFIER", 47, 53], ["distribution", "OBSERVATION_MODIFIER", 57, 69]]], ["1, 3 Eleven (100%) patients demonstrated an increase in clearance (CL) and a shorter half-life estimate as compared with the PI and the previous pediatric PRV trial.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["PRV", "SPECIES", 155, 158], ["an increase in clearance", "PROBLEM", 41, 65], ["increase", "OBSERVATION_MODIFIER", 44, 52]]], ["1, 3 All patients had adjustments made to their dosing regimens, specifically an adjustment to a more frequent dosing interval, to result in an AUC exposure closer to the AUC target described in the PI and the previous pediatric PRV trial and/ or to not allow for a prolonged period with concentrations < 10 lg/ml.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["PRV", "SPECIES", 229, 232], ["their dosing regimens", "TREATMENT", 42, 63], ["a more frequent dosing interval", "TREATMENT", 95, 126], ["an AUC exposure", "PROBLEM", 141, 156], ["a prolonged period with concentrations", "TREATMENT", 264, 302]]], ["1, 3 Ten (91%) patients were adjusted to an every-12-hour regimen and one (9%) patient was adjusted to an every-8hour regimen.", [["patients", "ORGANISM", 15, 23], ["patient", "ORGANISM", 79, 86], ["patients", "SPECIES", 15, 23], ["patient", "SPECIES", 79, 86], ["an every-8hour regimen", "TREATMENT", 103, 125]]], ["There were no adverse events associated with PRV treatment.ResultsAll patients tested positive for a virus via multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) testing.", [["patients", "ORGANISM", 70, 78], ["reverse transcriptase", "PROTEIN", 121, 142], ["patients", "SPECIES", 70, 78], ["PRV", "SPECIES", 45, 48], ["adverse events", "PROBLEM", 14, 28], ["PRV treatment", "TREATMENT", 45, 58], ["a virus", "PROBLEM", 99, 106], ["polymerase chain reaction", "PROBLEM", 143, 168], ["RT-PCR) testing", "TEST", 170, 185], ["no", "UNCERTAINTY", 11, 13]]], ["Eight (73%) patients tested positive for a strain of influenza A and three (27%) patients tested positive for influenza B; four of 11 (36%) patients tested positive for multiple viruses.", [["influenza A", "DISEASE", 53, 64], ["influenza B", "DISEASE", 110, 121], ["patients", "ORGANISM", 12, 20], ["influenza A", "CANCER", 53, 64], ["patients", "ORGANISM", 81, 89], ["influenza B", "ORGANISM", 110, 121], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 140, 148], ["influenza A", "SPECIES", 53, 64], ["a strain of influenza A", "PROBLEM", 41, 64], ["influenza B", "PROBLEM", 110, 121], ["multiple viruses", "PROBLEM", 169, 185], ["multiple", "OBSERVATION_MODIFIER", 169, 177], ["viruses", "OBSERVATION", 178, 185]]], ["All patients had respiratory failure, with three (27%) patients requiring intubation.", [["respiratory", "ANATOMY", 17, 28], ["respiratory failure", "DISEASE", 17, 36], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 55, 63], ["respiratory failure", "PROBLEM", 17, 36], ["intubation", "TREATMENT", 74, 84], ["respiratory failure", "OBSERVATION", 17, 36]]], ["The median length of stay was 8 days (IQR 5.5-9 days), and there were no deaths in this cohort.", [["deaths", "DISEASE", 73, 79], ["median", "OBSERVATION_MODIFIER", 4, 10], ["length", "OBSERVATION_MODIFIER", 11, 17], ["no", "UNCERTAINTY", 70, 72]]], ["The median duration of PRV treatment was 3 days (IQR 3-5.5 days).", [["PRV", "SPECIES", 23, 26], ["PRV treatment", "TREATMENT", 23, 36]]], ["All patients were changed to oral oseltamivir to finish a 10-day total treatment course (10 days including PRV and oseltamivir).DiscussionCurrently, PRV has an FDA approved indication for the treatment of acute uncomplicated influenza in patients 2 years of age and older who have been symptomatic for no more than 2 days.", [["oral", "ANATOMY", 29, 33], ["oseltamivir", "CHEMICAL", 34, 45], ["oseltamivir", "CHEMICAL", 115, 126], ["influenza", "DISEASE", 225, 234], ["oseltamivir", "CHEMICAL", 34, 45], ["oseltamivir", "CHEMICAL", 115, 126], ["patients", "ORGANISM", 4, 12], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 238, 246], ["PRV", "SPECIES", 107, 110], ["PRV", "SPECIES", 149, 152], ["oral oseltamivir", "TREATMENT", 29, 45], ["a 10-day total treatment course", "TREATMENT", 56, 87], ["PRV", "TREATMENT", 107, 110], ["oseltamivir", "TREATMENT", 115, 126], ["acute uncomplicated influenza", "PROBLEM", 205, 234], ["symptomatic", "PROBLEM", 286, 297], ["acute", "OBSERVATION_MODIFIER", 205, 210], ["uncomplicated", "OBSERVATION_MODIFIER", 211, 224], ["influenza", "OBSERVATION", 225, 234]]], ["1 The current FDA recommended dose of PRV in pediatric patients 2-12 years of age with acute uncomplicated influenza is a single 12 mg/ kg dose (up to a maximum dose of 600 mg), administered via intravenous infusion over 15-30 minutes.", [["intravenous", "ANATOMY", 195, 206], ["influenza", "DISEASE", 107, 116], ["PRV", "ORGANISM", 38, 41], ["patients", "ORGANISM", 55, 63], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 195, 206], ["patients", "SPECIES", 55, 63], ["PRV", "SPECIES", 38, 41], ["acute uncomplicated influenza", "PROBLEM", 87, 116]]], ["18, 19 Additionally, during the 2009 influenza, PRV was part of an emergency use authorization in the United States for patients with pandemic A (H1N1) 2009 virus to be given every 24 hours for a period of 5 to 10 days.", [["influenza", "DISEASE", 37, 46], ["patients", "ORGANISM", 120, 128], ["pandemic A (H1N1) 2009 virus", "ORGANISM", 134, 162], ["patients", "SPECIES", 120, 128], ["PRV", "SPECIES", 48, 51], ["pandemic A (H1N1) 2009 virus", "SPECIES", 134, 162], ["influenza", "PROBLEM", 37, 46], ["PRV", "TREATMENT", 48, 51], ["pandemic A (H1N1)", "TREATMENT", 134, 151]]], ["20 The current FDA-approved pediatric dosing regimen is recommended based on pharmacokinetic data to approximate a total drug exposure or AUC similar to that achieved in adults that was associated with safety and efficacy.", [["pediatric dosing regimen", "TREATMENT", 28, 52], ["pharmacokinetic data", "TEST", 77, 97], ["a total drug exposure", "PROBLEM", 113, 134], ["AUC", "PROBLEM", 138, 141]]], ["3, 21 Table 3 displays the pharmacokinetic parameter estimates for pediatric patients based on data from the PI and the single pediatric study.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["the single pediatric study", "TEST", 116, 142]]], ["1, 3 The pharmacokinetic data presented in this study (Table 2) suggest that the pharmacokinetics of PRV differ considerably in PICU patients with confirmed influenza viral infections as compared with the pharmacokinetic estimates reported in the PI and a trial.", [["influenza viral infections", "DISEASE", 157, 183], ["PRV", "ORGANISM", 101, 104], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["PRV", "SPECIES", 101, 104], ["The pharmacokinetic data", "TEST", 5, 29], ["this study", "TEST", 43, 53], ["influenza viral infections", "PROBLEM", 157, 183]]], ["3 The pharmacokinetic data from these 11 PICU patients suggest that dosing modifications would be needed for PRV to better achieve drug exposures similar to those described earlier 3 and in the PI.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["PRV", "SPECIES", 109, 112], ["The pharmacokinetic data", "TEST", 2, 26], ["dosing modifications", "TREATMENT", 68, 88], ["PRV", "TREATMENT", 109, 112]]], ["1, 3 The pharmacodynamic parameter suggested to affect morbidity and mortality is the AUC.", [["The pharmacodynamic parameter", "TEST", 5, 34], ["morbidity", "PROBLEM", 55, 64], ["the AUC", "TEST", 82, 89]]], ["2 Since AUC is a marker of total drug exposure, there are several options for the clinician to increase total drug exposure.", [["total drug exposure", "TREATMENT", 27, 46], ["total drug exposure", "TREATMENT", 104, 123]]], ["The two primary options are to either increase the dose (mg/kg or total mg dose) or adjust the dosing interval to allow for more frequent drug administration.", [["total mg dose", "TREATMENT", 66, 79], ["the dosing interval", "TREATMENT", 91, 110], ["more frequent drug administration", "TREATMENT", 124, 157]]], ["Current recommendations state that upon dilution of PRV to a concentration suitable for administration it should be administered immediately or stored at 2\u00b0C to 8\u00b0C for up to 24 hours; unused diluted solution should be discarded after 24 hours.", [["PRV", "ORGANISM", 52, 55], ["C", "SIMPLE_CHEMICAL", 163, 164], ["PRV", "SPECIES", 52, 55], ["PRV", "TREATMENT", 52, 55], ["administration", "TREATMENT", 88, 102], ["unused diluted solution", "TREATMENT", 185, 208]]], ["1 Combining this pharmacokinetic data with the limited stability information, utilizing a more frequent dosing regimen (i.e., every 8 or every 12 hours) may allow for reduced PRV waste, which depicts our approach to dosing regimen modifications in our patient population.", [["patient", "ORGANISM", 252, 259], ["patient", "SPECIES", 252, 259], ["PRV", "SPECIES", 175, 178], ["this pharmacokinetic data", "TEST", 12, 37], ["a more frequent dosing regimen", "TREATMENT", 88, 118], ["reduced PRV waste", "TREATMENT", 167, 184], ["dosing regimen modifications", "TREATMENT", 216, 244]]], ["These pharmacokinetic alterations are not unexpected as similar changes have previously been described in the PICU setting.", [["These pharmacokinetic alterations", "PROBLEM", 0, 33], ["pharmacokinetic alterations", "OBSERVATION", 6, 33]]], ["10-15, 22, 23 As TDM becomes more common to the practice of caring for critically ill children, recognition of pharmacokinetic variations similar to those described here will most likely become customary.", [["critically ill", "DISEASE", 71, 85], ["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94], ["pharmacokinetic variations", "PROBLEM", 111, 137]]], ["The 1997 Society for Healthcare Epidemiology of America (SHEA) and The Infectious Diseases Society of America (IDSA) guidelines for the prevention of antimicrobial resistance in hospitals suggested \". . .appropriate antimicrobial stewardship, that includes optimal drug selection, dose, and duration of treatment, as well as control of antibiotic use, will prevent or slow the emergence of resistance among microorganisms.\" 24 Often a \"one dose fits all\" mindset hinders clinicians in the treatment of infectious diseases; a paradigm that needs to end.", [["Infectious Diseases", "DISEASE", 71, 90], ["fits", "DISEASE", 445, 449], ["infectious diseases", "DISEASE", 502, 521], ["antimicrobial resistance", "TREATMENT", 150, 174], [".appropriate antimicrobial stewardship", "TREATMENT", 203, 241], ["optimal drug selection", "TREATMENT", 257, 279], ["treatment", "TREATMENT", 303, 312], ["antibiotic use", "TREATMENT", 336, 350], ["infectious diseases", "PROBLEM", 502, 521], ["Infectious", "OBSERVATION_MODIFIER", 71, 81], ["antimicrobial resistance", "OBSERVATION", 150, 174], ["infectious", "OBSERVATION", 502, 512]]], ["25 Reliance on an \"approved dose\" rather than achieving the target serum concentrations and exposures associated with safety and efficacy during the drug development and regulatory process is problematic.", [["serum", "ANATOMY", 67, 72], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["the drug development", "TREATMENT", 145, 165]]], ["Underdosing and low exposures have been associated with anti-infective resistance and increased morbidity and mortality, 12 whereas active management of antiinfective concentrations and exposures has been associated with improved outcomes.", [["low exposures", "PROBLEM", 16, 29], ["anti-infective resistance", "PROBLEM", 56, 81], ["increased morbidity", "PROBLEM", 86, 105], ["antiinfective concentrations", "PROBLEM", 153, 181], ["low exposures", "OBSERVATION_MODIFIER", 16, 29], ["associated with", "UNCERTAINTY", 40, 55], ["anti-infective resistance", "OBSERVATION", 56, 81], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["morbidity", "OBSERVATION", 96, 105]]], ["5, 12, [26] [27] [28] The concept of replacing \"approved dose\" with \"approved concentrations and exposures\" and tailoring dosing regimens to individual patients considering inter-and intra-patient variability across populations is profound.", [["[26] [27] [28", "SIMPLE_CHEMICAL", 7, 20], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["tailoring dosing regimens", "TREATMENT", 112, 137], ["inter-and intra-patient variability across populations", "PROBLEM", 173, 227], ["profound", "OBSERVATION_MODIFIER", 231, 239]]], ["25 With a growing body of literature demonstrating the benefit of anti-infective TDM, optimization of anti-infective pharmacokinetics and pharmacodynamics can dramatically change how infections are treated, allowing for customized and optimized anti-infective dosing, and allowing for a longer \"life-span\" of the currently approved antimicrobial agents and future anti-infective pipeline.", [["infections", "DISEASE", 183, 193], ["anti-infective TDM", "TREATMENT", 66, 84], ["anti-infective pharmacokinetics", "TREATMENT", 102, 133], ["pharmacodynamics", "TREATMENT", 138, 154], ["how infections", "PROBLEM", 179, 193], ["optimized anti-infective dosing", "TREATMENT", 235, 266], ["antimicrobial agents", "TREATMENT", 332, 352], ["future anti-infective pipeline", "TREATMENT", 357, 387]]], ["Similar to pharmacokinetic reports described previously, 11, 12 there are several limitations regarding this pharmacokinetic case series.", [["this pharmacokinetic case series", "TEST", 104, 136]]], ["First, this is a single center's experience utilizing PRV for suspected or confirmed influenza viral infections.", [["influenza viral infections", "DISEASE", 85, 111], ["PRV", "SPECIES", 54, 57], ["PRV", "TREATMENT", 54, 57], ["influenza viral infections", "PROBLEM", 85, 111], ["influenza", "OBSERVATION", 85, 94], ["viral infections", "OBSERVATION", 95, 111]]], ["Second, a single pharmacodynamic target was utilized and there is still debate regarding the optimal clinical pharmacodynamic target(s).", [["a single pharmacodynamic target", "TEST", 8, 39]]], ["Third, blood concentrations serve as a surrogate marker and do not necessarily reflect the PRV concentrations at other actual or potential sites of infection.", [["blood", "ANATOMY", 7, 12], ["infection", "DISEASE", 148, 157], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["PRV", "SPECIES", 91, 94], ["a surrogate marker", "TREATMENT", 37, 55], ["the PRV concentrations", "PROBLEM", 87, 109], ["infection", "PROBLEM", 148, 157], ["infection", "OBSERVATION", 148, 157]]], ["However, blood samples are more readily available and analyzable and are likely to correlate with the concentrations at the site of infection.", [["blood samples", "ANATOMY", 9, 22], ["infection", "DISEASE", 132, 141], ["blood samples", "ORGANISM_SUBSTANCE", 9, 22], ["blood samples", "TEST", 9, 22], ["the concentrations", "PROBLEM", 98, 116], ["infection", "PROBLEM", 132, 141], ["infection", "OBSERVATION", 132, 141]]], ["Fourth, drug concentration measurements were performed as total drug and not unbound drug concentrations with a static protein binding estimate.", [["drug concentration measurements", "TEST", 8, 39], ["total drug", "TREATMENT", 58, 68], ["unbound drug concentrations", "TREATMENT", 77, 104]]], ["Fifth, we utilized an opportunistic sampling strategy which may not be ideal to fully characterize the pharmacokinetics of PRV in each individual child.", [["PRV", "SPECIES", 123, 126], ["an opportunistic sampling strategy", "TREATMENT", 19, 53]]], ["Sixth, repeat PRV levels were not obtained to demonstrate whether the dosage adjustments resulted in expected observed concentrations based on the dosing calculation adjustments and whether concentrations might potentially be supra-therapeutic.", [["PRV", "SPECIES", 14, 17], ["repeat PRV levels", "TEST", 7, 24], ["the dosing calculation adjustments", "TREATMENT", 143, 177]]], ["However, individual parameter estimates are capable of providing a reasonable pharmacokinetic profile for individual patients and are commonly employed in clinical practice for aminoglycosides and vancomycin.ConclusionThe pharmacokinetics of PRV demonstrated in this PICU cohort differs in comparison to Half-life (hrs) 20 \"Similar to PI\" Vd (L/kg) 0.18 \"Similar to PI\" CL (ml/min/kg) 0.1 \"Similar to PI\" Peak (lg/ml) 46.8 33.1 AUC (lg/hr/ml) 102.7 \"Similar to PI\" \"Similar to PI\" = the authors of the trial 3 do not provide actual values yet explicitly state \"similar to PI\" in their manuscript.", [["aminoglycosides", "CHEMICAL", 177, 192], ["vancomycin", "CHEMICAL", 197, 207], ["aminoglycosides", "CHEMICAL", 177, 192], ["vancomycin", "CHEMICAL", 197, 207], ["patients", "ORGANISM", 117, 125], ["aminoglycosides", "SIMPLE_CHEMICAL", 177, 192], ["vancomycin", "SIMPLE_CHEMICAL", 197, 207], ["patients", "SPECIES", 117, 125], ["PRV", "SPECIES", 242, 245], ["individual parameter estimates", "TEST", 9, 39], ["aminoglycosides", "TREATMENT", 177, 192], ["vancomycin", "TREATMENT", 197, 207], ["The pharmacokinetics of PRV", "TREATMENT", 218, 245], ["CL", "TEST", 370, 372], ["Peak", "TEST", 405, 409], ["AUC", "TEST", 428, 431]]], ["AUC = area under the curve, CL = clearance; PI = package insert; PK = pharmacokinetic; V d = volume of distribution. a Package insert data, see Ref.", [["AUC", "TEST", 0, 3], ["the curve", "TEST", 17, 26], ["CL", "TEST", 28, 30], ["PI = package insert", "TREATMENT", 44, 63], ["PK", "TEST", 65, 67], ["a Package insert data", "TREATMENT", 117, 138]]], ["3 healthy pediatric and adult patients, and alterations to dosing regimens may be needed in PICU patients to achieve pharmacodynamic exposures.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 97, 105], ["dosing regimens", "TREATMENT", 59, 74], ["pharmacodynamic exposures", "PROBLEM", 117, 142]]], ["Additional investigations in the PICU population are needed to confirm these findings.", [["Additional investigations", "TEST", 0, 25]]]], "PMC7243146": [["BackgroundThe COVID-19 pandemic has created an unprecedented challenge for health care systems worldwide.1,2 Radiation therapy (RT) is regarded as essential in many clinical circumstances and must be provided even during these difficult times.", [["health care systems", "TREATMENT", 75, 94], ["Radiation therapy (RT)", "TREATMENT", 109, 131]]], ["Yet, limitations in resources, including space, equipment, and staff, may result in reduction of treatment capacity.", [["treatment capacity", "TREATMENT", 97, 115]]], ["Furthermore, exposure of high-risk patients should be minimized by limiting the number of visits for RT.BackgroundGeneral guidelines on RT under these conditions have been issued by several organizations.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["RT", "TREATMENT", 101, 103], ["RT", "TREATMENT", 136, 138]]], ["However, special considerations are pertinent for RT of hematological malignancies.", [["hematological malignancies", "ANATOMY", 56, 82], ["hematological malignancies", "DISEASE", 56, 82], ["hematological malignancies", "CANCER", 56, 82], ["hematological malignancies", "PROBLEM", 56, 82], ["hematological", "ANATOMY", 56, 69], ["malignancies", "OBSERVATION", 70, 82]]], ["The International Lymphoma Radiation Oncology Group (ILROG) is a well-recognized worldwide organization of radiation oncologists with a record of producing guidelines for modern RT of these diseases that have become standard.3-13 With the present guidelines, ILROG aims to help radiation oncologists treating hematological malignancies make rational choices regarding possible changes to reduce the pressure on RT institutions in the current emergency situation.", [["hematological malignancies", "ANATOMY", 309, 335], ["Lymphoma", "DISEASE", 18, 26], ["hematological malignancies", "DISEASE", 309, 335], ["malignancies", "CANCER", 323, 335], ["these diseases", "PROBLEM", 184, 198], ["radiation oncologists", "TREATMENT", 278, 299], ["hematological malignancies", "PROBLEM", 309, 335], ["rational choices", "TREATMENT", 341, 357], ["the pressure on RT institutions", "TREATMENT", 395, 426], ["Lymphoma", "OBSERVATION", 18, 26], ["diseases", "OBSERVATION", 190, 198], ["pressure", "OBSERVATION_MODIFIER", 399, 407]]], ["With regard to treatment techniques, keeping those with which the staff is familiar is recommended.", [["treatment techniques", "TREATMENT", 15, 35]]], ["Simpler techniques are encouraged when resources are limited.Omitting RT ::: StrategiesWhen the risk of severe outcomes from COVID-19 infection (for those aged \u226560 years and/or with serious underlying health conditions) outweighs the benefit of RT, omitting RT is to be considered in the following situations14,15:in a palliative setting, where alternatives can be offered (eg, optimizing pain control);for localized low-grade lymphomas if completely excised (eg, follicular lymphoma, marginal zone lymphoma, cutaneous B-cell lymphoma)13;for localized nodular lymphocyte-predominant Hodgkin lymphoma if completely excised16; andin consolidation RT for diffuse large B-cell lymphoma/aggressive non-Hodgkin lymphoma (NHL) in patients who have completed a full chemotherapy course and achieved a complete remission.However, if more chemotherapy needs to be given in order to omit RT, this may induce prolonged immunosuppression, which may, in many clinical situations, not be the best decision during a pandemic.", [["low-grade lymphomas", "ANATOMY", 417, 436], ["follicular lymphoma", "ANATOMY", 464, 483], ["marginal zone lymphoma", "ANATOMY", 485, 507], ["cutaneous B-cell lymphoma", "ANATOMY", 509, 534], ["nodular lymphocyte", "ANATOMY", 552, 570], ["Hodgkin lymphoma", "ANATOMY", 583, 599], ["diffuse large B-cell lymphoma", "ANATOMY", 652, 681], ["non-Hodgkin lymphoma", "ANATOMY", 693, 713], ["NHL", "ANATOMY", 715, 718], ["infection", "DISEASE", 134, 143], ["pain", "DISEASE", 389, 393], ["low-grade lymphomas", "DISEASE", 417, 436], ["follicular lymphoma", "DISEASE", 464, 483], ["marginal zone lymphoma", "DISEASE", 485, 507], ["cutaneous B-cell lymphoma", "DISEASE", 509, 534], ["Hodgkin lymphoma", "DISEASE", 583, 599], ["B-cell lymphoma", "DISEASE", 666, 681], ["aggressive non-Hodgkin lymphoma", "DISEASE", 682, 713], ["NHL", "DISEASE", 715, 718], ["low-grade lymphomas", "CANCER", 417, 436], ["follicular lymphoma", "CANCER", 464, 483], ["marginal zone lymphoma", "CANCER", 485, 507], ["cutaneous B-cell lymphoma", "CANCER", 509, 534], ["nodular lymphocyte-predominant Hodgkin lymphoma", "CANCER", 552, 599], ["diffuse large B-cell lymphoma", "CANCER", 652, 681], ["non-Hodgkin lymphoma", "CANCER", 693, 713], ["NHL", "CANCER", 715, 718], ["patients", "ORGANISM", 723, 731], ["patients", "SPECIES", 723, 731], ["COVID-19", "SPECIES", 125, 133], ["Simpler techniques", "TREATMENT", 0, 18], ["severe outcomes", "PROBLEM", 104, 119], ["COVID-19 infection", "PROBLEM", 125, 143], ["RT, omitting RT", "TREATMENT", 245, 260], ["optimizing pain control", "TREATMENT", 378, 401], ["localized low-grade lymphomas", "PROBLEM", 407, 436], ["follicular lymphoma", "PROBLEM", 464, 483], ["marginal zone lymphoma", "PROBLEM", 485, 507], ["cutaneous B-cell lymphoma", "PROBLEM", 509, 534], ["localized nodular lymphocyte", "PROBLEM", 542, 570], ["Hodgkin lymphoma", "PROBLEM", 583, 599], ["andin consolidation", "PROBLEM", 625, 644], ["diffuse large B-cell lymphoma", "PROBLEM", 652, 681], ["aggressive non-Hodgkin lymphoma", "PROBLEM", 682, 713], ["a full chemotherapy course", "TREATMENT", 751, 777], ["chemotherapy", "TREATMENT", 829, 841], ["RT", "TREATMENT", 877, 879], ["prolonged immunosuppression", "TREATMENT", 897, 924], ["a pandemic", "PROBLEM", 998, 1008], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["lymphomas", "OBSERVATION", 427, 436], ["follicular lymphoma", "OBSERVATION", 464, 483], ["marginal", "OBSERVATION_MODIFIER", 485, 493], ["zone lymphoma", "OBSERVATION", 494, 507], ["cutaneous", "ANATOMY", 509, 518], ["cell lymphoma", "OBSERVATION", 521, 534], ["nodular", "OBSERVATION_MODIFIER", 552, 559], ["lymphocyte", "OBSERVATION", 560, 570], ["predominant", "OBSERVATION_MODIFIER", 571, 582], ["Hodgkin lymphoma", "OBSERVATION", 583, 599], ["consolidation", "OBSERVATION", 631, 644], ["diffuse", "OBSERVATION_MODIFIER", 652, 659], ["large", "OBSERVATION_MODIFIER", 660, 665], ["B-cell lymphoma", "OBSERVATION", 666, 681], ["aggressive", "OBSERVATION_MODIFIER", 682, 692], ["non-Hodgkin lymphoma", "OBSERVATION", 693, 713], ["prolonged", "OBSERVATION_MODIFIER", 897, 906], ["immunosuppression", "OBSERVATION", 907, 924]]], ["Multidisciplinary discussion of each individual case is important.Delaying RT ::: StrategiesWhen there is no or little expected adverse effect on outcome from the delay, delaying RT is to be considered in the following situations:for asymptomatic localized low-grade lymphomas;for localized nodular lymphocyte-predominant Hodgkin lymphoma;in a palliative setting for low-grade lymphomas in stable patients; andfor patients who develop COVID-19 infection prior to commencing RT, until the infection is clear, provided the malignancy is not progressing.Shortening RT course ::: StrategiesUsing alternative hypofractionation RT regimens when RT cannot be omitted or delayed is to be considered with the aim of maintaining high cure/palliation rates without undue toxicity.", [["low-grade lymphomas", "ANATOMY", 257, 276], ["nodular lymphocyte", "ANATOMY", 291, 309], ["Hodgkin lymphoma", "ANATOMY", 322, 338], ["low-grade lymphomas", "ANATOMY", 367, 386], ["low-grade lymphomas", "DISEASE", 257, 276], ["Hodgkin lymphoma", "DISEASE", 322, 338], ["low-grade lymphomas", "DISEASE", 367, 386], ["infection", "DISEASE", 444, 453], ["infection", "DISEASE", 488, 497], ["malignancy", "DISEASE", 521, 531], ["toxicity", "DISEASE", 760, 768], ["low-grade lymphomas", "CANCER", 257, 276], ["nodular lymphocyte-predominant Hodgkin lymphoma", "CANCER", 291, 338], ["low-grade lymphomas", "CANCER", 367, 386], ["patients", "ORGANISM", 397, 405], ["patients", "ORGANISM", 414, 422], ["COVID-19", "ORGANISM", 435, 443], ["patients", "SPECIES", 397, 405], ["patients", "SPECIES", 414, 422], ["asymptomatic localized low-grade lymphomas", "PROBLEM", 234, 276], ["localized nodular lymphocyte", "PROBLEM", 281, 309], ["Hodgkin lymphoma", "PROBLEM", 322, 338], ["low-grade lymphomas", "PROBLEM", 367, 386], ["COVID-19 infection", "PROBLEM", 435, 453], ["RT", "TREATMENT", 474, 476], ["the infection", "PROBLEM", 484, 497], ["the malignancy", "PROBLEM", 517, 531], ["alternative hypofractionation RT regimens", "TREATMENT", 592, 633], ["RT", "TREATMENT", 639, 641], ["high cure/palliation rates", "TREATMENT", 719, 745], ["undue toxicity", "PROBLEM", 754, 768], ["no", "UNCERTAINTY", 106, 108], ["low-grade", "OBSERVATION_MODIFIER", 257, 266], ["lymphomas", "OBSERVATION", 267, 276], ["nodular", "OBSERVATION_MODIFIER", 291, 298], ["lymphocyte", "OBSERVATION", 299, 309], ["predominant", "OBSERVATION_MODIFIER", 310, 321], ["Hodgkin lymphoma", "OBSERVATION", 322, 338], ["lymphomas", "OBSERVATION", 377, 386], ["stable", "OBSERVATION_MODIFIER", 390, 396], ["infection", "OBSERVATION", 444, 453], ["infection", "OBSERVATION", 488, 497], ["malignancy", "OBSERVATION", 521, 531]]], ["Hypofractionation will always influence the effective dose for late effects, so risks need to be carefully weighed.", [["Hypofractionation", "TREATMENT", 0, 17]]], ["Radiobiological considerations and clinical experiences were used by the ILROG task force to generate the suggested altered dose and fractionation schedules described in Table 1:The fractionation sensitivity of hematologic malignancies is underreported in clinical series.", [["hematologic malignancies", "ANATOMY", 211, 235], ["hematologic malignancies", "DISEASE", 211, 235], ["hematologic malignancies", "CANCER", 211, 235], ["altered dose and fractionation schedules", "TREATMENT", 116, 156], ["The fractionation sensitivity", "TEST", 178, 207], ["hematologic malignancies", "PROBLEM", 211, 235], ["hematologic malignancies", "OBSERVATION", 211, 235]]], ["However, laboratory data suggest little to no shoulder on the linear-quadratic model of cell survival, leading to a large value of \u03b1/\u03b2.17 We therefore expect the biological effect of radiation on lymphoma cells, measured as equivalent dose in 2-Gy fractions (EQD2)18 to lie between EQD2 using \u03b1/\u03b2 = 10 Gy and EQD2 = total dose.The suggested hypofractionated schemes have little reduction of the total dose aiming to maintain the same level of tumor control.", [["shoulder", "ANATOMY", 46, 54], ["cell", "ANATOMY", 88, 92], ["lymphoma cells", "ANATOMY", 196, 210], ["tumor", "ANATOMY", 443, 448], ["lymphoma", "DISEASE", 196, 204], ["tumor", "DISEASE", 443, 448], ["shoulder", "ORGANISM_SUBDIVISION", 46, 54], ["cell", "CELL", 88, 92], ["lymphoma cells", "CELL", 196, 210], ["tumor", "CANCER", 443, 448], ["\u03b1/\u03b2.17", "CELL_LINE", 131, 137], ["lymphoma cells", "CELL_TYPE", 196, 210], ["\u03b1", "PROTEIN", 293, 294], ["laboratory data", "TEST", 9, 24], ["a large value", "TEST", 114, 127], ["radiation on lymphoma cells", "TREATMENT", 183, 210], ["EQD2", "TEST", 282, 286], ["EQD2", "TEST", 309, 313], ["hypofractionated schemes", "TREATMENT", 341, 365], ["the total dose aiming", "TREATMENT", 391, 412], ["tumor control", "TREATMENT", 443, 456], ["shoulder", "ANATOMY", 46, 54], ["cell survival", "OBSERVATION", 88, 101], ["large", "OBSERVATION_MODIFIER", 116, 121], ["lymphoma cells", "OBSERVATION", 196, 210], ["hypofractionated", "OBSERVATION", 341, 357], ["little", "OBSERVATION_MODIFIER", 371, 377], ["reduction", "OBSERVATION_MODIFIER", 378, 387], ["tumor", "OBSERVATION", 443, 448]]], ["The risks of acute and late toxicity to normal tissues associated with large dose per faction and higher EQD2 for \u03b1/\u03b2 = 3 Gy are currently mitigated by the use of modern conformal RT techniques.", [["tissues", "ANATOMY", 47, 54], ["toxicity", "DISEASE", 28, 36], ["tissues", "TISSUE", 47, 54], ["EQD2", "PROTEIN", 105, 109], ["acute and late toxicity", "PROBLEM", 13, 36], ["modern conformal RT techniques", "TREATMENT", 163, 193], ["acute", "OBSERVATION_MODIFIER", 13, 18]]], ["Modern technology offers steep dose gradients around the target tumor with most of the surrounding normal tissues in the low-dose volume.", [["tumor", "ANATOMY", 64, 69], ["tissues", "ANATOMY", 106, 113], ["tumor", "DISEASE", 64, 69], ["tumor", "CANCER", 64, 69], ["normal tissues", "TISSUE", 99, 113], ["steep dose gradients", "TREATMENT", 25, 45], ["the target tumor", "PROBLEM", 53, 69], ["target", "OBSERVATION_MODIFIER", 57, 63], ["tumor", "OBSERVATION", 64, 69], ["normal tissues", "OBSERVATION", 99, 113], ["low-dose volume", "OBSERVATION_MODIFIER", 121, 136]]], ["The risks are also mitigated by the low RT doses used in hematological malignancies, particularly the indolent types.The accuracy of the prediction of the \u03b1/\u03b2 model may be less for the larger fraction sizes.", [["hematological malignancies", "ANATOMY", 57, 83], ["hematological malignancies", "DISEASE", 57, 83], ["hematological malignancies", "CANCER", 57, 83], ["\u03b1/\u03b2", "GENE_OR_GENE_PRODUCT", 155, 158], ["\u03b1", "PROTEIN", 155, 156], ["\u03b2", "PROTEIN", 157, 158], ["the low RT doses", "TREATMENT", 32, 48], ["hematological malignancies", "PROBLEM", 57, 83], ["hematological malignancies", "OBSERVATION", 57, 83], ["indolent", "OBSERVATION_MODIFIER", 102, 110], ["larger", "OBSERVATION_MODIFIER", 185, 191], ["fraction", "OBSERVATION_MODIFIER", 192, 200], ["sizes", "OBSERVATION_MODIFIER", 201, 206]]], ["Therefore, to mitigate clinical risk, we have used dose-per-fractionation regimens that many in the clinical community are already familiar with and know are well tolerated.Hypofractionation has, however, not been rigorously tested in prospective randomized trials in the curative treatment of hematologic malignancies, and, therefore, the treatment schedules proposed are recommended to apply only to the emergency situation of the COVID-19 pandemic.", [["hematologic malignancies", "ANATOMY", 294, 318], ["hematologic malignancies", "DISEASE", 294, 318], ["hematologic malignancies", "CANCER", 294, 318], ["dose-per-fractionation regimens", "TREATMENT", 51, 82], ["Hypofractionation", "TREATMENT", 173, 190], ["prospective randomized trials", "TREATMENT", 235, 264], ["the curative treatment", "TREATMENT", 268, 290], ["hematologic malignancies", "PROBLEM", 294, 318], ["the treatment schedules", "TREATMENT", 336, 359], ["the COVID", "TEST", 429, 438], ["pandemic", "PROBLEM", 442, 450], ["hematologic malignancies", "OBSERVATION", 294, 318]]], ["For patients with substantial cardiac or lung exposure, standard (2-Gy) fractionation should be used if at all possible.In Table 1, we present guidelines for possible abbreviated fractionation schemes for different clinical presentations that could be used in an emergency like the present COVID-19 pandemic.", [["cardiac", "ANATOMY", 30, 37], ["lung", "ANATOMY", 41, 45], ["patients", "ORGANISM", 4, 12], ["cardiac", "ORGAN", 30, 37], ["lung", "ORGAN", 41, 45], ["patients", "SPECIES", 4, 12], ["substantial cardiac or lung exposure", "PROBLEM", 18, 54], ["standard (2-Gy) fractionation", "TREATMENT", 56, 85], ["abbreviated fractionation schemes", "TREATMENT", 167, 200], ["pandemic", "PROBLEM", 299, 307], ["cardiac", "ANATOMY", 30, 37], ["lung", "ANATOMY", 41, 45], ["exposure", "OBSERVATION", 46, 54]]], ["Other fractionation schemes could also be appropriate, depending on clinical circumstances, if the EQD2 is equivalent to curative standard treatment regimens.", [["Other fractionation schemes", "PROBLEM", 0, 27], ["curative standard treatment regimens", "TREATMENT", 121, 157], ["fractionation schemes", "OBSERVATION", 6, 27], ["could also be", "UNCERTAINTY", 28, 41]]], ["We have included guidance for constraints for doses to normal tissues, but it is important to note that the proposed abbreviated treatments should always be used with due consideration and clinical judgement in individual cases.", [["tissues", "ANATOMY", 62, 69], ["tissues", "TISSUE", 62, 69], ["the proposed abbreviated treatments", "TREATMENT", 104, 139]]]], "PMC420071": [["This symposium is Canada's premier critical care conference and attracts participants from across the country, the United States, Europe, Australia and Asia.", [["participants", "SPECIES", 73, 85]]], ["The attendance this year was in excess of 900 people and included the disciplines of medicine, nursing, respiratory therapy and other allied health care professionals.", [["people", "SPECIES", 46, 52], ["respiratory therapy", "TREATMENT", 104, 123]]], ["The themes of this year's meeting included sepsis, organ donation, blood conservation strategies, acute lung injury and ethics.", [["organ", "ANATOMY", 51, 56], ["blood", "ANATOMY", 67, 72], ["lung", "ANATOMY", 104, 108], ["sepsis", "DISEASE", 43, 49], ["acute lung injury", "DISEASE", 98, 115], ["organ", "ORGAN", 51, 56], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["lung", "ORGAN", 104, 108], ["sepsis", "PROBLEM", 43, 49], ["organ donation", "TREATMENT", 51, 65], ["blood conservation strategies", "TREATMENT", 67, 96], ["acute lung injury", "PROBLEM", 98, 115], ["sepsis", "OBSERVATION", 43, 49], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["lung", "ANATOMY", 104, 108], ["injury", "OBSERVATION", 109, 115]]], ["In addition, many of the plenary addresses reviewed the recent severe acute respiratory syndrome (SARS) crisis.", [["acute respiratory syndrome", "DISEASE", 70, 96], ["SARS", "DISEASE", 98, 102], ["the recent severe acute respiratory syndrome", "PROBLEM", 52, 96], ["SARS) crisis", "PROBLEM", 98, 110], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["respiratory syndrome", "OBSERVATION", 76, 96]]], ["The discussion surrounding SARS was particularly poignant as Toronto was the North American city most affected by the outbreak.Severe acute respiratory syndromeJohn Marshall (University of Toronto) kicked off the meeting with an informative review of the epidemiology of SARS: 'How it got from A to B'.", [["SARS", "DISEASE", 27, 31], ["SARS", "DISEASE", 271, 275], ["SARS", "PROBLEM", 27, 31], ["Severe acute respiratory syndromeJohn", "PROBLEM", 127, 164], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["respiratory syndromeJohn", "OBSERVATION", 140, 164]]], ["The origin of the disease in humans may have developed through contact with animal reservoirs for the virus.", [["humans", "ORGANISM", 29, 35], ["humans", "SPECIES", 29, 35], ["humans", "SPECIES", 29, 35], ["the disease in humans", "PROBLEM", 14, 35], ["animal reservoirs", "TREATMENT", 76, 93], ["the virus", "PROBLEM", 98, 107], ["origin", "OBSERVATION_MODIFIER", 4, 10], ["disease", "OBSERVATION", 18, 25]]], ["Indeed, the first affected individuals were food handlers who routinely came into contact with animals such as the Civet Cat that are sold as a delicacy in Chinese markets.Severe acute respiratory syndromeThe Metropole Hotel in the Kowloon province of Hong Kong has become perhaps one of the most infamous hotels in the world as it is regarded as the source of the index cases for SARS in Toronto, Hong Kong, Singapore and Hanoi.", [["acute respiratory syndrome", "DISEASE", 179, 205], ["SARS", "DISEASE", 381, 385], ["individuals", "ORGANISM", 27, 38], ["Severe acute respiratory syndrome", "SPECIES", 172, 205], ["Severe acute respiratory syndrome", "PROBLEM", 172, 205], ["SARS", "PROBLEM", 381, 385], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["respiratory syndrome", "OBSERVATION", 185, 205]]], ["It was with this visit that the health care system in Toronto became involved in the spread of SARS, with devastating consequences.", [["SARS", "DISEASE", 95, 99], ["SARS", "PROBLEM", 95, 99]]], ["There were a total of 375 cases in Ontario and there are presently 43 deaths attributed to SARS.Severe acute respiratory syndromeIn Toronto the primary spread of the disease was within the hospitals of the Greater Toronto area, essentially making SARS a 'nosocomial' illness.", [["deaths", "DISEASE", 70, 76], ["SARS", "DISEASE", 91, 95], ["SARS", "DISEASE", 247, 251], ["nosocomial' illness", "DISEASE", 255, 274], ["SARS", "PROBLEM", 91, 95], ["Severe acute respiratory syndromeIn", "PROBLEM", 96, 131], ["the disease", "PROBLEM", 162, 173], ["a 'nosocomial' illness", "PROBLEM", 252, 274], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory syndromeIn", "OBSERVATION", 109, 131], ["primary", "OBSERVATION_MODIFIER", 144, 151], ["spread", "OBSERVATION_MODIFIER", 152, 158], ["disease", "OBSERVATION", 166, 173], ["Greater", "OBSERVATION_MODIFIER", 206, 213]]], ["Following the initial outbreak a second wave of infection occurred in Toronto following exposure of patients and hospital staff to an elderly male patient in a convalescent home recovering from a hip fracture.", [["hip", "ANATOMY", 196, 199], ["infection", "DISEASE", 48, 57], ["fracture", "DISEASE", 200, 208], ["patients", "ORGANISM", 100, 108], ["patient", "ORGANISM", 147, 154], ["hip", "ORGANISM_SUBDIVISION", 196, 199], ["patients", "SPECIES", 100, 108], ["patient", "SPECIES", 147, 154], ["infection", "PROBLEM", 48, 57], ["a hip fracture", "PROBLEM", 194, 208], ["infection", "OBSERVATION", 48, 57], ["hip", "ANATOMY", 196, 199], ["fracture", "OBSERVATION", 200, 208]]], ["SARS II, therefore, was probably the result of premature relaxation of infection control measures and the late recognition of epidemiological linkages between cases.Severe acute respiratory syndromeWhy Toronto?", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 71, 80], ["acute respiratory syndrome", "DISEASE", 172, 198], ["Severe acute respiratory syndrome", "SPECIES", 165, 198], ["premature relaxation", "PROBLEM", 47, 67], ["infection control measures", "TREATMENT", 71, 97], ["Severe acute respiratory syndrome", "PROBLEM", 165, 198], ["infection", "OBSERVATION", 71, 80], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["respiratory syndrome", "OBSERVATION", 178, 198]]], ["Ease of travel, being a large cosmopolitan city, inadequate facilities and lax infection control were all cited as contributing factors.", [["infection", "DISEASE", 79, 88], ["lax infection control", "TREATMENT", 75, 96], ["large", "OBSERVATION_MODIFIER", 24, 29]]], ["However, just plan bad luck was probably the largest contributor to the choice of Toronto by the SARS coronavirusSevere acute respiratory syndromeThe medical system was ill prepared for SARS.", [["SARS coronavirus", "DISEASE", 97, 113], ["acute respiratory syndrome", "DISEASE", 120, 146], ["SARS", "DISEASE", 186, 190], ["SARS coronavirus", "ORGANISM", 97, 113], ["SARS coronavirusSevere acute respiratory syndrome", "SPECIES", 97, 146], ["the SARS coronavirusSevere acute respiratory syndrome", "PROBLEM", 93, 146], ["SARS", "PROBLEM", 186, 190], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["respiratory syndrome", "OBSERVATION", 126, 146]]], ["Indeed, the successful control of the infection was made through sheer will and tireless determination of individuals.", [["infection", "DISEASE", 38, 47], ["the infection", "PROBLEM", 34, 47], ["individuals", "PROBLEM", 106, 117], ["infection", "OBSERVATION", 38, 47]]], ["Judith Stein (University of Toronto) focused on several of the lessons to be learned from the way SARS was handled.", [["SARS", "DISEASE", 98, 102]]], ["Through her own investigative efforts she drew some distressing distinctions between the private and public sectors' ability to deal with crisis in any form.", [["crisis", "PROBLEM", 138, 144]]], ["She paralleled the private sectors response to the September 11th terror attacks in the United States with the public sector's ability to deal with the SARS crisis.Severe acute respiratory syndromeMost of the major financial institutions in North America have plans in place for disasters to allow them to rapidly and effectively continue to provide service to their customers.", [["SARS", "DISEASE", 152, 156], ["acute respiratory syndrome", "DISEASE", 171, 197], ["Severe acute respiratory syndrome", "SPECIES", 164, 197], ["the SARS crisis", "PROBLEM", 148, 163], ["Severe acute respiratory syndrome", "PROBLEM", 164, 197], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["respiratory syndrome", "OBSERVATION", 177, 197]]], ["Planning for the unexpected is all part of a sound 'business continuity plan' and not to do so would be foolish and would probably result in loss of revenue and possibly bankruptcy during times of crisis.", [["crisis", "PROBLEM", 197, 203]]], ["These business leaders not only ensure that systems and infrastructure have redundancy, but ensure that the people who are integral for the basic function of the organization are backed up.", [["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114]]], ["Redundancy is not a 'bad word' in the private sector; it is actually good business when applied properly.Severe acute respiratory syndromeStein has presented these thoughts to deputy ministers in the Canadian government and has received what she interpreted as a less than receptive response.", [["respiratory", "ANATOMY", 118, 129], ["Severe acute respiratory syndromeStein", "PROBLEM", 105, 143], ["good", "OBSERVATION_MODIFIER", 69, 73], ["business", "OBSERVATION", 74, 82], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory syndromeStein", "OBSERVATION", 118, 143]]], ["However, Stein provided the audience with a sound argument for the development of an action plan and the notion that the health care sector cannot afford to ignore the 'back up' of systems and human resources \u2013 the next time we may not be so fortunate.Severe acute respiratory syndromeContinuing on the SARS theme, Donald Low (University of Toronto) presented a further review on the outbreak in Toronto.", [["acute respiratory syndrome", "DISEASE", 259, 285], ["human", "ORGANISM", 193, 198], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 193, 198], ["Severe acute respiratory syndrome", "SPECIES", 252, 285], ["an action plan", "TREATMENT", 82, 96], ["Severe acute respiratory syndrome", "PROBLEM", 252, 285], ["acute", "OBSERVATION_MODIFIER", 259, 264], ["respiratory syndrome", "OBSERVATION", 265, 285]]], ["Low remains an integral member of the local, provincial and international effort to control the spread of this disease.", [["this disease", "PROBLEM", 106, 118]]], ["He was truly on the 'front lines' during the crisis in Toronto.", [["front lines", "CELL", 21, 32]]], ["Low described the two phases of the outbreak that occurred in Toronto and relayed the absolute devastation that was felt by the entire health care community and the public when the second outbreak of SARS occurred in Toronto.", [["SARS", "DISEASE", 200, 204], ["SARS", "PROBLEM", 200, 204]]], ["However, he passed on some lessons that were learned, that may help limit spread if SARS rears its ugly head again.", [["head", "ANATOMY", 104, 108], ["SARS", "DISEASE", 84, 88], ["head", "ORGANISM_SUBDIVISION", 104, 108], ["SARS", "PROBLEM", 84, 88]]], ["The importance of infection control procedures and lasting vigilance was emphasized.Severe acute respiratory syndromeThe period of infectivity and the range of incubation periods have been a cause for concern and debate.", [["infection", "DISEASE", 18, 27], ["acute respiratory syndrome", "DISEASE", 91, 117], ["Severe acute respiratory syndrome", "SPECIES", 84, 117], ["infection control procedures", "TREATMENT", 18, 46], ["Severe acute respiratory syndrome", "PROBLEM", 84, 117], ["infectivity", "PROBLEM", 131, 142], ["infection", "OBSERVATION", 18, 27], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory syndrome", "OBSERVATION", 97, 117], ["infectivity", "OBSERVATION", 131, 142]]], ["The disease in general is not infectious prior to the onset of symptoms, but the incubation period has been variably reported and in some instances may extend beyond 10 days.", [["The disease", "PROBLEM", 0, 11], ["infectious", "PROBLEM", 30, 40], ["symptoms", "PROBLEM", 63, 71], ["disease", "OBSERVATION", 4, 11], ["not", "UNCERTAINTY", 26, 29], ["infectious", "OBSERVATION", 30, 40]]], ["The disease itself peaks in infectivity at the 7-day to 10-day mark.", [["The disease itself", "PROBLEM", 0, 18], ["disease", "OBSERVATION", 4, 11], ["peaks", "OBSERVATION_MODIFIER", 19, 24], ["infectivity", "OBSERVATION_MODIFIER", 28, 39]]], ["In addition, there does seem to be the phenomenon of 'super spreaders', who may have an increased capacity to infect those that come into contact with them.", [["an increased capacity", "PROBLEM", 85, 106], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["capacity", "OBSERVATION", 98, 106]]], ["There is generally increased risk of spread with prolonged patient contact, in a linear fashion.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["generally", "OBSERVATION_MODIFIER", 9, 18], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["spread", "OBSERVATION_MODIFIER", 37, 43]]], ["At present there is no evidence of a prolonged carrier state.Severe acute respiratory syndromePatients can develop severe pneumonia and acute lung injury once ill with SARS.", [["respiratory", "ANATOMY", 74, 85], ["lung", "ANATOMY", 142, 146], ["acute respiratory syndromePatients", "DISEASE", 68, 102], ["pneumonia", "DISEASE", 122, 131], ["acute lung injury", "DISEASE", 136, 153], ["SARS", "DISEASE", 168, 172], ["lung", "ORGAN", 142, 146], ["a prolonged carrier state", "PROBLEM", 35, 60], ["Severe acute respiratory syndromePatients", "PROBLEM", 61, 102], ["severe pneumonia", "PROBLEM", 115, 131], ["acute lung injury", "PROBLEM", 136, 153], ["SARS", "PROBLEM", 168, 172], ["no evidence of", "UNCERTAINTY", 20, 34], ["prolonged", "OBSERVATION_MODIFIER", 37, 46], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndromePatients", "OBSERVATION", 74, 102], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["pneumonia", "OBSERVATION", 122, 131], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["lung", "ANATOMY", 142, 146], ["injury", "OBSERVATION", 147, 153]]], ["Stephen Lapinsky (University of Toronto) presented a review of Toronto's intensive care unit (ICU) experience with SARS.", [["SARS", "DISEASE", 115, 119], ["SARS", "PROBLEM", 115, 119]]], ["The mortality associated with a SARS patient who required admission to the ICU was about 40\u201350%.", [["SARS", "DISEASE", 32, 36], ["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44]]], ["Multiple therapies were attempted, such as antivirals, steroids and a variety of modes of mechanical ventilation [1,2].", [["steroids", "CHEMICAL", 55, 63], ["steroids", "CHEMICAL", 55, 63], ["steroids", "SIMPLE_CHEMICAL", 55, 63], ["Multiple therapies", "TREATMENT", 0, 18], ["antivirals", "TREATMENT", 43, 53], ["steroids", "TREATMENT", 55, 63], ["mechanical ventilation", "TREATMENT", 90, 112], ["mechanical ventilation", "OBSERVATION", 90, 112]]], ["Of particular interest to the audience was the safety precautions required while caring for a SARS patient.", [["SARS", "DISEASE", 94, 98], ["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["the safety precautions", "TREATMENT", 43, 65]]], ["Certain procedures have been identified as high risk for health care workers, not the least of which is assisting or performing intubation.", [["Certain procedures", "TREATMENT", 0, 18], ["intubation", "TREATMENT", 128, 138]]], ["High-risk procedures combined with the high-risk SARS patient require extraordinarily strict precautions and the use of full protective equipment.Transfusion medicineThe session on transfusion practices began with Dean Fergusson's (University of Ottawa) update on the effectiveness of leukoreduction (the removal of white blood cells from donated blood).", [["white blood cells", "ANATOMY", 316, 333], ["blood", "ANATOMY", 347, 352], ["SARS", "DISEASE", 49, 53], ["patient", "ORGANISM", 54, 61], ["blood cells", "CELL", 322, 333], ["blood", "ORGANISM_SUBSTANCE", 347, 352], ["white blood cells", "CELL_TYPE", 316, 333], ["patient", "SPECIES", 54, 61], ["High-risk procedures", "TREATMENT", 0, 20], ["extraordinarily strict precautions", "TREATMENT", 70, 104], ["full protective equipment", "TREATMENT", 120, 145], ["Transfusion medicine", "TREATMENT", 146, 166], ["transfusion practices", "TREATMENT", 181, 202], ["leukoreduction", "TREATMENT", 285, 299], ["the removal of white blood cells", "TREATMENT", 301, 333]]], ["Leukoreduction essentially reduces the average white blood cell content in a unit of packed cells from 3.0 \u00d7 109 to 2.5 \u00d7 105.", [["white blood cell", "ANATOMY", 47, 63], ["cells", "ANATOMY", 92, 97], ["blood cell", "CELL", 53, 63], ["cells", "CELL", 92, 97], ["packed cells", "CELL_TYPE", 85, 97], ["Leukoreduction", "TREATMENT", 0, 14], ["the average white blood cell content", "PROBLEM", 35, 71], ["a unit of packed cells", "TREATMENT", 75, 97], ["essentially", "OBSERVATION_MODIFIER", 15, 26], ["reduces", "OBSERVATION_MODIFIER", 27, 34], ["average", "OBSERVATION_MODIFIER", 39, 46], ["white blood", "OBSERVATION_MODIFIER", 47, 58], ["cell content", "OBSERVATION", 59, 71]]], ["The rationale for leukoreduction is to minimize exposure to transfused leukocytes, which can lead to adverse transfusion reactions or alterations in immunity or inflammation.", [["leukocytes", "ANATOMY", 71, 81], ["inflammation", "DISEASE", 161, 173], ["leukocytes", "CELL", 71, 81], ["transfused leukocytes", "CELL_TYPE", 60, 81], ["leukoreduction", "TREATMENT", 18, 32], ["transfused leukocytes", "PROBLEM", 60, 81], ["adverse transfusion reactions", "PROBLEM", 101, 130], ["alterations in immunity", "PROBLEM", 134, 157], ["inflammation", "PROBLEM", 161, 173], ["inflammation", "OBSERVATION", 161, 173]]], ["Since 1999 all blood in Canada has been leukoreduced.", [["blood", "ANATOMY", 15, 20], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["leukoreduced", "OBSERVATION", 40, 52]]], ["A large Canadian study recently examined the effect of this change in practice in adult high-risk surgical patients [3].", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["A large Canadian study", "TEST", 0, 22], ["this change", "PROBLEM", 55, 66], ["large", "OBSERVATION_MODIFIER", 2, 7]]], ["Fergusson reviewed the findings of their trial that showed a reduction in mortality, fever and antibiotic use, but failed to demonstrate a change in serious nosocomial infection.", [["fever", "DISEASE", 85, 90], ["nosocomial infection", "DISEASE", 157, 177], ["a reduction in mortality", "PROBLEM", 59, 83], ["fever", "PROBLEM", 85, 90], ["antibiotic use", "TREATMENT", 95, 109], ["a change in serious nosocomial infection", "PROBLEM", 137, 177], ["reduction", "OBSERVATION_MODIFIER", 61, 70], ["serious", "OBSERVATION_MODIFIER", 149, 156], ["nosocomial", "OBSERVATION_MODIFIER", 157, 167], ["infection", "OBSERVATION", 168, 177]]], ["Similarly, when they evaluated the effects in neonates (<1250 g) there was evidence of decreased morbidity and ICU stay following the implementation of leukoreduction [4].Transfusion medicineA reduction in transfusion rates in the ICU may help to reduce possible harm from blood products.", [["blood", "ANATOMY", 273, 278], ["neonates", "ORGANISM", 46, 54], ["blood", "ORGANISM_SUBSTANCE", 273, 278], ["decreased morbidity", "PROBLEM", 87, 106], ["the implementation of leukoreduction", "TREATMENT", 130, 166], ["Transfusion medicineA reduction", "TREATMENT", 171, 202], ["transfusion rates", "TREATMENT", 206, 223], ["harm from blood products", "PROBLEM", 263, 287], ["decreased", "OBSERVATION_MODIFIER", 87, 96], ["morbidity", "OBSERVATION", 97, 106], ["reduction", "OBSERVATION_MODIFIER", 193, 202]]], ["Between 20 and 30% of all blood transfusions occur in the ICU setting, and 85% of patients present in an ICU for longer than 1 week receive a transfusion [5].", [["blood", "ANATOMY", 26, 31], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["all blood transfusions", "TREATMENT", 22, 44], ["a transfusion", "TREATMENT", 140, 153]]], ["Higher transfusion rates have been associated with an increased length of stay and increased mortality versus matched controls [6].", [["Higher transfusion rates", "PROBLEM", 0, 24], ["increased mortality", "PROBLEM", 83, 102], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["length", "OBSERVATION_MODIFIER", 64, 70]]], ["Robert Fowler (University of Toronto) proposed several approaches to decrease the frequency of, and possibly the need for, transfusion in the ICU.", [["transfusion", "TREATMENT", 123, 134]]], ["Perioperatively, the use of autologous donation, the use of normovolemic hemodilution and the use of cell recovery are possible options.", [["cell", "ANATOMY", 101, 105], ["cell", "CELL", 101, 105], ["autologous donation", "TREATMENT", 28, 47], ["normovolemic hemodilution", "TREATMENT", 60, 85], ["cell recovery", "TREATMENT", 101, 114], ["normovolemic hemodilution", "OBSERVATION", 60, 85]]], ["Implementation of a lower hemoglobin threshold for transfusion, limitation in the use of 'routine' daily laboratory work, the use of antifibrinolytics, the use of erythropoietin and a reduction in the amount of phlebotomy performed for the purposes of laboratory testing were all suggested in the ICU.", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 26, 36], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 163, 177], ["hemoglobin", "PROTEIN", 26, 36], ["erythropoietin", "PROTEIN", 163, 177], ["a lower hemoglobin threshold", "TREATMENT", 18, 46], ["transfusion", "TREATMENT", 51, 62], ["antifibrinolytics", "TREATMENT", 133, 150], ["erythropoietin", "TREATMENT", 163, 177], ["a reduction", "TREATMENT", 182, 193], ["phlebotomy", "TREATMENT", 211, 221], ["laboratory testing", "TEST", 252, 270]]], ["In fact, one ICU study indicated that phlebotomy rates and volumes directly accounted for 30% of all blood transfusions [5].", [["blood", "ANATOMY", 101, 106], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["one ICU study", "TEST", 9, 22], ["phlebotomy rates", "TEST", 38, 54], ["volumes", "TEST", 59, 66], ["all blood transfusions", "TREATMENT", 97, 119]]], ["The use of pediatric phlebotomy tubes in adults and having closed arterial line systems to reduce wastage are viable options that have been shown to significantly reduce blood loss from phlebotomy [7,8].Transfusion medicineA large multicenter trial is underway to look at the effectiveness of some of these simple measures to reduce transfusion.", [["arterial line", "ANATOMY", 66, 79], ["blood", "ANATOMY", 170, 175], ["blood loss", "DISEASE", 170, 180], ["blood", "ORGANISM_SUBSTANCE", 170, 175], ["pediatric phlebotomy tubes", "TREATMENT", 11, 37], ["closed arterial line systems", "TREATMENT", 59, 87], ["blood loss", "PROBLEM", 170, 180], ["phlebotomy", "TEST", 186, 196], ["Transfusion medicineA large multicenter trial", "TREATMENT", 203, 248], ["these simple measures", "TREATMENT", 301, 322], ["transfusion", "TREATMENT", 333, 344], ["tubes", "OBSERVATION", 32, 37], ["arterial", "ANATOMY", 66, 74], ["large", "OBSERVATION_MODIFIER", 225, 230]]], ["The role of blood substitutes remains futuristic.", [["blood", "ANATOMY", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["futuristic", "PROBLEM", 38, 48]]], ["David Mazar (University of Toronto) reviewed the stormy experience to date with blood substitutes as an alternative to blood products.", [["blood", "ANATOMY", 80, 85], ["blood", "ANATOMY", 119, 124], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["blood substitutes", "TREATMENT", 80, 97], ["blood products", "TREATMENT", 119, 133]]], ["Although many alternatives are on the horizon, safety concerns and lack of proof of efficacy have limited their clinical application.Transfusion medicineMany of the aforementioned issues have become topical in critical care, in no small part due to the work of Paul Hebert (University of Ottawa).", [["Transfusion medicineMany", "TREATMENT", 133, 157]]], ["In a talk appropriately entitled, 'Still 70?', Hebert revisited the question of what hemoglobin value should be the threshold for transfusion.", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 85, 95], ["hemoglobin", "PROTEIN", 85, 95], ["hemoglobin value", "TEST", 85, 101], ["transfusion", "TREATMENT", 130, 141]]], ["Many people maintain that a value of 70 g/l remains the hemoglobin threshold for transfusion.", [["people", "ORGANISM", 5, 11], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 56, 66], ["hemoglobin", "PROTEIN", 56, 66], ["people", "SPECIES", 5, 11], ["the hemoglobin threshold", "TEST", 52, 76], ["transfusion", "TREATMENT", 81, 92]]], ["However, what people think and what they do in daily practice seems to be different.", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20]]], ["This disparity was emphasized in the anemia and blood transfusion in critically ill patients (ABC) trial.", [["blood", "ANATOMY", 48, 53], ["anemia", "DISEASE", 37, 43], ["critically ill", "DISEASE", 69, 83], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["the anemia", "PROBLEM", 33, 43], ["blood transfusion", "TREATMENT", 48, 65], ["anemia", "OBSERVATION", 37, 43]]], ["In that study of the transfusion practice of 146 European ICUs, the average hemoglobin at which patients were transfused was 84 \u00b1 1.3 g/l [6].", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 76, 86], ["patients", "ORGANISM", 96, 104], ["hemoglobin", "PROTEIN", 76, 86], ["patients", "SPECIES", 96, 104], ["the average hemoglobin", "TEST", 64, 86]]], ["More randomized controlled trials are needed to answer the question more definitively, particularly in patients with ischemic heart disease.", [["heart", "ANATOMY", 126, 131], ["ischemic heart disease", "DISEASE", 117, 139], ["patients", "ORGANISM", 103, 111], ["heart", "ORGAN", 126, 131], ["patients", "SPECIES", 103, 111], ["ischemic heart disease", "PROBLEM", 117, 139], ["heart", "ANATOMY", 126, 131], ["disease", "OBSERVATION", 132, 139]]], ["Hebert hinted that a value greater than 70 g/l might be reasonable in patients with ischemic heart disease, with 80 g/l being a possible threshold.End-of-life careDeborah Cook (McMaster University) presented 'Predictions and end of life decisions in the ICU', a topic that was sobering to many in the audience and gave food for thought surrounding clinicians' end-of-life decisions in a critical care setting.", [["heart", "ANATOMY", 93, 98], ["ischemic heart disease", "DISEASE", 84, 106], ["patients", "ORGANISM", 70, 78], ["heart", "ORGAN", 93, 98], ["patients", "SPECIES", 70, 78], ["ischemic heart disease", "PROBLEM", 84, 106], ["heart", "ANATOMY", 93, 98], ["disease", "OBSERVATION", 99, 106]]], ["Given a standard scenario, there was a wide degree of variation in ICU clinicians' decisions about the appropriate levels of care for the given patient [9].", [["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["wide degree", "OBSERVATION_MODIFIER", 39, 50]]], ["In addition, the confidence of these management choices was highest when the decisions were extreme in nature (i.e. withdrawal of life support) [10].", [["these management choices", "TREATMENT", 31, 55], ["life support", "TREATMENT", 130, 142]]], ["Factors that predict the implementation of withdrawal of life support include the use of inotropes or vasopressors, physician prediction of an ICU survival of less than 10%, physician prediction of poor residual cognitive function and physician perception of the patient's desire to limit life support [11].", [["patient", "ORGANISM", 263, 270], ["patient", "SPECIES", 263, 270], ["withdrawal of life support", "TREATMENT", 43, 69], ["inotropes", "TREATMENT", 89, 98], ["vasopressors", "TREATMENT", 102, 114], ["an ICU survival", "TREATMENT", 140, 155], ["poor residual cognitive function", "PROBLEM", 198, 230]]], ["Interestingly, physician prediction of ICU mortality is the greatest independent predictor of ICU death, even greater than the Acute Physiology and Chronic Health Evaluation II score or the multiple organ dysfunction score.", [["organ", "ANATOMY", 199, 204], ["death", "DISEASE", 98, 103], ["organ dysfunction", "DISEASE", 199, 216], ["organ", "ORGAN", 199, 204], ["ICU death", "PROBLEM", 94, 103], ["Chronic Health Evaluation II score", "PROBLEM", 148, 182], ["the multiple organ dysfunction score", "PROBLEM", 186, 222], ["Chronic", "OBSERVATION_MODIFIER", 148, 155], ["multiple", "OBSERVATION_MODIFIER", 190, 198], ["organ", "ANATOMY", 199, 204], ["dysfunction", "OBSERVATION", 205, 216]]], ["In summation, Cook stressed that uncertainty exists, as demonstrated in multiple studies examining confidence, predictions, perceptions and discomfort in end-of-life decisions.End-of-life careMoving on from physicians' perceptions in end-of-life issues, Daren Heyland's (Queen's University) discussion of the experience of dying from the perspective of the patient and of the family brought to light some areas of patient care that require greater attention [12].", [["patient", "ORGANISM", 357, 364], ["patient", "ORGANISM", 414, 421], ["patient", "SPECIES", 357, 364], ["patient", "SPECIES", 414, 421], ["discomfort", "PROBLEM", 140, 150]]], ["The majority of deaths in Canada occur in a hospital setting, from medial (noncancer) causes; however, palliative care seems oriented to cancer patients [13].", [["cancer", "ANATOMY", 137, 143], ["deaths", "DISEASE", 16, 22], ["noncancer", "DISEASE", 75, 84], ["cancer", "DISEASE", 137, 143], ["cancer", "CANCER", 137, 143], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["medial", "OBSERVATION_MODIFIER", 67, 73]]], ["For Canadian ICU patients and their family members the most important aspect of achieving quality end-of-life care was having trust in the doctors looking after you.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["Problem areas that were identified included a perceived gap between patient and family needs, and a shortfall in services to assist with care upon discharge from hospital.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["Problem areas", "PROBLEM", 0, 13]]], ["To improve patient satisfaction during end of life these gaps need to be targeted by concentrating on continuity of care, on patient\u2013doctor relationships and on relief of symptoms.End-of-life careThe experience in adults was contrasted to that in pediatrics.", [["patient", "ORGANISM", 11, 18], ["adults", "ORGANISM", 214, 220], ["patient", "SPECIES", 11, 18], ["symptoms", "PROBLEM", 171, 179]]], ["In pediatric hospitals 80% of inhospital deaths occur in the pediatric or neonatal ICU.", [["deaths", "DISEASE", 41, 47]]], ["Yet there is minimal evidence-based literature about end-of-life care or palliative care in pediatric ICUs.", [["end-of-life care", "TREATMENT", 53, 69], ["palliative care", "TREATMENT", 73, 88], ["minimal", "OBSERVATION_MODIFIER", 13, 20]]], ["Jacques Lacroix (University of Montreal) emphasized during his presentation the importance of a multidisciplinary approach to end-of-life care in children.", [["children", "ORGANISM", 146, 154], ["children", "SPECIES", 146, 154]]], ["The greatest source of conflict is secondary to poor communication, and this conflict can have serious detrimental effects on the child's care [17].", [["greatest", "OBSERVATION_MODIFIER", 4, 12]]], ["They should be reassured that nothing will be done to hasten the death of the child and that drugs will be used only for comfort and palliation [18].End-of-life careThe European experience surrounding issues of organ donation was reviewed by Jean-Louis Vincent (University of Brussels).", [["organ", "ANATOMY", 211, 216], ["death", "DISEASE", 65, 70], ["child", "ORGANISM", 78, 83], ["organ", "ORGAN", 211, 216], ["drugs", "TREATMENT", 93, 98], ["comfort and palliation", "TREATMENT", 121, 143], ["organ donation", "TREATMENT", 211, 225], ["organ", "ANATOMY", 211, 216]]], ["He based his philosophical discussion on the four main pillars of medical ethics: autonomy, beneficence, nonmaleficence and distributive justice.", [["distributive justice", "OBSERVATION", 124, 144]]], ["During his discussion, Vincent emphasized that any decisions about organ donation needed to represent a balance of these four concepts.", [["organ", "ANATOMY", 67, 72], ["organ", "ORGAN", 67, 72], ["organ donation", "TREATMENT", 67, 81]]], ["Vincent contrasted the North American style of obtained consent for organ donation with the approach of presumed consent practiced in some European centers.", [["organ", "ANATOMY", 68, 73], ["organ", "ORGAN", 68, 73], ["organ donation", "TREATMENT", 68, 82]]], ["In the latter situation, citizens have to register their objection to organ donation or it is presumed that they are willing donors.", [["organ", "ANATOMY", 70, 75], ["organ", "ORGAN", 70, 75], ["donors", "ORGANISM", 125, 131], ["organ donation", "TREATMENT", 70, 84]]], ["It was emphasized, however, that if a family of a brain-dead patient indicated that they felt their loved one was against donating, then those wishes should and would be respected.", [["brain", "ANATOMY", 50, 55], ["brain", "ORGAN", 50, 55], ["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["brain", "ANATOMY", 50, 55]]], ["Finally, the issue of nonheart-beating donors was touched upon, and further debate is almost certain as this is becoming a hot topic in transplant and critical care medicine.End-of-life careTo bring the session on end-of-life care to a conclusion, Sam Shemie (McGill University) presented a review of the determination of brain death in Canada.", [["brain", "ANATOMY", 322, 327], ["brain death", "DISEASE", 322, 333], ["donors", "ORGANISM", 39, 45], ["brain", "ORGAN", 322, 327], ["transplant", "TREATMENT", 136, 146], ["critical care medicine", "TREATMENT", 151, 173], ["brain death", "PROBLEM", 322, 333], ["brain", "ANATOMY", 322, 327], ["death", "OBSERVATION", 328, 333]]], ["The concept of brain death is medically and legally accepted as death in Canada and a majority of countries worldwide [19].", [["brain", "ANATOMY", 15, 20], ["brain death", "DISEASE", 15, 26], ["death", "DISEASE", 64, 69], ["brain", "ORGAN", 15, 20], ["brain death", "PROBLEM", 15, 26], ["brain", "ANATOMY", 15, 20], ["death", "OBSERVATION", 21, 26]]], ["Despite this national and international acceptance of brain death, however, there is no global consensus in diagnostic criteria [20].", [["brain", "ANATOMY", 54, 59], ["brain death", "DISEASE", 54, 65], ["brain", "ORGAN", 54, 59], ["brain death", "PROBLEM", 54, 65], ["diagnostic criteria", "TEST", 108, 127], ["brain", "ANATOMY", 54, 59], ["death", "OBSERVATION", 60, 65], ["no", "UNCERTAINTY", 85, 87]]], ["In the United States the concept is one of whole brain death, in the United Kingdom it is one of brainstem death, and finally in Canada there is no clear distinction between whole brain death versus brainstem death.End-of-life careA forum sponsored by the Canadian Council for Donation and Transplantation (Severe Brain Injury to Neurological Determination of Brain Death) was held in Canada in April 2003 to reach a national consensus on optimal management of patients with severe brain injury, and in particular for those who evolve to brain death.", [["brain", "ANATOMY", 49, 54], ["brainstem", "ANATOMY", 97, 106], ["brain", "ANATOMY", 180, 185], ["brainstem", "ANATOMY", 199, 208], ["brain", "ANATOMY", 482, 487], ["brain", "ANATOMY", 538, 543], ["brain death", "DISEASE", 49, 60], ["brainstem death", "DISEASE", 97, 112], ["brain death", "DISEASE", 180, 191], ["brainstem death", "DISEASE", 199, 214], ["Brain Injury", "DISEASE", 314, 326], ["Brain Death", "DISEASE", 360, 371], ["brain injury", "DISEASE", 482, 494], ["brain death", "DISEASE", 538, 549], ["brain", "ORGAN", 49, 54], ["brainstem", "ANATOMICAL_SYSTEM", 97, 106], ["brain", "ORGAN", 180, 185], ["brainstem", "ORGAN", 199, 208], ["patients", "ORGANISM", 461, 469], ["brain", "ORGAN", 482, 487], ["brain", "ORGAN", 538, 543], ["patients", "SPECIES", 461, 469], ["whole brain death", "PROBLEM", 43, 60], ["brainstem death", "PROBLEM", 97, 112], ["whole brain death", "PROBLEM", 174, 191], ["brainstem death", "PROBLEM", 199, 214], ["Donation", "TREATMENT", 277, 285], ["Transplantation", "TREATMENT", 290, 305], ["Severe Brain Injury", "PROBLEM", 307, 326], ["Brain Death", "PROBLEM", 360, 371], ["optimal management", "TREATMENT", 439, 457], ["severe brain injury", "PROBLEM", 475, 494], ["brain death", "PROBLEM", 538, 549], ["no", "UNCERTAINTY", 145, 147], ["brain", "ANATOMY", 180, 185], ["brainstem death", "OBSERVATION", 199, 214], ["Brain", "ANATOMY", 314, 319], ["Injury", "OBSERVATION", 320, 326], ["brain", "ANATOMY", 482, 487], ["injury", "OBSERVATION", 488, 494], ["brain", "ANATOMY", 538, 543], ["death", "OBSERVATION", 544, 549]]], ["Shemie drew our attention to the distinction between brain death (a concept that lacks clarity) and the neurological determination of brain death (NDD), which is the process and procedure to determine death based on neurological criteria.", [["brain", "ANATOMY", 53, 58], ["neurological", "ANATOMY", 104, 116], ["brain", "ANATOMY", 134, 139], ["brain death", "DISEASE", 53, 64], ["brain death", "DISEASE", 134, 145], ["NDD", "DISEASE", 147, 150], ["death", "DISEASE", 201, 206], ["brain", "ORGAN", 53, 58], ["brain", "ORGAN", 134, 139], ["brain death", "PROBLEM", 53, 64], ["brain death", "PROBLEM", 134, 145], ["procedure", "TREATMENT", 178, 187], ["death", "PROBLEM", 201, 206], ["brain", "ANATOMY", 53, 58], ["death", "OBSERVATION", 59, 64]]], ["The current evidence base for existing NDD guidelines is inadequate, and clear standards for NDD and the qualifications of physicians performing NDD need to be clarified.End-of-life careA variety of recommendations came out of this Canadian forum.", [["NDD", "DISEASE", 93, 96], ["NDD", "DISEASE", 145, 148], ["NDD", "CANCER", 145, 148], ["NDD", "PROBLEM", 93, 96]]], ["Accordingly, their definition of NDD was irreversible loss of the capacity of consciousness combined with the irreversible loss of brainstem reflexes, including the capacity to breathe.", [["brainstem", "ANATOMY", 131, 140], ["NDD", "DISEASE", 33, 36], ["loss of the capacity of consciousness", "DISEASE", 54, 91], ["loss of brainstem reflexes", "DISEASE", 123, 149], ["NDD", "CANCER", 33, 36], ["brainstem", "ORGANISM_SUBDIVISION", 131, 140], ["irreversible loss of the capacity of consciousness", "PROBLEM", 41, 91], ["the irreversible loss of brainstem reflexes", "PROBLEM", 106, 149], ["irreversible", "OBSERVATION_MODIFIER", 41, 53], ["loss", "OBSERVATION_MODIFIER", 54, 58], ["irreversible", "OBSERVATION_MODIFIER", 110, 122], ["loss", "OBSERVATION", 123, 127], ["brainstem reflexes", "OBSERVATION", 131, 149]]], ["The physicians performing this testing must have an independent license and have skill and knowledge in the care of brain-injured patients.", [["brain", "ANATOMY", 116, 121], ["brain-injured", "DISEASE", 116, 129], ["brain", "ORGAN", 116, 121], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["this testing", "TEST", 26, 38], ["brain", "ANATOMY", 116, 121]]], ["Recommendations were put forth for the minimal clinical criteria for NDD, including the appropriate brain stem reflexes to be tested.", [["brain stem", "ANATOMY", 100, 110], ["NDD", "DISEASE", 69, 72], ["NDD", "CANCER", 69, 72], ["brain stem", "TISSUE", 100, 110], ["NDD", "PROBLEM", 69, 72], ["brain stem", "ANATOMY", 100, 110]]], ["Confounding factors need to be absent in the diagnosis of brain death, such as shock, hypothermia (<34\u00b0C), metabolic disorders causing reversible coma, nerve or muscle dysfunction accounting for unresponsiveness, and medications or toxins accounting for the clinical state.", [["brain", "ANATOMY", 58, 63], ["nerve", "ANATOMY", 152, 157], ["muscle", "ANATOMY", 161, 167], ["brain death", "DISEASE", 58, 69], ["shock", "DISEASE", 79, 84], ["hypothermia", "DISEASE", 86, 97], ["metabolic disorders", "DISEASE", 107, 126], ["coma", "DISEASE", 146, 150], ["muscle dysfunction", "DISEASE", 161, 179], ["brain", "ORGAN", 58, 63], ["nerve", "MULTI-TISSUE_STRUCTURE", 152, 157], ["muscle", "ORGAN", 161, 167], ["Confounding factors", "PROBLEM", 0, 19], ["brain death", "PROBLEM", 58, 69], ["shock", "PROBLEM", 79, 84], ["hypothermia", "PROBLEM", 86, 97], ["metabolic disorders", "PROBLEM", 107, 126], ["reversible coma", "PROBLEM", 135, 150], ["nerve or muscle dysfunction", "PROBLEM", 152, 179], ["unresponsiveness", "PROBLEM", 195, 211], ["medications", "TREATMENT", 217, 228], ["toxins", "PROBLEM", 232, 238], ["brain", "ANATOMY", 58, 63], ["death", "OBSERVATION", 64, 69], ["reversible coma", "OBSERVATION", 135, 150], ["nerve", "ANATOMY", 152, 157], ["muscle", "ANATOMY", 161, 167], ["dysfunction", "OBSERVATION", 168, 179]]], ["With regards to the apnea test, the recommendation was to achieve PaCO2 \u2265 60 mmHg and \u226520 mmHg above baseline, and pH \u2264 7.28.", [["apnea", "DISEASE", 20, 25], ["the apnea test", "TEST", 16, 30], ["PaCO2", "TEST", 66, 71], ["pH", "TEST", 115, 117]]], ["A physician also needs to observe the patient throughout the entire test.End-of-life careThe panel concluded that there is no medical basis for the existing laws stating that two determinations of death are required for organ donation.", [["organ", "ANATOMY", 220, 225], ["death", "DISEASE", 197, 202], ["patient", "ORGANISM", 38, 45], ["organ", "ORGAN", 220, 225], ["patient", "SPECIES", 38, 45], ["the entire test", "TEST", 57, 72], ["The panel", "TEST", 89, 98], ["death", "PROBLEM", 197, 202], ["organ donation", "TREATMENT", 220, 234]]], ["This led to the recommendation that although two determinations of brain death are required by law, there should be no fixed examination interval.", [["brain", "ANATOMY", 67, 72], ["brain death", "DISEASE", 67, 78], ["brain", "ORGAN", 67, 72], ["brain death", "PROBLEM", 67, 78], ["fixed examination interval", "TEST", 119, 145], ["should be no", "UNCERTAINTY", 106, 118]]], ["Finally, NDD is primarily a clinical diagnosis, which only requires ancillary testing if there is an inability to complete any of the minimum clinical examination criteria or there are confounding factors that cannot be resolved.", [["NDD", "DISEASE", 9, 12], ["ancillary testing", "TEST", 68, 85], ["the minimum clinical examination criteria", "TEST", 130, 171], ["confounding factors", "PROBLEM", 185, 204]]], ["In this situation the ancillary test must demonstrate the absence of intracranial blood flow to diagnose brain death.", [["intracranial", "ANATOMY", 69, 81], ["blood", "ANATOMY", 82, 87], ["brain", "ANATOMY", 105, 110], ["brain death", "DISEASE", 105, 116], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["brain", "ORGAN", 105, 110], ["the ancillary test", "TEST", 18, 36], ["intracranial blood flow", "PROBLEM", 69, 92], ["diagnose brain death", "PROBLEM", 96, 116]]], ["Electroencephalogram is no longer recommended.End-of-life careThe report also focused on a variety of other issues including timing of declaration, reporting and legal issues surrounding brain death.", [["brain", "ANATOMY", 187, 192], ["brain death", "DISEASE", 187, 198], ["brain", "ORGAN", 187, 192], ["Electroencephalogram", "TEST", 0, 20], ["brain death", "PROBLEM", 187, 198], ["no longer", "UNCERTAINTY", 24, 33], ["brain", "ANATOMY", 187, 192], ["death", "OBSERVATION", 193, 198]]], ["It should also be noted that the forum had specific recommendations for children younger than 1 year of age and newborns that differ from the aforementioned recommendations.Nosocomial infectionsNosocomial infections affect about 30% of patients in ICUs and are on the increase [21].", [["Nosocomial infections", "DISEASE", 173, 194], ["Nosocomial infections", "DISEASE", 194, 215], ["children", "ORGANISM", 72, 80], ["newborns", "ORGANISM", 112, 120], ["patients", "ORGANISM", 236, 244], ["children", "SPECIES", 72, 80], ["patients", "SPECIES", 236, 244], ["Nosocomial infections", "PROBLEM", 173, 194], ["Nosocomial infections affect", "PROBLEM", 194, 222], ["infections", "OBSERVATION", 184, 194]]], ["The Sepsis Occurrence in the Acutely Ill Patient study undertaken by the European Sepsis Network taught us that Gram-negative and Gram-positive infections seem to be equally prevalent.", [["Sepsis", "DISEASE", 4, 10], ["Sepsis", "DISEASE", 82, 88], ["infections", "DISEASE", 144, 154], ["Gram-", "GENE_OR_GENE_PRODUCT", 112, 117], ["Gram-", "GENE_OR_GENE_PRODUCT", 130, 135], ["The Sepsis Occurrence", "PROBLEM", 0, 21], ["Patient study", "TEST", 41, 54], ["Gram-", "TEST", 112, 117], ["Gram-positive infections", "PROBLEM", 130, 154], ["Sepsis", "OBSERVATION", 4, 10]]], ["This study also showed increased mortality and increased ICU length of stay in patients who acquired a nosocomial infection.", [["nosocomial infection", "DISEASE", 103, 123], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["This study", "TEST", 0, 10], ["increased mortality", "PROBLEM", 23, 42], ["a nosocomial infection", "PROBLEM", 101, 123], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["mortality", "OBSERVATION", 33, 42], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["ICU length", "OBSERVATION_MODIFIER", 57, 67], ["nosocomial", "OBSERVATION_MODIFIER", 103, 113], ["infection", "OBSERVATION", 114, 123]]], ["The lungs seem to be the most common location of infection.", [["lungs", "ANATOMY", 4, 9], ["infection", "DISEASE", 49, 58], ["lungs", "ORGAN", 4, 9], ["infection", "PROBLEM", 49, 58], ["lungs", "ANATOMY", 4, 9], ["infection", "OBSERVATION", 49, 58]]], ["During his presentation, Vincent reviewed possible modalities to reduce the incidence of ventilator-associated pneumonia (VAP), including noninvasive ventilation, selective digestive decontamination and continuous subglottic aspiration [21].", [["digestive", "ANATOMY", 173, 182], ["subglottic", "ANATOMY", 214, 224], ["pneumonia", "DISEASE", 111, 120], ["VAP", "DISEASE", 122, 125], ["digestive", "ORGANISM_SUBDIVISION", 173, 182], ["modalities", "TREATMENT", 51, 61], ["ventilator-associated pneumonia", "PROBLEM", 89, 120], ["noninvasive ventilation", "TREATMENT", 138, 161], ["selective digestive decontamination", "TREATMENT", 163, 198], ["continuous subglottic aspiration", "TREATMENT", 203, 235], ["pneumonia", "OBSERVATION", 111, 120]]], ["He concluded by promoting an integrated care team for infected ICU patients.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["This team should include a microbiologist, an infectious disease consultant, infection control and a pharmacist.Nosocomial infectionsGram-positive organisms are the most common source of bacteremia in the ICU and their prevalence is increasing, as is the problem of antibiotic resistance.", [["infection", "DISEASE", 77, 86], ["Nosocomial infections", "DISEASE", 112, 133], ["bacteremia", "DISEASE", 187, 197], ["infection control", "TREATMENT", 77, 94], ["Nosocomial infections", "PROBLEM", 112, 133], ["Gram-positive organisms", "PROBLEM", 133, 156], ["bacteremia", "PROBLEM", 187, 197], ["antibiotic resistance", "TREATMENT", 266, 287], ["infections", "OBSERVATION", 123, 133], ["most common", "OBSERVATION_MODIFIER", 165, 176], ["bacteremia", "OBSERVATION", 187, 197], ["increasing", "OBSERVATION_MODIFIER", 233, 243], ["antibiotic resistance", "OBSERVATION", 266, 287]]], ["In particular, methicillin-resistant Staphylococcus aureus is a significant problem in industrialized nations [22].", [["methicillin", "CHEMICAL", 15, 26], ["Staphylococcus aureus", "DISEASE", 37, 58], ["methicillin", "CHEMICAL", 15, 26], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 15, 58], ["Staphylococcus aureus", "SPECIES", 37, 58], ["Staphylococcus aureus", "SPECIES", 37, 58], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 15, 58], ["Staphylococcus aureus", "OBSERVATION", 37, 58], ["significant", "OBSERVATION_MODIFIER", 64, 75]]], ["Mervyn Singer (London, UK) acknowledged that the dilemma is becoming particularly bad in the United Kingdom, with specific regions affected by methicillin-resistant Staphylococcus aureus[23].", [["methicillin", "CHEMICAL", 143, 154], ["Staphylococcus aureus", "DISEASE", 165, 186], ["methicillin", "CHEMICAL", 143, 154], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 143, 186], ["Staphylococcus aureus", "SPECIES", 165, 186], ["Staphylococcus aureus", "SPECIES", 165, 186], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 143, 186], ["Staphylococcus aureus", "OBSERVATION", 165, 186]]], ["The question of how to adequately treat Gram-positive bacteremia is not so clear.", [["bacteremia", "DISEASE", 54, 64], ["Gram-", "GENE_OR_GENE_PRODUCT", 40, 45], ["Gram-positive bacteremia", "PROBLEM", 40, 64], ["bacteremia", "OBSERVATION", 54, 64], ["clear", "OBSERVATION", 75, 80]]], ["The duration of therapy has traditionally been extended in comparison with other bacterial infections.", [["bacterial infections", "DISEASE", 81, 101], ["therapy", "TREATMENT", 16, 23], ["other bacterial infections", "PROBLEM", 75, 101], ["bacterial", "OBSERVATION_MODIFIER", 81, 90], ["infections", "OBSERVATION", 91, 101]]], ["It seems that if a microbiologist becomes involved in the care of these patients, then the treatment courses are usually shorter in duration.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["the treatment courses", "TREATMENT", 87, 108]]], ["Current treatment options include glycopeptides (vancomycin), synercid and linezolid.Nosocomial infectionsThe long-standing dogma of isolating these patients must also be looked at more critically.", [["vancomycin", "CHEMICAL", 49, 59], ["synercid", "CHEMICAL", 62, 70], ["linezolid", "CHEMICAL", 75, 84], ["Nosocomial infections", "DISEASE", 85, 106], ["vancomycin", "CHEMICAL", 49, 59], ["synercid", "CHEMICAL", 62, 70], ["linezolid", "CHEMICAL", 75, 84], ["glycopeptides", "SIMPLE_CHEMICAL", 34, 47], ["vancomycin", "SIMPLE_CHEMICAL", 49, 59], ["synercid", "SIMPLE_CHEMICAL", 62, 70], ["linezolid", "SIMPLE_CHEMICAL", 75, 84], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["Current treatment options", "TREATMENT", 0, 25], ["glycopeptides (vancomycin)", "TREATMENT", 34, 60], ["synercid", "TREATMENT", 62, 70], ["linezolid", "TREATMENT", 75, 84], ["Nosocomial infections", "PROBLEM", 85, 106], ["The long-standing dogma", "TREATMENT", 106, 129], ["infections", "OBSERVATION", 96, 106]]], ["Singer emphasized that isolated patients may actually receive suboptimal care with less frequent visits be the medical team [24].", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["In addition, the isolation does not seem to reduce cross-infection rates in high prevalence units.", [["cross-infection rates", "TEST", 51, 72]]], ["In summary, Singer impressed upon the audience that methicillin-resistant Staphylococcus aureus is probably here to stay and that the best combination of antibiotics and infection control practices remains to be determined.Nosocomial infectionsImproving diagnostic precision and the appropriate utilization of antibiotics may be one strategy to reduce the emergence of multiresistant pathogens.", [["methicillin", "CHEMICAL", 52, 63], ["Staphylococcus aureus", "DISEASE", 74, 95], ["infection", "DISEASE", 170, 179], ["Nosocomial infections", "DISEASE", 223, 244], ["methicillin", "CHEMICAL", 52, 63], ["methicillin-resistant", "ORGANISM", 52, 73], ["Staphylococcus aureus", "ORGANISM", 74, 95], ["Staphylococcus aureus", "SPECIES", 74, 95], ["Staphylococcus aureus", "SPECIES", 74, 95], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 52, 95], ["antibiotics", "TREATMENT", 154, 165], ["infection control practices", "TREATMENT", 170, 197], ["Nosocomial infections", "PROBLEM", 223, 244], ["antibiotics", "TREATMENT", 310, 321], ["multiresistant pathogens", "PROBLEM", 369, 393], ["Staphylococcus aureus", "OBSERVATION", 74, 95], ["infections", "OBSERVATION", 234, 244], ["multiresistant", "OBSERVATION_MODIFIER", 369, 383]]], ["Using VAP as a model for discussion, Heyland reviewed the 'Impact of diagnostic strategies on patient outcome'.", [["VAP", "DISEASE", 6, 9], ["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["VAP", "TREATMENT", 6, 9]]], ["VAP has an attributable mortality of 5.8% and increases the length of stay by 4.3 days [25].", [["VAP", "DISEASE", 0, 3], ["VAP", "PROBLEM", 0, 3]]], ["The importance of correct antibiotic selection from the start of treatment was stressed, since inappropriate antibiotic coverage from the outset has been shown to increase morbidity and mortality [26-28].", [["correct antibiotic selection", "TREATMENT", 18, 46], ["treatment", "TREATMENT", 65, 74], ["inappropriate antibiotic coverage", "TREATMENT", 95, 128], ["mortality", "TEST", 186, 195], ["increase", "OBSERVATION_MODIFIER", 163, 171], ["morbidity", "OBSERVATION", 172, 181]]], ["Therefore, if VAP is strongly suspected, the empiric use of broader spectrum antibiotics is probably the best approach.", [["VAP", "DISEASE", 14, 17], ["VAP", "PROBLEM", 14, 17], ["broader spectrum antibiotics", "TREATMENT", 60, 88]]], ["However, the use of broad-spectrum antibiotics can lead to increased resistance, cost and toxicity.", [["toxicity", "DISEASE", 90, 98], ["broad-spectrum antibiotics", "TREATMENT", 20, 46], ["increased resistance", "PROBLEM", 59, 79], ["cost and toxicity", "PROBLEM", 81, 98], ["increased resistance", "OBSERVATION", 59, 79]]], ["To help combat these drawbacks of broad-spectrum antibiotics, Heyland proposed a 'de-escalation' of antibiotic coverage once culture results are available.", [["Heyland", "CHEMICAL", 62, 69], ["broad-spectrum antibiotics", "TREATMENT", 34, 60], ["Heyland", "TREATMENT", 62, 69], ["a 'de-escalation", "TREATMENT", 79, 95], ["antibiotic coverage", "TREATMENT", 100, 119], ["culture results", "TEST", 125, 140]]], ["There is presently no gold standard for the diagnosis of VAP.Nosocomial infectionsThe use of bronchoscopy to help diagnose VAP has been shown to alter the amount and types of antibiotics used, but the effect on mortality is questionable [29-32].", [["VAP", "DISEASE", 57, 60], ["Nosocomial infections", "DISEASE", 61, 82], ["VAP", "DISEASE", 123, 126], ["VAP", "PROBLEM", 57, 60], ["Nosocomial infections", "PROBLEM", 61, 82], ["bronchoscopy", "TREATMENT", 93, 105], ["VAP", "PROBLEM", 123, 126], ["antibiotics", "TREATMENT", 175, 186], ["no", "UNCERTAINTY", 19, 21], ["gold standard", "OBSERVATION", 22, 35], ["VAP", "OBSERVATION", 57, 60], ["infections", "OBSERVATION", 72, 82]]], ["Heyland also eluded to the use of serum-based markers, such as procalcotonin, IL-6 and IL-8, to help diagnose VAP in the future [33].", [["serum", "ANATOMY", 34, 39], ["VAP", "DISEASE", 110, 113], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["procalcotonin", "SIMPLE_CHEMICAL", 63, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 78, 82], ["IL-8", "GENE_OR_GENE_PRODUCT", 87, 91], ["serum-based markers", "PROTEIN", 34, 53], ["procalcotonin", "PROTEIN", 63, 76], ["IL-6", "PROTEIN", 78, 82], ["IL", "PROTEIN", 87, 89], ["procalcotonin, IL", "TREATMENT", 63, 80], ["IL", "TREATMENT", 87, 89]]], ["A novel method of ruling out the diagnosis is through the interpretation of the waveform that is generated during the performance of the partial thromboplastin time assay.", [["thromboplastin", "GENE_OR_GENE_PRODUCT", 145, 159], ["the partial thromboplastin time assay", "TEST", 133, 170]]], ["The presence of an abnormal waveform is associated with increased mortality and can be a sensitive and specific indicator of disseminated intravascular coagulation.", [["intravascular", "ANATOMY", 138, 151], ["intravascular coagulation", "DISEASE", 138, 163], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 138, 151], ["an abnormal waveform", "PROBLEM", 16, 36], ["increased mortality", "PROBLEM", 56, 75], ["disseminated intravascular coagulation", "PROBLEM", 125, 163], ["abnormal", "OBSERVATION_MODIFIER", 19, 27], ["waveform", "OBSERVATION_MODIFIER", 28, 36], ["associated with", "UNCERTAINTY", 40, 55], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["mortality", "OBSERVATION", 66, 75], ["disseminated", "OBSERVATION_MODIFIER", 125, 137], ["intravascular coagulation", "OBSERVATION", 138, 163]]], ["The waveform changes may also precede the onset of clinical disease by 48 hours [34].", [["clinical disease", "PROBLEM", 51, 67], ["waveform", "OBSERVATION_MODIFIER", 4, 12], ["may also precede", "UNCERTAINTY", 21, 37]]], ["There seems to be a high negative predicative value if a specific type of waveform is absent, possibly helping to rule out infection.Nosocomial infectionsAlthough not classically felt to be a nosocomial infection, the threat of spread through donated blood makes West Nile a potential nosocomial pathogen.", [["blood", "ANATOMY", 251, 256], ["infection", "DISEASE", 123, 132], ["Nosocomial infections", "DISEASE", 133, 154], ["nosocomial infection", "DISEASE", 192, 212], ["blood", "ORGANISM_SUBSTANCE", 251, 256], ["West Nile", "ORGANISM", 263, 272], ["a high negative predicative value", "PROBLEM", 18, 51], ["infection", "PROBLEM", 123, 132], ["Nosocomial infections", "PROBLEM", 133, 154], ["a nosocomial infection", "PROBLEM", 190, 212], ["nosocomial pathogen", "PROBLEM", 285, 304], ["infection", "OBSERVATION", 123, 132], ["infections", "OBSERVATION", 144, 154], ["nosocomial", "OBSERVATION_MODIFIER", 192, 202], ["infection", "OBSERVATION", 203, 212]]], ["The potential impact on critically ill patients was highlighted in a report that reviewed the spread of West Nile to several solid organ transplant patients.", [["solid organ transplant", "ANATOMY", 125, 147], ["critically ill", "DISEASE", 24, 38], ["patients", "ORGANISM", 39, 47], ["West Nile", "ORGANISM", 104, 113], ["organ", "ORGAN", 131, 136], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 148, 156], ["West Nile", "SPECIES", 104, 113]]], ["They acquired the disease from an infected donor who initially was exposed from blood he received during his initial resuscitation for multiple trauma [35].", [["blood", "ANATOMY", 80, 85], ["trauma", "DISEASE", 144, 150], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["the disease", "PROBLEM", 14, 25], ["an infected donor", "TREATMENT", 31, 48], ["his initial resuscitation", "TREATMENT", 105, 130], ["multiple trauma", "PROBLEM", 135, 150], ["infected", "OBSERVATION", 34, 42]]], ["In his presentation, James Brunton (University of Toronto) reviewed the epidemiology and effects of the West Nile virus.", [["West Nile virus", "ORGANISM", 104, 119], ["West Nile virus", "SPECIES", 104, 119], ["the West Nile virus", "PROBLEM", 100, 119]]], ["The cases of West Nile are both geographically and temporally localized.", [["West Nile", "ORGANISM", 13, 22], ["West Nile", "SPECIES", 13, 22]]], ["The disease is most prevalent in the northeastern United States and the highest incidence occurs in August and September.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["most prevalent", "OBSERVATION_MODIFIER", 15, 29]]], ["However, there has been a gradual westward progression of the disease in the past few years.Nosocomial infectionsThe clinical course of West Nile follows a very generalized pattern, which unfortunately can make it hard to diagnose.", [["Nosocomial infections", "DISEASE", 92, 113], ["the disease", "PROBLEM", 58, 69], ["Nosocomial infections", "PROBLEM", 92, 113], ["gradual", "OBSERVATION_MODIFIER", 26, 33], ["westward", "OBSERVATION_MODIFIER", 34, 42], ["progression", "OBSERVATION_MODIFIER", 43, 54], ["disease", "OBSERVATION", 62, 69], ["infections", "OBSERVATION", 103, 113]]], ["The prodrome is generally 2\u20137 days followed by delirium, which is often attributed to another etiology.", [["delirium", "DISEASE", 47, 55], ["The prodrome", "PROBLEM", 0, 12], ["delirium", "PROBLEM", 47, 55], ["delirium", "OBSERVATION", 47, 55]]], ["The patient may then deteriorate and have a decreased level of consciousness, a lower motor neuron pattern of weakness and respiratory failure.", [["lower motor neuron", "ANATOMY", 80, 98], ["respiratory", "ANATOMY", 123, 134], ["decreased level of consciousness", "DISEASE", 44, 76], ["weakness", "DISEASE", 110, 118], ["respiratory failure", "DISEASE", 123, 142], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a decreased level of consciousness", "PROBLEM", 42, 76], ["a lower motor neuron pattern", "PROBLEM", 78, 106], ["weakness", "PROBLEM", 110, 118], ["respiratory failure", "PROBLEM", 123, 142], ["weakness", "OBSERVATION", 110, 118], ["respiratory failure", "OBSERVATION", 123, 142]]], ["The recovery phase can be varied in duration and at times protracted.", [["varied", "OBSERVATION_MODIFIER", 26, 32]]], ["Diagnosis can be aided by West Nile viral cultures and serology.", [["West Nile viral cultures", "TEST", 26, 50], ["serology", "TEST", 55, 63]]], ["In fact, blood is now tested prior to donation, which should hopefully reduce the risk of transmission.", [["blood", "ANATOMY", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 9, 14]]], ["The treatment of West Nile is really just in its infancy.", [["West Nile", "ORGANISM", 17, 26]]], ["Intravenous immune globulin has experienced conflicting results in case reports.", [["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["immune globulin", "GENE_OR_GENE_PRODUCT", 12, 27], ["Intravenous immune globulin", "TREATMENT", 0, 27]]], ["Interferon alpha 2b is an investigational treatment that may offer hope.", [["Interferon alpha 2b", "CHEMICAL", 0, 19], ["Interferon alpha 2b", "GENE_OR_GENE_PRODUCT", 0, 19], ["Interferon alpha 2b", "PROTEIN", 0, 19], ["Interferon alpha 2b", "TREATMENT", 0, 19], ["an investigational treatment", "TREATMENT", 23, 51]]], ["Finally, human trials may be on the horizon for the development of a vaccine.Novel strategies for the treatment of sepsisSeveral targets for modulation of the inflammatory response have been identified and are a source of ongoing investigations.", [["human", "ORGANISM", 9, 14], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["human trials", "TREATMENT", 9, 21], ["a vaccine", "TREATMENT", 67, 76], ["Novel strategies", "TREATMENT", 77, 93], ["the treatment", "TREATMENT", 98, 111], ["sepsisSeveral targets", "TREATMENT", 115, 136], ["the inflammatory response", "PROBLEM", 155, 180], ["ongoing investigations", "TEST", 222, 244], ["inflammatory", "OBSERVATION", 159, 171]]], ["One such treatment target is the high mobility group B1 (HGMB1), a nonhistone chromosomal protein.", [["chromosomal", "ANATOMY", 78, 89], ["high mobility group B1", "GENE_OR_GENE_PRODUCT", 33, 55], ["HGMB1", "GENE_OR_GENE_PRODUCT", 57, 62], ["chromosomal", "CELLULAR_COMPONENT", 78, 89], ["high mobility group B1", "PROTEIN", 33, 55], ["HGMB1", "PROTEIN", 57, 62], ["nonhistone chromosomal protein", "PROTEIN", 67, 97], ["a nonhistone chromosomal protein", "PROBLEM", 65, 97]]], ["There is evidence that HGMB1 may be involved as a late mediator of inflammation with cytokine-like activities [36].", [["inflammation", "DISEASE", 67, 79], ["HGMB1", "GENE_OR_GENE_PRODUCT", 23, 28], ["HGMB1", "PROTEIN", 23, 28], ["cytokine", "PROTEIN", 85, 93], ["inflammation", "PROBLEM", 67, 79], ["inflammation", "OBSERVATION", 67, 79]]], ["It is capable of inducing lung injury, liver injury and gut injury in mice [37,38].", [["lung", "ANATOMY", 26, 30], ["liver", "ANATOMY", 39, 44], ["gut", "ANATOMY", 56, 59], ["lung injury", "DISEASE", 26, 37], ["liver injury", "DISEASE", 39, 51], ["gut injury", "DISEASE", 56, 66], ["lung", "ORGAN", 26, 30], ["liver", "ORGAN", 39, 44], ["gut", "ORGANISM_SUBDIVISION", 56, 59], ["mice", "ORGANISM", 70, 74], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["inducing lung injury", "PROBLEM", 17, 37], ["liver injury", "PROBLEM", 39, 51], ["gut injury", "PROBLEM", 56, 66], ["lung", "ANATOMY", 26, 30], ["injury", "OBSERVATION", 31, 37], ["liver", "ANATOMY", 39, 44], ["injury", "OBSERVATION", 45, 51], ["gut", "ANATOMY", 56, 59], ["injury", "OBSERVATION", 60, 66]]], ["Mitchell Fink (University of Pittsburgh) presented his research on novel strategies for inhibiting the effects of HGMB1.", [["HGMB1", "CHEMICAL", 114, 119], ["HGMB1", "GENE_OR_GENE_PRODUCT", 114, 119], ["HGMB1", "PROTEIN", 114, 119], ["novel strategies", "TREATMENT", 67, 83]]], ["The administration of ethyl pyruvate has been shown to successfully modulate the inflammatory response in animal models of sepsis.", [["ethyl pyruvate", "CHEMICAL", 22, 36], ["sepsis", "DISEASE", 123, 129], ["ethyl pyruvate", "CHEMICAL", 22, 36], ["ethyl pyruvate", "SIMPLE_CHEMICAL", 22, 36], ["The administration of ethyl pyruvate", "TREATMENT", 0, 36], ["the inflammatory response", "PROBLEM", 77, 102], ["sepsis", "PROBLEM", 123, 129], ["inflammatory", "OBSERVATION_MODIFIER", 81, 93], ["sepsis", "OBSERVATION", 123, 129]]], ["Work is underway to evaluate its effects in humans.", [["humans", "ORGANISM", 44, 50], ["humans", "SPECIES", 44, 50], ["humans", "SPECIES", 44, 50]]], ["Other potential modulators of HGMB1 include an anti-HGMB1 monoclonal antibody and a recombinant segment (box A) of HGMB1 [39].", [["HGMB1", "GENE_OR_GENE_PRODUCT", 30, 35], ["HGMB1", "PROTEIN", 30, 35], ["anti-HGMB1 monoclonal antibody", "PROTEIN", 47, 77], ["recombinant segment", "PROTEIN", 84, 103], ["box A", "PROTEIN", 105, 110], ["HGMB1", "TEST", 30, 35], ["an anti-HGMB1 monoclonal antibody", "TEST", 44, 77], ["HGMB1", "TEST", 115, 120]]], ["Interestingly, it seems that strategies targeting HGMB1 may potentially offer benefit even in late sepsis.Novel strategies for the treatment of sepsisGregory Downey (University of Toronto) succinctly reviewed the importance of the modulation of signaling pathways in sepsis and in lung injury.", [["lung", "ANATOMY", 281, 285], ["HGMB1", "CHEMICAL", 50, 55], ["sepsis", "DISEASE", 99, 105], ["sepsis", "DISEASE", 144, 150], ["sepsis", "DISEASE", 267, 273], ["lung injury", "DISEASE", 281, 292], ["HGMB1", "GENE_OR_GENE_PRODUCT", 50, 55], ["lung", "ORGAN", 281, 285], ["HGMB1", "PROTEIN", 50, 55], ["late sepsis", "PROBLEM", 94, 105], ["Novel strategies", "TREATMENT", 106, 122], ["sepsis", "PROBLEM", 144, 150], ["signaling pathways", "PROBLEM", 245, 263], ["sepsis", "PROBLEM", 267, 273], ["lung injury", "PROBLEM", 281, 292], ["late", "OBSERVATION_MODIFIER", 94, 98], ["sepsis", "OBSERVATION", 99, 105], ["sepsis", "OBSERVATION", 144, 150], ["sepsis", "OBSERVATION", 267, 273], ["lung", "ANATOMY", 281, 285], ["injury", "OBSERVATION", 286, 292]]], ["The mechanisms of lung injury are complex and can be divided into early (proximal) and late events.", [["lung", "ANATOMY", 18, 22], ["lung injury", "DISEASE", 18, 29], ["lung", "ORGAN", 18, 22], ["lung injury", "PROBLEM", 18, 29], ["lung", "ANATOMY", 18, 22], ["injury", "OBSERVATION", 23, 29]]], ["One of the first events is bacterial endotoxin lipopolysaccharide binding to toll-like receptors.", [["lipopolysaccharide", "CHEMICAL", 47, 65], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 47, 65], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 77, 96], ["toll-like receptors", "PROTEIN", 77, 96], ["bacterial endotoxin lipopolysaccharide binding", "PROBLEM", 27, 73], ["bacterial", "OBSERVATION_MODIFIER", 27, 36], ["endotoxin lipopolysaccharide binding", "OBSERVATION", 37, 73]]], ["One possible way to achieve this is by the use of agents that bind lipopolysaccharide, such as antibodies.", [["lipopolysaccharide", "CHEMICAL", 67, 85], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 67, 85], ["antibodies", "PROTEIN", 95, 105], ["agents", "TREATMENT", 50, 56], ["lipopolysaccharide", "TREATMENT", 67, 85]]], ["Techniques to interrupt in the later stages of the sepsis cascade include antioxidants, such as alpha-tocopherol (vitamin E).", [["sepsis", "DISEASE", 51, 57], ["alpha-tocopherol", "CHEMICAL", 96, 112], ["vitamin E", "CHEMICAL", 114, 123], ["alpha-tocopherol", "CHEMICAL", 96, 112], ["vitamin E", "CHEMICAL", 114, 123], ["alpha-tocopherol", "SIMPLE_CHEMICAL", 96, 112], ["vitamin E", "SIMPLE_CHEMICAL", 114, 123], ["the sepsis cascade", "TREATMENT", 47, 65], ["antioxidants", "TREATMENT", 74, 86], ["alpha-tocopherol (vitamin E)", "TREATMENT", 96, 124], ["sepsis", "OBSERVATION", 51, 57]]], ["Interruption of these late stages has been shown in murine models to confer protection even if given 1 hour after the initiating stimulus.Novel strategies for the treatment of sepsisSinger concluded this section by providing an interesting teleological perspective on multi-organ failure (MOF).", [["multi-organ", "ANATOMY", 268, 279], ["sepsisSinger", "DISEASE", 176, 188], ["multi-organ failure", "DISEASE", 268, 287], ["MOF", "DISEASE", 289, 292], ["murine", "ORGANISM", 52, 58], ["multi-organ", "ORGAN", 268, 279], ["murine", "SPECIES", 52, 58], ["Novel strategies", "TREATMENT", 138, 154], ["the treatment of sepsisSinger", "TREATMENT", 159, 188], ["this section", "TREATMENT", 199, 211], ["multi-organ failure", "PROBLEM", 268, 287], ["late stages", "OBSERVATION_MODIFIER", 22, 33], ["multi-organ", "ANATOMY", 268, 279], ["failure", "OBSERVATION", 280, 287]]], ["He proposed that MOF represents cellular shutdown and is a late-stage adaptive response to a prolonged insult.", [["cellular", "ANATOMY", 32, 40], ["MOF", "DISEASE", 17, 20], ["cellular", "CELL", 32, 40], ["MOF", "PROBLEM", 17, 20], ["cellular shutdown", "PROBLEM", 32, 49], ["a late-stage adaptive response", "PROBLEM", 57, 87], ["a prolonged insult", "PROBLEM", 91, 109], ["MOF", "OBSERVATION_MODIFIER", 17, 20], ["cellular shutdown", "OBSERVATION", 32, 49]]], ["He challenged the audience that meddling with the immune response to prevent MOF may be counter-productive.", [["MOF", "DISEASE", 77, 80], ["MOF", "PROBLEM", 77, 80]]], ["In defense of this proposal, Singer argued that tissue oxygen levels increase and oxygen consumption decreases during sepsis [40-42].", [["tissue", "ANATOMY", 48, 54], ["oxygen", "CHEMICAL", 55, 61], ["oxygen", "CHEMICAL", 82, 88], ["sepsis", "DISEASE", 118, 124], ["oxygen", "CHEMICAL", 55, 61], ["oxygen", "CHEMICAL", 82, 88], ["tissue", "TISSUE", 48, 54], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["tissue oxygen levels", "TEST", 48, 68], ["oxygen consumption", "PROBLEM", 82, 100], ["sepsis", "PROBLEM", 118, 124], ["tissue", "OBSERVATION_MODIFIER", 48, 54], ["oxygen", "OBSERVATION_MODIFIER", 55, 61], ["levels", "OBSERVATION_MODIFIER", 62, 68], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["oxygen", "OBSERVATION_MODIFIER", 82, 88], ["consumption", "OBSERVATION_MODIFIER", 89, 100], ["decreases", "OBSERVATION_MODIFIER", 101, 110]]], ["This is associated with mitochondrial inhibition, yet ATP levels are often preserved [43].", [["mitochondrial", "ANATOMY", 24, 37], ["ATP", "CHEMICAL", 54, 57], ["ATP", "CHEMICAL", 54, 57], ["mitochondrial", "CELLULAR_COMPONENT", 24, 37], ["ATP", "SIMPLE_CHEMICAL", 54, 57], ["mitochondrial inhibition", "PROBLEM", 24, 48], ["ATP levels", "TEST", 54, 64], ["associated with", "UNCERTAINTY", 8, 23], ["mitochondrial inhibition", "OBSERVATION", 24, 48]]], ["Indeed, during MOF there is little histological evidence of cell death, and if the patient survives so do the organs [44,45].", [["cell", "ANATOMY", 60, 64], ["organs", "ANATOMY", 110, 116], ["MOF", "DISEASE", 15, 18], ["death", "DISEASE", 65, 70], ["cell", "CELL", 60, 64], ["patient", "ORGANISM", 83, 90], ["organs", "ORGAN", 110, 116], ["patient", "SPECIES", 83, 90], ["cell death", "PROBLEM", 60, 70], ["evidence of", "UNCERTAINTY", 48, 59], ["cell death", "OBSERVATION", 60, 70]]], ["In a sense, the cells of major organ systems go into a state of hibernation and re-emerge when the illness is resolving.", [["cells", "ANATOMY", 16, 21], ["organ systems", "ANATOMY", 31, 44], ["illness", "DISEASE", 99, 106], ["cells", "CELL", 16, 21], ["organ", "ORGAN", 31, 36], ["the illness", "PROBLEM", 95, 106], ["resolving", "OBSERVATION_MODIFIER", 110, 119]]], ["The analogy of hibernation not only applies to the animal kingdom, but can also be appreciated in the phenomenon of 'hibernating' myocardium.", [["myocardium", "ANATOMY", 130, 140], ["hibernating' myocardium", "TISSUE", 117, 140], ["hibernation", "OBSERVATION", 15, 26], ["myocardium", "ANATOMY", 130, 140]]], ["Cellular shutdown leading to organ failure may thus just be an adaptive response or a 'last-ditch' effort at organ preservation.Mechanical ventilationThe session surrounding mechanical ventilation began with Tom Stewart's (University of Toronto) discussion of lung recruitment.", [["Cellular", "ANATOMY", 0, 8], ["organ", "ANATOMY", 29, 34], ["organ", "ANATOMY", 109, 114], ["lung", "ANATOMY", 260, 264], ["organ failure", "DISEASE", 29, 42], ["organ", "ORGAN", 29, 34], ["organ", "ORGAN", 109, 114], ["lung", "ORGAN", 260, 264], ["Cellular shutdown", "PROBLEM", 0, 17], ["organ failure", "PROBLEM", 29, 42], ["organ preservation", "TREATMENT", 109, 127], ["Mechanical ventilation", "TREATMENT", 128, 150], ["mechanical ventilation", "TREATMENT", 174, 196], ["lung recruitment", "TREATMENT", 260, 276], ["shutdown", "OBSERVATION", 9, 17], ["organ", "ANATOMY", 29, 34], ["failure", "OBSERVATION", 35, 42], ["ventilation", "OBSERVATION", 139, 150], ["mechanical ventilation", "OBSERVATION", 174, 196], ["lung", "ANATOMY", 260, 264], ["recruitment", "OBSERVATION", 265, 276]]], ["Lung recruitment may have a role in cases of difficult oxygenation or ventilation and as an early protective strategy in patients with acute lung injury.", [["Lung", "ANATOMY", 0, 4], ["lung", "ANATOMY", 141, 145], ["acute lung injury", "DISEASE", 135, 152], ["Lung", "ORGAN", 0, 4], ["patients", "ORGANISM", 121, 129], ["lung", "ORGAN", 141, 145], ["patients", "SPECIES", 121, 129], ["difficult oxygenation", "PROBLEM", 45, 66], ["ventilation", "TREATMENT", 70, 81], ["an early protective strategy", "TREATMENT", 89, 117], ["acute lung injury", "PROBLEM", 135, 152], ["recruitment", "OBSERVATION", 5, 16], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["lung", "ANATOMY", 141, 145], ["injury", "OBSERVATION", 146, 152]]], ["Evidence does suggest that recruitment maneuvers lead to increased oxygenation, at least in the short term [46].", [["recruitment maneuvers", "TREATMENT", 27, 48], ["increased oxygenation", "PROBLEM", 57, 78], ["recruitment", "OBSERVATION", 27, 38], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["oxygenation", "OBSERVATION_MODIFIER", 67, 78]]], ["The success of lung recruitment maneuvers to increase the PaO2/FiO2 ratio depends on the stage of acute respiratory distress syndrome (ARDS), with increased success early in the course.", [["lung", "ANATOMY", 15, 19], ["respiratory", "ANATOMY", 104, 115], ["acute respiratory distress syndrome", "DISEASE", 98, 133], ["ARDS", "DISEASE", 135, 139], ["FiO2", "CHEMICAL", 63, 67], ["lung", "ORGAN", 15, 19], ["lung recruitment maneuvers", "TREATMENT", 15, 41], ["the PaO2", "TEST", 54, 62], ["FiO2 ratio", "TEST", 63, 73], ["acute respiratory distress syndrome", "PROBLEM", 98, 133], ["ARDS", "PROBLEM", 135, 139], ["lung", "ANATOMY", 15, 19], ["recruitment maneuvers", "OBSERVATION", 20, 41], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["respiratory distress", "OBSERVATION", 104, 124], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["success", "OBSERVATION_MODIFIER", 157, 164]]], ["Other factors include the severity of illness, the type of ARDS, patient positioning and positive end-expiratory pressure settings postmaneuver [47-50].", [["illness", "DISEASE", 38, 45], ["ARDS", "DISEASE", 59, 63], ["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["illness", "PROBLEM", 38, 45], ["ARDS", "PROBLEM", 59, 63], ["patient positioning", "TEST", 65, 84], ["positive end-expiratory pressure settings", "TREATMENT", 89, 130], ["ARDS", "OBSERVATION", 59, 63]]], ["Recruitment maneuvers have been shown to have low complication rates, with hemodynamic consequences being the most frequent [48].", [["Recruitment maneuvers", "TREATMENT", 0, 21], ["low complication rates", "PROBLEM", 46, 68], ["hemodynamic consequences", "PROBLEM", 75, 99]]], ["There are a variety of ways to perform recruitment maneuvers, but most of the maneuvers require the patient to be heavily sedated.", [["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["recruitment maneuvers", "TREATMENT", 39, 60], ["heavily sedated", "TREATMENT", 114, 129]]], ["Stewart also presented some promising interim analysis of the Lung Open Ventilation Study demonstrating the safety of recruitment maneuvers.Mechanical ventilationOn the flip side of the previous topic, Brian Kavanagh (University of Toronto) presented the implications of lung derecruitment.", [["Lung", "ANATOMY", 62, 66], ["lung", "ANATOMY", 271, 275], ["lung derecruitment", "DISEASE", 271, 289], ["Lung", "ORGAN", 62, 66], ["lung", "ORGAN", 271, 275], ["Open Ventilation Study", "TEST", 67, 89], ["recruitment maneuvers", "TREATMENT", 118, 139], ["Mechanical ventilationOn", "TREATMENT", 140, 164], ["lung derecruitment", "TREATMENT", 271, 289], ["Lung", "ANATOMY", 62, 66], ["Open Ventilation", "OBSERVATION", 67, 83], ["recruitment maneuvers", "OBSERVATION", 118, 139], ["lung", "ANATOMY", 271, 275], ["derecruitment", "OBSERVATION", 276, 289]]], ["He stressed that there are a variety of etiologies of lung derecruitment and that atelectasis is not straightforward [51].", [["lung", "ANATOMY", 54, 58], ["lung derecruitment", "DISEASE", 54, 72], ["atelectasis", "DISEASE", 82, 93], ["lung", "ORGAN", 54, 58], ["lung derecruitment", "PROBLEM", 54, 72], ["atelectasis", "PROBLEM", 82, 93], ["lung", "ANATOMY", 54, 58], ["derecruitment", "OBSERVATION", 59, 72], ["atelectasis", "OBSERVATION", 82, 93]]], ["The impact of atelectasis on the pulmonary vasculature may be greater than appreciated.", [["pulmonary vasculature", "ANATOMY", 33, 54], ["atelectasis", "DISEASE", 14, 25], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 33, 54], ["atelectasis on the pulmonary vasculature", "PROBLEM", 14, 54], ["atelectasis", "OBSERVATION", 14, 25], ["pulmonary vasculature", "ANATOMY", 33, 54], ["may be", "UNCERTAINTY", 55, 61], ["greater", "OBSERVATION_MODIFIER", 62, 69]]], ["In addition, atelectasis may lead to lung injury directly, through changes in microvascular permeability [52].", [["lung", "ANATOMY", 37, 41], ["microvascular", "ANATOMY", 78, 91], ["atelectasis", "DISEASE", 13, 24], ["lung injury", "DISEASE", 37, 48], ["lung", "ORGAN", 37, 41], ["microvascular", "TISSUE", 78, 91], ["atelectasis", "PROBLEM", 13, 24], ["lung injury", "PROBLEM", 37, 48], ["microvascular permeability", "TEST", 78, 104], ["atelectasis", "OBSERVATION", 13, 24], ["may lead to", "UNCERTAINTY", 25, 36], ["lung", "ANATOMY", 37, 41], ["injury", "OBSERVATION", 42, 48], ["microvascular", "OBSERVATION_MODIFIER", 78, 91], ["permeability", "OBSERVATION_MODIFIER", 92, 104]]], ["The effectiveness of modalities to reverse this injury depends on timing, the nature of the lung injury and the approach used.", [["lung", "ANATOMY", 92, 96], ["lung injury", "DISEASE", 92, 103], ["lung", "ORGAN", 92, 96], ["modalities", "TREATMENT", 21, 31], ["this injury", "PROBLEM", 43, 54], ["the lung injury", "PROBLEM", 88, 103], ["the approach", "TREATMENT", 108, 120], ["lung", "ANATOMY", 92, 96], ["injury", "OBSERVATION", 97, 103]]], ["The utility of early prevention of derecruitment requires further study.Mechanical ventilation'The chest wall vs. the abdomen' was the subject presented by Antonio Pesenti (Ospedale S. Gerardo, Monza, Italy).", [["chest wall", "ANATOMY", 99, 109], ["abdomen", "ANATOMY", 118, 125], ["chest wall", "MULTI-TISSUE_STRUCTURE", 99, 109], ["abdomen", "ORGAN", 118, 125], ["further study", "TEST", 58, 71], ["Mechanical ventilation'", "TREATMENT", 72, 95], ["The chest wall vs. the abdomen'", "PROBLEM", 95, 126], ["ventilation", "OBSERVATION", 83, 94], ["chest", "ANATOMY", 99, 104], ["wall", "ANATOMY_MODIFIER", 105, 109], ["abdomen", "ANATOMY", 118, 125]]], ["He eloquently described the physiological interaction between the abdomen and the chest wall during the respiratory cycle.", [["abdomen", "ANATOMY", 66, 73], ["chest wall", "ANATOMY", 82, 92], ["respiratory", "ANATOMY", 104, 115], ["abdomen", "ORGAN", 66, 73], ["chest wall", "MULTI-TISSUE_STRUCTURE", 82, 92], ["the physiological interaction between the abdomen and the chest wall", "PROBLEM", 24, 92], ["interaction", "OBSERVATION", 42, 53], ["abdomen", "ANATOMY", 66, 73], ["chest", "ANATOMY", 82, 87], ["wall", "ANATOMY_MODIFIER", 88, 92], ["respiratory cycle", "OBSERVATION", 104, 121]]], ["In the supine patient the pressure of the abdominal contents is directed on the diaphragm in a cephelad direction.", [["abdominal", "ANATOMY", 42, 51], ["diaphragm", "ANATOMY", 80, 89], ["patient", "ORGANISM", 14, 21], ["abdominal", "ORGANISM_SUBDIVISION", 42, 51], ["diaphragm", "ORGAN", 80, 89], ["patient", "SPECIES", 14, 21], ["pressure", "OBSERVATION_MODIFIER", 26, 34], ["abdominal", "ANATOMY", 42, 51], ["contents", "OBSERVATION", 52, 60], ["diaphragm", "ANATOMY", 80, 89]]], ["This subsequently causes atelectasis in the dependent lung zones near the diaphragm.", [["lung zones", "ANATOMY", 54, 64], ["diaphragm", "ANATOMY", 74, 83], ["atelectasis", "DISEASE", 25, 36], ["lung zones", "MULTI-TISSUE_STRUCTURE", 54, 64], ["diaphragm", "ORGAN", 74, 83], ["atelectasis in the dependent lung zones", "PROBLEM", 25, 64], ["atelectasis", "OBSERVATION", 25, 36], ["dependent", "ANATOMY_MODIFIER", 44, 53], ["lung", "ANATOMY", 54, 58], ["zones", "ANATOMY_MODIFIER", 59, 64], ["diaphragm", "ANATOMY", 74, 83]]], ["Increases in both chest wall compliance and abdominal pressure will exaggerate this effect.", [["chest wall", "ANATOMY", 18, 28], ["abdominal", "ANATOMY", 44, 53], ["chest wall", "MULTI-TISSUE_STRUCTURE", 18, 28], ["abdominal", "ORGANISM_SUBDIVISION", 44, 53], ["both chest wall compliance", "TREATMENT", 13, 39], ["abdominal pressure", "TREATMENT", 44, 62], ["both", "ANATOMY_MODIFIER", 13, 17], ["chest", "ANATOMY", 18, 23], ["wall", "ANATOMY_MODIFIER", 24, 28], ["compliance", "OBSERVATION", 29, 39], ["abdominal", "ANATOMY", 44, 53], ["pressure", "OBSERVATION", 54, 62]]], ["In fact, by decreasing chest wall compliance through the experimental use of weights directly applied to the chest wall, one can demonstrate a reduction in V/Q mismatch and an improvement in oxygenation.", [["chest wall", "ANATOMY", 23, 33], ["chest wall", "ANATOMY", 109, 119], ["chest wall", "MULTI-TISSUE_STRUCTURE", 23, 33], ["chest wall", "MULTI-TISSUE_STRUCTURE", 109, 119], ["decreasing chest wall compliance", "TREATMENT", 12, 44], ["weights", "TREATMENT", 77, 84], ["a reduction in V/Q mismatch", "PROBLEM", 141, 168], ["decreasing", "OBSERVATION_MODIFIER", 12, 22], ["chest wall", "ANATOMY", 23, 33], ["compliance", "OBSERVATION", 34, 44], ["chest", "ANATOMY", 109, 114], ["wall", "ANATOMY_MODIFIER", 115, 119], ["reduction", "OBSERVATION_MODIFIER", 143, 152], ["Q mismatch", "OBSERVATION", 158, 168], ["improvement", "OBSERVATION_MODIFIER", 176, 187], ["oxygenation", "OBSERVATION_MODIFIER", 191, 202]]], ["Pesenti left the audience with four simple words to remind us of the importance of the abdomen in respiratory mechanics: 'breathe with your belly'.Mechanical ventilationArthur Slutsky (University of Toronto) followed with the topic 'Mechanical ventilation and multiple organ dysfunction'.", [["abdomen", "ANATOMY", 87, 94], ["respiratory", "ANATOMY", 98, 109], ["organ", "ANATOMY", 269, 274], ["organ dysfunction", "DISEASE", 269, 286], ["abdomen", "ORGANISM_SUBDIVISION", 87, 94], ["belly", "ORGANISM_SUBDIVISION", 140, 145], ["organ", "ORGAN", 269, 274], ["Mechanical ventilation", "TREATMENT", 233, 255], ["multiple organ dysfunction'", "PROBLEM", 260, 287], ["abdomen", "ANATOMY", 87, 94], ["respiratory mechanics", "ANATOMY", 98, 119], ["belly", "ANATOMY", 140, 145], ["Mechanical ventilation", "OBSERVATION", 233, 255], ["organ", "ANATOMY", 269, 274], ["dysfunction", "OBSERVATION", 275, 286]]], ["The lung seems to be in a unique situation to contribute to multiple organ dysfunction.", [["lung", "ANATOMY", 4, 8], ["organ", "ANATOMY", 69, 74], ["organ dysfunction", "DISEASE", 69, 86], ["lung", "ORGAN", 4, 8], ["organ", "ORGAN", 69, 74], ["multiple organ dysfunction", "PROBLEM", 60, 86], ["lung", "ANATOMY", 4, 8], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["organ", "ANATOMY", 69, 74], ["dysfunction", "OBSERVATION", 75, 86]]], ["It receives all of the systemic circulation and contains 25\u201350% of the marginated neutrophil pool.", [["neutrophil", "ANATOMY", 82, 92], ["neutrophil", "CELL", 82, 92], ["the marginated neutrophil pool", "TREATMENT", 67, 97], ["systemic circulation", "ANATOMY", 23, 43], ["marginated", "OBSERVATION_MODIFIER", 71, 81], ["neutrophil pool", "OBSERVATION", 82, 97]]], ["A variety of studies have suggested the connection between lung injury and multiple organ dysfunction.", [["lung", "ANATOMY", 59, 63], ["organ", "ANATOMY", 84, 89], ["lung injury", "DISEASE", 59, 70], ["organ dysfunction", "DISEASE", 84, 101], ["lung", "ORGAN", 59, 63], ["organ", "ORGAN", 84, 89], ["A variety of studies", "TEST", 0, 20], ["lung injury", "PROBLEM", 59, 70], ["multiple organ dysfunction", "PROBLEM", 75, 101], ["lung", "ANATOMY", 59, 63], ["injury", "OBSERVATION", 64, 70], ["multiple", "OBSERVATION_MODIFIER", 75, 83], ["organ", "ANATOMY", 84, 89], ["dysfunction", "OBSERVATION", 90, 101]]], ["In particular, lung overinflation without positive end-expiratory pressure has been demonstrated to promote bacteremia, and there is pulmonary to systemic translocation of endotoxin [53,54].", [["lung", "ANATOMY", 15, 19], ["pulmonary", "ANATOMY", 133, 142], ["bacteremia", "DISEASE", 108, 118], ["endotoxin", "CHEMICAL", 172, 181], ["lung", "ORGAN", 15, 19], ["pulmonary", "ORGAN", 133, 142], ["endotoxin", "SIMPLE_CHEMICAL", 172, 181], ["lung overinflation", "PROBLEM", 15, 33], ["positive end-expiratory pressure", "PROBLEM", 42, 74], ["bacteremia", "PROBLEM", 108, 118], ["endotoxin", "TEST", 172, 181], ["lung", "ANATOMY", 15, 19], ["overinflation", "OBSERVATION", 20, 33], ["without", "UNCERTAINTY", 34, 41], ["positive", "OBSERVATION_MODIFIER", 42, 50], ["end", "OBSERVATION_MODIFIER", 51, 54], ["expiratory pressure", "OBSERVATION", 55, 74], ["bacteremia", "OBSERVATION", 108, 118], ["pulmonary", "ANATOMY", 133, 142], ["systemic", "OBSERVATION_MODIFIER", 146, 154]]], ["In addition, Slutsky discussed ongoing animal research that is looking into the relationship of injurious ventilatory strategies and apoptosis of organs distal to the lung (e.g. kidney, gut).", [["organs", "ANATOMY", 146, 152], ["lung", "ANATOMY", 167, 171], ["kidney", "ANATOMY", 178, 184], ["gut", "ANATOMY", 186, 189], ["organs", "ORGAN", 146, 152], ["lung", "ORGAN", 167, 171], ["kidney", "ORGAN", 178, 184], ["gut", "ORGANISM_SUBDIVISION", 186, 189], ["injurious ventilatory strategies", "TREATMENT", 96, 128], ["apoptosis of organs distal to the lung", "PROBLEM", 133, 171], ["injurious", "OBSERVATION", 96, 105], ["ventilatory strategies", "OBSERVATION", 106, 128], ["lung", "ANATOMY", 167, 171], ["kidney", "ANATOMY", 178, 184], ["gut", "ANATOMY", 186, 189]]], ["A reduction in cell death was noted in the lung protective strategies in this animal model.", [["cell", "ANATOMY", 15, 19], ["lung", "ANATOMY", 43, 47], ["death", "DISEASE", 20, 25], ["cell", "CELL", 15, 19], ["lung", "ORGAN", 43, 47], ["A reduction in cell death", "PROBLEM", 0, 25], ["the lung protective strategies", "TREATMENT", 39, 69], ["reduction", "OBSERVATION_MODIFIER", 2, 11], ["cell death", "OBSERVATION", 15, 25], ["lung", "ANATOMY", 43, 47], ["protective strategies", "OBSERVATION", 48, 69]]], ["Overall, both biochemical and biomechanical injury to the lungs causes the release of a variety of inflammatory mediators, such as cytokines, complement and neutrophils [55].", [["lungs", "ANATOMY", 58, 63], ["neutrophils", "ANATOMY", 157, 168], ["lungs", "ORGAN", 58, 63], ["complement", "GENE_OR_GENE_PRODUCT", 142, 152], ["neutrophils", "CELL", 157, 168], ["inflammatory mediators", "PROTEIN", 99, 121], ["cytokines", "PROTEIN", 131, 140], ["neutrophils", "CELL_TYPE", 157, 168], ["biomechanical injury to the lungs", "PROBLEM", 30, 63], ["inflammatory mediators", "PROBLEM", 99, 121], ["neutrophils", "TEST", 157, 168], ["biomechanical", "OBSERVATION_MODIFIER", 30, 43], ["injury", "OBSERVATION", 44, 50], ["lungs", "ANATOMY", 58, 63], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111]]], ["These mediators in turn may lead to MOF and contribute to the morbidity and mortality beyond the initial lung injury.Mechanical ventilationAs many of the aforementioned studies have noted, mechanical ventilation can lead to injury to both the lung and to other organs.", [["lung", "ANATOMY", 105, 109], ["lung", "ANATOMY", 243, 247], ["organs", "ANATOMY", 261, 267], ["MOF", "DISEASE", 36, 39], ["lung injury", "DISEASE", 105, 116], ["injury to both the lung", "DISEASE", 224, 247], ["lung", "ORGAN", 105, 109], ["lung", "ORGAN", 243, 247], ["organs", "ORGAN", 261, 267], ["MOF", "PROBLEM", 36, 39], ["the morbidity", "PROBLEM", 58, 71], ["the initial lung injury", "PROBLEM", 93, 116], ["Mechanical ventilationAs", "TREATMENT", 117, 141], ["the aforementioned studies", "TEST", 150, 176], ["mechanical ventilation", "TREATMENT", 189, 211], ["injury to both the lung", "PROBLEM", 224, 247], ["morbidity", "OBSERVATION", 62, 71], ["lung", "ANATOMY", 105, 109], ["injury", "OBSERVATION", 110, 116], ["mechanical ventilation", "OBSERVATION", 189, 211], ["lung", "ANATOMY", 243, 247], ["organs", "ANATOMY", 261, 267]]], ["Evidence is mounting that lung protective strategies may reduce the harm to patients secondary to injurious methods of ventilation.", [["lung", "ANATOMY", 26, 30], ["lung", "ORGAN", 26, 30], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["lung protective strategies", "TREATMENT", 26, 52], ["injurious methods of ventilation", "TREATMENT", 98, 130], ["lung", "ANATOMY", 26, 30]]], ["However, the knowledge of lung protective strategies has not translated into their widespread use in practice.", [["lung", "ANATOMY", 26, 30], ["lung", "ORGAN", 26, 30], ["lung protective strategies", "TREATMENT", 26, 52], ["lung", "ANATOMY", 26, 30], ["protective", "OBSERVATION", 31, 41]]], ["Gordon Rubenfeld (Washington University) cited many reasons for this discord.", [["this discord", "PROBLEM", 64, 76]]], ["Failure to recognize mild forms of acute lung injury/ARDS and lack of knowledge surrounding lung protection are continuing problems.", [["lung", "ANATOMY", 41, 45], ["lung", "ANATOMY", 92, 96], ["lung injury", "DISEASE", 41, 52], ["ARDS", "DISEASE", 53, 57], ["lung", "ORGAN", 41, 45], ["lung", "ORGAN", 92, 96], ["Failure", "PROBLEM", 0, 7], ["acute lung injury", "PROBLEM", 35, 52], ["ARDS", "PROBLEM", 53, 57], ["continuing problems", "PROBLEM", 112, 131], ["mild", "OBSERVATION_MODIFIER", 21, 25], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["lung", "ANATOMY", 41, 45], ["injury", "OBSERVATION", 46, 52], ["ARDS", "OBSERVATION", 53, 57], ["lung", "ANATOMY", 92, 96], ["protection", "OBSERVATION", 97, 107]]], ["The solution to this failure to apply the literature to everyday practice requires several approaches.", [["The solution", "TREATMENT", 0, 12], ["this failure", "PROBLEM", 16, 28], ["several approaches", "TREATMENT", 83, 101]]], ["Better training and improved documentation of patient's ventilation parameters at the bedside are starting points.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["patient's ventilation parameters", "TEST", 46, 78], ["improved", "OBSERVATION_MODIFIER", 20, 28]]], ["However, Rubenfeld indicated that standard protocols for ventilation might be the most efficient and effective solution.Mechanical ventilationIn a case of what is old is new again, the issues surrounding surfactant in lung-injured patients were revisited by Neil MacIntyre (Duke University).", [["lung", "ANATOMY", 218, 222], ["lung-injured", "DISEASE", 218, 230], ["surfactant", "SIMPLE_CHEMICAL", 204, 214], ["lung", "ORGAN", 218, 222], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["standard protocols", "TREATMENT", 34, 52], ["ventilation", "TREATMENT", 57, 68], ["Mechanical ventilation", "TREATMENT", 120, 142], ["ventilation", "OBSERVATION", 131, 142], ["new", "OBSERVATION_MODIFIER", 170, 173], ["surfactant", "OBSERVATION", 204, 214], ["lung", "ANATOMY", 218, 222]]], ["The rationale for using surfactant includes better mechanical function, anti-inflammatory properties and strong evidence in infant respiratory distress syndrome and in animal models.", [["respiratory", "ANATOMY", 131, 142], ["respiratory distress syndrome", "DISEASE", 131, 160], ["surfactant", "TREATMENT", 24, 34], ["better mechanical function", "TREATMENT", 44, 70], ["anti-inflammatory properties", "TREATMENT", 72, 100], ["infant respiratory distress syndrome", "PROBLEM", 124, 160], ["respiratory distress", "OBSERVATION", 131, 151]]], ["Improved mechanical function relates to less regional overdistention when adequate surfactant is available.", [["less regional overdistention", "PROBLEM", 40, 68], ["adequate surfactant", "TREATMENT", 74, 93], ["mechanical function", "OBSERVATION", 9, 28], ["less", "OBSERVATION_MODIFIER", 40, 44], ["regional", "OBSERVATION_MODIFIER", 45, 53], ["overdistention", "OBSERVATION", 54, 68]]], ["Previous attempts to study the use of surfactant replacement in ARDS have not shown an improvement in outcome.", [["ARDS", "DISEASE", 64, 68], ["surfactant", "SIMPLE_CHEMICAL", 38, 48], ["surfactant replacement", "TREATMENT", 38, 60], ["ARDS", "PROBLEM", 64, 68], ["ARDS", "OBSERVATION", 64, 68], ["improvement", "OBSERVATION_MODIFIER", 87, 98]]], ["However, these studies were complicated by inefficient delivery systems and surfactant preparations that may have been inadequate [56].", [["these studies", "TEST", 9, 22], ["inefficient delivery systems", "PROBLEM", 43, 71], ["surfactant preparations", "TREATMENT", 76, 99]]], ["More recent studies have pointed to improved oxygenation and possibly a trend towards decreased mortality [57].", [["decreased mortality", "PROBLEM", 86, 105]]], ["Issues that may be important in the effectiveness of surfactant as a therapy include the nature of the lung injury (direct versus indirect), the timing, the protein/phospholipid content and the dosing route.Mechanical ventilationThe emerging technology of neurally controlled ventilators was presented by Christer Sinderby (University of Toronto).", [["lung", "ANATOMY", 103, 107], ["lung injury", "DISEASE", 103, 114], ["surfactant", "SIMPLE_CHEMICAL", 53, 63], ["lung", "ORGAN", 103, 107], ["phospholipid", "SIMPLE_CHEMICAL", 165, 177], ["surfactant", "TREATMENT", 53, 63], ["a therapy", "TREATMENT", 67, 76], ["the lung injury", "PROBLEM", 99, 114], ["the protein/phospholipid content", "TREATMENT", 153, 185], ["the dosing route", "TREATMENT", 190, 206], ["Mechanical ventilation", "TREATMENT", 207, 229], ["neurally controlled ventilators", "TREATMENT", 256, 287], ["may be", "UNCERTAINTY", 12, 18], ["lung", "ANATOMY", 103, 107], ["injury", "OBSERVATION", 108, 114], ["ventilation", "OBSERVATION", 218, 229]]], ["Asynchrony between the patient and the ventilator is common in the critically ill.", [["critically ill", "DISEASE", 67, 81], ["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["Asynchrony", "PROBLEM", 0, 10], ["the ventilator", "TREATMENT", 35, 49]]], ["This often leads to ineffective ventilation, to ventilator-related complications (e.g. pneumothorax) and to increases in sedation.", [["pneumothorax", "DISEASE", 87, 99], ["ineffective ventilation", "TREATMENT", 20, 43], ["ventilator", "TREATMENT", 48, 58], ["related complications", "PROBLEM", 59, 80], ["pneumothorax", "PROBLEM", 87, 99], ["sedation", "TREATMENT", 121, 129], ["pneumothorax", "OBSERVATION", 87, 99]]], ["Neurally controlled ventilators would have the timing and possibly the magnitude of ventilatory assistance controlled via a neural input from the patient.", [["neural", "ANATOMY", 124, 130], ["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["Neurally controlled ventilators", "TREATMENT", 0, 31], ["ventilatory assistance", "TREATMENT", 84, 106]]], ["Diaphragmatic electrical activity can be monitored and can act as a signal to in effect \"inform\" the ventilator about a patient's respiratory cycle.", [["Diaphragmatic", "ANATOMY", 0, 13], ["respiratory", "ANATOMY", 130, 141], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["Diaphragmatic electrical activity", "PROBLEM", 0, 33], ["the ventilator", "TREATMENT", 97, 111], ["electrical activity", "OBSERVATION", 14, 33]]], ["With neurally adjusted ventilators the amount of mechanical support varies from moment to moment according to a mathematical function that converts diaphragmatic electrical activity to ventilator flow and pressure.", [["diaphragmatic", "ANATOMY", 148, 161], ["neurally adjusted ventilators", "TREATMENT", 5, 34], ["mechanical support", "TREATMENT", 49, 67], ["ventilator flow", "TEST", 185, 200], ["pressure", "TEST", 205, 213], ["mechanical support", "OBSERVATION", 49, 67], ["pressure", "OBSERVATION_MODIFIER", 205, 213]]], ["This mode of ventilation has significant relevance as it stands to improve patient\u2013ventilator synchrony, to reduce requirements for sedation and to facilitate weaning.", [["ventilation", "TREATMENT", 13, 24], ["sedation", "TREATMENT", 132, 140]]], ["Future research includes the use of neural-controlled ventilation in neonates and as a noninvasive modality [58].Mechanical ventilationAfter patients leave the critical care unit many critical care staff lose contact with them and have little perspective on their quality of life in the future.", [["neural", "ANATOMY", 36, 42], ["neonates", "ORGANISM", 69, 77], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["neural-controlled ventilation", "TREATMENT", 36, 65], ["a noninvasive modality", "TEST", 85, 107]]], ["Margaret Herridge (University of Toronto) presented a review of research looking at long-term outcomes in patients with ARDS [59].", [["ARDS", "DISEASE", 120, 124], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["ARDS", "PROBLEM", 120, 124]]], ["Patients were assessed 3, 6 and 12 months after discharge from the critical care unit.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["With regards to the pulmonary function tests, the lung volumes approached normal values by the 12-month mark, but the diffusion capacity remained substantially lower than predicted.", [["pulmonary", "ANATOMY", 20, 29], ["lung", "ANATOMY", 50, 54], ["pulmonary", "ORGAN", 20, 29], ["lung", "ORGAN", 50, 54], ["the pulmonary function tests", "TEST", 16, 44], ["the lung volumes", "TEST", 46, 62], ["the diffusion capacity", "TEST", 114, 136], ["pulmonary", "ANATOMY", 20, 29], ["lung", "ANATOMY", 50, 54], ["volumes", "ANATOMY_MODIFIER", 55, 62], ["normal", "OBSERVATION", 74, 80], ["substantially", "OBSERVATION_MODIFIER", 146, 159], ["lower", "OBSERVATION_MODIFIER", 160, 165]]], ["The distance walked over 6 min (a measure of patient functioning) was less than predicted at 12 months.", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52]]], ["This was attributed to global muscle weakness and wasting, to foot drop, to immobility of large joints and to dyspnea.", [["muscle", "ANATOMY", 30, 36], ["joints", "ANATOMY", 96, 102], ["muscle weakness", "DISEASE", 30, 45], ["wasting", "DISEASE", 50, 57], ["dyspnea", "DISEASE", 110, 117], ["muscle", "ORGAN", 30, 36], ["foot", "ORGANISM_SUBDIVISION", 62, 66], ["joints", "MULTI-TISSUE_STRUCTURE", 96, 102], ["global muscle weakness", "PROBLEM", 23, 45], ["wasting", "PROBLEM", 50, 57], ["foot drop", "PROBLEM", 62, 71], ["immobility of large joints", "PROBLEM", 76, 102], ["dyspnea", "PROBLEM", 110, 117], ["attributed to", "UNCERTAINTY", 9, 22], ["global", "OBSERVATION_MODIFIER", 23, 29], ["muscle", "ANATOMY", 30, 36], ["weakness", "OBSERVATION", 37, 45], ["wasting", "OBSERVATION", 50, 57], ["foot", "ANATOMY", 62, 66], ["drop", "OBSERVATION", 67, 71], ["large", "OBSERVATION_MODIFIER", 90, 95], ["joints", "ANATOMY", 96, 102], ["dyspnea", "OBSERVATION", 110, 117]]], ["Surprisingly, 49% of patients had returned to work 1 year after discharge, with the majority in their original position.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["The absence of systemic corticosteroids, the lack of acquired illness during the ICU stay and the rapid resolution of lung injury were associated with higher functional levels at 1 year.Mechanical ventilationHerridge's data call upon us to evaluate strategies to improve patient outcomes further by altering how we care for patients in the ICU (steroids, neuromuscular blockade, nutrition) as well as developing programs to promote rehabilitation both during and after the patient's ICU stay.", [["lung", "ANATOMY", 118, 122], ["neuromuscular", "ANATOMY", 355, 368], ["illness", "DISEASE", 62, 69], ["lung injury", "DISEASE", 118, 129], ["steroids", "CHEMICAL", 345, 353], ["corticosteroids", "CHEMICAL", 24, 39], ["steroids", "CHEMICAL", 345, 353], ["lung", "ORGAN", 118, 122], ["patient", "ORGANISM", 271, 278], ["patients", "ORGANISM", 324, 332], ["patient", "ORGANISM", 473, 480], ["patient", "SPECIES", 271, 278], ["patients", "SPECIES", 324, 332], ["patient", "SPECIES", 473, 480], ["systemic corticosteroids", "TREATMENT", 15, 39], ["acquired illness", "PROBLEM", 53, 69], ["lung injury", "PROBLEM", 118, 129], ["Mechanical ventilation", "TREATMENT", 186, 208], ["steroids", "TREATMENT", 345, 353], ["neuromuscular blockade", "TREATMENT", 355, 377], ["nutrition)", "TREATMENT", 379, 389], ["rehabilitation", "TREATMENT", 432, 446], ["systemic", "OBSERVATION_MODIFIER", 15, 23], ["corticosteroids", "OBSERVATION", 24, 39], ["lung", "ANATOMY", 118, 122], ["injury", "OBSERVATION", 123, 129], ["ventilation", "OBSERVATION", 197, 208]]], ["Herridge's results challenge us to expand the role of the ICU physician as an advocate for patient care during their convalescence.Mechanical ventilationPesenti wrapped up the session on mechanical ventilation with his talk 'How I manage ARDS'.", [["ARDS", "DISEASE", 238, 242], ["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["Mechanical ventilationPesenti", "TREATMENT", 131, 160], ["mechanical ventilation", "TREATMENT", 187, 209], ["ARDS", "PROBLEM", 238, 242]]], ["He began by reminding the audience that mechanical ventilation and ARDS are highly linked.", [["ARDS", "DISEASE", 67, 71], ["mechanical ventilation", "TREATMENT", 40, 62], ["ARDS", "PROBLEM", 67, 71], ["mechanical ventilation", "OBSERVATION", 40, 62], ["ARDS", "OBSERVATION", 67, 71]]], ["With this in mind, should we be attempting to ventilate non-normal critically ill patients to normal lung blood gases?", [["lung blood", "ANATOMY", 101, 111], ["critically ill", "DISEASE", 67, 81], ["patients", "ORGANISM", 82, 90], ["lung", "ORGAN", 101, 105], ["blood", "MULTI-TISSUE_STRUCTURE", 106, 111], ["patients", "SPECIES", 82, 90], ["blood gases", "TEST", 106, 117], ["lung", "ANATOMY", 101, 105]]], ["With controlled mechanical ventilation our goals should be low tidal volumes and low plateau pressures.", [["controlled mechanical ventilation", "TREATMENT", 5, 38], ["low tidal volumes", "PROBLEM", 59, 76], ["low plateau pressures", "PROBLEM", 81, 102], ["mechanical ventilation", "OBSERVATION", 16, 38], ["plateau pressures", "OBSERVATION", 85, 102]]], ["Permissive hypercapnia allows greater latitude in providing these less injurious ventilations to the patient with ARDS [60,61].Mechanical ventilationPesenti presented his rationale for the use of volume control over pressure control ventilation.", [["hypercapnia", "DISEASE", 11, 22], ["ARDS", "DISEASE", 114, 118], ["patient", "ORGANISM", 101, 108], ["patient", "SPECIES", 101, 108], ["Permissive hypercapnia", "PROBLEM", 0, 22], ["ARDS", "PROBLEM", 114, 118], ["Mechanical ventilationPesenti", "TREATMENT", 127, 156], ["volume control", "TREATMENT", 196, 210], ["pressure control ventilation", "TREATMENT", 216, 244], ["hypercapnia", "OBSERVATION", 11, 22], ["greater", "OBSERVATION_MODIFIER", 30, 37], ["ARDS", "OBSERVATION", 114, 118]]], ["The use of higher levels of positive end-expiratory pressure and recruitment maneuvers (including prone positioning) was encouraged.", [["positive end-expiratory pressure", "TREATMENT", 28, 60], ["recruitment maneuvers", "TREATMENT", 65, 86], ["prone positioning)", "TREATMENT", 98, 116]]], ["In his discussion of prone positioning, Pesenti reviewed the available data and suggested that a good indicator of survival in the prone patient is the responsiveness of the PaCO2.", [["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144], ["the PaCO2", "TEST", 170, 179]]], ["The benefits of early weaning and conversion to pressure support ventilation were also stressed.", [["early weaning", "TREATMENT", 16, 29], ["pressure support ventilation", "TREATMENT", 48, 76]]], ["Studies have shown that selected groups of ventilated patients can tolerate pressure support very well early in their ICU course [62].", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["Studies", "TEST", 0, 7], ["pressure support", "TREATMENT", 76, 92]]], ["These patients get the benefits of pressure support earlier, which include less sedation, decreased intrathoracic pressure, improved tidal volume distribution and less respiratory muscle atrophy.ConclusionThis summary is just a sample of the presentations at the 2003 Toronto Critical Care Medicine Symposium.", [["intrathoracic", "ANATOMY", 100, 113], ["respiratory muscle", "ANATOMY", 168, 186], ["respiratory muscle atrophy", "DISEASE", 168, 194], ["patients", "ORGANISM", 6, 14], ["intrathoracic", "ORGANISM_SUBDIVISION", 100, 113], ["muscle", "ORGAN", 180, 186], ["patients", "SPECIES", 6, 14], ["pressure support", "TREATMENT", 35, 51], ["less sedation", "TREATMENT", 75, 88], ["decreased intrathoracic pressure", "PROBLEM", 90, 122], ["improved tidal volume distribution", "PROBLEM", 124, 158], ["less respiratory muscle atrophy", "PROBLEM", 163, 194], ["decreased", "OBSERVATION_MODIFIER", 90, 99], ["intrathoracic", "ANATOMY", 100, 113], ["pressure", "OBSERVATION_MODIFIER", 114, 122], ["improved", "OBSERVATION_MODIFIER", 124, 132], ["tidal volume", "OBSERVATION", 133, 145], ["less", "OBSERVATION_MODIFIER", 163, 167], ["respiratory muscle atrophy", "OBSERVATION", 168, 194]]], ["Many other presentations touched on subjects including medical errors, sedation, team building, management of cardiac failure and specific pediatric critical care issues.", [["cardiac", "ANATOMY", 110, 117], ["cardiac failure", "DISEASE", 110, 125], ["cardiac", "ORGAN", 110, 117], ["sedation", "TREATMENT", 71, 79], ["management", "TREATMENT", 96, 106], ["cardiac failure", "PROBLEM", 110, 125], ["cardiac", "ANATOMY", 110, 117], ["failure", "OBSERVATION", 118, 125]]], ["Particularly entertaining sessions were several pro/con debates that occurred at the end of the symposium.", [["several pro/con debates", "TREATMENT", 40, 63]]], ["The topics debated were lung protective strategies, nontherapeutic ventilation and genomics.ConclusionOverall the 3-day conference was an enormous success.", [["lung", "ANATOMY", 24, 28], ["lung", "ORGAN", 24, 28], ["lung protective strategies", "TREATMENT", 24, 50], ["nontherapeutic ventilation", "TREATMENT", 52, 78], ["lung", "ANATOMY", 24, 28], ["enormous", "OBSERVATION_MODIFIER", 138, 146], ["success", "OBSERVATION", 147, 154]]], ["Save the dates.AbbreviationsARDS = acute respiratory distress syndrome; HGMB1 = high mobility group B1; ICU = intensive care unit; IL = interleukin; MOF = multi-organ failure; NDD = neurological determination of brain death; PaO2/FiO2 = arterial oxygen tension/inspired oxygen ratio; SARS = severe acute respiratory syndrome; VAP = ventilator-associated pneumonia.Competing interestsNone declared.", [["multi-organ", "ANATOMY", 155, 166], ["neurological", "ANATOMY", 182, 194], ["brain", "ANATOMY", 212, 217], ["arterial", "ANATOMY", 237, 245], ["ARDS", "DISEASE", 28, 32], ["acute respiratory distress syndrome", "DISEASE", 35, 70], ["multi-organ failure", "DISEASE", 155, 174], ["NDD", "DISEASE", 176, 179], ["brain death", "DISEASE", 212, 223], ["oxygen", "CHEMICAL", 246, 252], ["oxygen", "CHEMICAL", 270, 276], ["SARS", "DISEASE", 284, 288], ["acute respiratory syndrome", "DISEASE", 298, 324], ["VAP", "DISEASE", 326, 329], ["pneumonia", "DISEASE", 354, 363], ["oxygen", "CHEMICAL", 246, 252], ["oxygen", "CHEMICAL", 270, 276], ["brain", "ORGAN", 212, 217], ["arterial", "MULTI-TISSUE_STRUCTURE", 237, 245], ["oxygen", "SIMPLE_CHEMICAL", 246, 252], ["oxygen", "SIMPLE_CHEMICAL", 270, 276], ["interleukin", "PROTEIN", 136, 147], ["ARDS", "PROBLEM", 28, 32], ["acute respiratory distress syndrome", "PROBLEM", 35, 70], ["MOF", "PROBLEM", 149, 152], ["multi-organ failure", "PROBLEM", 155, 174], ["NDD", "PROBLEM", 176, 179], ["brain death", "PROBLEM", 212, 223], ["PaO2", "TEST", 225, 229], ["FiO2", "TEST", 230, 234], ["arterial oxygen tension", "TREATMENT", 237, 260], ["inspired oxygen ratio", "TEST", 261, 282], ["SARS", "PROBLEM", 284, 288], ["severe acute respiratory syndrome", "PROBLEM", 291, 324], ["VAP", "PROBLEM", 326, 329], ["pneumonia", "PROBLEM", 354, 363], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory distress", "OBSERVATION", 41, 61], ["multi-organ", "ANATOMY", 155, 166], ["failure", "OBSERVATION", 167, 174], ["brain", "ANATOMY", 212, 217], ["severe", "OBSERVATION_MODIFIER", 291, 297], ["acute", "OBSERVATION_MODIFIER", 298, 303], ["respiratory syndrome", "OBSERVATION", 304, 324], ["pneumonia", "OBSERVATION", 354, 363]]]], "c53f6ab8542fa870daf7f632b827128f87bd821b": [["Significant biological functions have been attributedto the sulfhydryl groups and disulfide bonds of viral proteins.", [["sulfhydryl", "CHEMICAL", 60, 70], ["sulfhydryl", "CHEMICAL", 60, 70], ["disulfide", "CHEMICAL", 82, 91], ["sulfhydryl", "SIMPLE_CHEMICAL", 60, 70], ["viral proteins", "PROTEIN", 101, 115], ["Significant biological functions", "PROBLEM", 0, 32], ["the sulfhydryl groups", "TREATMENT", 56, 77], ["viral proteins", "PROBLEM", 101, 115], ["viral proteins", "OBSERVATION", 101, 115]]], ["Early studies were directed to the effect of sulfhydryl blocking reagents on the capacity of viruses to initiate infection Choppin, 1960, 1962; Choppin and Philipson, 1961) .", [["sulfhydryl", "CHEMICAL", 45, 55], ["infection", "DISEASE", 113, 122], ["sulfhydryl", "CHEMICAL", 45, 55], ["sulfhydryl", "SIMPLE_CHEMICAL", 45, 55], ["Early studies", "TEST", 0, 13], ["sulfhydryl blocking reagents", "TREATMENT", 45, 73], ["infection", "PROBLEM", 113, 122]]], ["It was found that a number of sulfhydryl binding reagents reduced the infectivity of various picornaviruses.", [["sulfhydryl", "CHEMICAL", 30, 40], ["sulfhydryl", "CHEMICAL", 30, 40], ["sulfhydryl", "SIMPLE_CHEMICAL", 30, 40], ["sulfhydryl binding reagents", "TREATMENT", 30, 57], ["various picornaviruses", "PROBLEM", 85, 107], ["sulfhydryl binding", "OBSERVATION", 30, 48], ["various picornaviruses", "OBSERVATION", 85, 107]]], ["A sulfhydryl reagent was also found to inactivate hemagglutination by a wide variety of enveloped viruses (Philipson and Choppin, 1960) as well as the infectivity of influenza virus although adsorption was not affected (Choppin and Philipson, 1961) .", [["sulfhydryl", "CHEMICAL", 2, 12], ["influenza virus", "DISEASE", 166, 181], ["sulfhydryl", "CHEMICAL", 2, 12], ["sulfhydryl", "SIMPLE_CHEMICAL", 2, 12], ["influenza virus", "ORGANISM", 166, 181], ["influenza virus", "SPECIES", 166, 181], ["influenza virus", "SPECIES", 166, 181], ["A sulfhydryl reagent", "TREATMENT", 0, 20], ["hemagglutination", "PROBLEM", 50, 66], ["Choppin", "TREATMENT", 121, 128], ["influenza virus", "PROBLEM", 166, 181], ["enveloped", "OBSERVATION_MODIFIER", 88, 97], ["viruses", "OBSERVATION", 98, 105], ["influenza virus", "OBSERVATION", 166, 181]]], ["Sulfhydryl reagents also lowered the infectivity of paramyxoviruses Choppin, 1974, 1977) .", [["Sulfhydryl", "CHEMICAL", 0, 10], ["Sulfhydryl", "CHEMICAL", 0, 10], ["Sulfhydryl", "SIMPLE_CHEMICAL", 0, 10], ["Sulfhydryl reagents", "TREATMENT", 0, 19]]], ["More recent studies with measles virus (Hardwick and Bussell, 1978) have indicated the importance of disulfidelinked polypeptides for the biological activity of the surface glycoproteins.Significant biological functions have been attributedfunctions of the sulfhydryl groups and disulfide bridges of the well-characterized vesicular stomatitits virus (VSV).", [["surface", "ANATOMY", 165, 172], ["measles virus", "DISEASE", 25, 38], ["sulfhydryl", "CHEMICAL", 257, 267], ["sulfhydryl", "CHEMICAL", 257, 267], ["disulfide", "CHEMICAL", 279, 288], ["measles virus", "ORGANISM", 25, 38], ["surface glycoproteins", "GENE_OR_GENE_PRODUCT", 165, 186], ["sulfhydryl", "SIMPLE_CHEMICAL", 257, 267], ["vesicular stomatitits virus", "ORGANISM", 323, 350], ["VSV", "ORGANISM", 352, 355], ["surface glycoproteins", "PROTEIN", 165, 186], ["measles virus", "SPECIES", 25, 38], ["vesicular stomatitits virus", "SPECIES", 323, 350], ["measles virus", "SPECIES", 25, 38], ["vesicular stomatitits virus", "SPECIES", 323, 350], ["VSV", "SPECIES", 352, 355], ["measles virus", "PROBLEM", 25, 38], ["disulfidelinked polypeptides", "TREATMENT", 101, 129], ["Significant biological functions", "PROBLEM", 187, 219], ["the sulfhydryl groups", "TREATMENT", 253, 274], ["vesicular stomatitits", "OBSERVATION", 323, 344]]], ["Several, if not all, of the five VSV proteins appear to have free sulfhydryl groups which can be oxidized to crosslink proteins by forming disulfide bonds (Dubovi and Wagner, 1977) .", [["sulfhydryl", "CHEMICAL", 66, 76], ["sulfhydryl", "CHEMICAL", 66, 76], ["disulfide", "CHEMICAL", 139, 148], ["VSV", "ORGANISM", 33, 36], ["disulfide bonds", "SIMPLE_CHEMICAL", 139, 154], ["VSV proteins", "PROTEIN", 33, 45], ["crosslink proteins", "PROTEIN", 109, 127], ["VSV", "SPECIES", 33, 36], ["the five VSV proteins", "PROBLEM", 24, 45], ["free sulfhydryl groups", "TREATMENT", 61, 83]]], ["We first focused our attention on the single surface glycoprotein of VSV because of its obvious role in the initiation of infection (Bishop et al., 1977) and as the major antigenic determinant (Kelley et al., 1972) .", [["surface", "ANATOMY", 45, 52], ["infection", "DISEASE", 122, 131], ["VSV", "ORGANISM", 69, 72], ["surface glycoprotein", "PROTEIN", 45, 65], ["VSV", "SPECIES", 69, 72], ["the single surface glycoprotein of VSV", "TREATMENT", 34, 72], ["infection", "PROBLEM", 122, 131], ["infection", "OBSERVATION", 122, 131]]], ["Moreover, Kelley and Emerson (unpublished data) have uncovered evidence that three disulfide bridges contribute to the secondary structure of the VSV glycoprotein, thus making it a likely candidate for the effect of reducing and alkylating reagents.", [["alkylating", "CHEMICAL", 229, 239], ["disulfide", "CHEMICAL", 83, 92], ["VSV", "ORGANISM", 146, 149], ["disulfide bridges", "PROTEIN", 83, 100], ["VSV glycoprotein", "PROTEIN", 146, 162], ["VSV", "SPECIES", 146, 149], ["three disulfide bridges", "PROBLEM", 77, 100], ["the VSV glycoprotein", "PROBLEM", 142, 162], ["reducing and alkylating reagents", "TREATMENT", 216, 248], ["secondary structure", "OBSERVATION", 119, 138], ["VSV glycoprotein", "OBSERVATION", 146, 162]]], ["We soon discovered that SH groups of other VSV proteins appear to make more significant contributions to the biological activity of VSV.Significant biological functions have been attributedWe decided to investigate the biological MATERIALS AND METHODS 1 Present address: Center for Disease Control, Atlanta, 30033.Significant biological functions have been attributed* To whom reprint requests should be addressed.Significant biological functions have been attributedThe Indiana serotype (San Juan strain) of cloned VSV was produced by infecting BHK-21 cells at multiplicities ~0.01; infectivity was titrated by plaque assay on \" Purified VS virus preincubated for 30 min at room temperature alone or with 2-mercaptoethanol (&ME equimolar to SH reagent) was incubated for 30 min at room temperature with varying concentrations of iodoacetic acid (IAA), N-ethylmaleimide (NEM), or dextran-maleimide (MW = 10,000).", [["BHK-21 cells", "ANATOMY", 546, 558], ["plaque", "ANATOMY", 612, 618], ["2-mercaptoethanol", "CHEMICAL", 706, 723], ["&ME", "CHEMICAL", 725, 728], ["SH reagent", "CHEMICAL", 742, 752], ["iodoacetic acid", "CHEMICAL", 830, 845], ["IAA", "CHEMICAL", 847, 850], ["N-ethylmaleimide", "CHEMICAL", 853, 869], ["NEM", "CHEMICAL", 871, 874], ["dextran-maleimide", "CHEMICAL", 880, 897], ["2-mercaptoethanol", "CHEMICAL", 706, 723], ["&ME", "CHEMICAL", 725, 728], ["SH", "CHEMICAL", 742, 744], ["iodoacetic acid", "CHEMICAL", 830, 845], ["IAA", "CHEMICAL", 847, 850], ["N-ethylmaleimide", "CHEMICAL", 853, 869], ["NEM", "CHEMICAL", 871, 874], ["maleimide", "CHEMICAL", 888, 897], ["VSV", "ORGANISM", 43, 46], ["VSV", "ORGANISM", 132, 135], ["Indiana serotype", "ORGANISM", 471, 487], ["San Juan strain", "ORGANISM", 489, 504], ["VSV", "ORGANISM", 516, 519], ["BHK-21 cells", "CELL", 546, 558], ["VS virus", "ORGANISM", 639, 647], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 706, 723], ["&ME", "SIMPLE_CHEMICAL", 725, 728], ["iodoacetic acid", "SIMPLE_CHEMICAL", 830, 845], ["IAA", "SIMPLE_CHEMICAL", 847, 850], ["N-ethylmaleimide", "SIMPLE_CHEMICAL", 853, 869], ["NEM", "SIMPLE_CHEMICAL", 871, 874], ["dextran-maleimide", "SIMPLE_CHEMICAL", 880, 897], ["VSV proteins", "PROTEIN", 43, 55], ["BHK-21 cells", "CELL_LINE", 546, 558], ["VSV", "SPECIES", 43, 46], ["VSV", "SPECIES", 132, 135], ["VSV", "SPECIES", 516, 519], ["BHK-21", "SPECIES", 546, 552], ["Purified VS virus", "SPECIES", 630, 647], ["other VSV proteins", "PROBLEM", 37, 55], ["Significant biological functions", "PROBLEM", 136, 168], ["Significant biological functions", "PROBLEM", 314, 346], ["Significant biological functions", "PROBLEM", 414, 446], ["cloned VSV", "PROBLEM", 509, 519], ["multiplicities", "TEST", 562, 576], ["infectivity", "PROBLEM", 584, 595], ["Purified VS virus", "PROBLEM", 630, 647], ["mercaptoethanol", "TREATMENT", 708, 723], ["SH reagent", "TREATMENT", 742, 752], ["iodoacetic acid (IAA)", "TREATMENT", 830, 851], ["N-ethylmaleimide (NEM", "TREATMENT", 853, 874], ["dextran-maleimide", "TREATMENT", 880, 897]]], ["Each treated or untreated control virus preparation was serially diluted lo-fold in PBS and assayed for infectivity by plating 0.2 ml of each dilution on duplicate monolayer cultures of L cells.", [["monolayer cultures", "ANATOMY", 164, 182], ["L cells", "ANATOMY", 186, 193], ["monolayer cultures", "CELL", 164, 182], ["L cells", "CELL", 186, 193], ["L cells", "CELL_TYPE", 186, 193], ["untreated control virus preparation", "TREATMENT", 16, 51], ["infectivity", "PROBLEM", 104, 115], ["each dilution", "TEST", 137, 150], ["duplicate monolayer cultures", "TEST", 154, 182], ["L cells", "ANATOMY", 186, 193]]], ["Infectivity of VS virus was not affected (or slightly enhanced) by exposure to Z-ME alone (up to 100 mM) or to dextran alone (up to 10 mM). monolayer-s of L cells (Wagner et al., 1963) .", [["monolayer-s of L cells", "ANATOMY", 140, 162], ["Z-ME", "CHEMICAL", 79, 83], ["dextran", "CHEMICAL", 111, 118], ["Z-ME", "CHEMICAL", 79, 83], ["VS virus", "ORGANISM", 15, 23], ["Z-ME", "SIMPLE_CHEMICAL", 79, 83], ["dextran", "SIMPLE_CHEMICAL", 111, 118], ["monolayer", "CELL", 140, 149], ["L cells", "CELL", 155, 162], ["L cells", "CELL_TYPE", 155, 162], ["VS virus", "SPECIES", 15, 23], ["Infectivity of VS virus", "PROBLEM", 0, 23], ["VS virus", "OBSERVATION", 15, 23], ["slightly", "OBSERVATION_MODIFIER", 45, 53], ["enhanced", "OBSERVATION_MODIFIER", 54, 62]]], ["Virus purified by differential and rate zonal centrifugation (Dubovi and Wagner, 1977) was exposed for 30 min at 25\" with either iodoacetic acid (IAA), N-ethylmaleimide (NEM) (Pierce Company, Rockford, Ill.), or dextran-maleimide which was kindly supplied by Agnete Faegri of this department, who synthesized the compound by the method of Abbott and Schacter (1976) .", [["iodoacetic acid", "CHEMICAL", 129, 144], ["IAA", "CHEMICAL", 146, 149], ["N-ethylmaleimide", "CHEMICAL", 152, 168], ["NEM", "CHEMICAL", 170, 173], ["dextran-maleimide", "CHEMICAL", 212, 229], ["iodoacetic acid", "CHEMICAL", 129, 144], ["IAA", "CHEMICAL", 146, 149], ["N-ethylmaleimide", "CHEMICAL", 152, 168], ["NEM", "CHEMICAL", 170, 173], ["maleimide", "CHEMICAL", 220, 229], ["Virus", "ORGANISM", 0, 5], ["iodoacetic acid", "SIMPLE_CHEMICAL", 129, 144], ["IAA", "SIMPLE_CHEMICAL", 146, 149], ["N-ethylmaleimide", "SIMPLE_CHEMICAL", 152, 168], ["NEM", "SIMPLE_CHEMICAL", 170, 173], ["dextran-maleimide", "SIMPLE_CHEMICAL", 212, 229], ["Virus", "PROBLEM", 0, 5], ["iodoacetic acid", "TREATMENT", 129, 144], ["N-ethylmaleimide (NEM", "TREATMENT", 152, 173], ["dextran-maleimide", "TREATMENT", 212, 229]]], ["The infectivity of reduced and/or alkylated VSV was determined by plating on L cells.", [["L cells", "ANATOMY", 77, 84], ["VSV", "ORGANISM", 44, 47], ["L cells", "CELL", 77, 84], ["L cells", "CELL_TYPE", 77, 84], ["VSV", "SPECIES", 44, 47], ["alkylated VSV", "PROBLEM", 34, 47], ["infectivity", "OBSERVATION_MODIFIER", 4, 15], ["reduced", "OBSERVATION_MODIFIER", 19, 26]]], ["Reduced and/or alkylated VSV repurified by centrifugation through a 50% glycerol cushion was assayed for polymerase activity after disruption in 2% Triton X-100 in buffered high salt solution, as previously described (Hunt and Wagner, 1975) .", [["glycerol", "CHEMICAL", 72, 80], ["Triton X-100", "CHEMICAL", 148, 160], ["glycerol", "CHEMICAL", 72, 80], ["Triton X-100", "CHEMICAL", 148, 160], ["VSV", "ORGANISM", 25, 28], ["glycerol", "SIMPLE_CHEMICAL", 72, 80], ["Triton X-100", "SIMPLE_CHEMICAL", 148, 160], ["VSV", "SPECIES", 25, 28], ["alkylated VSV", "TREATMENT", 15, 28], ["a 50% glycerol cushion", "TREATMENT", 66, 88], ["polymerase activity", "PROBLEM", 105, 124], ["disruption", "PROBLEM", 131, 141], ["2% Triton", "TREATMENT", 145, 154], ["buffered high salt solution", "TREATMENT", 164, 191]]], ["The presence of free sulfhydryl groups or reducible disulfide bonds on VSV protein was determined by electrophoresis on 2% SDS-7.5% polyacrylamide gels (Dubovi and Wagner, 1977) after reacting reduced or unreduced virus with ['\"Cliodoacetic acid (200 mCi/mmol) (New England Nuclear, Boston, Mass.); before electrophoresis the virus was dialyzed overnight to remove free ['\"Cliodoacetic acid and was boiled for 2 min in 2% SDS.", [["sulfhydryl", "CHEMICAL", 21, 31], ["['\"Cliodoacetic acid", "CHEMICAL", 225, 245], ["'\"Cliodoacetic acid", "CHEMICAL", 371, 390], ["sulfhydryl", "CHEMICAL", 21, 31], ["disulfide", "CHEMICAL", 52, 61], ["polyacrylamide", "CHEMICAL", 132, 146], ["['\"Cliodoacetic acid", "CHEMICAL", 225, 245], ["['\"Cliodoacetic acid", "CHEMICAL", 370, 390], ["sulfhydryl", "SIMPLE_CHEMICAL", 21, 31], ["VSV", "ORGANISM", 71, 74], ["Dubovi", "SIMPLE_CHEMICAL", 153, 159], ["['\"Cliodoacetic acid", "SIMPLE_CHEMICAL", 225, 245], ["'\"Cliodoacetic acid", "SIMPLE_CHEMICAL", 371, 390], ["VSV protein", "PROTEIN", 71, 82], ["VSV", "SPECIES", 71, 74], ["free sulfhydryl groups", "TREATMENT", 16, 38], ["reducible disulfide bonds", "PROBLEM", 42, 67], ["VSV protein", "TEST", 71, 82], ["electrophoresis", "TEST", 101, 116], ["SDS", "TEST", 123, 126], ["7.5% polyacrylamide gels", "TREATMENT", 127, 151], ["unreduced virus", "PROBLEM", 204, 219], ["Cliodoacetic acid", "TREATMENT", 228, 245], ["Mass", "PROBLEM", 291, 295], ["electrophoresis the virus", "PROBLEM", 306, 331], ["free ['\"Cliodoacetic acid", "TREATMENT", 365, 390], ["free sulfhydryl groups", "OBSERVATION", 16, 38], ["reducible", "OBSERVATION_MODIFIER", 42, 51], ["disulfide bonds", "OBSERVATION", 52, 67]]], ["All reactions of VSV with sulkydryl reagents were carried out in Tris-HCI buffer, pH 7.2.RESULTSTo determine whether free sulfhydryl groups andlor disulfide bonds influence infectivity, intact VS virions were exposed to IAA alone or after incubation of virions with 2-ME.", [["VS virions", "ANATOMY", 193, 203], ["virions", "ANATOMY", 253, 260], ["sulkydryl", "CHEMICAL", 26, 35], ["Tris-HCI", "CHEMICAL", 65, 73], ["sulfhydryl", "CHEMICAL", 122, 132], ["IAA", "CHEMICAL", 220, 223], ["sulkydryl", "CHEMICAL", 26, 35], ["Tris-HCI", "CHEMICAL", 65, 73], ["sulfhydryl", "CHEMICAL", 122, 132], ["disulfide", "CHEMICAL", 147, 156], ["IAA", "CHEMICAL", 220, 223], ["VSV", "ORGANISM", 17, 20], ["sulkydryl reagents", "SIMPLE_CHEMICAL", 26, 44], ["Tris-HCI", "SIMPLE_CHEMICAL", 65, 73], ["sulfhydryl", "SIMPLE_CHEMICAL", 122, 132], ["andlor disulfide bonds", "SIMPLE_CHEMICAL", 140, 162], ["VS virions", "ORGANISM", 193, 203], ["IAA", "SIMPLE_CHEMICAL", 220, 223], ["VSV", "SPECIES", 17, 20], ["All reactions of VSV", "PROBLEM", 0, 20], ["sulkydryl reagents", "TREATMENT", 26, 44], ["pH", "TEST", 82, 84], ["free sulfhydryl groups andlor disulfide bonds influence infectivity", "PROBLEM", 117, 184]]], ["The infectivity of VS virions was not reduced by exposure to 2-ME alone, even at a concentration of 100 mlw; in fact, 2-ME slightly enhanced the plating efficiency of VSV (data not shown).", [["2-ME", "CHEMICAL", 61, 65], ["2-ME", "CHEMICAL", 118, 122], ["2-ME", "CHEMICAL", 61, 65], ["2-ME", "CHEMICAL", 118, 122], ["VS virions", "ORGANISM", 19, 29], ["2-ME", "SIMPLE_CHEMICAL", 61, 65], ["2-ME", "SIMPLE_CHEMICAL", 118, 122], ["VSV", "ORGANISM", 167, 170], ["VSV", "SPECIES", 167, 170], ["The infectivity of VS virions", "PROBLEM", 0, 29], ["infectivity", "OBSERVATION_MODIFIER", 4, 15]]], ["The effect of IAA at various concentrations was determined by incubation at room temperature for 30 min with VSV without or after 30min incubation with 2-ME at equimolar concentration.", [["IAA", "CHEMICAL", 14, 17], ["2-ME", "CHEMICAL", 152, 156], ["IAA", "CHEMICAL", 14, 17], ["2-ME", "CHEMICAL", 152, 156], ["IAA", "SIMPLE_CHEMICAL", 14, 17], ["VSV", "ORGANISM", 109, 112], ["2-ME", "SIMPLE_CHEMICAL", 152, 156], ["VSV", "SPECIES", 109, 112], ["IAA at various concentrations", "PROBLEM", 14, 43]]], ["Table 1 shows that the infectivity of unreduced VS virus was only slightly affected by IAA even at a concentration of 50 m&Z; only at a concentration of 100 mM did IAA inhibit infectivity markedly.", [["IAA", "CHEMICAL", 87, 90], ["IAA", "CHEMICAL", 164, 167], ["IAA", "CHEMICAL", 87, 90], ["IAA", "CHEMICAL", 164, 167], ["VS virus", "ORGANISM", 48, 56], ["IAA", "SIMPLE_CHEMICAL", 87, 90], ["IAA", "SIMPLE_CHEMICAL", 164, 167], ["VS virus", "SPECIES", 48, 56], ["unreduced VS virus", "PROBLEM", 38, 56], ["slightly affected", "PROBLEM", 66, 83]]], ["Prior reduc-tion of disulfide bonds by 2-ME resulted in greater susceptibility of VSV to inactivation by IAA.", [["2-ME", "CHEMICAL", 39, 43], ["IAA", "CHEMICAL", 105, 108], ["disulfide", "CHEMICAL", 20, 29], ["2-ME", "CHEMICAL", 39, 43], ["IAA", "CHEMICAL", 105, 108], ["disulfide bonds", "SIMPLE_CHEMICAL", 20, 35], ["2-ME", "SIMPLE_CHEMICAL", 39, 43], ["VSV", "ORGANISM", 82, 85], ["IAA", "SIMPLE_CHEMICAL", 105, 108], ["VSV", "SPECIES", 82, 85], ["disulfide bonds", "PROBLEM", 20, 35], ["greater", "OBSERVATION_MODIFIER", 56, 63], ["susceptibility", "OBSERVATION_MODIFIER", 64, 78]]], ["The data depicted in Table 1 indicate that increased acetylation of previously reduced disulfide bonds results in gradual decline in infectivity of VSV.RESULTSA possible explanation for loss in infectivity after reduction and/or alkylation of VSV might be attributed to alteration in the cell-surface receptor-binding function of the G protein (Bishop et al., 1975) .", [["cell", "ANATOMY", 288, 292], ["surface", "ANATOMY", 293, 300], ["disulfide", "CHEMICAL", 87, 96], ["VSV", "ORGANISM", 148, 151], ["VSV", "ORGANISM", 243, 246], ["cell", "CELL", 288, 292], ["G protein", "GENE_OR_GENE_PRODUCT", 334, 343], ["cell-surface receptor", "PROTEIN", 288, 309], ["G protein", "PROTEIN", 334, 343], ["VSV", "SPECIES", 148, 151], ["VSV", "SPECIES", 243, 246], ["The data", "TEST", 0, 8], ["increased acetylation of previously reduced disulfide bonds", "PROBLEM", 43, 102], ["gradual decline in infectivity of VSV", "PROBLEM", 114, 151], ["loss in infectivity", "PROBLEM", 186, 205], ["reduction", "TREATMENT", 212, 221], ["alkylation of VSV", "TREATMENT", 229, 246], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["acetylation", "OBSERVATION", 53, 64], ["gradual", "OBSERVATION_MODIFIER", 114, 121], ["decline", "OBSERVATION_MODIFIER", 122, 129], ["infectivity", "OBSERVATION_MODIFIER", 133, 144], ["possible explanation for", "UNCERTAINTY", 161, 185]]], ["One way to measure the role of the G protein in adsorption to cell surfaces is by hemagglutination of goose erythrocytes (Schloemer and Wagner, 1975) .", [["cell surfaces", "ANATOMY", 62, 75], ["erythrocytes", "ANATOMY", 108, 120], ["G protein", "GENE_OR_GENE_PRODUCT", 35, 44], ["cell", "CELL", 62, 66], ["goose", "ORGANISM", 102, 107], ["erythrocytes", "CELL", 108, 120], ["G protein", "PROTEIN", 35, 44], ["goose erythrocytes", "CELL_TYPE", 102, 120], ["goose", "SPECIES", 102, 107], ["goose", "SPECIES", 102, 107], ["the G protein", "TREATMENT", 31, 44], ["goose erythrocytes", "OBSERVATION", 102, 120]]], ["To this end concentrated VSV, previously treated with PBS or 10 m&f 2-ME, was exposed for 30 min at 25\" to 10 m&f IAA or 1 m&f NEM.", [["m&f 2-ME", "CHEMICAL", 64, 72], ["IAA", "CHEMICAL", 114, 117], ["NEM", "CHEMICAL", 127, 130], ["IAA", "CHEMICAL", 114, 117], ["NEM", "CHEMICAL", 127, 130], ["VSV", "ORGANISM", 25, 28], ["VSV", "SPECIES", 25, 28], ["PBS", "TREATMENT", 54, 57]]], ["Each reduced and/or alkylated preparation of virus was then tested for its ability to agglutinate goose erythrocytes (Schloemer and Wagner, 1975) .", [["erythrocytes", "ANATOMY", 104, 116], ["goose", "ORGANISM", 98, 103], ["erythrocytes", "CELL", 104, 116], ["goose erythrocytes", "CELL_TYPE", 98, 116], ["goose", "SPECIES", 98, 103], ["goose", "SPECIES", 98, 103], ["alkylated preparation of virus", "TREATMENT", 20, 50]]], ["In all cases the virus completely retained its hemagglutinating titer of 1:32.", [["the virus", "PROBLEM", 13, 22], ["virus", "OBSERVATION", 17, 22], ["hemagglutinating", "OBSERVATION_MODIFIER", 47, 63]]], ["These results indicate that the loss of VSV infectivity caused by 2-ME and IAA or by NEM is not attributable to significant alteration in the receptor-binding function of the G protein.RESULTSIn much earlier studies Philipson and Choppin (1960) had shown that different sulfhydryl blocking reagents vary considerably in their capacity to inactivate the infectivity of viruses.", [["2-ME", "CHEMICAL", 66, 70], ["IAA", "CHEMICAL", 75, 78], ["NEM", "CHEMICAL", 85, 88], ["sulfhydryl", "CHEMICAL", 270, 280], ["2-ME", "CHEMICAL", 66, 70], ["IAA", "CHEMICAL", 75, 78], ["NEM", "CHEMICAL", 85, 88], ["sulfhydryl", "CHEMICAL", 270, 280], ["VSV", "ORGANISM", 40, 43], ["2-ME", "SIMPLE_CHEMICAL", 66, 70], ["IAA", "SIMPLE_CHEMICAL", 75, 78], ["NEM", "SIMPLE_CHEMICAL", 85, 88], ["G protein", "GENE_OR_GENE_PRODUCT", 175, 184], ["sulfhydryl", "SIMPLE_CHEMICAL", 270, 280], ["G protein", "PROTEIN", 175, 184], ["VSV", "SPECIES", 40, 43], ["the loss of VSV infectivity", "PROBLEM", 28, 55], ["significant alteration", "PROBLEM", 112, 134], ["different sulfhydryl blocking reagents", "TREATMENT", 260, 298], ["the infectivity of viruses", "PROBLEM", 349, 375], ["VSV infectivity", "OBSERVATION", 40, 55], ["not attributable to", "UNCERTAINTY", 92, 111], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["alteration", "OBSERVATION", 124, 134], ["viruses", "OBSERVATION", 368, 375]]], ["It seems likely that such differential reactivity could be due to the degree of permeability of the alkylating reagents.", [["alkylating", "CHEMICAL", 100, 110], ["the alkylating reagents", "TREATMENT", 96, 119], ["seems likely", "UNCERTAINTY", 3, 15], ["alkylating reagents", "OBSERVATION", 100, 119]]], ["To this end we compared the antiviral effect of highly permeable N-ethylmaleimide (NEM) with that of the impermeant analog, dextran-maleimide (Abbott and Schacter, 1976) .", [["N-ethylmaleimide", "CHEMICAL", 65, 81], ["NEM", "CHEMICAL", 83, 86], ["dextran-maleimide", "CHEMICAL", 124, 141], ["N-ethylmaleimide", "CHEMICAL", 65, 81], ["NEM", "CHEMICAL", 83, 86], ["maleimide", "CHEMICAL", 132, 141], ["permeable N-ethylmaleimide", "SIMPLE_CHEMICAL", 55, 81], ["NEM", "SIMPLE_CHEMICAL", 83, 86], ["dextran-maleimide", "SIMPLE_CHEMICAL", 124, 141], ["highly permeable N-ethylmaleimide (NEM", "TREATMENT", 48, 86], ["the impermeant analog", "TREATMENT", 101, 122], ["dextran-maleimide", "TREATMENT", 124, 141]]], ["In each case the capacity of these two reagents to compromise the infectivity of VSV was tested in the presence or absence of the reducing agent, 2-ME.", [["VSV", "ORGANISM", 81, 84], ["VSV", "SPECIES", 81, 84], ["these two reagents", "TREATMENT", 29, 47], ["the infectivity of VSV", "PROBLEM", 62, 84], ["the reducing agent", "TREATMENT", 126, 144]]], ["Table 1 illustrates the marked effect of NEM on the infectivity of VS virus; 1 mM NEM reduced plating efficiency of the virus by -10p5, whereas equivalent concentrations of IAA had no effect.", [["NEM", "CHEMICAL", 41, 44], ["NEM", "CHEMICAL", 82, 85], ["IAA", "CHEMICAL", 173, 176], ["NEM", "CHEMICAL", 41, 44], ["NEM", "CHEMICAL", 82, 85], ["IAA", "CHEMICAL", 173, 176], ["NEM", "SIMPLE_CHEMICAL", 41, 44], ["VS virus", "ORGANISM", 67, 75], ["NEM", "SIMPLE_CHEMICAL", 82, 85], ["IAA", "SIMPLE_CHEMICAL", 173, 176], ["VS virus", "SPECIES", 67, 75], ["NEM", "PROBLEM", 41, 44], ["VS virus", "PROBLEM", 67, 75], ["1 mM NEM reduced plating efficiency", "PROBLEM", 77, 112], ["the virus", "PROBLEM", 116, 125], ["marked", "OBSERVATION_MODIFIER", 24, 30]]], ["No infectious virus could be detected after exposure to 10 n&f NEM, a dose at which IAA had a barely detectable effect.RESULTSWe next compared the effect of the im-per-meant, high molecular weight analog of maleimide, dextran-maleimide (MW = lO,OOO), which Abbott and Schachter (1976) had shown efficiently labels surface sulfhydryl groups but does not penetrate the erythrocyte membrane.", [["surface", "ANATOMY", 314, 321], ["erythrocyte membrane", "ANATOMY", 367, 387], ["NEM", "CHEMICAL", 63, 66], ["IAA", "CHEMICAL", 84, 87], ["maleimide", "CHEMICAL", 207, 216], ["dextran-maleimide", "CHEMICAL", 218, 235], ["sulfhydryl", "CHEMICAL", 322, 332], ["NEM", "CHEMICAL", 63, 66], ["IAA", "CHEMICAL", 84, 87], ["maleimide", "CHEMICAL", 207, 216], ["maleimide", "CHEMICAL", 226, 235], ["lO", "CHEMICAL", 242, 244], ["OOO", "CHEMICAL", 245, 248], ["sulfhydryl", "CHEMICAL", 322, 332], ["NEM", "SIMPLE_CHEMICAL", 63, 66], ["IAA", "SIMPLE_CHEMICAL", 84, 87], ["maleimide", "SIMPLE_CHEMICAL", 207, 216], ["dextran-maleimide", "SIMPLE_CHEMICAL", 218, 235], ["MW = lO", "SIMPLE_CHEMICAL", 237, 244], ["OOO", "SIMPLE_CHEMICAL", 245, 248], ["erythrocyte membrane", "CELLULAR_COMPONENT", 367, 387], ["infectious virus", "PROBLEM", 3, 19], ["NEM", "TREATMENT", 63, 66], ["maleimide", "TREATMENT", 207, 216], ["dextran-maleimide", "TREATMENT", 218, 235], ["infectious", "OBSERVATION_MODIFIER", 3, 13], ["virus", "OBSERVATION", 14, 19], ["detectable effect", "OBSERVATION", 101, 118], ["erythrocyte membrane", "OBSERVATION", 367, 387]]], ["Table 1 shows that even 10 m&f dextran-maleimide had little or no effect on the infectivity of VS virus; an equivalent concentration of the permeable maleimide reduces the plaque titer of VSV by at least 10e7.", [["plaque", "ANATOMY", 172, 178], ["dextran-maleimide", "CHEMICAL", 31, 48], ["maleimide", "CHEMICAL", 150, 159], ["maleimide", "CHEMICAL", 39, 48], ["maleimide", "CHEMICAL", 150, 159], ["dextran-maleimide", "SIMPLE_CHEMICAL", 31, 48], ["VS virus", "ORGANISM", 95, 103], ["maleimide", "SIMPLE_CHEMICAL", 150, 159], ["plaque", "PATHOLOGICAL_FORMATION", 172, 178], ["VSV", "ORGANISM", 188, 191], ["VS virus", "SPECIES", 95, 103], ["VSV", "SPECIES", 188, 191], ["dextran-maleimide", "TREATMENT", 31, 48], ["the infectivity of VS virus", "PROBLEM", 76, 103], ["the permeable maleimide", "TREATMENT", 136, 159], ["plaque", "OBSERVATION", 172, 178]]], ["Even the presence of 2-ME did not result in significant decline of infectivity after exposure to dextran-maleimide.RESULTSThese data appear to indicate that a highly diffusible sulfhydryl reagent can cause drastic loss in infectivity of VSV.", [["2-ME", "CHEMICAL", 21, 25], ["dextran-maleimide", "CHEMICAL", 97, 114], ["sulfhydryl", "CHEMICAL", 177, 187], ["2-ME", "CHEMICAL", 21, 25], ["maleimide", "CHEMICAL", 105, 114], ["sulfhydryl", "CHEMICAL", 177, 187], ["2-ME", "SIMPLE_CHEMICAL", 21, 25], ["dextran-maleimide", "SIMPLE_CHEMICAL", 97, 114], ["sulfhydryl", "SIMPLE_CHEMICAL", 177, 187], ["VSV", "ORGANISM", 237, 240], ["VSV", "SPECIES", 237, 240], ["significant decline of infectivity", "PROBLEM", 44, 78], ["dextran-maleimide", "TREATMENT", 97, 114], ["a highly diffusible sulfhydryl reagent", "TREATMENT", 157, 195], ["drastic loss in infectivity of VSV", "PROBLEM", 206, 240], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["decline", "OBSERVATION", 56, 63], ["infectivity", "OBSERVATION", 67, 78], ["drastic", "OBSERVATION_MODIFIER", 206, 213], ["loss", "OBSERVATION", 214, 218], ["infectivity", "OBSERVATION_MODIFIER", 222, 233]]], ["Conversely, sulfhydryl blockers of low permeability are far less capable of inactivating virus infectivity; impermeable reagents have little or no effect even in the presence of a reducing agent.", [["sulfhydryl", "CHEMICAL", 12, 22], ["sulfhydryl", "CHEMICAL", 12, 22], ["sulfhydryl blockers", "SIMPLE_CHEMICAL", 12, 31], ["sulfhydryl blockers", "TREATMENT", 12, 31], ["low permeability", "PROBLEM", 35, 51], ["inactivating virus infectivity", "PROBLEM", 76, 106], ["impermeable reagents", "TREATMENT", 108, 128], ["a reducing agent", "TREATMENT", 178, 194], ["low permeability", "OBSERVATION_MODIFIER", 35, 51]]], ["It seemed likely from these experiments that the major effect of sulfhydryl blocking reagents was on viral proteins internal to the limiting membrane rather than the external glycoprotein.RESULTSIt was of interest to determine the degree to which iodoacetic acid could react with free sulfhydryl groups and reduced disulfides of proteins located internal to the limiting membrane of intact VSV, as well as those located on the external G protein.RESULTSFor this purpose, purified, intact virions were exposed to 50 mJ4 [14C]iodoacetic acid alone or following pretreatment with 50 m&f 2-ME; free [14C]iodoacetic acid was removed by overnight dialysis at 4\" against 4000 vol of PBS.", [["membrane", "ANATOMY", 141, 149], ["membrane", "ANATOMY", 371, 379], ["virions", "ANATOMY", 488, 495], ["sulfhydryl", "CHEMICAL", 65, 75], ["iodoacetic acid", "CHEMICAL", 247, 262], ["sulfhydryl", "CHEMICAL", 285, 295], ["[14C]iodoacetic acid", "CHEMICAL", 519, 539], ["2-ME", "CHEMICAL", 584, 588], ["[14C]iodoacetic acid", "CHEMICAL", 595, 615], ["sulfhydryl", "CHEMICAL", 65, 75], ["iodoacetic acid", "CHEMICAL", 247, 262], ["sulfhydryl", "CHEMICAL", 285, 295], ["[14C]iodoacetic acid", "CHEMICAL", 519, 539], ["2-ME", "CHEMICAL", 584, 588], ["[14C]iodoacetic acid", "CHEMICAL", 595, 615], ["sulfhydryl", "SIMPLE_CHEMICAL", 65, 75], ["membrane", "CELLULAR_COMPONENT", 141, 149], ["iodoacetic acid", "SIMPLE_CHEMICAL", 247, 262], ["free sulfhydryl groups", "SIMPLE_CHEMICAL", 280, 302], ["membrane", "CELLULAR_COMPONENT", 371, 379], ["VSV", "GENE_OR_GENE_PRODUCT", 390, 393], ["external G protein", "GENE_OR_GENE_PRODUCT", 427, 445], ["virions", "CELL", 488, 495], ["[14C]iodoacetic acid", "SIMPLE_CHEMICAL", 519, 539], ["2-ME", "SIMPLE_CHEMICAL", 584, 588], ["[14C]iodoacetic acid", "SIMPLE_CHEMICAL", 595, 615], ["viral proteins", "PROTEIN", 101, 115], ["external glycoprotein", "PROTEIN", 166, 187], ["external G protein", "PROTEIN", 427, 445], ["sulfhydryl blocking reagents", "TREATMENT", 65, 93], ["viral proteins", "TREATMENT", 101, 115], ["the external glycoprotein", "TREATMENT", 162, 187], ["iodoacetic acid", "PROBLEM", 247, 262], ["free sulfhydryl groups", "TREATMENT", 280, 302], ["reduced disulfides of proteins", "PROBLEM", 307, 337], ["the external G protein", "TREATMENT", 423, 445], ["intact virions", "TREATMENT", 481, 495], ["iodoacetic acid", "TREATMENT", 524, 539], ["iodoacetic acid", "TREATMENT", 600, 615], ["dialysis", "TREATMENT", 641, 649], ["seemed likely", "UNCERTAINTY", 3, 16], ["intact VSV", "OBSERVATION", 383, 393]]], ["Proteins of unreduced and reduced virions were extracted by boiling in 2% SDS and analyzed by electrophoresis on 7.5% polyacrylamide gels.RESULTSThe electropherograms shown in Fig (1 mg/ml = 4.25 x lo'* particles/mg) was incubated for periods of 30 min at 25\u00b0C with 50 miW IAA alone or 50 mM 2-ME followed by 50 mM IAA.", [["virions", "ANATOMY", 34, 41], ["IAA", "CHEMICAL", 273, 276], ["2-ME", "CHEMICAL", 292, 296], ["IAA", "CHEMICAL", 315, 318], ["polyacrylamide", "CHEMICAL", 118, 132], ["IAA", "CHEMICAL", 273, 276], ["2-ME", "CHEMICAL", 292, 296], ["IAA", "CHEMICAL", 315, 318], ["IAA", "SIMPLE_CHEMICAL", 273, 276], ["2-ME", "SIMPLE_CHEMICAL", 292, 296], ["IAA", "SIMPLE_CHEMICAL", 315, 318], ["Proteins of unreduced", "PROBLEM", 0, 21], ["reduced virions", "PROBLEM", 26, 41], ["electrophoresis", "TEST", 94, 109], ["7.5% polyacrylamide gels", "TREATMENT", 113, 137], ["RESULTSThe electropherograms", "TEST", 138, 166], ["unreduced", "OBSERVATION", 12, 21], ["reduced", "OBSERVATION_MODIFIER", 26, 33], ["virions", "OBSERVATION_MODIFIER", 34, 41]]], ["Viral proteins were extracted by boiling for 2 min in 2% SDS and separated by electrophoresis for 16 hr on 7.5% polyacrylamide gels at 4 mA/gel.", [["polyacrylamide", "CHEMICAL", 112, 126], ["Viral", "ORGANISM", 0, 5], ["Viral proteins", "PROTEIN", 0, 14], ["Viral proteins", "PROBLEM", 0, 14], ["electrophoresis", "TEST", 78, 93], ["7.5% polyacrylamide gels", "TREATMENT", 107, 131]]], ["The gels were sliced into l-mm fractions and the radioactivity was determined by scintillation spectroscopy.", [["The gels", "TREATMENT", 0, 8], ["scintillation spectroscopy", "TEST", 81, 107]]], ["The letters L, G, N, NS and M designated the peak positions of coelectrophoresed VSV SH-protein markers. and especially the L protein.", [["VSV", "ORGANISM", 81, 84], ["coelectrophoresed VSV SH-protein markers", "PROTEIN", 63, 103], ["L protein", "PROTEIN", 124, 133], ["NS", "TREATMENT", 21, 23]]], ["Also shown in Fig. 1 is evidence for free SH groups in the external G protein spike as well as confirmation for the existence of disulfide bonds that could be labeled with [14C]iodoacetic acid after reduction by 2-ME.", [["[14C]iodoacetic acid", "CHEMICAL", 172, 192], ["SH", "CHEMICAL", 42, 44], ["disulfide", "CHEMICAL", 129, 138], ["[14C]iodoacetic acid", "CHEMICAL", 172, 192], ["disulfide bonds", "SIMPLE_CHEMICAL", 129, 144], ["[14C]iodoacetic acid", "SIMPLE_CHEMICAL", 172, 192], ["free SH groups", "PROBLEM", 37, 51], ["the external G protein spike", "TREATMENT", 55, 83], ["disulfide bonds", "PROBLEM", 129, 144], ["iodoacetic acid", "TREATMENT", 177, 192], ["Fig", "OBSERVATION", 14, 17], ["evidence for", "UNCERTAINTY", 24, 36], ["free", "OBSERVATION_MODIFIER", 37, 41], ["protein spike", "OBSERVATION", 70, 83]]], ["When VSV, unreduced or reduced with 2-ME, was disrupted by exposure to 2% Triton X-100, the proteins were labeled with [14C] iodoacetic acid to about the same extent as were the proteins of the intact virus (data not shown).", [["2-ME", "CHEMICAL", 36, 40], ["Triton X-100", "CHEMICAL", 74, 86], ["[14C] iodoacetic acid", "CHEMICAL", 119, 140], ["2-ME", "CHEMICAL", 36, 40], ["Triton X-100", "CHEMICAL", 74, 86], ["[14C] iodoacetic acid", "CHEMICAL", 119, 140], ["VSV", "ORGANISM", 5, 8], ["2-ME", "SIMPLE_CHEMICAL", 36, 40], ["Triton X-100", "SIMPLE_CHEMICAL", 74, 86], ["[14C] iodoacetic acid", "SIMPLE_CHEMICAL", 119, 140], ["VSV", "SPECIES", 5, 8], ["VSV", "PROBLEM", 5, 8], ["iodoacetic acid", "TREATMENT", 125, 140], ["intact virus", "OBSERVATION", 194, 206]]], ["These findings suggest that the VSV membrane does not serve to any great extent as a barrier to IAA or 2-ME.RESULTSThe marked affinity noted above of iodoacetic acid for L protein, the putative VSV polymerase enzyme (Emerson and Wagner, 1973) , led us to undertake to determine whether loss of VSV infectivity caused by sulfiydryl reagents could be attributed to their acting on the virion polymerase.", [["membrane", "ANATOMY", 36, 44], ["IAA", "CHEMICAL", 96, 99], ["iodoacetic acid", "CHEMICAL", 150, 165], ["sulfiydryl", "CHEMICAL", 320, 330], ["IAA", "CHEMICAL", 96, 99], ["iodoacetic acid", "CHEMICAL", 150, 165], ["sulfiydryl", "CHEMICAL", 320, 330], ["VSV", "ORGANISM", 32, 35], ["IAA", "SIMPLE_CHEMICAL", 96, 99], ["iodoacetic acid", "SIMPLE_CHEMICAL", 150, 165], ["L protein", "GENE_OR_GENE_PRODUCT", 170, 179], ["VSV", "ORGANISM", 194, 197], ["VSV", "ORGANISM", 294, 297], ["sulfiydryl reagents", "SIMPLE_CHEMICAL", 320, 339], ["L protein", "PROTEIN", 170, 179], ["VSV polymerase enzyme", "PROTEIN", 194, 215], ["virion polymerase", "PROTEIN", 383, 400], ["VSV", "SPECIES", 32, 35], ["VSV", "SPECIES", 294, 297], ["the VSV membrane", "PROBLEM", 28, 44], ["marked affinity", "PROBLEM", 119, 134], ["iodoacetic acid", "TREATMENT", 150, 165], ["L protein", "TEST", 170, 179], ["VSV infectivity", "PROBLEM", 294, 309], ["sulfiydryl reagents", "TREATMENT", 320, 339], ["the virion polymerase", "TREATMENT", 379, 400], ["VSV membrane", "OBSERVATION", 32, 44], ["VSV infectivity", "OBSERVATION", 294, 309]]], ["Therefore, purified intact VSV was exposed to varying concentrations of SH-blocking reagents IAA or NEM, with or without prior exposure to 2-ME.", [["IAA", "CHEMICAL", 93, 96], ["NEM", "CHEMICAL", 100, 103], ["SH", "CHEMICAL", 72, 74], ["IAA", "CHEMICAL", 93, 96], ["NEM", "CHEMICAL", 100, 103], ["VSV", "ORGANISM", 27, 30], ["IAA", "SIMPLE_CHEMICAL", 93, 96], ["NEM", "SIMPLE_CHEMICAL", 100, 103], ["VSV", "SPECIES", 27, 30], ["SH-blocking reagents", "TREATMENT", 72, 92], ["NEM", "PROBLEM", 100, 103], ["intact VSV", "OBSERVATION", 20, 30]]], ["After removal of excess reagents by centrifugation, control and treated virus was disrupted in Tritonhigh salt solubilizer and polymerase activity was assayed by incorporation of [3H]uridine into acid-precipitable RNA (Emerson and Wagner, 1973) .", [["[3H]uridine", "CHEMICAL", 179, 190], ["[3H]uridine", "CHEMICAL", 179, 190], ["Tritonhigh salt solubilizer", "SIMPLE_CHEMICAL", 95, 122], ["[3H]uridine", "SIMPLE_CHEMICAL", 179, 190], ["acid-precipitable", "SIMPLE_CHEMICAL", 196, 213], ["removal of excess reagents", "TREATMENT", 6, 32], ["centrifugation", "TREATMENT", 36, 50], ["treated virus", "PROBLEM", 64, 77], ["Tritonhigh salt solubilizer", "TREATMENT", 95, 122], ["uridine", "TREATMENT", 183, 190], ["excess reagents", "OBSERVATION", 17, 32]]], ["Figure 2 shows that in vitro transcriptase activity of intact VSV was progres-.05 J 1 mM FIG.", [["FIG", "CHEMICAL", 89, 92], ["VSV", "ORGANISM", 62, 65], ["VSV", "SPECIES", 62, 65], ["intact VSV", "OBSERVATION", 55, 65]]], ["Comparative inhibition of RNA synthesized by VSV after exposing intact virions to varying concentrations of (A) 2-mercaptoethanol alone (ME A), iodoacetic acid alone (IAA 01, or 2mereaptoethanoI + iodoacetic acid (ME + IAA a), or (B)N-etbylmaleimide alone (NEM 0) or N-ethylmaleimide + Zmercaptoethanol (NEM + ME e).", [["virions", "ANATOMY", 71, 78], ["2-mercaptoethanol", "CHEMICAL", 112, 129], ["ME A", "CHEMICAL", 137, 141], ["iodoacetic acid", "CHEMICAL", 144, 159], ["IAA", "CHEMICAL", 167, 170], ["2mereaptoethanoI", "CHEMICAL", 178, 194], ["iodoacetic acid", "CHEMICAL", 197, 212], ["ME", "CHEMICAL", 214, 216], ["IAA", "CHEMICAL", 219, 222], ["N-etbylmaleimide", "CHEMICAL", 233, 249], ["NEM", "CHEMICAL", 257, 260], ["N-ethylmaleimide", "CHEMICAL", 267, 283], ["Zmercaptoethanol", "CHEMICAL", 286, 302], ["NEM", "CHEMICAL", 304, 307], ["(A) 2-mercaptoethanol", "CHEMICAL", 108, 129], ["iodoacetic acid", "CHEMICAL", 144, 159], ["IAA 01", "CHEMICAL", 167, 173], ["2mereaptoethanoI", "CHEMICAL", 178, 194], ["iodoacetic acid", "CHEMICAL", 197, 212], ["IAA a", "CHEMICAL", 219, 224], ["(B)N-etbylmaleimide", "CHEMICAL", 230, 249], ["NEM", "CHEMICAL", 257, 260], ["N-ethylmaleimide", "CHEMICAL", 267, 283], ["Zmercaptoethanol", "CHEMICAL", 286, 302], ["NEM", "CHEMICAL", 304, 307], ["VSV", "ORGANISM", 45, 48], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 112, 129], ["ME A", "SIMPLE_CHEMICAL", 137, 141], ["iodoacetic acid", "SIMPLE_CHEMICAL", 144, 159], ["IAA 01", "SIMPLE_CHEMICAL", 167, 173], ["2mereaptoethanoI + iodoacetic acid", "SIMPLE_CHEMICAL", 178, 212], ["ME + IAA", "SIMPLE_CHEMICAL", 214, 222], ["(B)N-etbylmaleimide", "SIMPLE_CHEMICAL", 230, 249], ["NEM 0)", "SIMPLE_CHEMICAL", 257, 263], ["N-ethylmaleimide + Zmercaptoethanol", "SIMPLE_CHEMICAL", 267, 302], ["NEM", "SIMPLE_CHEMICAL", 304, 307], ["VSV", "SPECIES", 45, 48], ["Comparative inhibition of RNA synthesized", "PROBLEM", 0, 41], ["intact virions to varying concentrations of (A)", "TREATMENT", 64, 111], ["mercaptoethanol alone (ME A)", "TREATMENT", 114, 142], ["iodoacetic acid", "TREATMENT", 144, 159], ["2mereaptoethanoI + iodoacetic acid", "TREATMENT", 178, 212], ["(B)N-etbylmaleimide alone (NEM", "TREATMENT", 230, 260], ["N-ethylmaleimide", "TREATMENT", 267, 283], ["Zmercaptoethanol", "TREATMENT", 286, 302]]], ["Purified intact virus was incubated for 30 min at 25\" with buffer (controls) or with various concentrations of each of the reagents.", [["Purified intact virus", "PROBLEM", 0, 21], ["buffer (controls)", "TREATMENT", 59, 76], ["the reagents", "TREATMENT", 119, 131], ["intact", "OBSERVATION_MODIFIER", 9, 15], ["virus", "OBSERVATION", 16, 21]]], ["Unreaeted reagents were removed by pelleting the virus by centrifugation through a 50% glycerol cushion.", [["glycerol", "CHEMICAL", 87, 95], ["glycerol", "CHEMICAL", 87, 95], ["glycerol", "SIMPLE_CHEMICAL", 87, 95], ["Unreaeted reagents", "TREATMENT", 0, 18], ["a 50% glycerol cushion", "TREATMENT", 81, 103]]], ["As previously described (Hunt and Wagner, 1975) , transcriptase activity of the virions was assayed by mixing 1 vol of virus suspension in RSB-16% glycerol with 1 vol of 2x Triton-high salt solubiliir for 2 min at 0\" and then by mixing with 3 vol of RSB-15% glycerol and 5 vol of prereaction mixture consisting of 1.3 mM dithiothreitol, 8 m&f magnesium acetate, and 50 mM Tris-hydrochloride (pH 8.0) containing 1.4 mM each of ATP, GTP, CTP, and 0.133 m&f rHj-UTP (230 &i/mmol).RESULTSReaction mixtures were incubated in stoppered tubes at 31\" for 1 hr.", [["virions", "ANATOMY", 80, 87], ["glycerol", "CHEMICAL", 147, 155], ["RSB", "CHEMICAL", 250, 253], ["glycerol", "CHEMICAL", 258, 266], ["dithiothreitol", "CHEMICAL", 321, 335], ["magnesium acetate", "CHEMICAL", 343, 360], ["Tris-hydrochloride", "CHEMICAL", 372, 390], ["ATP", "CHEMICAL", 426, 429], ["GTP", "CHEMICAL", 431, 434], ["CTP", "CHEMICAL", 436, 439], ["UTP", "CHEMICAL", 459, 462], ["glycerol", "CHEMICAL", 147, 155], ["glycerol", "CHEMICAL", 258, 266], ["dithiothreitol", "CHEMICAL", 321, 335], ["magnesium acetate", "CHEMICAL", 343, 360], ["Tris-hydrochloride", "CHEMICAL", 372, 390], ["ATP", "CHEMICAL", 426, 429], ["GTP", "CHEMICAL", 431, 434], ["CTP", "CHEMICAL", 436, 439], ["UTP", "CHEMICAL", 459, 462], ["glycerol", "SIMPLE_CHEMICAL", 147, 155], ["Triton", "SIMPLE_CHEMICAL", 173, 179], ["RSB", "SIMPLE_CHEMICAL", 250, 253], ["glycerol", "SIMPLE_CHEMICAL", 258, 266], ["dithiothreitol", "SIMPLE_CHEMICAL", 321, 335], ["magnesium acetate", "SIMPLE_CHEMICAL", 343, 360], ["Tris-hydrochloride", "SIMPLE_CHEMICAL", 372, 390], ["ATP", "SIMPLE_CHEMICAL", 426, 429], ["GTP", "SIMPLE_CHEMICAL", 431, 434], ["CTP", "SIMPLE_CHEMICAL", 436, 439], ["rHj-UTP", "SIMPLE_CHEMICAL", 455, 462], ["transcriptase activity of the virions", "TREATMENT", 50, 87], ["virus suspension", "TREATMENT", 119, 135], ["RSB", "TEST", 139, 142], ["glycerol", "TREATMENT", 147, 155], ["2x Triton", "TREATMENT", 170, 179], ["high salt solubiliir", "TREATMENT", 180, 200], ["RSB", "TEST", 250, 253], ["glycerol", "TREATMENT", 258, 266], ["prereaction mixture", "TREATMENT", 280, 299], ["1.3 mM dithiothreitol", "TREATMENT", 314, 335], ["magnesium acetate", "TREATMENT", 343, 360], ["hydrochloride", "TREATMENT", 377, 390], ["pH", "TEST", 392, 394], ["ATP", "TEST", 426, 429], ["GTP", "TEST", 431, 434], ["CTP", "TEST", 436, 439], ["UTP", "TEST", 459, 462], ["RESULTSReaction mixtures", "TREATMENT", 477, 501]]], ["Duplicate samples of 100 ~1 each were precipitated with 10% trichloroacetic acid and the insoluble RNA was counted by scintillation spectroscopy.", [["samples", "ANATOMY", 10, 17], ["trichloroacetic acid", "CHEMICAL", 60, 80], ["trichloroacetic acid", "CHEMICAL", 60, 80], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 60, 80], ["insoluble RNA", "RNA", 89, 102], ["Duplicate samples", "TEST", 0, 17], ["10% trichloroacetic acid", "TREATMENT", 56, 80], ["the insoluble RNA", "PROBLEM", 85, 102], ["scintillation spectroscopy", "TEST", 118, 144]]], ["The results are expressed as percentage of the control polymerase reactions in the absence of inhibitory reagents. sively inhibited by exposure to increasing concentrations of IAA and drastically inhibited by very small amounts of NEM.", [["IAA", "CHEMICAL", 176, 179], ["NEM", "CHEMICAL", 231, 234], ["IAA", "CHEMICAL", 176, 179], ["NEM", "CHEMICAL", 231, 234], ["IAA", "SIMPLE_CHEMICAL", 176, 179], ["NEM", "SIMPLE_CHEMICAL", 231, 234], ["the control polymerase reactions", "PROBLEM", 43, 75], ["inhibitory reagents", "TREATMENT", 94, 113], ["increasing concentrations of IAA", "PROBLEM", 147, 179], ["very small amounts of NEM", "PROBLEM", 209, 234], ["increasing", "OBSERVATION_MODIFIER", 147, 157], ["concentrations", "OBSERVATION_MODIFIER", 158, 172], ["very", "OBSERVATION_MODIFIER", 209, 213], ["small", "OBSERVATION_MODIFIER", 214, 219], ["amounts", "OBSERVATION_MODIFIER", 220, 227], ["NEM", "OBSERVATION", 231, 234]]], ["The effect of IAA on transcription was greater when intact virions were previously exposed to 2-ME, reaching ~10% of the control level of RNA synthesis at 20-25 mM IAA ( Fig. 2A) .", [["virions", "ANATOMY", 59, 66], ["IAA", "CHEMICAL", 14, 17], ["2-ME", "CHEMICAL", 94, 98], ["IAA", "CHEMICAL", 164, 167], ["IAA", "CHEMICAL", 14, 17], ["2-ME", "CHEMICAL", 94, 98], ["IAA", "CHEMICAL", 164, 167], ["IAA", "SIMPLE_CHEMICAL", 14, 17], ["2-ME", "SIMPLE_CHEMICAL", 94, 98], ["IAA", "SIMPLE_CHEMICAL", 164, 167], ["IAA on transcription", "TREATMENT", 14, 34], ["intact virions", "PROBLEM", 52, 66], ["RNA synthesis", "TEST", 138, 151]]], ["As expected, prior exposure to 2-ME alone had no effect on VSV transcription ( Fig. 2A) .", [["2-ME", "CHEMICAL", 31, 35], ["2-ME", "CHEMICAL", 31, 35], ["2-ME", "SIMPLE_CHEMICAL", 31, 35], ["VSV", "ORGANISM", 59, 62], ["VSV", "SPECIES", 59, 62], ["VSV transcription", "TREATMENT", 59, 76]]], ["In sharp contrast, 50 pmol of NEM reduced VSV transcriptase activity at least 96%, regardless of whether 2-ME was present (Fig. 2B) .", [["NEM", "CHEMICAL", 30, 33], ["NEM", "CHEMICAL", 30, 33], ["2-ME", "CHEMICAL", 105, 109], ["NEM", "SIMPLE_CHEMICAL", 30, 33], ["VSV", "ORGANISM", 42, 45], ["2-ME", "SIMPLE_CHEMICAL", 105, 109], ["VSV transcriptase", "PROTEIN", 42, 59], ["VSV", "SPECIES", 42, 45], ["NEM reduced VSV transcriptase activity", "TREATMENT", 30, 68]]], ["These results indicate that sulfhydryl reagents inactivate transcriptase activity of intact VSV to varying degrees, potentially accounting for their capacity to reduce infectivity to a corresponding degree.", [["sulfhydryl", "CHEMICAL", 28, 38], ["sulfhydryl", "CHEMICAL", 28, 38], ["sulfhydryl reagents", "SIMPLE_CHEMICAL", 28, 47], ["VSV", "ORGANISM", 92, 95], ["VSV", "SPECIES", 92, 95], ["sulfhydryl reagents", "TREATMENT", 28, 47], ["intact VSV", "TREATMENT", 85, 95], ["their capacity", "PROBLEM", 143, 157], ["infectivity", "PROBLEM", 168, 179], ["intact VSV", "OBSERVATION", 85, 95], ["varying degrees", "OBSERVATION_MODIFIER", 99, 114]]], ["Of considerable interest was the finding that the nonpenetrating sulfhydryl reagent, dextran-maleimide, had no capacity to reduce the transcriptase activity of intact VSV; however, 100 pmol of dextran maleimide inhibited in vitro RNA synthesis of T&on-disrupted VSV by 99% (data not shown).DISCUSSIONEarlier studies on the antiviral activity of sulfhydryl reagents implicated surface components of virions as the targets presumably by compromising cellular adsorption and/or penetration of the virus.", [["surface", "ANATOMY", 376, 383], ["virions", "ANATOMY", 398, 405], ["cellular", "ANATOMY", 448, 456], ["sulfhydryl", "CHEMICAL", 65, 75], ["dextran-maleimide", "CHEMICAL", 85, 102], ["dextran maleimide", "CHEMICAL", 193, 210], ["sulfhydryl", "CHEMICAL", 345, 355], ["sulfhydryl", "CHEMICAL", 65, 75], ["maleimide", "CHEMICAL", 93, 102], ["maleimide", "CHEMICAL", 201, 210], ["sulfhydryl", "CHEMICAL", 345, 355], ["sulfhydryl reagent", "SIMPLE_CHEMICAL", 65, 83], ["dextran-maleimide", "SIMPLE_CHEMICAL", 85, 102], ["VSV", "ORGANISM", 167, 170], ["dextran maleimide", "SIMPLE_CHEMICAL", 193, 210], ["VSV", "ORGANISM", 262, 265], ["sulfhydryl reagents", "SIMPLE_CHEMICAL", 345, 364], ["cellular", "CELL", 448, 456], ["VSV", "SPECIES", 167, 170], ["VSV", "SPECIES", 262, 265], ["the nonpenetrating sulfhydryl reagent", "TREATMENT", 46, 83], ["dextran-maleimide", "TREATMENT", 85, 102], ["capacity", "PROBLEM", 111, 119], ["dextran maleimide", "TREATMENT", 193, 210], ["vitro RNA synthesis", "TREATMENT", 224, 243], ["DISCUSSIONEarlier studies", "TEST", 290, 315], ["sulfhydryl reagents", "TREATMENT", 345, 364], ["virions", "TREATMENT", 398, 405], ["compromising cellular adsorption", "PROBLEM", 435, 467], ["the virus", "PROBLEM", 490, 499], ["virions", "OBSERVATION", 398, 405], ["cellular adsorption", "OBSERVATION", 448, 467]]], ["Evidence that sulfhydryl reagents can affeet capsid proteins or glycoproteins of enveloped virus was largely based on inhibition of hemagglutination by picornaviruses (Philipson and Choppin, 1962) , paramyxoviruses (Scheid and Choppin, 1974) , coronavirus (Pocock, 1978) , and measles virus (Hardwick and Bussell, 1978) .", [["sulfhydryl", "CHEMICAL", 14, 24], ["measles virus", "DISEASE", 277, 290], ["sulfhydryl", "CHEMICAL", 14, 24], ["sulfhydryl reagents", "SIMPLE_CHEMICAL", 14, 33], ["enveloped virus", "ORGANISM", 81, 96], ["picornaviruses", "ORGANISM", 152, 166], ["Philipson", "SIMPLE_CHEMICAL", 168, 177], ["paramyxoviruses", "ORGANISM", 199, 214], ["coronavirus", "ORGANISM", 244, 255], ["measles virus", "ORGANISM", 277, 290], ["affeet capsid proteins", "PROTEIN", 38, 60], ["coronavirus", "SPECIES", 244, 255], ["measles virus", "SPECIES", 277, 290], ["measles virus", "SPECIES", 277, 290], ["sulfhydryl reagents", "TREATMENT", 14, 33], ["capsid proteins", "PROBLEM", 45, 60], ["glycoproteins of enveloped virus", "PROBLEM", 64, 96], ["hemagglutination", "PROBLEM", 132, 148], ["picornaviruses", "PROBLEM", 152, 166], ["Choppin", "TREATMENT", 182, 189], ["paramyxoviruses", "PROBLEM", 199, 214], ["coronavirus", "PROBLEM", 244, 255], ["measles virus", "PROBLEM", 277, 290], ["sulfhydryl reagents", "OBSERVATION", 14, 33]]], ["Our experiments reveal that potent sulfhydryl reagents have no effect on the hemagglutinating activity of vesicular stomatitis virus even though the free sulfhydryl groups and reduced disulfides of VSV glycoprotein are effectively blocked.", [["sulfhydryl", "CHEMICAL", 35, 45], ["vesicular stomatitis", "DISEASE", 106, 126], ["sulfhydryl", "CHEMICAL", 154, 164], ["sulfhydryl", "CHEMICAL", 35, 45], ["sulfhydryl", "CHEMICAL", 154, 164], ["sulfhydryl reagents", "SIMPLE_CHEMICAL", 35, 54], ["vesicular stomatitis virus", "ORGANISM", 106, 132], ["VSV", "ORGANISM", 198, 201], ["VSV glycoprotein", "PROTEIN", 198, 214], ["vesicular stomatitis virus", "SPECIES", 106, 132], ["VSV", "SPECIES", 198, 201], ["Our experiments", "TEST", 0, 15], ["potent sulfhydryl reagents", "TREATMENT", 28, 54], ["vesicular stomatitis virus", "PROBLEM", 106, 132], ["the free sulfhydryl groups", "TREATMENT", 145, 171], ["reduced disulfides of VSV glycoprotein", "PROBLEM", 176, 214], ["vesicular stomatitis", "OBSERVATION", 106, 126], ["reduced disulfides", "OBSERVATION", 176, 194], ["VSV glycoprotein", "OBSERVATION", 198, 214]]], ["Sulfhydryl reagents capable of penetrating the VSV membrane and reacting with internal proteins quite effectively impaired viral infectivity regardless of whether protein disulfide bonds were reduced.", [["membrane", "ANATOMY", 51, 59], ["Sulfhydryl", "CHEMICAL", 0, 10], ["Sulfhydryl", "CHEMICAL", 0, 10], ["disulfide", "CHEMICAL", 171, 180], ["Sulfhydryl", "SIMPLE_CHEMICAL", 0, 10], ["VSV", "ORGANISM", 47, 50], ["membrane", "CELLULAR_COMPONENT", 51, 59], ["internal proteins", "PROTEIN", 78, 95], ["Sulfhydryl reagents", "TREATMENT", 0, 19], ["penetrating the VSV membrane", "PROBLEM", 31, 59], ["internal proteins", "PROBLEM", 78, 95], ["effectively impaired viral infectivity", "PROBLEM", 102, 140], ["protein disulfide bonds", "PROBLEM", 163, 186], ["penetrating", "OBSERVATION", 31, 42], ["VSV membrane", "OBSERVATION", 47, 59], ["effectively", "OBSERVATION_MODIFIER", 102, 113], ["impaired", "OBSERVATION", 114, 122], ["viral infectivity", "OBSERVATION", 123, 140], ["disulfide bonds", "OBSERVATION", 171, 186]]], ["Con-versely, the impermeant bulky reagent, dextran-malemide, had no effect on the infectivity of VSV.", [["dextran-malemide", "CHEMICAL", 43, 59], ["malemide", "CHEMICAL", 51, 59], ["dextran-malemide", "SIMPLE_CHEMICAL", 43, 59], ["VSV", "ORGANISM", 97, 100], ["VSV", "SPECIES", 97, 100], ["the impermeant bulky reagent", "TREATMENT", 13, 41], ["dextran-malemide", "TREATMENT", 43, 59], ["the infectivity of VSV", "PROBLEM", 78, 100]]], ["The permeable sulfhydryl reagents, iodoacetic acid and Nethyl-maleimide, inhibited the RNA polymerase of intact VSV, whereas dextranmaleimide did not unless the virion membrane was disrupted with Triton X-100.", [["membrane", "ANATOMY", 168, 176], ["sulfhydryl", "CHEMICAL", 14, 24], ["iodoacetic acid", "CHEMICAL", 35, 50], ["Nethyl-maleimide", "CHEMICAL", 55, 71], ["dextranmaleimide", "CHEMICAL", 125, 141], ["Triton X-100", "CHEMICAL", 196, 208], ["sulfhydryl", "CHEMICAL", 14, 24], ["iodoacetic acid", "CHEMICAL", 35, 50], ["Nethyl-maleimide", "CHEMICAL", 55, 71], ["dextranmaleimide", "CHEMICAL", 125, 141], ["Triton X-100", "CHEMICAL", 196, 208], ["sulfhydryl reagents", "SIMPLE_CHEMICAL", 14, 33], ["iodoacetic acid", "SIMPLE_CHEMICAL", 35, 50], ["Nethyl-maleimide", "SIMPLE_CHEMICAL", 55, 71], ["VSV", "ORGANISM", 112, 115], ["dextranmaleimide", "SIMPLE_CHEMICAL", 125, 141], ["membrane", "CELLULAR_COMPONENT", 168, 176], ["Triton X-100", "SIMPLE_CHEMICAL", 196, 208], ["RNA polymerase", "PROTEIN", 87, 101], ["VSV", "SPECIES", 112, 115], ["The permeable sulfhydryl reagents", "TREATMENT", 0, 33], ["iodoacetic acid", "TREATMENT", 35, 50], ["Nethyl-maleimide", "TREATMENT", 55, 71], ["sulfhydryl reagents", "OBSERVATION", 14, 33], ["intact VSV", "OBSERVATION", 105, 115]]], ["These data suggest that sulfhydryl reagents will inactivate the infectivity of intact VSV only if they are capable of penetrating the membrane and attack the endogenous RNA polymerase of the virion.", [["membrane", "ANATOMY", 134, 142], ["sulfhydryl", "CHEMICAL", 24, 34], ["sulfhydryl", "CHEMICAL", 24, 34], ["sulfhydryl reagents", "SIMPLE_CHEMICAL", 24, 43], ["VSV", "ORGANISM", 86, 89], ["membrane", "CELLULAR_COMPONENT", 134, 142], ["virion", "CELLULAR_COMPONENT", 191, 197], ["endogenous RNA polymerase", "PROTEIN", 158, 183], ["VSV", "SPECIES", 86, 89], ["These data", "TEST", 0, 10], ["sulfhydryl reagents", "TREATMENT", 24, 43], ["penetrating the membrane", "PROBLEM", 118, 142], ["intact VSV", "OBSERVATION", 79, 89], ["endogenous RNA", "OBSERVATION", 158, 172]]]], "727672b3e6896b8e140f263413f71b541a0fe3e6": [["The presence of co-infections in pigs with clinical signs of PMWS in The Netherlands: a case-control studyIntroductionPost-weaning multisystemic wasting syndrome (PMWS) causes considerable economic losses in pig production and the disease has been associated with porcine circovirus type 2 (PCV2) infections (Allan et al., 1999a) .", [["co-infections", "DISEASE", 16, 29], ["PMWS", "DISEASE", 61, 65], ["multisystemic wasting syndrome", "DISEASE", 131, 161], ["PMWS", "DISEASE", 163, 167], ["porcine circovirus type 2 (PCV2) infections", "DISEASE", 264, 307], ["pigs", "ORGANISM", 33, 37], ["pig", "ORGANISM", 208, 211], ["porcine circovirus type 2", "ORGANISM", 264, 289], ["PCV2", "ORGANISM", 291, 295], ["pigs", "SPECIES", 33, 37], ["pig", "SPECIES", 208, 211], ["porcine circovirus", "SPECIES", 264, 282], ["pigs", "SPECIES", 33, 37], ["pig", "SPECIES", 208, 211], ["porcine circovirus type 2", "SPECIES", 264, 289], ["PCV2", "SPECIES", 291, 295], ["co-infections", "PROBLEM", 16, 29], ["PMWS", "PROBLEM", 61, 65], ["multisystemic wasting syndrome", "PROBLEM", 131, 161], ["PMWS", "PROBLEM", 163, 167], ["considerable economic losses in pig production", "PROBLEM", 176, 222], ["the disease", "PROBLEM", 227, 238], ["porcine circovirus type 2 (PCV2) infections", "PROBLEM", 264, 307], ["co-infections", "OBSERVATION", 16, 29], ["considerable", "OBSERVATION_MODIFIER", 176, 188], ["economic", "OBSERVATION_MODIFIER", 189, 197], ["losses", "OBSERVATION", 198, 204], ["pig production", "OBSERVATION", 208, 222], ["disease", "OBSERVATION", 231, 238], ["circovirus", "OBSERVATION", 272, 282]]], ["Under experimental conditions, the reproduction of PMWS in pigs infected with PCV2 alone was difficult to achieve, and PCV2 infected pigs developed only mild to moderate PMWS specific lesions (Balasch et al., 1999; Krakowka et al., 2000) .", [["lesions", "ANATOMY", 184, 191], ["PMWS", "DISEASE", 51, 55], ["PCV2 infected", "DISEASE", 119, 132], ["PMWS", "DISEASE", 170, 174], ["pigs", "ORGANISM", 59, 63], ["PCV2", "ORGANISM", 78, 82], ["PCV2", "ORGANISM", 119, 123], ["pigs", "ORGANISM", 133, 137], ["lesions", "PATHOLOGICAL_FORMATION", 184, 191], ["pigs", "SPECIES", 59, 63], ["pigs", "SPECIES", 133, 137], ["pigs", "SPECIES", 59, 63], ["PCV2", "SPECIES", 78, 82], ["pigs", "SPECIES", 133, 137], ["PMWS", "PROBLEM", 51, 55], ["PCV2", "TREATMENT", 78, 82], ["PCV2 infected pigs", "PROBLEM", 119, 137], ["mild to moderate PMWS specific lesions", "PROBLEM", 153, 191], ["mild", "OBSERVATION_MODIFIER", 153, 157], ["moderate", "OBSERVATION_MODIFIER", 161, 169], ["PMWS", "OBSERVATION_MODIFIER", 170, 174], ["specific", "OBSERVATION_MODIFIER", 175, 183], ["lesions", "OBSERVATION", 184, 191]]], ["Serological studies showed that antibodies directed against PCV2 were detected in pigs of more than 94% of the Dutch pig herds (Elbers and de Jong, 2002) , but not all PCV2 infected pigs will develop PMWS.", [["PCV2 infected", "DISEASE", 168, 181], ["PMWS", "DISEASE", 200, 204], ["PCV2", "ORGANISM", 60, 64], ["pigs", "ORGANISM", 82, 86], ["pig", "ORGANISM", 117, 120], ["PCV2", "ORGANISM", 168, 172], ["pigs", "ORGANISM", 182, 186], ["antibodies", "PROTEIN", 32, 42], ["pigs", "SPECIES", 82, 86], ["pig", "SPECIES", 117, 120], ["pigs", "SPECIES", 182, 186], ["PCV2", "SPECIES", 60, 64], ["pigs", "SPECIES", 82, 86], ["pig", "SPECIES", 117, 120], ["pigs", "SPECIES", 182, 186], ["Serological studies", "TEST", 0, 19], ["antibodies", "TEST", 32, 42], ["PCV2", "PROBLEM", 60, 64], ["PMWS", "PROBLEM", 200, 204], ["PCV2", "OBSERVATION", 168, 172]]], ["This indicated that the course of most PCV2 infections is more or less sub-clinical and that PCV2 may need co-factors to fully reproduce PMWS.", [["PCV2 infections", "DISEASE", 39, 54], ["PMWS", "DISEASE", 137, 141], ["PCV2", "ORGANISM", 39, 43], ["PCV2", "ORGANISM", 93, 97], ["most PCV2 infections", "PROBLEM", 34, 54], ["PCV2", "PROBLEM", 93, 97], ["PMWS", "PROBLEM", 137, 141], ["PCV2", "OBSERVATION_MODIFIER", 39, 43], ["infections", "OBSERVATION", 44, 54]]], ["Data from experimental co-infections with porcine parvovirus (PPV) (Allan et al., 1999b; Ellis et al., 2000; Krakowka et al., 2000) or PRRSV (Harms et al., 2001) supported this theory.", [["co-infections", "DISEASE", 23, 36], ["porcine parvovirus", "DISEASE", 42, 60], ["porcine parvovirus", "ORGANISM", 42, 60], ["PRRSV", "ORGANISM", 135, 140], ["porcine parvovirus", "SPECIES", 42, 60], ["porcine parvovirus", "SPECIES", 42, 60], ["PPV", "SPECIES", 62, 65], ["PRRSV", "SPECIES", 135, 140], ["porcine parvovirus (PPV", "TREATMENT", 42, 65]]], ["Furthermore, the stimulation of the immune system might be a pivotal event in the production of PMWS in PCV2 infected pigs (Krakowka et al., 2001) , although contradictory data have also been generated regarding this subject (Ladekjaer-Mikkelsen et al., 2002) .IntroductionField studies showed that PRRSV can be detected often in PMWS affected pigs (Sorden et al., 1998; Segal es et al., 2002) , and under experimental conditions severe disease can be reproduced in pigs concurrently infected with PCV2 and PRRSV (Harms et al., 2001; Rovira et al., 2002; Stockhofe-Zurwieden et al., 2003) .", [["immune system", "ANATOMY", 36, 49], ["PMWS", "DISEASE", 96, 100], ["PCV2 infected", "DISEASE", 104, 117], ["PMWS", "DISEASE", 330, 334], ["PCV2", "ORGANISM", 104, 108], ["pigs", "ORGANISM", 118, 122], ["PRRSV", "ORGANISM", 299, 304], ["pigs", "ORGANISM", 344, 348], ["pigs", "ORGANISM", 466, 470], ["PCV2", "ORGANISM", 498, 502], ["PRRSV", "ORGANISM", 507, 512], ["pigs", "SPECIES", 118, 122], ["pigs", "SPECIES", 344, 348], ["pigs", "SPECIES", 466, 470], ["PRRSV", "SPECIES", 507, 512], ["pigs", "SPECIES", 118, 122], ["PRRSV", "SPECIES", 299, 304], ["pigs", "SPECIES", 344, 348], ["pigs", "SPECIES", 466, 470], ["PCV2", "SPECIES", 498, 502], ["PRRSV", "SPECIES", 507, 512], ["a pivotal event", "PROBLEM", 59, 74], ["PMWS", "PROBLEM", 96, 100], ["IntroductionField studies", "TEST", 261, 286], ["PRRSV", "PROBLEM", 299, 304], ["severe disease", "PROBLEM", 430, 444], ["PCV2", "PROBLEM", 498, 502], ["severe", "OBSERVATION_MODIFIER", 430, 436], ["disease", "OBSERVATION", 437, 444]]], ["However, whether these findings are relevant for the field situation remains to be established as no reports have been published on the frequency of PRRSV infections in PMWS herds versus PMWS-free control herds, and there is no information on the frequency of co-infections of European-(EU) and American (US)type PRRSV in PMWS herds and PMWS-free control herds.IntroductionA case-control study was performed to get more insights into the presence of co-infections, such as infections of EU-and US-type PRRSV, in pig herds with (cases) and without (controls) clinical signs of PMWS in the Netherlands.Herds and pigsFrom 20 different pig herds in the Netherlands, 3 pigs each diagnosed for clinical signs of PMWS (cases) and 8 to approximately 14 weeks of age, were selected and examined postmortem (n \u00bc 60).", [["PRRSV infections", "DISEASE", 149, 165], ["PMWS", "DISEASE", 169, 173], ["PMWS", "DISEASE", 187, 191], ["co-infections", "DISEASE", 260, 273], ["PMWS", "DISEASE", 322, 326], ["PMWS", "DISEASE", 337, 341], ["co-infections", "DISEASE", 450, 463], ["infections", "DISEASE", 473, 483], ["PMWS", "DISEASE", 576, 580], ["PMWS", "DISEASE", 706, 710], ["PRRSV", "ORGANISM", 149, 154], ["PRRSV", "ORGANISM", 313, 318], ["US-type PRRSV", "ORGANISM", 494, 507], ["pig", "ORGANISM", 512, 515], ["pigs", "ORGANISM", 610, 614], ["pig", "ORGANISM", 632, 635], ["pigs", "ORGANISM", 664, 668], ["PRRSV", "SPECIES", 313, 318], ["PRRSV", "SPECIES", 502, 507], ["pig", "SPECIES", 512, 515], ["pigs", "SPECIES", 610, 614], ["pig", "SPECIES", 632, 635], ["pigs", "SPECIES", 664, 668], ["PRRSV", "SPECIES", 149, 154], ["PRRSV", "SPECIES", 313, 318], ["PRRSV", "SPECIES", 502, 507], ["pig", "SPECIES", 512, 515], ["pig", "SPECIES", 632, 635], ["pigs", "SPECIES", 664, 668], ["PRRSV infections", "PROBLEM", 149, 165], ["PMWS", "PROBLEM", 187, 191], ["control study", "TEST", 380, 393], ["co-infections", "PROBLEM", 450, 463], ["type PRRSV", "PROBLEM", 497, 507], ["PMWS", "PROBLEM", 576, 580], ["pigs", "TREATMENT", 610, 614], ["PMWS", "PROBLEM", 706, 710], ["infections", "OBSERVATION", 155, 165], ["co-infections", "OBSERVATION", 450, 463], ["PMWS", "OBSERVATION", 576, 580]]], ["Criteria for the selection of cases were the combination of wasting, pallor, fever (>39.7\u00b0C), respiratory distress and enlarged inguinal lymph nodes as observed by palpation.", [["respiratory", "ANATOMY", 94, 105], ["inguinal lymph nodes", "ANATOMY", 128, 148], ["wasting", "DISEASE", 60, 67], ["pallor", "DISEASE", 69, 75], ["fever", "DISEASE", 77, 82], ["respiratory distress", "DISEASE", 94, 114], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 137, 148], ["wasting", "PROBLEM", 60, 67], ["pallor", "PROBLEM", 69, 75], ["fever", "PROBLEM", 77, 82], ["respiratory distress", "PROBLEM", 94, 114], ["enlarged inguinal lymph nodes", "PROBLEM", 119, 148], ["palpation", "TEST", 164, 173], ["wasting", "OBSERVATION", 60, 67], ["respiratory", "ANATOMY", 94, 105], ["distress", "OBSERVATION", 106, 114], ["enlarged", "OBSERVATION_MODIFIER", 119, 127], ["inguinal", "ANATOMY", 128, 136], ["lymph nodes", "OBSERVATION", 137, 148]]], ["For each case, control pigs of the same age as cases but without clinical signs of PMWS were also selected and examined postmortem.", [["PMWS", "DISEASE", 83, 87], ["pigs", "ORGANISM", 23, 27], ["pigs", "SPECIES", 23, 27], ["pigs", "SPECIES", 23, 27], ["PMWS", "PROBLEM", 83, 87], ["postmortem", "TEST", 120, 130]]], ["Control pigs were selected: (1) housed within the same compartment as cases (n \u00bc 60), (2) from a different compartment but within the same case herd (n \u00bc 60), and (3) from another pig herd within the same geographical region as the case herd, and without a recent history of PMWS and porcine dermatitis and nephropathy syndrome (PDNS) (n \u00bc 60).Macroscopic lesions and sample collectionAt necropsy, each pig was examined for gross pathological findings, and at least four different organs and tissues e.g. lung, mesenteric and inguinal lymph nodes, spleen and kidney were sampled for virology and bacteriological examinations.", [["Macroscopic lesions", "ANATOMY", 344, 363], ["sample", "ANATOMY", 368, 374], ["organs", "ANATOMY", 481, 487], ["tissues", "ANATOMY", 492, 499], ["lung", "ANATOMY", 505, 509], ["mesenteric", "ANATOMY", 511, 521], ["inguinal lymph nodes", "ANATOMY", 526, 546], ["spleen", "ANATOMY", 548, 554], ["kidney", "ANATOMY", 559, 565], ["PMWS", "DISEASE", 275, 279], ["porcine dermatitis", "DISEASE", 284, 302], ["nephropathy syndrome", "DISEASE", 307, 327], ["PDNS", "DISEASE", 329, 333], ["pigs", "ORGANISM", 8, 12], ["pig", "ORGANISM", 180, 183], ["Macroscopic lesions", "CANCER", 344, 363], ["pig", "ORGANISM", 403, 406], ["organs", "ORGAN", 481, 487], ["tissues", "TISSUE", 492, 499], ["lung", "ORGAN", 505, 509], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 511, 521], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 526, 546], ["spleen", "ORGAN", 548, 554], ["kidney", "ORGAN", 559, 565], ["pigs", "SPECIES", 8, 12], ["pig", "SPECIES", 180, 183], ["porcine", "SPECIES", 284, 291], ["pig", "SPECIES", 403, 406], ["pigs", "SPECIES", 8, 12], ["pig", "SPECIES", 180, 183], ["pig", "SPECIES", 403, 406], ["PMWS", "PROBLEM", 275, 279], ["porcine dermatitis", "PROBLEM", 284, 302], ["nephropathy syndrome", "PROBLEM", 307, 327], ["Macroscopic lesions", "PROBLEM", 344, 363], ["sample collection", "TEST", 368, 385], ["gross pathological findings", "PROBLEM", 424, 451], ["bacteriological examinations", "TEST", 596, 624], ["porcine dermatitis", "OBSERVATION", 284, 302], ["nephropathy", "OBSERVATION", 307, 318], ["lesions", "OBSERVATION", 356, 363], ["collection", "OBSERVATION_MODIFIER", 375, 385], ["tissues", "ANATOMY", 492, 499], ["lung", "ANATOMY", 505, 509], ["mesenteric", "ANATOMY", 511, 521], ["inguinal", "ANATOMY", 526, 534], ["lymph nodes", "OBSERVATION", 535, 546], ["spleen", "ANATOMY", 548, 554], ["kidney", "ANATOMY", 559, 565]]], ["For histological examinations, parts of e.g. kidney, lung and mesenteric and inguinal lymph nodes were fixed in 10% neutral buffered formalin, in paraffin embedded, sectioned at 5 lm, and stained with haematoxylin and eosin (HE).", [["kidney", "ANATOMY", 45, 51], ["lung", "ANATOMY", 53, 57], ["mesenteric", "ANATOMY", 62, 72], ["inguinal lymph nodes", "ANATOMY", 77, 97], ["formalin", "CHEMICAL", 133, 141], ["paraffin", "CHEMICAL", 146, 154], ["haematoxylin", "CHEMICAL", 201, 213], ["eosin", "CHEMICAL", 218, 223], ["kidney", "ORGAN", 45, 51], ["lung", "ORGAN", 53, 57], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 62, 72], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 77, 97], ["formalin", "SIMPLE_CHEMICAL", 133, 141], ["haematoxylin", "SIMPLE_CHEMICAL", 201, 213], ["eosin", "SIMPLE_CHEMICAL", 218, 223], ["histological examinations", "TEST", 4, 29], ["parts of e.g. kidney, lung and mesenteric and inguinal lymph nodes", "PROBLEM", 31, 97], ["neutral buffered formalin", "TREATMENT", 116, 141], ["haematoxylin", "TEST", 201, 213], ["kidney", "ANATOMY", 45, 51], ["lung", "ANATOMY", 53, 57], ["mesenteric", "ANATOMY", 62, 72], ["inguinal", "ANATOMY", 77, 85], ["lymph nodes", "OBSERVATION", 86, 97]]], ["Blood was collected from all pigs and serum was used for antibody detection (stored at )70\u00b0C).Virus isolationSmall blocks of organs and tissues from each pig (lung, mesenteric and inguinal lymph nodes, spleen and kidney) were selected and of each organ or tissue a 10% organ suspension was prepared in Earle's minimal essential medium (EMEM).", [["Blood", "ANATOMY", 0, 5], ["serum", "ANATOMY", 38, 43], ["organs", "ANATOMY", 125, 131], ["tissues", "ANATOMY", 136, 143], ["lung", "ANATOMY", 159, 163], ["mesenteric", "ANATOMY", 165, 175], ["inguinal lymph nodes", "ANATOMY", 180, 200], ["spleen", "ANATOMY", 202, 208], ["kidney", "ANATOMY", 213, 219], ["organ", "ANATOMY", 247, 252], ["tissue", "ANATOMY", 256, 262], ["organ", "ANATOMY", 269, 274], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["pigs", "ORGANISM", 29, 33], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["Virus", "ORGANISM", 94, 99], ["organs", "ORGAN", 125, 131], ["tissues", "TISSUE", 136, 143], ["pig", "ORGANISM", 154, 157], ["lung", "ORGAN", 159, 163], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 165, 175], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 180, 200], ["spleen", "ORGAN", 202, 208], ["kidney", "ORGAN", 213, 219], ["organ", "ORGAN", 247, 252], ["tissue", "TISSUE", 256, 262], ["organ", "ORGAN", 269, 274], ["pigs", "SPECIES", 29, 33], ["pig", "SPECIES", 154, 157], ["pigs", "SPECIES", 29, 33], ["pig", "SPECIES", 154, 157], ["Blood", "TEST", 0, 5], ["serum", "TEST", 38, 43], ["antibody detection", "TEST", 57, 75], ["Virus isolation", "TREATMENT", 94, 109], ["a 10% organ suspension", "TREATMENT", 263, 285], ["Small", "OBSERVATION_MODIFIER", 109, 114], ["blocks", "OBSERVATION_MODIFIER", 115, 121], ["organs", "ANATOMY", 125, 131], ["lung", "ANATOMY", 159, 163], ["mesenteric", "ANATOMY", 165, 175], ["inguinal", "ANATOMY", 180, 188], ["lymph nodes", "OBSERVATION", 189, 200], ["spleen", "ANATOMY", 202, 208], ["kidney", "ANATOMY", 213, 219]]], ["Porcine circovirus 2 isolation was performed on PK-15 cells and DULAC cells and after incubation for 3-4 days at 37\u00b0C (5% CO 2 ), a serum sample, collected from a specified pathogen free (SPF) pig infected with PCV2 only, was used for the detection of viral antigens in infected cell cultures.", [["PK-15 cells", "ANATOMY", 48, 59], ["DULAC cells", "ANATOMY", 64, 75], ["serum sample", "ANATOMY", 132, 144], ["cell cultures", "ANATOMY", 279, 292], ["Porcine circovirus 2", "ORGANISM", 0, 20], ["PK-15 cells", "CELL", 48, 59], ["DULAC cells", "CELL", 64, 75], ["serum", "ORGANISM_SUBSTANCE", 132, 137], ["pig", "ORGANISM", 193, 196], ["PCV2", "ORGANISM", 211, 215], ["cell cultures", "CELL", 279, 292], ["PK-15 cells", "CELL_LINE", 48, 59], ["DULAC cells", "CELL_LINE", 64, 75], ["viral antigens", "PROTEIN", 252, 266], ["infected cell cultures", "CELL_LINE", 270, 292], ["Porcine circovirus", "SPECIES", 0, 18], ["pig", "SPECIES", 193, 196], ["Porcine circovirus", "SPECIES", 0, 18], ["PK-15", "SPECIES", 48, 53], ["pig", "SPECIES", 193, 196], ["PCV2", "SPECIES", 211, 215], ["Porcine circovirus 2 isolation", "TREATMENT", 0, 30], ["PK", "TEST", 48, 50], ["DULAC cells", "TEST", 64, 75], ["incubation", "TEST", 86, 96], ["a serum sample", "TEST", 130, 144], ["PCV2", "TREATMENT", 211, 215], ["viral antigens in infected cell cultures", "PROBLEM", 252, 292], ["infected cell cultures", "OBSERVATION", 270, 292]]], ["The immunoperoxidase monolayer assay (IPMA) was further performed as described earlier (Wellenberg et al., 2000) , using a HRPO-labelled rabbit anti-swine-Ig conjugate (Dakopatt, Glostrup, Denmark).", [["monolayer", "ANATOMY", 21, 30], ["HRPO", "CHEMICAL", 123, 127], ["HRPO", "SIMPLE_CHEMICAL", 123, 127], ["rabbit", "ORGANISM", 137, 143], ["anti-swine-Ig conjugate", "SIMPLE_CHEMICAL", 144, 167], ["Dakopatt", "SIMPLE_CHEMICAL", 169, 177], ["Ig conjugate", "PROTEIN", 155, 167], ["rabbit", "SPECIES", 137, 143], ["rabbit", "SPECIES", 137, 143], ["The immunoperoxidase monolayer assay", "TEST", 0, 36], ["a HRPO", "TEST", 121, 127]]], ["Non-inoculated PCV-free PK-15 cells and DULAC-cells served as negative cell control and an organ pool suspension collected from a PMWS affected pig served as positive control.DNA and RNA extractions and PCR tests for the detection of viral genomic sequencesTotal DNA and total RNA from lung, mesenteric and inguinal lymph nodes, spleen and kidney were extracted from 10% organ suspensions by column chromatography using the QIAamp Blood and Tissue kit (Qiagen, Westburg, The Netherlands) for DNA and the High Pure RNA Isolation kit for RNA (Roche Diagnostics, Germany).", [["PK-15 cells", "ANATOMY", 24, 35], ["DULAC-cells", "ANATOMY", 40, 51], ["cell", "ANATOMY", 71, 75], ["organ", "ANATOMY", 91, 96], ["lung", "ANATOMY", 286, 290], ["mesenteric", "ANATOMY", 292, 302], ["inguinal lymph nodes", "ANATOMY", 307, 327], ["spleen", "ANATOMY", 329, 335], ["kidney", "ANATOMY", 340, 346], ["organ", "ANATOMY", 371, 376], ["PMWS", "DISEASE", 130, 134], ["PK-15 cells", "CELL", 24, 35], ["DULAC-cells", "CELL", 40, 51], ["cell", "CELL", 71, 75], ["organ", "ORGAN", 91, 96], ["pig", "ORGANISM", 144, 147], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["DNA", "CELLULAR_COMPONENT", 263, 266], ["lung", "ORGAN", 286, 290], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 292, 302], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 307, 327], ["spleen", "ORGAN", 329, 335], ["kidney", "ORGAN", 340, 346], ["organ", "ORGAN", 371, 376], ["Blood", "ORGANISM_SUBSTANCE", 431, 436], ["DNA", "CELLULAR_COMPONENT", 492, 495], ["Non-inoculated PCV-free PK-15 cells", "CELL_LINE", 0, 35], ["DULAC-cells", "CELL_LINE", 40, 51], ["viral genomic sequences", "DNA", 234, 257], ["pig", "SPECIES", 144, 147], ["pig", "SPECIES", 144, 147], ["Non-inoculated PCV", "TEST", 0, 18], ["free PK", "TEST", 19, 26], ["DULAC-cells", "TREATMENT", 40, 51], ["cell control", "TREATMENT", 71, 83], ["an organ pool suspension", "TREATMENT", 88, 112], ["a PMWS affected pig", "TREATMENT", 128, 147], ["DNA", "PROBLEM", 175, 178], ["RNA extractions", "TREATMENT", 183, 198], ["PCR tests", "TEST", 203, 212], ["the detection", "TEST", 217, 230], ["viral genomic sequences", "PROBLEM", 234, 257], ["Total DNA", "TEST", 257, 266], ["total RNA from lung, mesenteric and inguinal lymph nodes", "PROBLEM", 271, 327], ["column chromatography", "TEST", 392, 413], ["the QIAamp Blood", "TREATMENT", 420, 436], ["Tissue kit", "TEST", 441, 451], ["DNA", "PROBLEM", 492, 495], ["organ", "ANATOMY", 91, 96], ["DNA", "OBSERVATION", 263, 266], ["total RNA", "OBSERVATION_MODIFIER", 271, 280], ["lung", "ANATOMY", 286, 290], ["mesenteric", "ANATOMY", 292, 302], ["inguinal", "ANATOMY", 307, 315], ["lymph nodes", "OBSERVATION", 316, 327], ["spleen", "ANATOMY", 329, 335], ["kidney", "ANATOMY", 340, 346]]], ["Cell lysis, precipitation, and elution of DNA or RNA were performed as recommended by the manufacturer.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["Cell lysis", "TREATMENT", 0, 10], ["precipitation", "TREATMENT", 12, 25], ["DNA or RNA", "PROBLEM", 42, 52]]], ["The elution products were stored at )20\u00b0C. PCRs were performed for the detection of PCV2 (Wellenberg et al., 2000) and porcine parvovirus (PPV) DNA (Soares et al., 1999) , and an rt-PCR for the detection of EU and US type PRRSV RNA.", [["porcine parvovirus", "DISEASE", 119, 137], ["PCV2", "ORGANISM", 84, 88], ["porcine parvovirus", "ORGANISM", 119, 137], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["PRRSV", "ORGANISM", 222, 227], ["EU and US type PRRSV RNA", "RNA", 207, 231], ["porcine parvovirus", "SPECIES", 119, 137], ["porcine parvovirus", "SPECIES", 119, 137], ["PPV", "SPECIES", 139, 142], ["US type PRRSV", "SPECIES", 214, 227], ["The elution products", "TREATMENT", 0, 20], ["PCRs", "TEST", 43, 47], ["the detection", "TEST", 67, 80], ["PCV2", "PROBLEM", 84, 88], ["porcine parvovirus (PPV", "TREATMENT", 119, 142], ["an rt-PCR", "TEST", 176, 185], ["the detection", "TEST", 190, 203], ["PRRSV RNA", "OBSERVATION", 222, 231]]], ["The type of PRRSV strain (EU or US) was determined by fragmentlength rt-PCR (Oleksiewicz et al., 1998) and sequence analyses.Quantitative PCV2 PCRTo quantify the amount of PCV2 DNA copies in organ samples, a real-time fluorescent-probe PCR was used.", [["organ samples", "ANATOMY", 191, 204], ["PRRSV", "ORGANISM", 12, 17], ["PCV2", "ORGANISM", 138, 142], ["PCV2", "ORGANISM", 172, 176], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["organ samples", "CANCER", 191, 204], ["PCV2 DNA copies", "DNA", 172, 187], ["PRRSV", "SPECIES", 12, 17], ["PCV2", "SPECIES", 172, 176], ["PRRSV strain", "PROBLEM", 12, 24], ["sequence analyses", "TEST", 107, 124], ["Quantitative PCV2 PCRTo", "TEST", 125, 148], ["organ samples", "TEST", 191, 204], ["fluorescent-probe PCR", "TEST", 218, 239], ["PRRSV strain", "OBSERVATION", 12, 24], ["organ", "ANATOMY", 191, 196]]], ["The Light-Cycler probes (LC red 640 -ATC TCA TCA TGT CCA CCG CCC AGG A) (FL fluorescein -CGT TGT ACT GTG GTA CGC TTG ACA GT) and the primers (1391; 5 0 -CTC CCC TGT CAC CCT GGG TG -3 0 ) and (1577; 5 0 -CTC TCC CGC ACC TTC GGA TAT-3 0 ) amplifying a 186-bp fragment from the cap gene of PCV2 were designed.", [["fluorescein", "CHEMICAL", 76, 87], ["fluorescein", "CHEMICAL", 76, 87], ["TAT-3 0", "CHEMICAL", 227, 234], ["PCV2", "ORGANISM", 287, 291], ["Light-Cycler probes", "DNA", 4, 23], ["ATC TCA TCA TGT CCA CCG CCC AGG A", "DNA", 37, 70], ["FL fluorescein -CGT TGT ACT GTG GTA CGC TTG ACA GT", "DNA", 73, 123], ["TG -3 0", "DNA", 177, 184], ["CTC TCC", "DNA", 203, 210], ["ACC TTC", "DNA", 215, 222], ["TAT-3 0", "DNA", 227, 234], ["186-bp fragment", "DNA", 250, 265], ["cap gene", "DNA", 275, 283], ["PCV2", "SPECIES", 287, 291], ["Cycler probes", "TEST", 10, 23], ["LC", "TEST", 25, 27], ["TCA", "TEST", 41, 44], ["TCA", "TEST", 45, 48], ["TGT", "TEST", 49, 52], ["CCA", "TEST", 53, 56], ["CCG", "TEST", 57, 60], ["CCC", "TEST", 61, 64], ["AGG", "TEST", 65, 68], ["A", "TEST", 69, 70], ["FL fluorescein", "TEST", 73, 87], ["CGT", "TEST", 89, 92], ["TGT", "TEST", 93, 96], ["GTG", "TEST", 101, 104], ["GTA", "TEST", 105, 108], ["CGC", "TEST", 109, 112], ["TTG", "TEST", 113, 116], ["the primers", "TEST", 129, 140], ["CTC", "TEST", 153, 156], ["TGT", "TEST", 161, 164], ["CAC", "TEST", 165, 168], ["CCT", "TEST", 169, 172], ["GGG", "TEST", 173, 176], ["TG", "TEST", 177, 179], ["CTC TCC", "TEST", 203, 210], ["CGC", "TEST", 211, 214], ["ACC", "TEST", 215, 218], ["TTC", "TEST", 219, 222], ["TAT", "TEST", 227, 230], ["a 186-bp fragment", "TREATMENT", 248, 265], ["the cap gene of PCV2", "TREATMENT", 271, 291]]], ["The Light-Cycler PCV2 PCR was performed in a total volume of 20ll containing a 10ll aliquot of DNA preparation.", [["PCV2", "ORGANISM", 17, 21], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["Light-Cycler PCV2 PCR", "DNA", 4, 25], ["The Light-Cycler PCV2 PCR", "TEST", 0, 25], ["a 10ll aliquot of DNA preparation", "TREATMENT", 77, 110]]], ["Final concentra-tions were 1\u00c2 standard buffer (containing dNTPs and Taq polymerase (Roche Diagnostics GmbH, Mannheim, Germany)), 4 mM magnesium chloride, 0.5 lM of each primer and 0.15 lM of each probe.", [["dNTPs", "CHEMICAL", 58, 63], ["magnesium chloride", "CHEMICAL", 134, 152], ["dNTPs", "CHEMICAL", 58, 63], ["magnesium chloride", "CHEMICAL", 134, 152], ["dNTPs", "SIMPLE_CHEMICAL", 58, 63], ["magnesium chloride", "SIMPLE_CHEMICAL", 134, 152], ["Taq polymerase", "PROTEIN", 68, 82], ["dNTPs", "TREATMENT", 58, 63], ["Taq polymerase", "TEST", 68, 82], ["4 mM magnesium chloride", "TREATMENT", 129, 152]]], ["Cycling parameters were 95\u00b0C for 10 min and 45 cycles at 95\u00b0C for 10 s, 58\u00b0C for 12 s, and 72\u00b0C for 20 s.", [["Cycling parameters", "TEST", 0, 18]]], ["For standard curve, serial dilutions of plasmid (PCV2 cloned in pCR21) of 1-10 11 /ll copies were used.Antibody detectionFor the detection of porcine circovirus type 1 (PCV1) or PCV2 antibodies in porcine sera immunoperoxidase monolayer assays (IPMA) were used (Wellenberg et al., 2000) .", [["plasmid", "ANATOMY", 40, 47], ["sera", "ANATOMY", 205, 209], ["monolayer", "ANATOMY", 227, 236], ["PCV2", "ORGANISM", 49, 53], ["porcine circovirus type 1", "ORGANISM", 142, 167], ["PCV1", "ORGANISM", 169, 173], ["PCV2", "ORGANISM", 178, 182], ["porcine", "ORGANISM", 197, 204], ["sera", "ORGANISM_SUBSTANCE", 205, 209], ["plasmid", "DNA", 40, 47], ["PCV2 antibodies", "PROTEIN", 178, 193], ["porcine circovirus type", "SPECIES", 142, 165], ["porcine", "SPECIES", 197, 204], ["porcine circovirus type 1", "SPECIES", 142, 167], ["PCV1", "SPECIES", 169, 173], ["PCV2", "SPECIES", 178, 182], ["porcine", "SPECIES", 197, 204], ["standard curve", "TEST", 4, 18], ["serial dilutions of plasmid (PCV2", "TREATMENT", 20, 53], ["Antibody detection", "TEST", 103, 121], ["the detection", "TEST", 125, 138], ["porcine circovirus type", "TEST", 142, 165], ["PCV1", "TEST", 169, 173], ["PCV2 antibodies", "TEST", 178, 193], ["porcine sera immunoperoxidase monolayer assays", "TEST", 197, 243]]], ["Briefly, PCV1 or PCV2 infected PK-15 cells were formaldehyde-fixed and pre-incubated with a solution of 10% Triton X-100 and additionally with 10% horse serum in phosphate-buffered salt solution.", [["PK-15 cells", "ANATOMY", 31, 42], ["serum", "ANATOMY", 153, 158], ["formaldehyde", "CHEMICAL", 48, 60], ["Triton X-100", "CHEMICAL", 108, 120], ["phosphate", "CHEMICAL", 162, 171], ["formaldehyde", "CHEMICAL", 48, 60], ["phosphate", "CHEMICAL", 162, 171], ["PCV1", "ORGANISM", 9, 13], ["PCV2", "ORGANISM", 17, 21], ["PK-15 cells", "CELL", 31, 42], ["formaldehyde", "SIMPLE_CHEMICAL", 48, 60], ["Triton X-100", "SIMPLE_CHEMICAL", 108, 120], ["horse", "ORGANISM", 147, 152], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["phosphate-buffered salt solution", "SIMPLE_CHEMICAL", 162, 194], ["PCV1 or PCV2 infected PK-15 cells", "CELL_LINE", 9, 42], ["PCV1", "SPECIES", 9, 13], ["PCV2", "SPECIES", 17, 21], ["PCV1", "TEST", 9, 13], ["PCV2 infected PK", "PROBLEM", 17, 33], ["a solution of 10% Triton", "TREATMENT", 90, 114], ["10% horse serum in phosphate", "TREATMENT", 143, 171], ["buffered salt solution", "TREATMENT", 172, 194]]], ["The antibody titres were determined by preparing twofold dilutions in 10% horse serum in phosphate-buffered salt solution starting at a dilution of 1:100.", [["serum", "ANATOMY", 80, 85], ["phosphate-buffered salt", "CHEMICAL", 89, 112], ["phosphate", "CHEMICAL", 89, 98], ["horse", "ORGANISM", 74, 79], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["phosphate-buffered salt", "SIMPLE_CHEMICAL", 89, 112], ["horse", "SPECIES", 74, 79], ["horse", "SPECIES", 74, 79], ["The antibody titres", "TEST", 0, 19], ["phosphate-buffered salt solution", "TREATMENT", 89, 121]]], ["Serum dilutions were incubated for 1 h at 37\u00b0C. The IPMA was further performed as described above, using a HRPO-labelled rabbit-anti-swine-Ig conjugate (Dakopatt, Glostrup, Denmark).Antibody detectionELISAs were used for the specific detection of PPV (Cedi-Diagnostics, Lelystad, the Netherlands) and PRRSV (Idexx, USA) antibodies.", [["Serum", "ANATOMY", 0, 5], ["HRPO", "CHEMICAL", 107, 111], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IPMA", "SIMPLE_CHEMICAL", 52, 56], ["HRPO", "SIMPLE_CHEMICAL", 107, 111], ["rabbit", "ORGANISM", 121, 127], ["swine", "ORGANISM", 133, 138], ["Ig conjugate", "SIMPLE_CHEMICAL", 139, 151], ["Dakopatt", "SIMPLE_CHEMICAL", 153, 161], ["PRRSV", "ORGANISM", 301, 306], ["Ig conjugate", "PROTEIN", 139, 151], ["PRRSV (Idexx, USA) antibodies", "PROTEIN", 301, 330], ["rabbit", "SPECIES", 121, 127], ["swine", "SPECIES", 133, 138], ["rabbit", "SPECIES", 121, 127], ["PRRSV", "SPECIES", 301, 306], ["Serum dilutions", "TEST", 0, 15], ["The IPMA", "TREATMENT", 48, 56], ["a HRPO", "TEST", 105, 111], ["Antibody detectionELISAs", "TEST", 182, 206], ["PPV", "TEST", 247, 250], ["Cedi", "TEST", 252, 256], ["Lelystad", "TEST", 270, 278], ["PRRSV", "PROBLEM", 301, 306]]], ["ELISAs were performed according to the instructions of the manufacturers.", [["ELISAs", "TEST", 0, 6]]], ["Additionally, an ELISA has been developed to discriminate between antibodies against PRRSV-EU and PRRSV-US (ID-Lelystad, the Netherlands).", [["PRRSV-EU", "ORGANISM", 85, 93], ["PRRSV", "ORGANISM", 98, 103], ["PRRSV", "SPECIES", 85, 90], ["PRRSV", "SPECIES", 85, 90], ["PRRSV", "SPECIES", 98, 103], ["an ELISA", "TEST", 14, 22], ["antibodies", "TEST", 66, 76], ["PRRSV", "PROBLEM", 85, 90]]], ["In addition, 20 randomly chosen serum samples from PMWS cases and controls from PMWS-free herds were screened for the presence of antibodies against other viral infections such as the coronaviruses; porcine epidemic diarrhoea virus (PEDV), transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV), the influenza viruses H1N1, H1N2, and H3N2.", [["serum samples", "ANATOMY", 32, 45], ["PMWS", "DISEASE", 51, 55], ["PMWS", "DISEASE", 80, 84], ["viral infections", "DISEASE", 155, 171], ["porcine epidemic diarrhoea virus", "DISEASE", 199, 231], ["transmissible gastroenteritis virus", "DISEASE", 240, 275], ["TGEV", "DISEASE", 277, 281], ["porcine respiratory coronavirus", "DISEASE", 287, 318], ["influenza viruses H1N1, H1N2, and H3N2", "DISEASE", 331, 369], ["serum samples", "ORGANISM_SUBSTANCE", 32, 45], ["porcine epidemic diarrhoea virus", "ORGANISM", 199, 231], ["transmissible gastroenteritis virus", "ORGANISM", 240, 275], ["TGEV", "ORGANISM", 277, 281], ["porcine respiratory coronavirus", "ORGANISM", 287, 318], ["influenza viruses H1N1", "ORGANISM", 331, 353], ["antibodies", "PROTEIN", 130, 140], ["porcine epidemic diarrhoea virus", "SPECIES", 199, 231], ["transmissible gastroenteritis virus", "SPECIES", 240, 275], ["TGEV", "SPECIES", 277, 281], ["porcine respiratory coronavirus", "SPECIES", 287, 318], ["influenza viruses H1N1", "SPECIES", 331, 353], ["H3N2", "SPECIES", 365, 369], ["porcine epidemic diarrhoea virus", "SPECIES", 199, 231], ["PEDV", "SPECIES", 233, 237], ["transmissible gastroenteritis virus", "SPECIES", 240, 275], ["TGEV", "SPECIES", 277, 281], ["porcine respiratory coronavirus", "SPECIES", 287, 318], ["PRCV", "SPECIES", 320, 324], ["serum samples", "TEST", 32, 45], ["PMWS cases", "TEST", 51, 61], ["PMWS", "PROBLEM", 80, 84], ["antibodies", "PROBLEM", 130, 140], ["other viral infections", "PROBLEM", 149, 171], ["the coronaviruses", "PROBLEM", 180, 197], ["porcine epidemic diarrhoea virus", "PROBLEM", 199, 231], ["PEDV", "PROBLEM", 233, 237], ["transmissible gastroenteritis virus (TGEV", "PROBLEM", 240, 281], ["porcine respiratory coronavirus", "PROBLEM", 287, 318], ["the influenza viruses H1N1", "PROBLEM", 327, 353], ["H1N2", "PROBLEM", 355, 359], ["H3N2", "PROBLEM", 365, 369], ["respiratory coronavirus", "OBSERVATION", 295, 318]]], ["This to get an impression on the occurrence of other (endemic) virus infections in case herds and PMWS-free herds.BacteriologyAll affected organs at necropsy were investigated for the presence of pathogenic bacteria, e.g. Haemophilus spp., Mycoplasma spp.", [["organs", "ANATOMY", 139, 145], ["infections", "DISEASE", 69, 79], ["PMWS", "DISEASE", 98, 102], ["Haemophilus spp.", "DISEASE", 222, 238], ["Mycoplasma spp", "DISEASE", 240, 254], ["organs", "ORGAN", 139, 145], ["Haemophilus spp.", "ORGANISM", 222, 238], ["Mycoplasma spp", "ORGANISM", 240, 254], ["Haemophilus spp.", "SPECIES", 222, 238], ["Mycoplasma spp", "SPECIES", 240, 254], ["Haemophilus spp.", "SPECIES", 222, 238], ["other (endemic) virus infections", "PROBLEM", 47, 79], ["PMWS", "PROBLEM", 98, 102], ["Bacteriology", "TEST", 114, 126], ["pathogenic bacteria", "PROBLEM", 196, 215], ["Haemophilus spp.", "PROBLEM", 222, 238], ["Mycoplasma spp", "PROBLEM", 240, 254], ["pathogenic", "OBSERVATION_MODIFIER", 196, 206], ["bacteria", "OBSERVATION", 207, 215]]], ["Fifteen randomly chosen faeces samples were collected for the detection of Salmonella spp.", [["faeces samples", "ANATOMY", 24, 38], ["faeces samples", "CANCER", 24, 38], ["Salmonella spp", "ORGANISM", 75, 89], ["faeces samples", "TEST", 24, 38], ["Salmonella spp", "PROBLEM", 75, 89], ["Salmonella spp", "OBSERVATION", 75, 89]]], ["Standard procedures were used for the detection of bacteria in affected organs and tissues.Epidemiological dataData on the PMWS and PDNS history, and the use of vaccines against e.g. PRRSV and Mycoplasma hyo-pneumoniae were collected from each case and control herd.Statistical methodsStatistical analysis (v 2 ) was performed to compare; (a) the proportion of PCV2 positive pigs (by virus isolation and/or PCR) within the case group with the proportion of PCV2 positive control pigs in the 3 control groups, (b) the proportion of cases with high PCV2 DNA loads in mesenteric and inguinal lymph nodes (> 10 5 copies/ll) with the proportion of control pigs within the three control groups with high PCV2 DNA loads, and (c) the proportion of PRRSV infected pigs (rt-PCR and/or ELISA antibodies positive) within the case group with the proportion of PRRSV positive control pigs within the three control groups.Statistical methodsFisher exact test was performed to compare the proportion of co-infections of PRRSV-EU and -US in case herds with that of the PMWS-free control herds.Macroscopic and histopathological lesionsEnlargement of the lymph nodes and spleen, pneumonia and kidneys with white spots were the most dominant macroscopic changes in cases (Fig. 1) .", [["organs", "ANATOMY", 72, 78], ["tissues", "ANATOMY", 83, 90], ["mesenteric", "ANATOMY", 565, 575], ["inguinal lymph nodes", "ANATOMY", 580, 600], ["lesions", "ANATOMY", 1110, 1117], ["lymph nodes", "ANATOMY", 1136, 1147], ["spleen", "ANATOMY", 1152, 1158], ["kidneys", "ANATOMY", 1174, 1181], ["PMWS", "DISEASE", 123, 127], ["PRRSV infected", "DISEASE", 740, 754], ["PMWS", "DISEASE", 1052, 1056], ["Enlargement of the lymph nodes", "DISEASE", 1117, 1147], ["pneumonia", "DISEASE", 1160, 1169], ["organs", "ORGAN", 72, 78], ["tissues", "TISSUE", 83, 90], ["PRRSV", "ORGANISM", 183, 188], ["Mycoplasma hyo-pneumoniae", "ORGANISM", 193, 218], ["PCV2", "ORGANISM", 361, 365], ["pigs", "ORGANISM", 375, 379], ["PCV2", "ORGANISM", 457, 461], ["pigs", "ORGANISM", 479, 483], ["PCV2", "ORGANISM", 547, 551], ["DNA", "CELLULAR_COMPONENT", 552, 555], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 565, 575], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 580, 600], ["pigs", "ORGANISM", 651, 655], ["PCV2", "ORGANISM", 698, 702], ["DNA", "CELLULAR_COMPONENT", 703, 706], ["PRRSV", "ORGANISM", 740, 745], ["pigs", "ORGANISM", 755, 759], ["PRRSV", "ORGANISM", 847, 852], ["pigs", "ORGANISM", 870, 874], ["PRRSV", "ORGANISM", 1004, 1009], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 1136, 1147], ["spleen", "ORGAN", 1152, 1158], ["kidneys", "ORGAN", 1174, 1181], ["ELISA antibodies", "PROTEIN", 775, 791], ["PRRSV", "SPECIES", 183, 188], ["Mycoplasma hyo-pneumoniae", "SPECIES", 193, 218], ["pigs", "SPECIES", 375, 379], ["pigs", "SPECIES", 479, 483], ["pigs", "SPECIES", 651, 655], ["pigs", "SPECIES", 755, 759], ["pigs", "SPECIES", 870, 874], ["PRRSV", "SPECIES", 183, 188], ["Mycoplasma hyo-pneumoniae", "SPECIES", 193, 218], ["pigs", "SPECIES", 375, 379], ["PCV2", "SPECIES", 457, 461], ["pigs", "SPECIES", 479, 483], ["PCV2", "SPECIES", 547, 551], ["pigs", "SPECIES", 651, 655], ["PCV2", "SPECIES", 698, 702], ["PRRSV", "SPECIES", 740, 745], ["pigs", "SPECIES", 755, 759], ["PRRSV", "SPECIES", 847, 852], ["pigs", "SPECIES", 870, 874], ["PRRSV", "SPECIES", 1004, 1009], ["Standard procedures", "TREATMENT", 0, 19], ["the detection", "TEST", 34, 47], ["bacteria in affected organs and tissues", "PROBLEM", 51, 90], ["vaccines", "TREATMENT", 161, 169], ["PRRSV", "PROBLEM", 183, 188], ["Mycoplasma hyo-pneumoniae", "PROBLEM", 193, 218], ["PCV2 positive pigs", "PROBLEM", 361, 379], ["virus isolation", "TREATMENT", 384, 399], ["PCR", "TEST", 407, 410], ["PCV2 positive control pigs", "TREATMENT", 457, 483], ["high PCV2 DNA loads in mesenteric and inguinal lymph nodes", "PROBLEM", 542, 600], ["control pigs", "TREATMENT", 643, 655], ["high PCV2 DNA loads", "PROBLEM", 693, 712], ["PRRSV infected pigs (rt-PCR", "PROBLEM", 740, 767], ["ELISA antibodies positive", "PROBLEM", 775, 800], ["PRRSV positive control pigs", "TREATMENT", 847, 874], ["Fisher exact test", "TEST", 926, 943], ["the PMWS", "TEST", 1048, 1056], ["Macroscopic and histopathological lesions", "PROBLEM", 1076, 1117], ["Enlargement of the lymph nodes", "PROBLEM", 1117, 1147], ["pneumonia", "PROBLEM", 1160, 1169], ["kidneys", "PROBLEM", 1174, 1181], ["white spots", "PROBLEM", 1187, 1198], ["bacteria", "OBSERVATION", 51, 59], ["organs", "ANATOMY", 72, 78], ["tissues", "ANATOMY", 83, 90], ["Mycoplasma hyo-pneumoniae", "OBSERVATION", 193, 218], ["PCV2", "OBSERVATION", 361, 365], ["positive pigs", "OBSERVATION", 366, 379], ["PCV2", "OBSERVATION", 457, 461], ["high PCV2", "OBSERVATION", 542, 551], ["DNA loads", "OBSERVATION", 552, 561], ["mesenteric", "ANATOMY", 565, 575], ["inguinal", "ANATOMY", 580, 588], ["lymph nodes", "OBSERVATION", 589, 600], ["high PCV2", "OBSERVATION", 693, 702], ["DNA loads", "OBSERVATION", 703, 712], ["PRRSV", "OBSERVATION", 740, 745], ["infected pigs", "OBSERVATION", 746, 759], ["PRRSV", "OBSERVATION", 847, 852], ["positive control", "OBSERVATION", 853, 869], ["histopathological", "OBSERVATION_MODIFIER", 1092, 1109], ["lesions", "OBSERVATION", 1110, 1117], ["lymph nodes", "OBSERVATION", 1136, 1147], ["spleen", "ANATOMY", 1152, 1158], ["pneumonia", "OBSERVATION", 1160, 1169], ["kidneys", "ANATOMY", 1174, 1181], ["white spots", "OBSERVATION", 1187, 1198], ["most dominant", "OBSERVATION_MODIFIER", 1208, 1221], ["macroscopic", "OBSERVATION", 1222, 1233]]], ["In most of the cases, pneumonia was characterised by mild to severe interstitial oedema, firm tissue with decreased retraction and focal catarrhal or fibrous inflammation.", [["interstitial", "ANATOMY", 68, 80], ["tissue", "ANATOMY", 94, 100], ["focal catarrhal", "ANATOMY", 131, 146], ["fibrous", "ANATOMY", 150, 157], ["pneumonia", "DISEASE", 22, 31], ["interstitial oedema", "DISEASE", 68, 87], ["catarrhal", "DISEASE", 137, 146], ["fibrous inflammation", "DISEASE", 150, 170], ["interstitial oedema", "PATHOLOGICAL_FORMATION", 68, 87], ["tissue", "TISSUE", 94, 100], ["catarrhal", "PATHOLOGICAL_FORMATION", 137, 146], ["fibrous inflammation", "PATHOLOGICAL_FORMATION", 150, 170], ["pneumonia", "PROBLEM", 22, 31], ["mild to severe interstitial oedema", "PROBLEM", 53, 87], ["firm tissue", "PROBLEM", 89, 100], ["decreased retraction", "PROBLEM", 106, 126], ["focal catarrhal", "PROBLEM", 131, 146], ["fibrous inflammation", "PROBLEM", 150, 170], ["pneumonia", "OBSERVATION", 22, 31], ["mild", "OBSERVATION_MODIFIER", 53, 57], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["interstitial", "ANATOMY_MODIFIER", 68, 80], ["oedema", "OBSERVATION", 81, 87], ["firm tissue", "OBSERVATION", 89, 100], ["decreased", "OBSERVATION_MODIFIER", 106, 115], ["retraction", "OBSERVATION_MODIFIER", 116, 126], ["focal", "OBSERVATION_MODIFIER", 131, 136], ["catarrhal", "OBSERVATION_MODIFIER", 137, 146], ["fibrous inflammation", "OBSERVATION", 150, 170]]], ["Stomach ulcers were observed in 32% of the PMWS cases.", [["Stomach ulcers", "ANATOMY", 0, 14], ["Stomach ulcers", "DISEASE", 0, 14], ["PMWS", "DISEASE", 43, 47], ["Stomach ulcers", "PATHOLOGICAL_FORMATION", 0, 14], ["Stomach ulcers", "PROBLEM", 0, 14], ["ulcers", "OBSERVATION", 8, 14]]], ["Histopathological examinations of mesenteric and inguinal lymph nodes revealed lymphocytic depletion in follicular and parafollicular areas in most but not in all of the examined pigs with clinical signs of PMWS.", [["mesenteric", "ANATOMY", 34, 44], ["inguinal lymph nodes", "ANATOMY", 49, 69], ["lymphocytic", "ANATOMY", 79, 90], ["follicular", "ANATOMY", 104, 114], ["parafollicular areas", "ANATOMY", 119, 139], ["PMWS", "DISEASE", 207, 211], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 34, 44], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 49, 69], ["follicular", "CANCER", 104, 114], ["pigs", "ORGANISM", 179, 183], ["pigs", "SPECIES", 179, 183], ["pigs", "SPECIES", 179, 183], ["Histopathological examinations", "TEST", 0, 30], ["mesenteric and inguinal lymph nodes", "PROBLEM", 34, 69], ["lymphocytic depletion in follicular and parafollicular areas", "PROBLEM", 79, 139], ["PMWS", "PROBLEM", 207, 211], ["mesenteric", "ANATOMY", 34, 44], ["inguinal", "ANATOMY", 49, 57], ["lymph nodes", "OBSERVATION", 58, 69], ["lymphocytic depletion", "OBSERVATION", 79, 100], ["follicular", "OBSERVATION_MODIFIER", 104, 114], ["parafollicular", "ANATOMY", 119, 133], ["PMWS", "OBSERVATION", 207, 211]]], ["Gross lesions consisted of hyperplasia, probably of the follicular dendritic cells in the follicular areas, were also found in lymph nodes from pigs with clinical signs of PMWS.", [["Gross lesions", "ANATOMY", 0, 13], ["follicular dendritic cells", "ANATOMY", 56, 82], ["follicular areas", "ANATOMY", 90, 106], ["lymph nodes", "ANATOMY", 127, 138], ["hyperplasia", "DISEASE", 27, 38], ["PMWS", "DISEASE", 172, 176], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["follicular dendritic cells", "CELL", 56, 82], ["follicular areas", "MULTI-TISSUE_STRUCTURE", 90, 106], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 127, 138], ["pigs", "ORGANISM", 144, 148], ["follicular dendritic cells", "CELL_TYPE", 56, 82], ["pigs", "SPECIES", 144, 148], ["pigs", "SPECIES", 144, 148], ["Gross lesions", "PROBLEM", 0, 13], ["hyperplasia", "PROBLEM", 27, 38], ["the follicular dendritic cells", "PROBLEM", 52, 82], ["lymph nodes", "PROBLEM", 127, 138], ["PMWS", "PROBLEM", 172, 176], ["lesions", "OBSERVATION", 6, 13], ["hyperplasia", "OBSERVATION", 27, 38], ["probably of", "UNCERTAINTY", 40, 51], ["follicular dendritic cells", "OBSERVATION", 56, 82], ["follicular", "ANATOMY", 90, 100], ["lymph nodes", "OBSERVATION", 127, 138], ["PMWS", "OBSERVATION", 172, 176]]], ["Most of these lesions were characterised histologically by infiltration of mononuclear cells often in combination with the presence of giant cells.", [["lesions", "ANATOMY", 14, 21], ["mononuclear cells", "ANATOMY", 75, 92], ["giant cells", "ANATOMY", 135, 146], ["lesions", "PATHOLOGICAL_FORMATION", 14, 21], ["mononuclear cells", "CELL", 75, 92], ["giant cells", "CELL", 135, 146], ["mononuclear cells", "CELL_TYPE", 75, 92], ["giant cells", "CELL_TYPE", 135, 146], ["these lesions", "PROBLEM", 8, 21], ["infiltration of mononuclear cells", "PROBLEM", 59, 92], ["giant cells", "PROBLEM", 135, 146], ["lesions", "OBSERVATION", 14, 21], ["histologically", "OBSERVATION_MODIFIER", 41, 55], ["infiltration", "OBSERVATION", 59, 71], ["mononuclear cells", "OBSERVATION", 75, 92], ["giant cells", "OBSERVATION", 135, 146]]], ["Interstitial pneumonia with bronchovasculo-interstitial infiltrations of leukocytes was a dominant histopathological finding in pigs with clinical signs of PMWS.", [["Interstitial", "ANATOMY", 0, 12], ["bronchovasculo", "ANATOMY", 28, 42], ["interstitial", "ANATOMY", 43, 55], ["leukocytes", "ANATOMY", 73, 83], ["Interstitial pneumonia", "DISEASE", 0, 22], ["PMWS", "DISEASE", 156, 160], ["bronchovasculo-interstitial", "PATHOLOGICAL_FORMATION", 28, 55], ["leukocytes", "CELL", 73, 83], ["pigs", "ORGANISM", 128, 132], ["leukocytes", "CELL_TYPE", 73, 83], ["pigs", "SPECIES", 128, 132], ["pigs", "SPECIES", 128, 132], ["Interstitial pneumonia", "PROBLEM", 0, 22], ["bronchovasculo-interstitial infiltrations of leukocytes", "PROBLEM", 28, 83], ["PMWS", "PROBLEM", 156, 160], ["pneumonia", "OBSERVATION", 13, 22], ["bronchovasculo", "OBSERVATION_MODIFIER", 28, 42], ["interstitial", "ANATOMY_MODIFIER", 43, 55], ["infiltrations", "OBSERVATION", 56, 69], ["leukocytes", "OBSERVATION", 73, 83], ["dominant", "OBSERVATION_MODIFIER", 90, 98], ["histopathological", "OBSERVATION", 99, 116], ["PMWS", "OBSERVATION", 156, 160]]], ["In 76% of the kidneys from pigs with clinical signs of PMWS an interstitial nephritis was found, which varied in severity.Porcine circovirus type 2In 87% of the 60 cases, moderate to high levels of infectious PCV2 were detected in lung, mesenteric and inguinal lymph nodes, spleen and kidney by virus isolation on PK-15 cells, and DULAC cells as well (Table 1 ).", [["kidneys", "ANATOMY", 14, 21], ["interstitial", "ANATOMY", 63, 75], ["lung", "ANATOMY", 231, 235], ["mesenteric", "ANATOMY", 237, 247], ["inguinal lymph nodes", "ANATOMY", 252, 272], ["spleen", "ANATOMY", 274, 280], ["kidney", "ANATOMY", 285, 291], ["PK-15 cells", "ANATOMY", 314, 325], ["DULAC cells", "ANATOMY", 331, 342], ["PMWS", "DISEASE", 55, 59], ["interstitial nephritis", "DISEASE", 63, 85], ["kidneys", "ORGAN", 14, 21], ["pigs", "ORGANISM", 27, 31], ["Porcine circovirus type 2In", "ORGANISM", 122, 149], ["PCV2", "ORGANISM", 209, 213], ["lung", "ORGAN", 231, 235], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 237, 247], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 252, 272], ["spleen", "ORGAN", 274, 280], ["kidney", "ORGAN", 285, 291], ["PK-15 cells", "CELL", 314, 325], ["DULAC cells", "CELL", 331, 342], ["PK-15 cells", "CELL_LINE", 314, 325], ["DULAC cells", "CELL_LINE", 331, 342], ["pigs", "SPECIES", 27, 31], ["Porcine circovirus", "SPECIES", 122, 140], ["pigs", "SPECIES", 27, 31], ["Porcine circovirus type 2In 87", "SPECIES", 122, 152], ["PCV2", "SPECIES", 209, 213], ["PMWS", "PROBLEM", 55, 59], ["an interstitial nephritis", "PROBLEM", 60, 85], ["Porcine circovirus type", "TEST", 122, 145], ["moderate to high levels of infectious PCV2", "PROBLEM", 171, 213], ["PK", "TEST", 314, 316], ["DULAC cells", "PROBLEM", 331, 342], ["kidneys", "ANATOMY", 14, 21], ["interstitial", "OBSERVATION_MODIFIER", 63, 75], ["nephritis", "OBSERVATION", 76, 85], ["varied", "OBSERVATION_MODIFIER", 103, 109], ["severity", "OBSERVATION_MODIFIER", 113, 121], ["moderate", "OBSERVATION_MODIFIER", 171, 179], ["high levels", "OBSERVATION_MODIFIER", 183, 194], ["infectious", "OBSERVATION_MODIFIER", 198, 208], ["PCV2", "OBSERVATION", 209, 213], ["lung", "ANATOMY", 231, 235], ["mesenteric", "ANATOMY", 237, 247], ["inguinal", "ANATOMY", 252, 260], ["lymph nodes", "OBSERVATION", 261, 272], ["spleen", "ANATOMY", 274, 280], ["kidney", "ANATOMY", 285, 291], ["virus", "OBSERVATION", 295, 300]]], ["In the remaining 13% of the cases no infectious or low levels of infectious PCV2 were detected.", [["PCV2", "ORGANISM", 76, 80], ["infectious", "PROBLEM", 37, 47], ["low levels of infectious PCV2", "PROBLEM", 51, 80], ["infectious", "OBSERVATION_MODIFIER", 37, 47], ["low levels", "OBSERVATION_MODIFIER", 51, 61], ["infectious PCV2", "OBSERVATION", 65, 80]]], ["However, high levels of PCV2 DNA (> 10 5 copies/ll organ suspension) were found in lymph nodes of these pigs by the quantitative real-time PCV2 PCR, and in sera of 5 of these 8 cases high antibody titres against PCV2 (>1:102400) were detected.Porcine circovirus type 2Infectious PCV2 was detected by virus isolation in 30% of the control pigs from PMWS-free herds, but the number of PCV2 infected PK-15 or DULAC cells after inoculation with organ suspensions from control pigs was much lower than the number of PCV2 infected PK-15 or DULAC cells after inoculation with organ suspensions from cases (data not shown).", [["organ", "ANATOMY", 51, 56], ["lymph nodes", "ANATOMY", 83, 94], ["sera", "ANATOMY", 156, 160], ["DULAC cells", "ANATOMY", 406, 417], ["organ suspensions", "ANATOMY", 441, 458], ["DULAC cells", "ANATOMY", 534, 545], ["organ suspensions", "ANATOMY", 569, 586], ["PMWS", "DISEASE", 348, 352], ["PCV2", "ORGANISM", 24, 28], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["organ", "ORGAN", 51, 56], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 83, 94], ["pigs", "ORGANISM", 104, 108], ["PCV2", "ORGANISM", 139, 143], ["sera", "ORGANISM_SUBSTANCE", 156, 160], ["PCV2", "ORGANISM", 212, 216], ["Porcine circovirus type 2Infectious PCV2", "ORGANISM", 243, 283], ["pigs", "ORGANISM", 338, 342], ["PCV2", "ORGANISM", 383, 387], ["PK-15", "CELL", 397, 402], ["DULAC cells", "CELL", 406, 417], ["organ", "ORGAN", 441, 446], ["pigs", "ORGANISM", 472, 476], ["PCV2", "ORGANISM", 511, 515], ["PK-15", "CELL", 525, 530], ["DULAC cells", "CELL", 534, 545], ["organ", "ORGAN", 569, 574], ["PCV2 DNA", "DNA", 24, 32], ["DULAC cells", "CELL_LINE", 406, 417], ["DULAC cells", "CELL_LINE", 534, 545], ["pigs", "SPECIES", 104, 108], ["Porcine circovirus", "SPECIES", 243, 261], ["pigs", "SPECIES", 338, 342], ["pigs", "SPECIES", 472, 476], ["PCV2", "SPECIES", 24, 28], ["pigs", "SPECIES", 104, 108], ["Porcine circovirus type 2Infectious PCV2", "SPECIES", 243, 283], ["pigs", "SPECIES", 338, 342], ["PCV2", "SPECIES", 383, 387], ["pigs", "SPECIES", 472, 476], ["PCV2", "SPECIES", 511, 515], ["PCV2 DNA", "PROBLEM", 24, 32], ["copies/ll organ suspension", "TREATMENT", 41, 67], ["PCV2 PCR", "TEST", 139, 147], ["sera", "TEST", 156, 160], ["high antibody titres", "TEST", 183, 203], ["PCV2", "PROBLEM", 212, 216], ["Porcine circovirus type 2Infectious PCV2", "PROBLEM", 243, 283], ["virus isolation", "TREATMENT", 300, 315], ["PMWS", "PROBLEM", 348, 352], ["PCV2 infected PK", "TEST", 383, 399], ["DULAC cells", "PROBLEM", 406, 417], ["inoculation", "TREATMENT", 424, 435], ["organ suspensions", "TREATMENT", 441, 458], ["PCV2 infected PK", "TEST", 511, 527], ["DULAC cells", "PROBLEM", 534, 545], ["organ suspensions", "TEST", 569, 586], ["lymph nodes", "OBSERVATION", 83, 94], ["PCV2", "OBSERVATION", 279, 283]]], ["PCV2 DNA was detected in 100% of the examined cases and in 50% of the controls from PMWS-free herds.", [["PMWS", "DISEASE", 84, 88], ["PCV2", "ORGANISM", 0, 4], ["DNA", "CELLULAR_COMPONENT", 5, 8], ["PCV2 DNA", "DNA", 0, 8], ["PCV2", "SPECIES", 0, 4], ["PCV2 DNA", "TEST", 0, 8], ["PMWS", "PROBLEM", 84, 88]]], ["The mean 10 log PCV2 DNA copy number in mesenteric and inguinal lymph nodes was higher in cases than in the control groups, and at least 10 5 times higher than the mean 10 log PCV2 DNA copy number in controls of PMWSfree herds (Table 2 ).Porcine circovirus type 2In 6 (17%) of the 35 investigated lymph nodes from controls of PMWS-free herds, the PCV2 DNA loads were between 10 5 and 6 \u00c2 10 8 DNA copies/ll organ suspension.", [["mesenteric", "ANATOMY", 40, 50], ["inguinal lymph nodes", "ANATOMY", 55, 75], ["lymph nodes", "ANATOMY", 297, 308], ["organ", "ANATOMY", 407, 412], ["PMWS", "DISEASE", 326, 330], ["PCV2", "ORGANISM", 16, 20], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 40, 50], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 55, 75], ["PCV2", "ORGANISM", 176, 180], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["Porcine circovirus type 2In", "ORGANISM", 238, 265], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 297, 308], ["PCV2", "ORGANISM", 347, 351], ["DNA", "CELLULAR_COMPONENT", 352, 355], ["DNA", "CELLULAR_COMPONENT", 393, 396], ["organ", "ORGAN", 407, 412], ["Porcine circovirus", "SPECIES", 238, 256], ["PCV2", "SPECIES", 16, 20], ["Porcine circovirus type 2In 6", "SPECIES", 238, 267], ["PCV2", "SPECIES", 347, 351], ["The mean", "TEST", 0, 8], ["mesenteric and inguinal lymph nodes", "PROBLEM", 40, 75], ["Porcine circovirus type", "TEST", 238, 261], ["lymph nodes", "TEST", 297, 308], ["PMWS", "PROBLEM", 326, 330], ["the PCV2 DNA loads", "TEST", 343, 361], ["DNA copies/ll organ suspension", "TREATMENT", 393, 423], ["mesenteric", "ANATOMY", 40, 50], ["inguinal", "ANATOMY", 55, 63], ["lymph nodes", "OBSERVATION", 64, 75], ["higher", "OBSERVATION_MODIFIER", 80, 86], ["circovirus", "OBSERVATION", 246, 256], ["lymph nodes", "OBSERVATION", 297, 308]]], ["In 4 of these 6 control pigs without clinical signs of PMWS, mild to moderate macroscopic changes such as white spotted kidneys, pneumonia, enlarged spleen, and/or enlarged and haemorrhagic lymph nodes were observed.Porcine circovirus type 2Statistical analysis (v 2 ) revealed that the proportion of PCV2 positive pigs (by virus isolation and/or PCR) within the case group was significantly higher than the proportion of PCV2 positive control pigs; (a) housed within the same compartment (p \u00bc 0:003), (b) from other compartments within case herds (p \u00bc 0:0000), and (c) from PMWS-free herds (p \u00bc 0:0000). v 2 Analysis also showed significant differences between the proportion of cases with high PCV2 DNA copy loads in mesenteric and inguinal lymph nodes (>10 5 copies/ll) and the proportion of control pigs within the three control groups with high PCV2 DNA copy loads (p < 0:001).", [["kidneys", "ANATOMY", 120, 127], ["spleen", "ANATOMY", 149, 155], ["lymph nodes", "ANATOMY", 190, 201], ["mesenteric", "ANATOMY", 719, 729], ["inguinal lymph nodes", "ANATOMY", 734, 754], ["PMWS", "DISEASE", 55, 59], ["pneumonia", "DISEASE", 129, 138], ["PMWS", "DISEASE", 575, 579], ["pigs", "ORGANISM", 24, 28], ["kidneys", "ORGAN", 120, 127], ["spleen", "ORGAN", 149, 155], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 190, 201], ["Porcine circovirus", "ORGANISM", 216, 234], ["PCV2", "ORGANISM", 301, 305], ["pigs", "ORGANISM", 315, 319], ["PCV2", "ORGANISM", 422, 426], ["pigs", "ORGANISM", 444, 448], ["PCV2", "ORGANISM", 696, 700], ["DNA", "CELLULAR_COMPONENT", 701, 704], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 719, 729], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 734, 754], ["pigs", "ORGANISM", 803, 807], ["PCV2", "ORGANISM", 850, 854], ["DNA", "CELLULAR_COMPONENT", 855, 858], ["pigs", "SPECIES", 24, 28], ["Porcine circovirus", "SPECIES", 216, 234], ["pigs", "SPECIES", 315, 319], ["pigs", "SPECIES", 444, 448], ["pigs", "SPECIES", 803, 807], ["pigs", "SPECIES", 24, 28], ["Porcine circovirus type 2Statistical", "SPECIES", 216, 252], ["PCV2", "SPECIES", 301, 305], ["pigs", "SPECIES", 315, 319], ["pigs", "SPECIES", 444, 448], ["pigs", "SPECIES", 803, 807], ["PMWS", "PROBLEM", 55, 59], ["mild to moderate macroscopic changes", "PROBLEM", 61, 97], ["white spotted kidneys", "PROBLEM", 106, 127], ["pneumonia", "PROBLEM", 129, 138], ["enlarged spleen", "PROBLEM", 140, 155], ["enlarged and haemorrhagic lymph nodes", "PROBLEM", 164, 201], ["Porcine circovirus type 2Statistical analysis", "TEST", 216, 261], ["PCV2 positive pigs", "PROBLEM", 301, 319], ["virus isolation", "TREATMENT", 324, 339], ["PCR", "TEST", 347, 350], ["v 2 Analysis", "TEST", 605, 617], ["high PCV2 DNA copy loads in mesenteric and inguinal lymph nodes", "PROBLEM", 691, 754], ["PMWS", "OBSERVATION", 55, 59], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["moderate", "OBSERVATION_MODIFIER", 69, 77], ["macroscopic", "OBSERVATION", 78, 89], ["white", "OBSERVATION_MODIFIER", 106, 111], ["spotted", "OBSERVATION_MODIFIER", 112, 119], ["kidneys", "ANATOMY", 120, 127], ["pneumonia", "OBSERVATION", 129, 138], ["enlarged", "OBSERVATION_MODIFIER", 140, 148], ["spleen", "ANATOMY", 149, 155], ["enlarged", "OBSERVATION_MODIFIER", 164, 172], ["haemorrhagic", "OBSERVATION_MODIFIER", 177, 189], ["lymph nodes", "OBSERVATION", 190, 201], ["PCV2", "OBSERVATION", 301, 305], ["positive pigs", "OBSERVATION", 306, 319], ["PCV2", "OBSERVATION", 422, 426], ["significant", "OBSERVATION_MODIFIER", 630, 641], ["high PCV2", "OBSERVATION", 691, 700], ["mesenteric", "ANATOMY", 719, 729], ["inguinal", "ANATOMY", 734, 742], ["lymph nodes", "OBSERVATION", 743, 754], ["high PCV2", "OBSERVATION", 845, 854]]], ["In 27% of the cases no PCV2 antibodies could be detected by IPMA, or the PCV2 antibody titre was very low (<1:400).", [["PCV2", "ORGANISM", 23, 27], ["PCV2", "ORGANISM", 73, 77], ["PCV2 antibodies", "PROTEIN", 23, 38], ["IPMA", "PROTEIN", 60, 64], ["PCV2", "SPECIES", 23, 27], ["PCV2", "SPECIES", 73, 77], ["PCV2 antibodies", "PROBLEM", 23, 38], ["IPMA", "TEST", 60, 64], ["the PCV2 antibody titre", "TEST", 69, 92]]], ["The PCV2 antibody titres in 61% of the cases varied between 1:400 and approximately 1:102400, while very high PCV2 antibody titres of P 1:409600 were found in the remaining cases (Fig. 2) .", [["PCV2", "ORGANISM", 4, 8], ["PCV2", "ORGANISM", 110, 114], ["P 1:409600", "DNA", 134, 144], ["PCV2", "SPECIES", 4, 8], ["PCV2", "SPECIES", 110, 114], ["The PCV2 antibody titres", "TEST", 0, 24], ["the cases", "TEST", 35, 44], ["very high PCV2 antibody titres of P", "PROBLEM", 100, 135]]], ["In herds from these latter cases, also pigs showing signs of PDNS were observed.Porcine circovirus type 1PCV1 antibodies were detected in serum of 38% of the cases and in 22% of the controls from PMWS-free herds.", [["serum", "ANATOMY", 138, 143], ["PDNS", "DISEASE", 61, 65], ["PMWS", "DISEASE", 196, 200], ["pigs", "ORGANISM", 39, 43], ["PDNS", "CANCER", 61, 65], ["Porcine circovirus type 1PCV1", "ORGANISM", 80, 109], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["Porcine circovirus type 1PCV1 antibodies", "PROTEIN", 80, 120], ["pigs", "SPECIES", 39, 43], ["Porcine circovirus", "SPECIES", 80, 98], ["pigs", "SPECIES", 39, 43], ["Porcine circovirus type 1PCV1", "SPECIES", 80, 109], ["PDNS", "PROBLEM", 61, 65], ["Porcine circovirus type 1PCV1 antibodies", "TEST", 80, 120], ["serum", "TEST", 138, 143], ["the cases", "TEST", 154, 163], ["PMWS", "PROBLEM", 196, 200]]], ["The PCV1 antibody titres in cases ranged between <1:100 and 1:6400 and in sera of PMWS-free control pigs the PCV1 antibody titres ranged between <1:100 and 1:1600.Porcine parvovirusPPV DNA could not be detected in lung, mesenteric and inguinal lymph nodes, spleen and kidney of 38 examined cases.", [["sera", "ANATOMY", 74, 78], ["lung", "ANATOMY", 214, 218], ["mesenteric", "ANATOMY", 220, 230], ["inguinal lymph nodes", "ANATOMY", 235, 255], ["spleen", "ANATOMY", 257, 263], ["kidney", "ANATOMY", 268, 274], ["PMWS", "DISEASE", 82, 86], ["PCV1 antibody", "GENE_OR_GENE_PRODUCT", 4, 17], ["sera", "ORGANISM_SUBSTANCE", 74, 78], ["pigs", "ORGANISM", 100, 104], ["PCV1", "ORGANISM", 109, 113], ["Porcine", "ORGANISM", 163, 170], ["parvovirusPPV", "GENE_OR_GENE_PRODUCT", 171, 184], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["lung", "ORGAN", 214, 218], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 220, 230], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 235, 255], ["spleen", "ORGAN", 257, 263], ["kidney", "ORGAN", 268, 274], ["PCV1 antibody", "PROTEIN", 4, 17], ["Porcine parvovirusPPV DNA", "DNA", 163, 188], ["pigs", "SPECIES", 100, 104], ["Porcine", "SPECIES", 163, 170], ["PCV1", "SPECIES", 4, 8], ["pigs", "SPECIES", 100, 104], ["PCV1", "SPECIES", 109, 113], ["parvovirusPPV", "SPECIES", 171, 184], ["The PCV1 antibody titres", "TEST", 0, 24], ["PMWS", "TEST", 82, 86], ["the PCV1 antibody titres", "TEST", 105, 129], ["Porcine parvovirusPPV DNA", "PROBLEM", 163, 188], ["could not be detected", "UNCERTAINTY", 189, 210], ["lung", "ANATOMY", 214, 218], ["mesenteric", "ANATOMY", 220, 230], ["inguinal", "ANATOMY", 235, 243], ["lymph nodes", "OBSERVATION", 244, 255], ["spleen", "ANATOMY", 257, 263], ["kidney", "ANATOMY", 268, 274]]], ["Porcine parvovirus antibodies were detected in 63% of the examined cases and in 67% of the PMWS-free controls.", [["PMWS", "DISEASE", 91, 95], ["Porcine parvovirus", "ORGANISM", 0, 18], ["Porcine parvovirus antibodies", "PROTEIN", 0, 29], ["Porcine", "SPECIES", 0, 7], ["Porcine parvovirus", "SPECIES", 0, 18], ["Porcine parvovirus antibodies", "TEST", 0, 29], ["the PMWS", "TEST", 87, 95], ["parvovirus antibodies", "OBSERVATION", 8, 29]]], ["However, ELISA positive reactions might have been the results of the presence of PPV maternal antibodies.PRRSVIn 90% of the pigs from the case herds and 45% of the pigs from control herds PRRSV RNA and/or PRRSV antibodies were detected.", [["pigs", "ORGANISM", 124, 128], ["pigs", "ORGANISM", 164, 168], ["PRRSV", "ORGANISM", 188, 193], ["PRRSV", "ORGANISM", 205, 210], ["PPV maternal antibodies", "PROTEIN", 81, 104], ["PRRSV RNA", "RNA", 188, 197], ["PRRSV antibodies", "PROTEIN", 205, 221], ["pigs", "SPECIES", 124, 128], ["pigs", "SPECIES", 164, 168], ["PRRSV", "SPECIES", 188, 193], ["PRRSV", "SPECIES", 205, 210], ["pigs", "SPECIES", 124, 128], ["pigs", "SPECIES", 164, 168], ["PRRSV", "SPECIES", 188, 193], ["PRRSV", "SPECIES", 205, 210], ["ELISA positive reactions", "PROBLEM", 9, 33], ["PPV maternal antibodies", "PROBLEM", 81, 104], ["the pigs", "TREATMENT", 120, 128], ["the pigs", "TREATMENT", 160, 168], ["control herds PRRSV RNA", "TREATMENT", 174, 197], ["PRRSV antibodies", "PROBLEM", 205, 221]]], ["PRRSV RNA and/or PRRSV antibodies were detected in 83% of the cases and 35% of the control pigs from PMWS-free herds (Table 3) , while PRRSV RNA was detected in 73% of the examined PMWS cases and in 27% of the controls from PMWSfree herds.", [["PMWS", "DISEASE", 101, 105], ["PMWS", "DISEASE", 181, 185], ["PRRSV", "ORGANISM", 0, 5], ["PRRSV", "ORGANISM", 17, 22], ["pigs", "ORGANISM", 91, 95], ["PRRSV", "ORGANISM", 135, 140], ["PRRSV RNA", "RNA", 0, 9], ["PRRSV antibodies", "PROTEIN", 17, 33], ["PRRSV RNA", "RNA", 135, 144], ["PRRSV", "SPECIES", 0, 5], ["pigs", "SPECIES", 91, 95], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 17, 22], ["pigs", "SPECIES", 91, 95], ["PRRSV", "SPECIES", 135, 140], ["PRRSV RNA", "TEST", 0, 9], ["PRRSV antibodies", "TEST", 17, 33], ["PMWS", "PROBLEM", 101, 105], ["PRRSV RNA", "PROBLEM", 135, 144]]], ["PRRS-virus RNA was not only found in lung tissue and in mesenteric and inguinal lymph nodes, but could also be detected in spleen and in kidneys.", [["lung tissue", "ANATOMY", 37, 48], ["mesenteric", "ANATOMY", 56, 66], ["inguinal lymph nodes", "ANATOMY", 71, 91], ["spleen", "ANATOMY", 123, 129], ["kidneys", "ANATOMY", 137, 144], ["PRRS-virus", "ORGANISM", 0, 10], ["lung tissue", "TISSUE", 37, 48], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 56, 66], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 71, 91], ["spleen", "ORGAN", 123, 129], ["kidneys", "ORGAN", 137, 144], ["PRRS-virus RNA", "RNA", 0, 14], ["PRRS-virus", "SPECIES", 0, 10], ["PRRS-virus", "SPECIES", 0, 10], ["virus RNA", "PROBLEM", 5, 14], ["mesenteric and inguinal lymph nodes", "PROBLEM", 56, 91], ["virus RNA", "OBSERVATION", 5, 14], ["not only found", "UNCERTAINTY", 19, 33], ["lung", "ANATOMY", 37, 41], ["tissue", "OBSERVATION", 42, 48], ["mesenteric", "ANATOMY", 56, 66], ["inguinal", "ANATOMY", 71, 79], ["lymph nodes", "OBSERVATION", 80, 91], ["spleen", "ANATOMY", 123, 129], ["kidneys", "ANATOMY", 137, 144]]], ["Statistical analysis (v 2 ) further revealed that the proportion of PRRSV infected pigs (rt-PCR and/or ELISA antibodies positive) within the case group was significantly higher than the proportion of PRRSV positive control pigs; (a) housed within the same compartment (p \u00bc 0:02), (b) from another compartment (p \u00bc 0:0000), and (c) from PMWS-free herds (p \u00bc 0:0000).PRRSVSequence analyses on PRRSV rt-PCR products of ORF6 and ORF7 revealed the presence of EU-and UStype PRRSV in Dutch pigs.", [["PRRSV infected", "DISEASE", 68, 82], ["PMWS", "DISEASE", 336, 340], ["PRRSV", "ORGANISM", 68, 73], ["pigs", "ORGANISM", 83, 87], ["PRRSV", "ORGANISM", 200, 205], ["pigs", "ORGANISM", 223, 227], ["PRRSV", "ORGANISM", 391, 396], ["ORF6", "GENE_OR_GENE_PRODUCT", 416, 420], ["ORF7", "GENE_OR_GENE_PRODUCT", 425, 429], ["EU", "GENE_OR_GENE_PRODUCT", 455, 457], ["UStype PRRSV", "ORGANISM", 462, 474], ["pigs", "ORGANISM", 484, 488], ["ELISA antibodies", "PROTEIN", 103, 119], ["PRRSV rt-PCR products", "DNA", 391, 412], ["ORF6", "PROTEIN", 416, 420], ["ORF7", "PROTEIN", 425, 429], ["EU", "PROTEIN", 455, 457], ["pigs", "SPECIES", 83, 87], ["pigs", "SPECIES", 223, 227], ["PRRSV", "SPECIES", 469, 474], ["pigs", "SPECIES", 484, 488], ["PRRSV", "SPECIES", 68, 73], ["pigs", "SPECIES", 83, 87], ["PRRSV", "SPECIES", 200, 205], ["pigs", "SPECIES", 223, 227], ["PRRSV", "SPECIES", 391, 396], ["PRRSV", "SPECIES", 469, 474], ["Dutch pigs", "SPECIES", 478, 488], ["Statistical analysis", "TEST", 0, 20], ["PRRSV infected pigs", "PROBLEM", 68, 87], ["rt-PCR", "TEST", 89, 95], ["ELISA antibodies", "TEST", 103, 119], ["PMWS", "PROBLEM", 336, 340], ["PRRSVSequence analyses", "TEST", 365, 387], ["PRRSV rt", "TREATMENT", 391, 399], ["ORF6", "TEST", 416, 420], ["ORF7", "TEST", 425, 429], ["EU", "TEST", 455, 457], ["PRRSV", "OBSERVATION_MODIFIER", 68, 73], ["infected", "OBSERVATION", 74, 82], ["UStype PRRSV", "OBSERVATION", 462, 474]]], ["Co-infections of EU-and US-type PRRSV were detected in 60% of the case herds while in only one (5%) out of 20 PMWS-free control herds a co-infection of EU-and US-type PRRSV was recorded (Fisher exact test: p \u00bc 0:0005).", [["PMWS", "DISEASE", 110, 114], ["EU", "GENE_OR_GENE_PRODUCT", 17, 19], ["US-type PRRSV", "ORGANISM", 24, 37], ["PRRSV", "ORGANISM", 167, 172], ["PRRSV", "SPECIES", 32, 37], ["US-type PRRSV", "SPECIES", 24, 37], ["PRRSV", "SPECIES", 167, 172], ["EU", "TEST", 17, 19], ["US", "TEST", 24, 26], ["type PRRSV", "PROBLEM", 27, 37], ["type PRRSV", "PROBLEM", 162, 172]]], ["This control herd had clinical signs of PMWS 1-1.5 year before sampling (Table 4 ).", [["PMWS", "DISEASE", 40, 44], ["PMWS", "PROBLEM", 40, 44]]], ["In 8 PMWS-free control herds, PRRSV infections of only EU-or US-type could be detected in pigs.VaccinationsIn 14 out of 20 case herds and in none of the 20 control herds vaccines against PRRSV (modified live vaccines) were used (v 2 analysis, p \u00bc 0:0000).", [["PMWS", "DISEASE", 5, 9], ["infections", "DISEASE", 36, 46], ["PRRSV", "DISEASE", 187, 192], ["PRRSV", "ORGANISM", 30, 35], ["pigs", "ORGANISM", 90, 94], ["PRRSV", "ORGANISM", 187, 192], ["PRRSV", "SPECIES", 30, 35], ["pigs", "SPECIES", 90, 94], ["PRRSV", "SPECIES", 187, 192], ["PRRSV", "SPECIES", 30, 35], ["pigs", "SPECIES", 90, 94], ["PRRSV", "SPECIES", 187, 192], ["PRRSV infections", "PROBLEM", 30, 46], ["VaccinationsIn", "TEST", 95, 109], ["herds vaccines", "TREATMENT", 164, 178], ["PRRSV (modified live vaccines", "TREATMENT", 187, 216]]], ["Twelve case herds started with the vaccination against PRRSV after the observation of PRRS-like/PMWS symptoms.", [["PRRS", "DISEASE", 86, 90], ["PMWS", "DISEASE", 96, 100], ["PRRSV", "ORGANISM", 55, 60], ["PRRS", "ORGANISM", 86, 90], ["PRRSV", "SPECIES", 55, 60], ["PRRSV", "SPECIES", 55, 60], ["PRRS", "SPECIES", 86, 90], ["the vaccination", "TREATMENT", 31, 46], ["PRRSV", "TREATMENT", 55, 60], ["PRRS", "PROBLEM", 86, 90], ["PMWS symptoms", "PROBLEM", 96, 109]]], ["In most cases, the PRRS diagnosis was based on clinical observations and not confirmed by laboratory diagnoses.", [["PRRS", "DISEASE", 19, 23], ["PRRS", "SPECIES", 19, 23]]], ["Co-infections of EU-and US-type PRRSV were also detected in 3 (50%) out of 6 case herds that did not use vaccines against PRRSV.VaccinationsIn 8 case herds and 4 control herds, vaccines against Mycoplasma hyopneumoniae were used.", [["PRRSV", "DISEASE", 122, 127], ["Mycoplasma hyopneumoniae", "DISEASE", 194, 218], ["EU", "GENE_OR_GENE_PRODUCT", 17, 19], ["US-type PRRSV", "ORGANISM", 24, 37], ["PRRSV", "ORGANISM", 122, 127], ["Mycoplasma hyopneumoniae", "ORGANISM", 194, 218], ["PRRSV", "SPECIES", 32, 37], ["PRRSV", "SPECIES", 122, 127], ["Mycoplasma hyopneumoniae", "SPECIES", 194, 218], ["US-type PRRSV", "SPECIES", 24, 37], ["PRRSV", "SPECIES", 122, 127], ["Mycoplasma hyopneumoniae", "SPECIES", 194, 218], ["EU", "TEST", 17, 19], ["US", "TEST", 24, 26], ["type PRRSV", "PROBLEM", 27, 37], ["vaccines", "TREATMENT", 105, 113], ["PRRSV", "PROBLEM", 122, 127], ["VaccinationsIn", "TREATMENT", 128, 142], ["vaccines", "TREATMENT", 177, 185], ["Mycoplasma hyopneumoniae", "PROBLEM", 194, 218]]], ["No significant differences were recorded between case and control herds concerning the use of vaccines against e.g. PPV and Escherichia coli.", [["Escherichia coli", "ORGANISM", 124, 140], ["Escherichia coli", "SPECIES", 124, 140], ["Escherichia coli", "SPECIES", 124, 140], ["significant differences", "PROBLEM", 3, 26], ["vaccines", "TREATMENT", 94, 102], ["PPV", "PROBLEM", 116, 119], ["Escherichia coli", "PROBLEM", 124, 140], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION", 15, 26], ["Escherichia coli", "OBSERVATION", 124, 140]]], ["Case and control herds used on compulsory bases vaccines against pseudorabies virus.Other viral co-infectionsNo infections of TGEV or PEDV could be detected in cases or in control pigs from PMWS-free herds by serological methods.", [["pseudorabies virus", "DISEASE", 65, 83], ["viral co-infections", "DISEASE", 90, 109], ["infections", "DISEASE", 112, 122], ["PEDV", "CHEMICAL", 134, 138], ["PMWS", "DISEASE", 190, 194], ["pseudorabies virus", "ORGANISM", 65, 83], ["TGEV", "ORGANISM", 126, 130], ["PEDV", "GENE_OR_GENE_PRODUCT", 134, 138], ["pigs", "ORGANISM", 180, 184], ["pseudorabies virus", "SPECIES", 65, 83], ["pigs", "SPECIES", 180, 184], ["pseudorabies virus", "SPECIES", 65, 83], ["TGEV", "SPECIES", 126, 130], ["PEDV", "SPECIES", 134, 138], ["pigs", "SPECIES", 180, 184], ["compulsory bases vaccines", "TREATMENT", 31, 56], ["pseudorabies virus", "PROBLEM", 65, 83], ["Other viral co-infections", "PROBLEM", 84, 109], ["infections", "PROBLEM", 112, 122], ["TGEV", "PROBLEM", 126, 130], ["PEDV", "PROBLEM", 134, 138], ["PMWS", "PROBLEM", 190, 194], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["co-infections", "OBSERVATION", 96, 109], ["infections", "OBSERVATION", 112, 122], ["TGEV", "OBSERVATION", 126, 130]]], ["Comparable frequencies of antibodies against H1N1, H3N2 and PRCV could be detected in cases and controls as well (data not shown).", [["H3N2", "ORGANISM", 51, 55], ["PRCV", "CANCER", 60, 64], ["antibodies", "PROTEIN", 26, 36], ["H3N2", "SPECIES", 51, 55], ["PRCV", "SPECIES", 60, 64], ["antibodies", "TREATMENT", 26, 36], ["H1N1", "PROBLEM", 45, 49], ["H3N2", "PROBLEM", 51, 55], ["PRCV", "TREATMENT", 60, 64]]], ["In 5% of the cases, antibodies against H1N2 were detected and in none of the examined control pigs from PMWSfree herds.BacteriologyBacteriological examination of organs at necropsy revealed by occasion the detection of pathogenic bacteria in cases, e.g. Streptococcus suis type 2 (1\u00c2), Actinobacillus pleuropneumoniae (3\u00c2), Mycoplasma spp.", [["organs", "ANATOMY", 162, 168], ["Streptococcus suis", "DISEASE", 254, 272], ["Actinobacillus pleuropneumoniae", "DISEASE", 286, 317], ["Mycoplasma spp", "DISEASE", 324, 338], ["pigs", "ORGANISM", 94, 98], ["organs", "ORGAN", 162, 168], ["Streptococcus suis type 2", "ORGANISM", 254, 279], ["Actinobacillus pleuropneumoniae", "ORGANISM", 286, 317], ["Mycoplasma spp", "ORGANISM", 324, 338], ["antibodies", "PROTEIN", 20, 30], ["pigs", "SPECIES", 94, 98], ["Streptococcus suis", "SPECIES", 254, 272], ["Actinobacillus pleuropneumoniae", "SPECIES", 286, 317], ["Mycoplasma spp", "SPECIES", 324, 338], ["H1N2", "SPECIES", 39, 43], ["pigs", "SPECIES", 94, 98], ["Streptococcus suis type 2", "SPECIES", 254, 279], ["Actinobacillus pleuropneumoniae", "SPECIES", 286, 317], ["antibodies", "TREATMENT", 20, 30], ["H1N2", "PROBLEM", 39, 43], ["Bacteriology", "TEST", 119, 131], ["Bacteriological examination", "TEST", 131, 158], ["organs at necropsy", "TEST", 162, 180], ["pathogenic bacteria in cases", "PROBLEM", 219, 247], ["Streptococcus suis type", "TEST", 254, 277], ["Actinobacillus pleuropneumoniae", "PROBLEM", 286, 317], ["Mycoplasma spp", "PROBLEM", 324, 338], ["pathogenic bacteria", "OBSERVATION", 219, 238], ["Mycoplasma spp", "OBSERVATION", 324, 338]]], ["(3\u00c2), Streptococcus intermedius (1\u00c2), and Haemophilus.", [["Streptococcus intermedius", "ORGANISM", 6, 31], ["Haemophilus", "ORGANISM", 42, 53], ["Streptococcus intermedius", "SPECIES", 6, 31], ["Streptococcus intermedius", "SPECIES", 6, 31], ["Streptococcus intermedius", "PROBLEM", 6, 31], ["Haemophilus", "PROBLEM", 42, 53], ["Streptococcus intermedius", "ANATOMY", 6, 31], ["Haemophilus", "OBSERVATION", 42, 53]]], ["(1\u00c2), but in control pigs of PMWS-free herds also Actinobacillus pleuropneumoniae (1\u00c2), Mycoplasma (1\u00c2), and Haemophilus (1\u00c2) were detected including Aerococcus viridans (1\u00c2).", [["PMWS", "DISEASE", 29, 33], ["pigs", "ORGANISM", 21, 25], ["Actinobacillus pleuropneumoniae", "ORGANISM", 50, 81], ["Mycoplasma", "ORGANISM", 88, 98], ["Haemophilus", "ORGANISM", 109, 120], ["Aerococcus viridans", "ORGANISM", 150, 169], ["pigs", "SPECIES", 21, 25], ["Actinobacillus pleuropneumoniae", "SPECIES", 50, 81], ["Aerococcus viridans", "SPECIES", 150, 169], ["pigs", "SPECIES", 21, 25], ["Actinobacillus pleuropneumoniae", "SPECIES", 50, 81], ["Aerococcus viridans", "SPECIES", 150, 169], ["PMWS", "PROBLEM", 29, 33], ["Actinobacillus pleuropneumoniae", "PROBLEM", 50, 81], ["Mycoplasma", "PROBLEM", 88, 98], ["Haemophilus", "PROBLEM", 109, 120], ["Aerococcus viridans", "PROBLEM", 150, 169], ["Aerococcus viridans", "OBSERVATION", 150, 169]]], ["Salmonella spp., namely S. typhimurium, S. reading, and S. london, were detected in 3 out of 15 faeces samples collected from cases.", [["samples", "ANATOMY", 103, 110], ["Salmonella spp.", "ORGANISM", 0, 15], ["S. typhimurium", "ORGANISM", 24, 38], ["S. reading", "ORGANISM", 40, 50], ["S. london", "ORGANISM", 56, 65], ["Salmonella spp.", "SPECIES", 0, 15], ["S. typhimurium", "SPECIES", 24, 38], ["S. london", "SPECIES", 56, 65], ["Salmonella spp.", "SPECIES", 0, 15], ["S. typhimurium", "SPECIES", 24, 38], ["S. london", "SPECIES", 56, 65], ["Salmonella spp.", "PROBLEM", 0, 15], ["faeces samples", "TEST", 96, 110]]], ["No Salmonella was found in faeces samples from controls of PMWS-free herds.DiscussionThis case-control study indicates an association between the amount of infectious PCV2 (and PCV2 DNA copy load) and clinical signs as documented for PMWS (Ellis et al., 1999; Quintana et al., 2001) .", [["faeces samples", "ANATOMY", 27, 41], ["PMWS", "DISEASE", 59, 63], ["PMWS", "DISEASE", 234, 238], ["faeces samples", "ORGANISM_SUBSTANCE", 27, 41], ["PCV2", "ORGANISM", 167, 171], ["PCV2", "ORGANISM", 177, 181], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["Salmonella", "SPECIES", 3, 13], ["Salmonella", "PROBLEM", 3, 13], ["faeces samples", "TEST", 27, 41], ["PMWS", "PROBLEM", 59, 63], ["control study", "TEST", 95, 108], ["infectious PCV2", "PROBLEM", 156, 171], ["PCV2 DNA copy load", "TREATMENT", 177, 195], ["clinical signs", "TEST", 201, 215], ["PMWS", "PROBLEM", 234, 238], ["Salmonella", "OBSERVATION", 3, 13], ["infectious", "OBSERVATION", 156, 166]]], ["The mean PCV2 DNA copy number in mesenteric and inguinal lymph nodes of pigs with clinical signs of PMWS was more than 10 5 times higher than in control pigs from PMWS-free herds, and 10 2 times higher than in control pigs within the same compartment.", [["mesenteric", "ANATOMY", 33, 43], ["inguinal lymph nodes", "ANATOMY", 48, 68], ["PMWS", "DISEASE", 100, 104], ["PMWS", "DISEASE", 163, 167], ["PCV2", "ORGANISM", 9, 13], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 33, 43], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 48, 68], ["pigs", "ORGANISM", 72, 76], ["pigs", "ORGANISM", 153, 157], ["pigs", "ORGANISM", 218, 222], ["pigs", "SPECIES", 72, 76], ["pigs", "SPECIES", 153, 157], ["pigs", "SPECIES", 218, 222], ["PCV2", "SPECIES", 9, 13], ["pigs", "SPECIES", 72, 76], ["pigs", "SPECIES", 153, 157], ["pigs", "SPECIES", 218, 222], ["The mean PCV2 DNA", "TEST", 0, 17], ["mesenteric and inguinal lymph nodes of pigs", "TREATMENT", 33, 76], ["clinical signs", "TEST", 82, 96], ["PMWS", "PROBLEM", 100, 104], ["mean PCV2", "OBSERVATION", 4, 13], ["mesenteric", "ANATOMY", 33, 43], ["inguinal", "ANATOMY", 48, 56], ["lymph nodes", "OBSERVATION", 57, 68], ["PMWS", "OBSERVATION", 100, 104]]], ["However, within this latter group, mild to moderate macroscopic lesions were frequently observed, which might be an indication of pr e-clinical PMWS stages.", [["lesions", "ANATOMY", 64, 71], ["PMWS", "DISEASE", 144, 148], ["lesions", "PATHOLOGICAL_FORMATION", 64, 71], ["mild to moderate macroscopic lesions", "PROBLEM", 35, 71], ["pr e-clinical PMWS stages", "PROBLEM", 130, 155], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["moderate", "OBSERVATION_MODIFIER", 43, 51], ["macroscopic", "OBSERVATION_MODIFIER", 52, 63], ["lesions", "OBSERVATION", 64, 71]]], ["Infectious PCV2 or PCV2 DNA was detected in 50% of the control pigs from PMWS-free herds, but the amount of infectious PCV2 and the PCV2 DNA copy load remained low in most of these pigs.", [["PMWS", "DISEASE", 73, 77], ["PCV2", "ORGANISM", 11, 15], ["PCV2", "ORGANISM", 19, 23], ["DNA", "CELLULAR_COMPONENT", 24, 27], ["pigs", "ORGANISM", 63, 67], ["PCV2", "ORGANISM", 119, 123], ["PCV2", "ORGANISM", 132, 136], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["pigs", "ORGANISM", 181, 185], ["pigs", "SPECIES", 63, 67], ["pigs", "SPECIES", 181, 185], ["PCV2", "SPECIES", 19, 23], ["pigs", "SPECIES", 63, 67], ["PCV2", "SPECIES", 119, 123], ["PCV2", "SPECIES", 132, 136], ["pigs", "SPECIES", 181, 185], ["Infectious PCV2", "PROBLEM", 0, 15], ["PCV2 DNA", "PROBLEM", 19, 27], ["PMWS", "PROBLEM", 73, 77], ["infectious PCV2", "PROBLEM", 108, 123], ["the PCV2 DNA copy load", "TEST", 128, 150], ["PCV2 DNA", "OBSERVATION", 19, 27], ["infectious", "OBSERVATION_MODIFIER", 108, 118], ["PCV2", "OBSERVATION", 119, 123]]], ["In these pigs the course of the PCV2 infections was mild and sub-clinical.", [["PCV2 infections", "DISEASE", 32, 47], ["pigs", "ORGANISM", 9, 13], ["PCV2", "ORGANISM", 32, 36], ["pigs", "SPECIES", 9, 13], ["the PCV2 infections", "PROBLEM", 28, 47], ["PCV2 infections", "OBSERVATION", 32, 47], ["mild", "OBSERVATION_MODIFIER", 52, 56], ["sub-", "OBSERVATION_MODIFIER", 61, 65]]], ["Above-mentioned data on PCV2 loads indicate that for the development of clinical signs of PMWS a threshold level of PCV2 is required.", [["PMWS", "DISEASE", 90, 94], ["PCV2", "ORGANISM", 24, 28], ["PCV2", "ORGANISM", 116, 120], ["PCV2", "SPECIES", 116, 120], ["PCV2 loads", "TREATMENT", 24, 34], ["PMWS", "PROBLEM", 90, 94], ["PCV2", "PROBLEM", 116, 120]]], ["This hypothesis is supported by the data recently published by Rovira et al. (2002) .DiscussionThe PCV2 IPMA, in combination with the PCV2 virus isolation method and the quantitative real-time PCV2 PCR, showed that in 27% of the cases the PCV2 antibody titres were low or even not detectable while high PCV2 virus and DNA copy loads were detected.", [["PCV2", "ORGANISM", 99, 103], ["PCV2", "ORGANISM", 134, 138], ["PCV2", "ORGANISM", 193, 197], ["PCV2", "ORGANISM", 239, 243], ["PCV2 virus", "ORGANISM", 303, 313], ["DNA", "CELLULAR_COMPONENT", 318, 321], ["PCV2", "SPECIES", 99, 103], ["PCV2 virus", "SPECIES", 134, 144], ["PCV2", "SPECIES", 239, 243], ["PCV2 virus", "SPECIES", 303, 313], ["The PCV2 IPMA", "TREATMENT", 95, 108], ["the PCV2 virus isolation method", "TREATMENT", 130, 161], ["the quantitative real-time PCV2 PCR", "TEST", 166, 201], ["the cases", "TEST", 225, 234], ["the PCV2 antibody titres", "TEST", 235, 259], ["high PCV2 virus", "PROBLEM", 298, 313], ["DNA copy loads", "TEST", 318, 332], ["PCV2 IPMA", "OBSERVATION", 99, 108], ["PCV2 virus", "OBSERVATION", 303, 313]]], ["This indicates that in PMWS the immune system may be suppressed.", [["immune system", "ANATOMY", 32, 45], ["PMWS", "DISEASE", 23, 27]]], ["Above-mentioned data are in agreement with those found in our experimental infection study, in which PCV2 infected specified pathogen free (SPF) pigs developed clinical signs and macroscopic and histopathological lesions comparable to those described for PMWS.", [["lesions", "ANATOMY", 213, 220], ["infection", "DISEASE", 75, 84], ["PCV2 infected", "DISEASE", 101, 114], ["PMWS", "DISEASE", 255, 259], ["PCV2", "ORGANISM", 101, 105], ["pigs", "ORGANISM", 145, 149], ["lesions", "PATHOLOGICAL_FORMATION", 213, 220], ["pigs", "SPECIES", 145, 149], ["pigs", "SPECIES", 145, 149], ["our experimental infection study", "TEST", 58, 90], ["clinical signs", "TEST", 160, 174], ["macroscopic and histopathological lesions", "PROBLEM", 179, 220], ["PMWS", "PROBLEM", 255, 259], ["infection", "OBSERVATION", 75, 84], ["macroscopic", "OBSERVATION_MODIFIER", 179, 190], ["lesions", "OBSERVATION", 213, 220]]], ["In 2 out of the 4 PCV2-infected pigs, the PCV2 DNA copy loads in e.g. mesenteric and inguinal lymph nodes were also very high (>10 8 copies/ll organ suspension) while the PCV2 antibody titres were very low (<1:100 and 1:100) (Stockhofe-Zurwieden et al., 2003) .DiscussionIn this case-control study, organs from cases had high PCV2 DNA copy loads and showed severe macroscopic lesions.", [["mesenteric", "ANATOMY", 70, 80], ["inguinal lymph nodes", "ANATOMY", 85, 105], ["organ", "ANATOMY", 143, 148], ["organs", "ANATOMY", 299, 305], ["lesions", "ANATOMY", 376, 383], ["PCV2", "ORGANISM", 18, 22], ["pigs", "ORGANISM", 32, 36], ["PCV2", "ORGANISM", 42, 46], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 70, 80], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 85, 105], ["organ", "ORGAN", 143, 148], ["PCV2", "ORGANISM", 171, 175], ["organs", "ORGAN", 299, 305], ["PCV2", "ORGANISM", 326, 330], ["DNA", "CELLULAR_COMPONENT", 331, 334], ["lesions", "PATHOLOGICAL_FORMATION", 376, 383], ["pigs", "SPECIES", 32, 36], ["pigs", "SPECIES", 32, 36], ["PCV2", "SPECIES", 42, 46], ["PCV2", "SPECIES", 171, 175], ["infected pigs", "TREATMENT", 23, 36], ["the PCV2 DNA copy loads", "TEST", 38, 61], ["mesenteric and inguinal lymph nodes", "PROBLEM", 70, 105], ["copies/ll organ suspension", "TREATMENT", 133, 159], ["the PCV2 antibody titres", "TEST", 167, 191], ["control study", "TEST", 284, 297], ["high PCV2 DNA copy loads", "PROBLEM", 321, 345], ["severe macroscopic lesions", "PROBLEM", 357, 383], ["infected pigs", "OBSERVATION", 23, 36], ["mesenteric", "ANATOMY", 70, 80], ["inguinal", "ANATOMY", 85, 93], ["lymph nodes", "OBSERVATION", 94, 105], ["very", "OBSERVATION_MODIFIER", 116, 120], ["high", "OBSERVATION_MODIFIER", 121, 125], ["severe", "OBSERVATION_MODIFIER", 357, 363], ["macroscopic", "OBSERVATION_MODIFIER", 364, 375], ["lesions", "OBSERVATION", 376, 383]]], ["However, in controls the course of the PCV2 infection was more or less sub-clinical, or resulted in only mild to moderate macroscopic lesions.", [["lesions", "ANATOMY", 134, 141], ["PCV2 infection", "DISEASE", 39, 53], ["PCV2", "ORGANISM", 39, 43], ["lesions", "PATHOLOGICAL_FORMATION", 134, 141], ["PCV2", "SPECIES", 39, 43], ["the PCV2 infection", "PROBLEM", 35, 53], ["mild to moderate macroscopic lesions", "PROBLEM", 105, 141], ["PCV2", "OBSERVATION_MODIFIER", 39, 43], ["infection", "OBSERVATION", 44, 53], ["mild", "OBSERVATION_MODIFIER", 105, 109], ["moderate", "OBSERVATION_MODIFIER", 113, 121], ["macroscopic", "OBSERVATION_MODIFIER", 122, 133], ["lesions", "OBSERVATION", 134, 141]]], ["Not all PCV2 infected pigs will develop severe clinical signs as described for PMWS.", [["PCV2 infected", "DISEASE", 8, 21], ["PMWS", "DISEASE", 79, 83], ["PCV2", "ORGANISM", 8, 12], ["pigs", "ORGANISM", 22, 26], ["pigs", "SPECIES", 22, 26], ["pigs", "SPECIES", 22, 26], ["severe clinical signs", "PROBLEM", 40, 61], ["PMWS", "PROBLEM", 79, 83], ["PCV2", "OBSERVATION_MODIFIER", 8, 12], ["infected", "OBSERVATION", 13, 21]]], ["This suggests that certain co-factors modulate the severity of PCV2 infections.", [["PCV2 infections", "DISEASE", 63, 78], ["PCV2", "ORGANISM", 63, 67], ["PCV2", "SPECIES", 63, 67], ["PCV2 infections", "PROBLEM", 63, 78], ["severity", "OBSERVATION_MODIFIER", 51, 59], ["PCV2 infections", "OBSERVATION", 63, 78]]], ["Our casecontrol study, which was also performed to get more insights in which co-factors might play a role in development of clinical signs as described for PMWS, showed that, except for PRRSV, no clear differences were found in the frequencies of PCV1, PPV, TGEV, PEDV, PRCV, H1N1, H1N2 and H3N2 infections between cases and controls from PMWS-free herds.", [["PMWS", "DISEASE", 157, 161], ["H3N2 infections", "DISEASE", 292, 307], ["PMWS", "DISEASE", 340, 344], ["PCV1", "GENE_OR_GENE_PRODUCT", 248, 252], ["TGEV", "ORGANISM", 259, 263], ["PEDV", "GENE_OR_GENE_PRODUCT", 265, 269], ["PRCV", "GENE_OR_GENE_PRODUCT", 271, 275], ["H1N1, H1N2", "ORGANISM", 277, 287], ["H3N2", "ORGANISM", 292, 296], ["H3N2", "SPECIES", 292, 296], ["PRRSV", "SPECIES", 187, 192], ["TGEV", "SPECIES", 259, 263], ["PEDV", "SPECIES", 265, 269], ["PRCV", "SPECIES", 271, 275], ["Our casecontrol study", "TEST", 0, 21], ["clinical signs", "TEST", 125, 139], ["PMWS", "PROBLEM", 157, 161], ["PRRSV", "PROBLEM", 187, 192], ["PCV1", "TEST", 248, 252], ["PPV", "TREATMENT", 254, 257], ["TGEV", "PROBLEM", 259, 263], ["PEDV", "PROBLEM", 265, 269], ["PRCV", "TREATMENT", 271, 275], ["H1N1", "PROBLEM", 277, 281], ["H1N2", "PROBLEM", 283, 287], ["H3N2 infections", "PROBLEM", 292, 307], ["PMWS", "PROBLEM", 340, 344], ["H3N2", "OBSERVATION", 292, 296]]], ["Also others reported the occurrence of concurrent infections of PCV2 and PRRSV in PMWS affected pigs (Sorden et al., 1998; Segal es et al., 2002) .", [["infections", "DISEASE", 50, 60], ["PMWS", "DISEASE", 82, 86], ["PCV2", "ORGANISM", 64, 68], ["PRRSV", "ORGANISM", 73, 78], ["pigs", "ORGANISM", 96, 100], ["PRRSV", "SPECIES", 73, 78], ["pigs", "SPECIES", 96, 100], ["PCV2", "SPECIES", 64, 68], ["PRRSV", "SPECIES", 73, 78], ["pigs", "SPECIES", 96, 100], ["concurrent infections", "PROBLEM", 39, 60], ["PCV2", "PROBLEM", 64, 68], ["PRRSV", "PROBLEM", 73, 78], ["infections", "OBSERVATION", 50, 60], ["PCV2", "OBSERVATION", 64, 68]]], ["Rovira et al. (2002) showed that a concurrent infection of PCV2 and PRRSV could result in increased PCV2 viral copy numbers, and that PRRSV infections enhanced PCV2 replication.", [["infection", "DISEASE", 46, 55], ["PRRSV infections", "DISEASE", 134, 150], ["PCV2", "ORGANISM", 59, 63], ["PRRSV", "ORGANISM", 68, 73], ["PCV2", "ORGANISM", 100, 104], ["PRRSV", "ORGANISM", 134, 139], ["PCV2", "ORGANISM", 160, 164], ["PCV2", "SPECIES", 59, 63], ["PRRSV", "SPECIES", 68, 73], ["PCV2", "SPECIES", 100, 104], ["PRRSV", "SPECIES", 134, 139], ["PCV2", "SPECIES", 160, 164], ["a concurrent infection of PCV2", "PROBLEM", 33, 63], ["PRRSV", "PROBLEM", 68, 73], ["increased PCV2 viral copy numbers", "PROBLEM", 90, 123], ["PRRSV infections enhanced PCV2 replication", "TREATMENT", 134, 176], ["infection", "OBSERVATION", 46, 55], ["PCV2", "OBSERVATION", 59, 63], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["PCV2", "OBSERVATION", 100, 104], ["PRRSV infections", "OBSERVATION", 134, 150], ["PCV2 replication", "OBSERVATION", 160, 176]]], ["The PCV2 load in serum was higher in pigs PRRSV inoculated one week before PCV2 challenge, than in pigs inoculated with PCV2 only.", [["serum", "ANATOMY", 17, 22], ["PCV2", "ORGANISM", 4, 8], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["pigs PRRSV", "ORGANISM", 37, 47], ["PCV2", "ORGANISM", 75, 79], ["pigs", "ORGANISM", 99, 103], ["PCV2", "ORGANISM", 120, 124], ["pigs PRRSV", "SPECIES", 37, 47], ["pigs", "SPECIES", 99, 103], ["pigs", "SPECIES", 37, 41], ["PRRSV", "SPECIES", 42, 47], ["PCV2", "SPECIES", 75, 79], ["pigs", "SPECIES", 99, 103], ["PCV2", "SPECIES", 120, 124], ["The PCV2 load in serum", "TEST", 0, 22], ["pigs PRRSV", "TREATMENT", 37, 47], ["PCV2 challenge", "TREATMENT", 75, 89], ["PCV2", "TREATMENT", 120, 124], ["PCV2 load", "OBSERVATION", 4, 13], ["PCV2", "OBSERVATION", 120, 124]]], ["Studies from Rovira et al. (2002) , this case-control study and the PCV2-PRRSV experimental infection study (Stockhofe-Zurwieden et al., 2003) all support the hypothesis that PRRSV can be an important predisposing factor to the development of PMWS under experimental and field conditions.DiscussionRemarkably, restriction-length PCR and sequence analyses showed that PCV2 and concurrent co-infections of PRRSV-EU and -US occurred only in case herds, and in one control herd with a PMWS history 1.5 years before sampling.", [["infection", "DISEASE", 92, 101], ["PMWS", "DISEASE", 243, 247], ["PMWS", "DISEASE", 481, 485], ["PCV2", "ORGANISM", 68, 72], ["PRRSV", "ORGANISM", 175, 180], ["PCV2", "ORGANISM", 367, 371], ["PRRSV-EU", "ORGANISM", 404, 412], ["PRRSV", "SPECIES", 404, 409], ["PCV2-PRRSV", "SPECIES", 68, 78], ["PRRSV", "SPECIES", 175, 180], ["PRRSV", "SPECIES", 404, 409], ["control study", "TEST", 46, 59], ["the PCV2", "TEST", 64, 72], ["PRRSV experimental infection study", "TEST", 73, 107], ["PRRSV", "PROBLEM", 175, 180], ["PMWS", "PROBLEM", 243, 247], ["length PCR", "TEST", 322, 332], ["sequence analyses", "TEST", 337, 354], ["PCV2", "PROBLEM", 367, 371], ["PRRSV", "PROBLEM", 404, 409], ["PCV2", "OBSERVATION", 367, 371]]], ["A high frequency of coinfections with different types of PRRSV in herds with clinical signs of PMWS has not been reported before, and therefore it might be of interest in the further research for co-factors involved in the development of PMWS.", [["coinfections", "DISEASE", 20, 32], ["PRRSV", "DISEASE", 57, 62], ["PMWS", "DISEASE", 95, 99], ["PMWS", "DISEASE", 238, 242], ["PRRSV", "ORGANISM", 57, 62], ["PRRSV", "SPECIES", 57, 62], ["PRRSV", "SPECIES", 57, 62], ["A high frequency of coinfections", "PROBLEM", 0, 32], ["PRRSV", "TREATMENT", 57, 62], ["PMWS", "PROBLEM", 95, 99], ["PMWS", "PROBLEM", 238, 242], ["high frequency", "OBSERVATION_MODIFIER", 2, 16], ["coinfections", "OBSERVATION", 20, 32]]], ["In most case herds, vaccines against PRRSV were used.", [["PRRSV", "ORGANISM", 37, 42], ["PRRSV", "SPECIES", 37, 42], ["PRRSV", "SPECIES", 37, 42], ["vaccines", "TREATMENT", 20, 28], ["PRRSV", "TREATMENT", 37, 42]]], ["But according to our opinion, the use of vaccines in case herds had no influences on our data concerning the reported frequencies of PRRSV infections and on the frequencies of concurrent co-infections of EU-and US-type PRRSV as found in cases and controls.", [["PRRSV infections", "DISEASE", 133, 149], ["PRRSV", "ORGANISM", 133, 138], ["US-type PRRSV", "ORGANISM", 211, 224], ["PRRSV", "SPECIES", 133, 138], ["PRRSV", "SPECIES", 219, 224], ["vaccines", "TREATMENT", 41, 49], ["our data", "TEST", 85, 93], ["PRRSV infections", "PROBLEM", 133, 149], ["EU", "TEST", 204, 206], ["type PRRSV", "PROBLEM", 214, 224]]], ["This conclusion is based on: (a) the sequences within regions of ORF-6 and ORF-7 from EU-and US-type PRRSV strains found in cases and control pigs were not similar to the (modified)-live virus strains used in PRRSV-vaccines (data not shown), (b) the detection of PRRSV ELISA antibodies in pigs older than 8-9 weeks indicates an active immune response to PRRSV (Nodelijk et al., 1997) , and (c) also the detection of PRRSV RNA in pigs at this age indicates an acute PRRSV infection.", [["PRRSV infection", "DISEASE", 465, 480], ["ORF-6", "GENE_OR_GENE_PRODUCT", 65, 70], ["ORF-7", "GENE_OR_GENE_PRODUCT", 75, 80], ["EU", "GENE_OR_GENE_PRODUCT", 86, 88], ["US-type PRRSV strains", "ORGANISM", 93, 114], ["pigs", "ORGANISM", 142, 146], ["live virus strains", "ORGANISM", 182, 200], ["PRRSV", "ORGANISM", 209, 214], ["PRRSV", "ORGANISM", 263, 268], ["pigs", "ORGANISM", 289, 293], ["PRRSV", "ORGANISM", 354, 359], ["PRRSV", "ORGANISM", 416, 421], ["pigs", "ORGANISM", 429, 433], ["PRRSV", "ORGANISM", 465, 470], ["ORF-6", "DNA", 65, 70], ["ORF-7", "DNA", 75, 80], ["PRRSV ELISA antibodies", "PROTEIN", 263, 285], ["PRRSV RNA", "RNA", 416, 425], ["pigs", "SPECIES", 142, 146], ["pigs", "SPECIES", 289, 293], ["pigs", "SPECIES", 429, 433], ["PRRSV", "SPECIES", 465, 470], ["PRRSV", "SPECIES", 101, 106], ["pigs", "SPECIES", 142, 146], ["PRRSV", "SPECIES", 209, 214], ["PRRSV", "SPECIES", 263, 268], ["pigs", "SPECIES", 289, 293], ["PRRSV", "SPECIES", 354, 359], ["PRRSV", "SPECIES", 416, 421], ["pigs", "SPECIES", 429, 433], ["PRRSV", "SPECIES", 465, 470], ["ORF", "TEST", 65, 68], ["ORF", "TEST", 75, 78], ["EU", "TEST", 86, 88], ["US", "TEST", 93, 95], ["type PRRSV strains", "PROBLEM", 96, 114], ["live virus strains", "PROBLEM", 182, 200], ["PRRSV-vaccines", "TREATMENT", 209, 223], ["PRRSV ELISA antibodies", "TEST", 263, 285], ["an active immune response", "PROBLEM", 325, 350], ["PRRSV RNA", "PROBLEM", 416, 425], ["an acute PRRSV infection", "PROBLEM", 456, 480], ["active", "OBSERVATION_MODIFIER", 328, 334], ["immune response", "OBSERVATION", 335, 350], ["PRRSV RNA", "OBSERVATION", 416, 425], ["acute", "OBSERVATION_MODIFIER", 459, 464], ["PRRSV infection", "OBSERVATION", 465, 480]]], ["In addition, also in 50% of the case herds that did not use vaccines against PRRSV, concurrent co-infections of EU-and US-type PRRSV were recorded.DiscussionWe do not have any clear evidence whether the introduction of new PRRSV strains, or the appearance of PRRSV mutants, has played a role in the increase of clinical PMWS cases in the Netherlands within the last 5 years.", [["PRRSV", "DISEASE", 77, 82], ["PMWS", "DISEASE", 320, 324], ["PRRSV", "ORGANISM", 77, 82], ["US-type PRRSV", "ORGANISM", 119, 132], ["PRRSV", "ORGANISM", 223, 228], ["PRRSV", "ORGANISM", 259, 264], ["PRRSV", "SPECIES", 77, 82], ["PRRSV", "SPECIES", 127, 132], ["PRRSV", "SPECIES", 77, 82], ["PRRSV", "SPECIES", 127, 132], ["PRRSV", "SPECIES", 223, 228], ["PRRSV", "SPECIES", 259, 264], ["vaccines", "TREATMENT", 60, 68], ["PRRSV", "PROBLEM", 77, 82], ["EU", "TEST", 112, 114], ["US", "TEST", 119, 121], ["type PRRSV", "PROBLEM", 122, 132], ["new PRRSV strains", "PROBLEM", 219, 236], ["PRRSV mutants", "PROBLEM", 259, 272]]], ["However, in 8 case herds with severe clinical cases of PMWS only the US-type PRRSV in combination with EU-and/or US-type PRRSV antibodies were detected.", [["PMWS", "DISEASE", 55, 59], ["PRRSV", "ORGANISM", 77, 82], ["US-type", "ORGANISM", 113, 120], ["PRRSV", "ORGANISM", 121, 126], ["EU", "PROTEIN", 103, 105], ["PRRSV antibodies", "PROTEIN", 121, 137], ["PRRSV", "SPECIES", 77, 82], ["PRRSV", "SPECIES", 121, 126], ["PMWS", "PROBLEM", 55, 59], ["the US", "TEST", 65, 71], ["type PRRSV", "PROBLEM", 72, 82], ["EU", "TEST", 103, 105], ["US", "TEST", 113, 115], ["type PRRSV antibodies", "PROBLEM", 116, 137]]], ["As far as we know we had no PRRSV-US strains in the Netherlands at the beginning of the '90.", [["PRRSV", "ORGANISM", 28, 33], ["PRRSV", "PROBLEM", 28, 33]]], ["Also new PRRSV-EU variants with increased pathogenicity might have been responsible for new epizootics within the Dutch pig populations and might have contributed to an increase of reported PMWS cases.", [["PMWS", "DISEASE", 190, 194], ["PRRSV-EU", "ORGANISM", 9, 17], ["pig", "ORGANISM", 120, 123], ["pig", "SPECIES", 120, 123], ["PRRSV", "SPECIES", 9, 14], ["pig", "SPECIES", 120, 123], ["new PRRSV-EU variants", "PROBLEM", 5, 26], ["increased pathogenicity", "PROBLEM", 32, 55], ["new epizootics", "PROBLEM", 88, 102], ["an increase of reported PMWS cases", "PROBLEM", 166, 200], ["new", "OBSERVATION_MODIFIER", 5, 8], ["PRRSV", "OBSERVATION", 9, 14], ["EU variants", "OBSERVATION", 15, 26], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["pathogenicity", "OBSERVATION", 42, 55], ["responsible for", "UNCERTAINTY", 72, 87], ["new", "OBSERVATION_MODIFIER", 88, 91], ["epizootics", "OBSERVATION", 92, 102], ["increase", "OBSERVATION_MODIFIER", 169, 177]]], ["Mutations in strains of EU-or US-type PRRSV can result in co-infections of new PRRSV strains with different phenotypes within herds, or even within the same pig.", [["EU", "GENE_OR_GENE_PRODUCT", 24, 26], ["US-type PRRSV", "ORGANISM", 30, 43], ["PRRSV", "ORGANISM", 79, 84], ["pig", "ORGANISM", 157, 160], ["pig", "SPECIES", 157, 160], ["PRRSV", "SPECIES", 38, 43], ["PRRSV", "SPECIES", 79, 84], ["pig", "SPECIES", 157, 160], ["Mutations in strains", "PROBLEM", 0, 20], ["type PRRSV", "PROBLEM", 33, 43], ["co-infections", "PROBLEM", 58, 71], ["new PRRSV strains", "PROBLEM", 75, 92], ["different phenotypes", "PROBLEM", 98, 118], ["new", "OBSERVATION_MODIFIER", 75, 78], ["PRRSV strains", "OBSERVATION", 79, 92]]], ["The appearance of quasi-species, and emergence of a PRRSV sub-population during infection in pigs has been reported (Rowland et al., 1999) .", [["infection", "DISEASE", 80, 89], ["PRRSV", "ORGANISM", 52, 57], ["pigs", "ORGANISM", 93, 97], ["pigs", "SPECIES", 93, 97], ["PRRSV", "SPECIES", 52, 57], ["pigs", "SPECIES", 93, 97], ["quasi-species", "PROBLEM", 18, 31], ["a PRRSV sub-population", "TREATMENT", 50, 72], ["infection", "PROBLEM", 80, 89], ["infection", "OBSERVATION", 80, 89]]], ["Subsequently, mutations within the PRRSV genome can be responsible for a reduced but also for an increased virulence (Allende et al., 2000; Nielsen et al., 2001) .DiscussionSemen isolates from another Arterivirus, equine arteritis virus (EAV), seems generally of low pathogenicity but variants with increased pathogenicity might arise during secondary spread of the virus and are perhaps responsible for new epizootics (Timoney and McCollum, 1993) .", [["equine arteritis", "DISEASE", 214, 230], ["epizootics", "DISEASE", 408, 418], ["PRRSV", "ORGANISM", 35, 40], ["Arterivirus", "ORGANISM", 201, 212], ["equine arteritis virus", "ORGANISM", 214, 236], ["EAV", "ORGANISM", 238, 241], ["PRRSV genome", "DNA", 35, 47], ["equine arteritis virus", "SPECIES", 214, 236], ["PRRSV", "SPECIES", 35, 40], ["equine arteritis virus", "SPECIES", 214, 236], ["EAV", "SPECIES", 238, 241], ["mutations within the PRRSV genome", "PROBLEM", 14, 47], ["an increased virulence", "PROBLEM", 94, 116], ["equine arteritis virus", "PROBLEM", 214, 236], ["low pathogenicity", "PROBLEM", 263, 280], ["increased pathogenicity", "PROBLEM", 299, 322], ["the virus", "PROBLEM", 362, 371], ["PRRSV genome", "OBSERVATION", 35, 47], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["virulence", "OBSERVATION", 107, 116], ["arteritis", "OBSERVATION", 221, 230], ["low pathogenicity", "OBSERVATION_MODIFIER", 263, 280], ["increased", "OBSERVATION_MODIFIER", 299, 308], ["pathogenicity", "OBSERVATION", 309, 322], ["perhaps responsible for", "UNCERTAINTY", 380, 403]]], ["Harms et al. (2001) reported, besides PCV2, the detection of PRRSV strains with increased pathogenicity in swine with atypical PRRS in many Midwestern swine herds in the United States.", [["PRRS", "DISEASE", 127, 131], ["PCV2", "ORGANISM", 38, 42], ["PRRSV", "ORGANISM", 61, 66], ["swine", "ORGANISM", 107, 112], ["swine", "SPECIES", 107, 112], ["swine", "SPECIES", 151, 156], ["PRRSV", "SPECIES", 61, 66], ["swine", "SPECIES", 107, 112], ["PRRS", "SPECIES", 127, 131], ["swine", "SPECIES", 151, 156], ["PCV2", "PROBLEM", 38, 42], ["PRRSV strains", "PROBLEM", 61, 74], ["increased pathogenicity", "PROBLEM", 80, 103], ["atypical PRRS", "PROBLEM", 118, 131], ["PRRSV strains", "OBSERVATION", 61, 74], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["pathogenicity", "OBSERVATION", 90, 103]]], ["Beginning in 1996, outbreaks of atypical PRRS often occurred in sow herds that had received multiple doses of modified live PRRSV vaccines (Harms et al., 2001) .", [["PRRS", "DISEASE", 41, 45], ["PRRS", "ORGANISM", 41, 45], ["PRRSV", "ORGANISM", 124, 129], ["sow", "SPECIES", 64, 67], ["PRRS", "SPECIES", 41, 45], ["PRRSV", "SPECIES", 124, 129], ["atypical PRRS", "PROBLEM", 32, 45], ["modified live PRRSV vaccines", "TREATMENT", 110, 138]]], ["Whether the use of vaccines against PPRSV has any influence on the chance for the appearance of new PRRSV mutants is unknown.DiscussionInfections of pathogenic bacteria, e.g. Streptococcus suis type 2, Actinobacillus pleuropneumoniae, Mycoplasma spp., Haemophilus spp., and Salmonella spp. were found in cases, but the frequency was low or the pathogenic bacteria could also be detected in control pigs from PMWS-free herds, as found for Actinobacillus pleuropneumoniae, Mycoplasma, and Haemophilus.", [["PPRSV", "CHEMICAL", 36, 41], ["Streptococcus suis", "DISEASE", 175, 193], ["Haemophilus spp.", "DISEASE", 252, 268], ["PMWS", "DISEASE", 408, 412], ["PPRSV", "GENE_OR_GENE_PRODUCT", 36, 41], ["PRRSV", "ORGANISM", 100, 105], ["Streptococcus suis type 2", "ORGANISM", 175, 200], ["Actinobacillus pleuropneumoniae", "ORGANISM", 202, 233], ["Mycoplasma spp.", "ORGANISM", 235, 250], ["Haemophilus spp.", "ORGANISM", 252, 268], ["Salmonella spp.", "ORGANISM", 274, 289], ["pigs", "ORGANISM", 398, 402], ["Actinobacillus pleuropneumoniae", "ORGANISM", 438, 469], ["Haemophilus.", "ORGANISM", 487, 499], ["Streptococcus suis", "SPECIES", 175, 193], ["Actinobacillus pleuropneumoniae", "SPECIES", 202, 233], ["Mycoplasma spp.", "SPECIES", 235, 250], ["Haemophilus spp.", "SPECIES", 252, 268], ["Salmonella spp.", "SPECIES", 274, 289], ["pigs", "SPECIES", 398, 402], ["Actinobacillus pleuropneumoniae", "SPECIES", 438, 469], ["PPRSV", "SPECIES", 36, 41], ["PRRSV", "SPECIES", 100, 105], ["Streptococcus suis type 2", "SPECIES", 175, 200], ["Actinobacillus pleuropneumoniae", "SPECIES", 202, 233], ["Mycoplasma spp.", "SPECIES", 235, 250], ["Haemophilus spp.", "SPECIES", 252, 268], ["Salmonella spp.", "SPECIES", 274, 289], ["pigs", "SPECIES", 398, 402], ["Actinobacillus pleuropneumoniae", "SPECIES", 438, 469], ["vaccines", "TREATMENT", 19, 27], ["PPRSV", "TREATMENT", 36, 41], ["new PRRSV mutants", "PROBLEM", 96, 113], ["pathogenic bacteria", "PROBLEM", 149, 168], ["Streptococcus suis type", "TEST", 175, 198], ["Actinobacillus pleuropneumoniae", "PROBLEM", 202, 233], ["Mycoplasma spp.", "PROBLEM", 235, 250], ["Haemophilus spp.", "TREATMENT", 252, 268], ["Salmonella spp.", "TREATMENT", 274, 289], ["the pathogenic bacteria", "PROBLEM", 340, 363], ["PMWS", "PROBLEM", 408, 412], ["Actinobacillus pleuropneumoniae", "PROBLEM", 438, 469], ["Mycoplasma", "PROBLEM", 471, 481], ["Haemophilus", "PROBLEM", 487, 498], ["pathogenic bacteria", "OBSERVATION", 149, 168], ["Haemophilus", "OBSERVATION", 487, 498]]], ["The increased frequency of (secondary) endemic bacterial infections in our cases might be due to accompanying PCV2 and/or other viral infections such as PRRSV.DiscussionIn summary, this case-control study indicates an association between the amount of infectious PCV2, the PCV2 DNA copy load, and clinical signs as documented for PMWS.", [["bacterial infections", "DISEASE", 47, 67], ["viral infections", "DISEASE", 128, 144], ["PMWS", "DISEASE", 330, 334], ["PCV2", "ORGANISM", 110, 114], ["PRRSV", "ORGANISM", 153, 158], ["PCV2", "ORGANISM", 263, 267], ["PCV2", "ORGANISM", 273, 277], ["DNA", "CELLULAR_COMPONENT", 278, 281], ["PRRSV", "SPECIES", 153, 158], ["PRRSV", "SPECIES", 153, 158], ["The increased frequency of (secondary) endemic bacterial infections", "PROBLEM", 0, 67], ["accompanying PCV2", "PROBLEM", 97, 114], ["other viral infections", "PROBLEM", 122, 144], ["PRRSV", "PROBLEM", 153, 158], ["control study", "TEST", 191, 204], ["infectious PCV2", "PROBLEM", 252, 267], ["the PCV2 DNA copy load", "TEST", 269, 291], ["clinical signs", "TEST", 297, 311], ["PMWS", "PROBLEM", 330, 334], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["frequency", "OBSERVATION_MODIFIER", 14, 23], ["endemic", "OBSERVATION_MODIFIER", 39, 46], ["bacterial", "OBSERVATION_MODIFIER", 47, 56], ["infections", "OBSERVATION", 57, 67], ["might be due to", "UNCERTAINTY", 81, 96], ["PCV2", "OBSERVATION", 110, 114], ["viral", "OBSERVATION_MODIFIER", 128, 133], ["infections", "OBSERVATION", 134, 144], ["infectious", "OBSERVATION", 252, 262]]], ["Although, most of the pigs within the clinically affected PMWS group showed histopathological lesions characteristic for PMWS, in lymph nodes from some of the pigs within this group, lesions consisted of hyperplasia often in combination with the presence of giant cells.", [["lesions", "ANATOMY", 94, 101], ["lymph nodes", "ANATOMY", 130, 141], ["lesions", "ANATOMY", 183, 190], ["giant cells", "ANATOMY", 258, 269], ["PMWS", "DISEASE", 58, 62], ["PMWS", "DISEASE", 121, 125], ["hyperplasia", "DISEASE", 204, 215], ["pigs", "ORGANISM", 22, 26], ["PMWS", "CANCER", 58, 62], ["histopathological lesions", "PATHOLOGICAL_FORMATION", 76, 101], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 130, 141], ["pigs", "ORGANISM", 159, 163], ["lesions", "PATHOLOGICAL_FORMATION", 183, 190], ["giant cells", "CELL", 258, 269], ["giant cells", "CELL_TYPE", 258, 269], ["pigs", "SPECIES", 22, 26], ["pigs", "SPECIES", 159, 163], ["pigs", "SPECIES", 22, 26], ["pigs", "SPECIES", 159, 163], ["histopathological lesions", "PROBLEM", 76, 101], ["PMWS", "PROBLEM", 121, 125], ["lymph nodes", "PROBLEM", 130, 141], ["lesions", "PROBLEM", 183, 190], ["hyperplasia", "PROBLEM", 204, 215], ["giant cells", "PROBLEM", 258, 269], ["lesions", "OBSERVATION", 94, 101], ["lymph nodes", "OBSERVATION", 130, 141], ["pigs", "OBSERVATION_MODIFIER", 159, 163], ["lesions", "OBSERVATION", 183, 190], ["hyperplasia", "OBSERVATION", 204, 215], ["giant cells", "OBSERVATION", 258, 269]]], ["As lymphoid hyperplasia is not a common feature of PMWS, some of the pigs within this group probably cannot be fully characterised as PMWS-affected, despite the presence of: (a) clinical signs as documented for PMWS, (b) histopathological lesions in e.g. lung and kidneys, and (c) the detection (high levels) of PCV2 in affected organs.", [["lymphoid hyperplasia", "ANATOMY", 3, 23], ["lesions", "ANATOMY", 239, 246], ["lung", "ANATOMY", 255, 259], ["kidneys", "ANATOMY", 264, 271], ["organs", "ANATOMY", 329, 335], ["lymphoid hyperplasia", "DISEASE", 3, 23], ["PMWS", "DISEASE", 51, 55], ["PMWS", "DISEASE", 134, 138], ["PMWS", "DISEASE", 211, 215], ["lymphoid hyperplasia", "PATHOLOGICAL_FORMATION", 3, 23], ["pigs", "ORGANISM", 69, 73], ["lesions", "PATHOLOGICAL_FORMATION", 239, 246], ["lung", "ORGAN", 255, 259], ["kidneys", "ORGAN", 264, 271], ["PCV2", "ORGANISM", 312, 316], ["organs", "ORGAN", 329, 335], ["pigs", "SPECIES", 69, 73], ["pigs", "SPECIES", 69, 73], ["PCV2", "SPECIES", 312, 316], ["lymphoid hyperplasia", "PROBLEM", 3, 23], ["PMWS", "PROBLEM", 51, 55], ["PMWS", "PROBLEM", 134, 138], ["clinical signs", "TEST", 178, 192], ["PMWS", "PROBLEM", 211, 215], ["histopathological lesions in e.g. lung and kidneys", "PROBLEM", 221, 271], ["the detection", "TEST", 281, 294], ["PCV2 in affected organs", "PROBLEM", 312, 335], ["lymphoid", "ANATOMY", 3, 11], ["hyperplasia", "OBSERVATION", 12, 23], ["not a", "UNCERTAINTY", 27, 32], ["common feature", "OBSERVATION_MODIFIER", 33, 47], ["PMWS", "OBSERVATION", 51, 55], ["lesions", "OBSERVATION", 239, 246], ["lung", "ANATOMY", 255, 259], ["kidneys", "ANATOMY", 264, 271], ["PCV2", "OBSERVATION", 312, 316], ["organs", "ANATOMY", 329, 335]]], ["Furthermore, concurrent PCV2 and PRRSV infections were recorded significantly more often in Dutch pigs with clinical signs than in healthy controls, and co-infections with both EU-and US-type PRRSV were detected very frequently in Dutch case herds.", [["PRRSV infections", "DISEASE", 33, 49], ["co-infections", "DISEASE", 153, 166], ["PCV2", "ORGANISM", 24, 28], ["PRRSV", "ORGANISM", 33, 38], ["pigs", "ORGANISM", 98, 102], ["US-type PRRSV", "ORGANISM", 184, 197], ["PRRSV", "SPECIES", 33, 38], ["pigs", "SPECIES", 98, 102], ["PRRSV", "SPECIES", 192, 197], ["PCV2", "SPECIES", 24, 28], ["PRRSV", "SPECIES", 33, 38], ["pigs", "SPECIES", 98, 102], ["PRRSV", "SPECIES", 192, 197], ["concurrent PCV2", "PROBLEM", 13, 28], ["PRRSV infections", "PROBLEM", 33, 49], ["clinical signs", "TEST", 108, 122], ["co-infections", "PROBLEM", 153, 166], ["type PRRSV", "PROBLEM", 187, 197], ["PCV2", "OBSERVATION", 24, 28], ["PRRSV infections", "OBSERVATION", 33, 49]]]], "PMC7096085": [["Das Prinzip der GentherapieDie Gentherapie erm\u00f6glicht den Transfer von spezifischen Gensequenzen eines gew\u00fcnschten Proteins in das Erbgut einer beliebigen Zelle.", [["Das Prinzip der GentherapieDie Gentherapie", "TREATMENT", 0, 42]]], ["Diese gentechnisch ver\u00e4nderte Zelle wird somit gezwungen das entsprechende Protein herzustellen, welches normalerweise nicht oder nur in geringen Mengen von dieser Zelle produziert wird.", [["Diese", "TEST", 0, 5]]], ["Je nach Eigenschaft des neu zu synthetisierenden Proteins kann dieses entweder intrazellul\u00e4re Steuerungsmechanismen beeinflussen oder als biologisch aktiver Mediator sezerniert werden und so den Organismus lokal und/oder systemisch beeinflussen [31].Das Prinzip der GentherapieVerglichen mit der klassischen Methode der Medikamentenapplikation benutzt die Gentherapie den Zielorganismus zur Herstellung des gew\u00fcnschten Wirkstoffs aus k\u00f6rpereigenen Proteinen.", [["Je nach Eigenschaft des neu zu synthetisierenden Proteins kann dieses entweder intrazellul\u00e4re Steuerungsmechanismen beeinflussen oder als biologisch aktiver Mediator sezerniert werden und so den Organismus lokal und/oder systemisch beeinflussen", "SPECIES", 0, 244], ["Das Prinzip der GentherapieVerglichen mit der klassischen Methode der Medikamentenapplikation benutzt die Gentherapie den Zielorganismus zur Herstellung des gew\u00fcnschten Wirkstoffs aus k\u00f6rpereigenen Proteinen", "SPECIES", 250, 457], ["Je nach Eigenschaft des neu zu synthetisierenden Proteins", "TREATMENT", 0, 57], ["intrazellul\u00e4re Steuerungsmechanismen", "TREATMENT", 79, 115], ["Das Prinzip der GentherapieVerglichen mit der klassischen Methode der Medikamentenapplikation benutzt die Gentherapie", "TREATMENT", 250, 367]]], ["W\u00e4hrend bei der klassischen Arzneimitteltherapie in Abh\u00e4ngigkeit der Halbwertszeit des Medikaments pharmakologisch wirksame Konzentrationen \u00fcber einen gewissen Zeitraum nur durch die wiederholte Verabreichung erreicht werden, k\u00f6nnen gentherapeutisch ver\u00e4nderte Zellen das gew\u00fcnschte Protein in gleich bleibender Konzentration \u00fcber einen bestimmten Zeitraum eigenst\u00e4ndig synthetisieren.", [["bei der klassischen Arzneimitteltherapie", "TREATMENT", 8, 48], ["Abh\u00e4ngigkeit der Halbwertszeit des Medikaments pharmakologisch", "TREATMENT", 52, 114], ["Protein", "TEST", 283, 290]]], ["Die Halbwertszeit dieser implantierten Gene betr\u00e4gt Tage bis Monate und ist sowohl vom verwendeten Vektor (z.", [["Gene betr\u00e4gt Tage bis", "TREATMENT", 39, 60]]], ["B. Viren oder rezeptorbindende Schleusenmolek\u00fcle) sowie dem nat\u00fcrlichen Lebenszyklus der transfizierten Zelle abh\u00e4ngig [18, 41, 49].Das Prinzip der GentherapieDennoch birgt die Gentherapie auch Gefahren.", [["Das Prinzip der GentherapieDennoch birgt", "TREATMENT", 132, 172]]], ["So wurde beim retroviralen Gentransfer im Rahmen der Behandlung von Kindern mit einer schweren angeborenen Immunschw\u00e4che (\u201eX-linked severe combined immunodeficiency\u201c, X-SCID) von einer Insertionsmutagenese berichtet, die eine lebensbedrohliche Leuk\u00e4mie verursachte [1, 9].", [["immunodeficiency\u201c, X-SCID", "DISEASE", 148, 173], ["X-linked severe combined immunodeficiency\u201c", "PROBLEM", 123, 165]]], ["Bei einem anderem Fall endete die adenovirusvermittelte Gentherapie eines jungen Patienten mit einem angeborenen Mangel des Enzyms Ornithin-Transcarbamoylase (OTCD) t\u00f6dlich, da alleine durch das Adenovirus bereits eine \u00fcberschie\u00dfende Aktivierung des Immunsystems induziert wurde [2, 16].", [["Bei einem anderem Fall endete die adenovirusvermittelte Gentherapie eines jungen Patienten mit einem angeborenen Mangel des Enzyms Ornithin-Transcarbamoylase (OTCD) t\u00f6dlich, da alleine durch das Adenovirus bereits eine \u00fcberschie\u00dfende Aktivierung des Immunsystems induziert wurde", "SPECIES", 0, 278], ["Fall endete die", "PROBLEM", 18, 33], ["Gentherapie eines", "TREATMENT", 56, 73], ["Patienten mit einem angeborenen", "TREATMENT", 81, 112], ["Transcarbamoylase (OTCD)", "TREATMENT", 140, 164], ["da alleine durch das Adenovirus", "TREATMENT", 174, 205]]], ["Neuere Vektorkonstruktionen (viral und nicht-viral) sollen daher die allgemeine Pathogenit\u00e4t reduzieren und die Steuerbarkeit in den verschiedenen Applikationsformen deutlich verbessern.Werkzeuge der GentherapieDer Einbau einer gew\u00fcnschten Gensequenz in das Erbgut einer Zelle wird als \u201eTransfektion\u201c bezeichnet.", [["Werkzeuge der GentherapieDer Einbau einer gew\u00fcnschten Gensequenz in das Erbgut einer Zelle wird als \u201eTransfektion\u201c bezeichnet", "SPECIES", 186, 311]]], ["Diese in vitro transfizierten Zellen werden dann entweder systemisch oder lokal an den gew\u00fcnschten Ort im Organismus reappliziert.", [["vitro transfizierten Zellen", "TREATMENT", 9, 36]]], ["Der \u201eVektor\u201c gilt dabei als Transportmittel, um das spezifische Gen in die Zelle zu tragen.", [["Der \u201eVektor\u201c gilt dabei als Transportmittel, um das spezifische Gen in die Zelle zu tragen", "SPECIES", 0, 90]]], ["B. Adenovirus, adenoassoziierter Virus, Retrovirus) oder nicht-viral mechanisch (z.", [["B. Adenovirus", "ORGANISM", 0, 13], ["adenoassoziierter Virus", "ORGANISM", 15, 38], ["B. Adenovirus", "SPECIES", 0, 13], ["B. Adenovirus", "SPECIES", 0, 13], ["B. Adenovirus, adenoassoziierter Virus", "PROBLEM", 0, 38], ["viral mechanisch", "PROBLEM", 63, 79], ["viral mechanisch", "OBSERVATION", 63, 79]]], ["B. \u00fcber oszillierende Tattoo-Nadeln, Goldpl\u00e4ttchen) sowie als Tr\u00e4germolek\u00fcl (z.", [["B. \u00fcber oszillierende Tattoo-Nadeln", "SPECIES", 0, 35], ["Nadeln", "TREATMENT", 29, 35]]], ["B. kationische Liposomen, Rezeptorliganden, Immunolipoplexe) appliziert werden [46].Werkzeuge der GentherapieDie im Vektor verpackte Gensequenz besteht im Wesentlichen aus einem \u201ePromotor\u201c und einem \u201eTransgen\u201c.", [["Werkzeuge der GentherapieDie im Vektor verpackte Gensequenz besteht im Wesentlichen aus einem \u201ePromotor\u201c und einem \u201eTransgen\u201c", "SPECIES", 84, 209], ["Werkzeuge der GentherapieDie", "TREATMENT", 84, 112], ["verpackte Gensequenz", "TREATMENT", 123, 143]]], ["Die Gensequenz des Promotors (\u201eStarter-DNA\u201c) bestimmt, wann und in welchen Zellen das Transgen gelesen wird und dient in der aktiven Form als \u201eAntriebsaggregat\u201c der Genexpression.", [["Die Gensequenz des Promotors (\u201eStarter-DNA\u201c) bestimmt, wann und in welchen Zellen das Transgen gelesen wird und dient in der aktiven Form als \u201eAntriebsaggregat\u201c der Genexpression", "SPECIES", 0, 178]]], ["Dabei unterscheidet man zwischen unspezifischen und spezifischen Promotoren.", [["man", "SPECIES", 20, 23]]], ["Durch den nat\u00fcrlichen Tropismus dieses viralen Promotors kann das Transgen von jeder transfizierten Zelle gelesen werden.", [["Durch", "TREATMENT", 0, 5]]], ["Im Gegensatz hierzu stehen spezifische endogene Promotoren, die entweder organspezifisch (z.", [["Im Gegensatz hierzu stehen", "TREATMENT", 0, 26]]], ["B. der hepatozytenspezifischer Promotor Phenylalanin-Hydroxylase) oder funktionsabh\u00e4ngig (z.", [["Phenylalanin", "CHEMICAL", 40, 52], ["B. der hepatozytenspezifischer Promotor Phenylalanin-Hydroxylase) oder funktionsabh\u00e4ngig", "SPECIES", 0, 88], ["B. der hepatozytenspezifischer Promotor Phenylalanin", "TREATMENT", 0, 52]]], ["B. dendritische Zellen und Monozyten, die wesentlichen Komponenten unseres zellul\u00e4ren Abwehrsystems dar.", [["B. dendritische Zellen und Monozyten, die wesentlichen Komponenten unseres zellul\u00e4ren Abwehrsystems dar", "SPECIES", 0, 103]]], ["Diese immunkompetenten Zellen zirkulieren durch das Blut- und Lymphsystem oder residieren im entsprechenden Gewebe, um den Organismus st\u00e4ndig hinsichtlich gewebefremder Stoffe und Antigene zu \u00fcberwachen.", [["Diese immunkompetenten Zellen zirkulieren durch das Blut- und Lymphsystem oder residieren im entsprechenden Gewebe, um den Organismus st\u00e4ndig hinsichtlich gewebefremder Stoffe und Antigene zu \u00fcberwachen", "SPECIES", 0, 202], ["Diese", "TEST", 0, 5]]], ["B. freie Sauerstoffradikale, Hitze-Schock-Proteine, Zytokine, Chemokine, DNA-Fragmente) oder durch k\u00f6rperfremde Pathogene, wie z.", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["B. freie Sauerstoffradikale, Hitze-Schock-Proteine", "SPECIES", 0, 50], ["Sauerstoffradikale", "TEST", 9, 27], ["Hitze", "TEST", 29, 34], ["Schock", "TREATMENT", 35, 41], ["Proteine", "TREATMENT", 42, 50], ["Zytokine", "TREATMENT", 52, 60]]], ["B. Bakterien, Viren und Pilze und deren molekularen Bestandteile.", [["Viren und Pilze und deren molekularen Bestandteile", "SPECIES", 14, 64]]], ["Diese Stressproteine sowie k\u00f6rperfremdes Material werden vom Immunsystem durch entsprechende W\u00e4chterzellen wie Monozyten und dendritische Zellen sofort erkannt, dessen Aktivierung wiederum zur Freisetzung von entz\u00fcndlichen (proinflammatorisch oder antiinflammatorisch) Mediatoren (Zytokine und Chemokine) f\u00fchrt.Die immunologische Antwort auf die akute InflammationDie Bilanz dieser inflammatorischen Kaskade dient im kontrollierten Falle dem Ziel das Entz\u00fcndungsgeschehen \u00f6rtlich einzugrenzen und weitere immunkompetente Zellen zur Elimination der entsprechenden Noxe zu rekrutieren.", [["Diese Stressproteine sowie k\u00f6rperfremdes Material werden vom Immunsystem durch entsprechende W\u00e4chterzellen wie Monozyten und dendritische Zellen sofort erkannt, dessen Aktivierung wiederum zur Freisetzung von entz\u00fcndlichen (proinflammatorisch oder antiinflammatorisch) Mediatoren (Zytokine und Chemokine) f\u00fchrt", "SPECIES", 0, 310], ["Die immunologische Antwort auf die akute InflammationDie Bilanz dieser inflammatorischen Kaskade dient im kontrollierten Falle dem Ziel das Entz\u00fcndungsgeschehen \u00f6rtlich einzugrenzen und weitere immunkompetente Zellen zur Elimination der entsprechenden Noxe zu rekrutieren", "SPECIES", 311, 582], ["Diese Stressproteine sowie k\u00f6rperfremdes Material", "TREATMENT", 0, 49], ["Immunsystem durch entsprechende", "TREATMENT", 61, 92], ["Monozyten", "TREATMENT", 111, 120], ["zur Freisetzung von entz\u00fcndlichen (proinflammatorisch oder antiinflammatorisch)", "TREATMENT", 189, 268], ["Mediatoren (Zytokine und Chemokine)", "TREATMENT", 269, 304], ["Inflammation", "PROBLEM", 352, 364], ["Bilanz dieser", "TREATMENT", 368, 381], ["Kaskade dient", "TREATMENT", 400, 413], ["Entz\u00fcndungsgeschehen \u00f6rtlich einzugrenzen", "TREATMENT", 451, 492]]], ["Die klassischen proinflammatorischen Proteine f\u00fchren dabei zur typischen lokalen Entz\u00fcndungsreaktion mit Rubor, Tumor, Calor und Dolor.", [["klassischen", "TREATMENT", 4, 15], ["Proteine", "TREATMENT", 37, 45], ["Tumor", "OBSERVATION", 112, 117]]], ["Im schweren Gewebeschaden (nach mechanischem Trauma, Isch\u00e4mie und Reperfusion, Verbrennung) bedarf der lokale Schaden jedoch oft eine \u201eMassenrekrutierung\u201c aktiver immunologischer Zellen, die wiederum neue inflammatorische Proteine produzieren.", [["Trauma", "PROBLEM", 45, 51]]], ["Dies f\u00fchrt schlussendlich zu einer \u00dcberschwemmung des gesamten Systems mit inflammatorischen Mediatoren (\u201esystemic inflammatory response syndrome\u201c, SIRS), welches nach den klassischen Prodromi mit Fieber und Unwohlsein zu Gerinnungsst\u00f6rungen, diversen Organfunktionsst\u00f6rungen mit konsekutivem Multiorganversagen bis hin zum Tode f\u00fchren kann.", [["SIRS", "DISEASE", 148, 152], ["Dies f\u00fchrt schlussendlich zu einer \u00dcberschwemmung des gesamten Systems mit inflammatorischen Mediatoren (\u201esystemic inflammatory response syndrome\u201c, SIRS), welches nach den klassischen Prodromi mit Fieber und Unwohlsein zu Gerinnungsst\u00f6rungen, diversen Organfunktionsst\u00f6rungen mit konsekutivem Multiorganversagen bis hin zum Tode f\u00fchren kann", "SPECIES", 0, 340], ["\u201esystemic inflammatory response syndrome", "PROBLEM", 105, 145], ["SIRS", "PROBLEM", 148, 152]]], ["2).Die immunologische Antwort auf die akute InflammationW\u00e4hrend dieser initialen Phase der \u00fcberm\u00e4\u00dfigen Produktion an proinflammatorischen Botenstoffen versucht der Organismus zeitgleich dieser \u00dcberreaktion des Immunsystems durch diverse antiinflammatorische Regulationsmechanismen entgegen zu wirken.", [["Inflammation", "PROBLEM", 44, 56], ["an proinflammatorischen Botenstoffen versucht der Organismus zeitgleich dieser \u00dcberreaktion des", "TREATMENT", 114, 209]]], ["Hierbei spielen zum einen die Produktion antiinflammatorischer Zytokine [z.", [["Hierbei spielen zum", "TREATMENT", 0, 19]]], ["B. Interleukin (IL)-4 und \u221210] sowie der physiologische Zelltod (Apoptose) antigenpr\u00e4sentierender Zellen wie Monozyten, dendritische Zellen und Lymphozyten eine entscheidende Rolle [23].", [["B. Interleukin (IL)", "TREATMENT", 0, 19], ["sowie der physiologische Zelltod (Apoptose)", "TREATMENT", 31, 74], ["Monozyten", "TREATMENT", 109, 118], ["dendritische Zellen", "TREATMENT", 120, 139]]], ["Bei einer erh\u00f6hten Apoptose wird die Anzahl verf\u00fcgbarer immunologisch und inflammatorisch wirksamer Zellen vermindert, wodurch eine Reduktion der immunologischen Kapazit\u00e4t erreicht wird.", [["Bei einer erh\u00f6hten Apoptose wird die Anzahl verf\u00fcgbarer immunologisch und inflammatorisch wirksamer Zellen vermindert, wodurch eine Reduktion der immunologischen Kapazit\u00e4t erreicht wird", "SPECIES", 0, 185], ["Bei einer erh\u00f6hten", "TREATMENT", 0, 18], ["Anzahl verf\u00fcgbarer immunologisch", "TREATMENT", 37, 69]]], ["Dieses Stadium der Immunparalyse nennt man auch \u201ecompensatory anti-inflammatory response syndrome\u201c (CARS) und besteht zeitlich wesentlich l\u00e4nger als die Ganzk\u00f6rperinflammation (SIRS).", [["SIRS", "DISEASE", 177, 181], ["man", "SPECIES", 39, 42], ["anti-inflammatory response syndrome", "PROBLEM", 62, 97]]], ["B. Monozyten, Lymphozyten und dendritische Zellen) zur signifikant verbesserten \u00dcberlebenschance septischer Tiere f\u00fchren kann [15, 33, 35].", [["Lymphozyten", "TREATMENT", 14, 25]]], ["Das Ziel unserer Forschung war es bislang, diese Immunparalyse mit Hilfe der Gentherapie zu verz\u00f6gern bzw. zu verhindern.Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtDie stetige Weiterentwicklung viraler und nicht-viraler Vektoren hat die Handhabung und klinische Sicherheit dieser verschiedenen Verfahren sowohl in vitro als auch in vivo deutlich verbessert.", [["Erfahrungsbericht", "CHEMICAL", 195, 212], ["Das Ziel unserer Forschung war es bislang, diese Immunparalyse mit Hilfe der Gentherapie zu verz\u00f6gern bzw", "SPECIES", 0, 105], ["Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein Erfahrungsbericht", "SPECIES", 121, 212], ["Die stetige Weiterentwicklung viraler und nicht-viraler Vektoren hat die Handhabung und klinische Sicherheit dieser verschiedenen Verfahren sowohl", "SPECIES", 212, 358], ["Inflammation", "PROBLEM", 176, 188]]], ["Durch die im Vergleich zum nat\u00fcrlich vorkommenden Adenovirus verminderte Anzahl vireneigener Proteine wurde die virusinduzierte Aktivierung des Immunsystems deutlich reduziert.", [["Durch die", "TREATMENT", 0, 9], ["Vergleich zum nat\u00fcrlich vorkommenden Adenovirus", "TREATMENT", 13, 60], ["Anzahl vireneigener", "TREATMENT", 73, 92], ["Proteine wurde", "TREATMENT", 93, 107]]], ["Unsere initialen Versuche mit isolierten Leukozytensubpopulationen der Maus zeigten jedoch, dass sich isolierte Lymphozyten nicht effektiv mit dem Adenovirus transfizieren lie\u00dfen.", [["Unsere initialen Versuche mit isolierten", "TREATMENT", 0, 40], ["dass sich isolierte", "TREATMENT", 92, 111], ["Lymphozyten", "TREATMENT", 112, 123]]], ["Interessanterweise war aber die Transfektionsrate f\u00fcr Monozyten und myeloide dendritische Zellen deutlich gesteigert [34].Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtDurch die potente Eigenschaft dendritischer Zellen, die klonale Ausbreitung von T-Lymphozyten zu aktivieren und diese in gleichem Ma\u00dfe in ihrer Immunantwort hinsichtlich der Zytokinproduktion zu steuern, fand sich somit ein Ansatz die Lymphozytenapoptose indirekt zu regulieren.", [["Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtDurch die potente Eigenschaft dendritischer Zellen, die klonale Ausbreitung von T-Lymphozyten zu aktivieren und diese in gleichem Ma\u00dfe in ihrer Immunantwort hinsichtlich der Zytokinproduktion zu steuern, fand sich somit ein Ansatz die Lymphozytenapoptose indirekt zu regulieren", "SPECIES", 122, 490], ["Der gentherapeutische", "TEST", 122, 143], ["Inflammation", "PROBLEM", 177, 189], ["Eigenschaft dendritischer Zellen", "PROBLEM", 231, 263], ["Lymphozyten zu aktivieren", "TREATMENT", 295, 320]]], ["Da dem antiinflammatorischen Zytokin IL-10 auch die Eigenschaft die Apoptose von Lymphozyten zu vermindern zugeschrieben wird [7, 13, 24, 36], w\u00e4hlten wir das IL-10 zu unserem gew\u00fcnschtem Transgen [29].", [["Da dem antiinflammatorischen Zytokin IL", "TREATMENT", 0, 39]]], ["Mit der \u00dcberexpression an IL-10 konnten wir im septischen Tiermodell der Maus eine signifikant geringere Mortalit\u00e4t im Vergleich zu Kontrolltieren aufzeichnen [26].", [["Mit der \u00dcberexpression", "TREATMENT", 0, 22], ["an IL", "TREATMENT", 23, 28]]], ["Zus\u00e4tzlich lie\u00df sich die Verminderung der Apoptoserate von Lymphozyten z.", [["Zus\u00e4tzlich lie\u00df sich die Verminderung der Apoptoserate von Lymphozyten z.", "SPECIES", 0, 73], ["Zus\u00e4tzlich lie\u00df sich", "TREATMENT", 0, 20]]], ["T. auf eine IL-10-induzierte Hochregulation von antiapoptotischem BcL-2-Protein zur\u00fcckf\u00fchren.", [["T. auf eine IL-10-induzierte Hochregulation von antiapoptotischem BcL-2-Protein zur\u00fcckf\u00fchren", "SPECIES", 0, 92], ["T. auf eine IL", "TEST", 0, 14], ["BcL", "TEST", 66, 69]]], ["Anhand dieser Daten konnten wir den positiven Einfluss der gentherapeutischen Manipulation des Immunsystems best\u00e4tigen.Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtUm die Applikationsmethode hinsichtlich der klinischen Anwendung zu verbessern, war jedoch ein alternativer Weg zur intrathymischen Injektion der ex vivo behandelten Immunzellen notwendig.", [["Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtUm die Applikationsmethode hinsichtlich der klinischen Anwendung zu verbessern, war jedoch ein alternativer", "SPECIES", 119, 317], ["Anhand dieser", "TREATMENT", 0, 13], ["Der gentherapeutische Ansatz zur", "TREATMENT", 119, 151], ["Inflammation", "PROBLEM", 174, 186]]], ["Dabei wurde in allen Versuchen die entsprechende Partikeldosis Adenovirus appliziert, um das Transgen IL-10 nur lokal entlang der Lymphabflusswege und nicht systemisch messbar erscheinen zu lassen [19].", [["Adenovirus appliziert, um das Transgen IL-10 nur lokal entlang der Lymphabflusswege und nicht systemisch messbar erscheinen zu lassen", "SPECIES", 63, 196], ["Transgen IL", "TREATMENT", 93, 104]]], ["Wir konnten in diesen Versuchen best\u00e4tigen, dass die transfizierten dendritischen Zellen von der Haut gem\u00e4\u00df ihrer immunologischen Eigenschaft zum n\u00e4chsten Lymphknoten wanderten, um dort das fremde Protein durch \u00dcberexpression und vermehrte Produktion ortsst\u00e4ndiger Lymphozyten zu pr\u00e4sentieren.", [["Haut gem\u00e4\u00df ihrer immunologischen Eigenschaft zum n\u00e4chsten Lymphknoten wanderten, um dort das fremde Protein durch \u00dcberexpression und vermehrte Produktion ortsst\u00e4ndiger Lymphozyten zu pr\u00e4sentieren", "SPECIES", 97, 292], ["Protein durch \u00dcberexpression", "TREATMENT", 197, 225]]], ["Im gleichen Mausmodell der Sepsis f\u00fchrte diese Applikation des IL-10-exprimierenden Adenovirus erneut zur signifikanten Verbesserung der \u00dcberlebensrate im Vergleich zur unbehandelten septischen Kontrollgruppe [26].Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtZur Erweiterung dieser Ergebnisse in die klinisch-tierexperimentelle Anwendung z\u00fcchteten wir myeloide dendritischen Zellen ex vivo aus murinem Knochenmark und transfizierten sie in Kultur.", [["Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtZur Erweiterung dieser Ergebnisse in die klinisch-tierexperimentelle Anwendung z\u00fcchteten wir myeloide dendritischen Zellen ex vivo aus murinem Knochenmark und transfizierten sie", "SPECIES", 214, 482], ["der Sepsis", "TEST", 23, 33], ["des IL", "TEST", 59, 65], ["Adenovirus", "PROBLEM", 84, 94], ["Inflammation", "PROBLEM", 269, 281], ["klinisch", "TEST", 346, 354], ["tierexperimentelle", "TREATMENT", 355, 373]]], ["Diese ex vivo transfizierten dendritischen Zellen wurden den Tieren schlie\u00dflich reappliziert und der therapeutische Effekt im Sepsismodell (Z\u00e4kumligatur und Perforation mit konsekutiver generalisierter Peritonitis) evaluiert.", [["Peritonitis", "DISEASE", 202, 213], ["Diese ex vivo transfizierten dendritischen Zellen wurden den Tieren schlie\u00dflich reappliziert und der therapeutische Effekt im Sepsismodell (Z\u00e4kumligatur und Perforation mit konsekutiver generalisierter Peritonitis) evaluiert", "SPECIES", 0, 224], ["Diese ex vivo transfizierten dendritischen Zellen wurden", "TREATMENT", 0, 56], ["Sepsismodell (Z\u00e4kumligatur und Perforation mit konsekutiver generalisierter", "TREATMENT", 126, 201], ["Peritonitis", "PROBLEM", 202, 213], ["Peritonitis", "OBSERVATION", 202, 213]]], ["Analog der Versuchsreihe mit direkter Virusapplikation zeigten die behandelten Tiere eine gesteigerte IL-10-Produktion mit signifikant verbesserter \u00dcberlebensrate [27].", [["der Versuchsreihe mit direkter Virusapplikation zeigten die behandelten Tiere eine gesteigerte IL-10-Produktion mit signifikant verbesserter \u00dcberlebensrate", "SPECIES", 7, 162], ["Analog der Versuchsreihe mit direkter Virusapplikation zeigten", "TREATMENT", 0, 62]]], ["Obwohl der genaue Signalmechanismus dieses beobachteten Ph\u00e4nomens noch nicht im Detail gekl\u00e4rt ist, scheint die Transfektion dendritischer Zellen anhand unserer Erkenntnisse ein neues therapeutisches Instrument zur Behandlung der chronischen und akuten Inflammation darzustellen.Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein Erfahrungsbericht\u00c4hnliche Erfolge dieser gentherapeutischen Ans\u00e4tze zur Behandlung der akuten Inflammation wurden auch von anderen internationalen Arbeitsgruppen berichtet.", [["Obwohl der genaue Signalmechanismus dieses beobachteten Ph\u00e4nomens noch nicht im Detail gekl\u00e4rt ist, scheint die Transfektion dendritischer Zellen anhand unserer Erkenntnisse ein neues therapeutisches Instrument zur Behandlung der chronischen und akuten Inflammation darzustellen", "SPECIES", 0, 278], ["Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein Erfahrungsbericht\u00c4hnliche Erfolge dieser gentherapeutischen Ans\u00e4tze zur Behandlung der akuten Inflammation wurden auch von anderen internationalen Arbeitsgruppen berichtet", "SPECIES", 279, 524], ["Inflammation darzustellen", "PROBLEM", 253, 278], ["Der gentherapeutische", "TEST", 279, 300], ["Inflammation", "PROBLEM", 334, 346]]], ["Dabei stand bislang die \u00dcberexpression antiinflammatorischer Zytokine zur Neutralisation der proinflammatorischen Zytokinantwort im Vordergrund [4, 38, 42].", [["Dabei stand bislang die", "TREATMENT", 0, 23], ["Zytokine zur Neutralisation", "TREATMENT", 61, 88]]], ["In einem murinen Endotoxinmodell konnte die intraperitoneale Injektion von plasmidbeladenen Liposomen mit IL-10 oder dem TNF-Rezeptor p55 die \u00dcberlebensrate der behandelten M\u00e4use signifikant steigern [38].", [["TNF", "PROTEIN", 121, 124], ["einem murinen Endotoxinmodell konnte die intraperitoneale Injektion von plasmidbeladenen Liposomen mit IL-10 oder dem TNF-Rezeptor p55 die \u00dcberlebensrate der behandelten M\u00e4use signifikant steigern", "SPECIES", 3, 199], ["einem murinen Endotoxinmodell konnte", "TREATMENT", 3, 39], ["von plasmidbeladenen Liposomen mit IL", "TREATMENT", 71, 108], ["Rezeptor", "TREATMENT", 125, 133]]], ["Die i.m.-Applikation von IL-10-exprimierendem Adenovirus zeigte gleicherma\u00dfen antiinflammatorische Wirksamkeit [35, 47].", [["von IL", "TEST", 21, 27]]], ["Weitere tierexperimentelle Ans\u00e4tze zur Untersuchung von Alveolarzellen im Modell des \u201eadult-respiratory distress syndrome\u201c (ARDS) bewiesen eine Reduktion der lokalen Entz\u00fcndungsreaktion und der daraus resultierenden Gewebesch\u00e4den durch die gentherapeutisch induzierte \u00dcberproduktion inflammatorischer Antagonisten wie das \u03b11-Antitrypsin [20], Prostaglandine [8], dem Hitze-Schock-Protein 70 (HSP-70 [45]) oder einem \u201eNuklear-Faktor-kB-Inhibitor\u201c [3].Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtObwohl die Mehrzahl dieser Erkenntnisse aus dem Tiermodell stammt, bietet die Gentherapie in solch diversen akuten und chronisch-entz\u00fcndlichen Prozessen, wie Frakturheilung [11], Wundheilung [10], Sehnenheilung [37], Knorpelheilung [44], Wirbels\u00e4ulenerkrankungen [21], Pankreatitis [6], Kolitis [22], Arthritis [17, 40] und der Artheriosklerose [48] ein modernes und erfolgversprechendes Behandlungskonzept.Fazit f\u00fcr die PraxisDie Gentherapie kann, wie unsere und andere Studien gezeigt haben, die inflammatorische Reaktion auf eine gewebesch\u00e4digende Noxe positiv beeinflussen.", [["respiratory distress syndrome", "DISEASE", 92, 121], ["ARDS", "DISEASE", 124, 128], ["Prostaglandine", "CHEMICAL", 343, 357], ["Prostaglandine", "CHEMICAL", 343, 357], ["Prostaglandine [8]", "SIMPLE_CHEMICAL", 343, 361], ["Hitze-Schock-Protein 70", "SIMPLE_CHEMICAL", 367, 390], ["Nuklear-Faktor-kB", "GENE_OR_GENE_PRODUCT", 417, 434], ["HSP", "PROTEIN", 392, 395], ["kB", "PROTEIN", 432, 434], ["Weitere tierexperimentelle Ans\u00e4tze zur Untersuchung von Alveolarzellen im Modell des \u201eadult-respiratory distress syndrome\u201c (ARDS) bewiesen eine Reduktion der lokalen Entz\u00fcndungsreaktion und der daraus resultierenden Gewebesch\u00e4den durch die gentherapeutisch induzierte \u00dcberproduktion inflammatorischer Antagonisten wie das \u03b11-Antitrypsin", "SPECIES", 0, 336], ["Der gentherapeutische Ansatz zur Behandlung der akuten Inflammation \u2013 ein ErfahrungsberichtObwohl die Mehrzahl dieser Erkenntnisse aus dem Tiermodell stammt, bietet die Gentherapie in solch diversen akuten und chronisch-entz\u00fcndlichen Prozessen, wie Frakturheilung", "SPECIES", 450, 713], ["Fazit f\u00fcr die PraxisDie Gentherapie kann, wie unsere und andere Studien gezeigt haben, die inflammatorische Reaktion auf eine gewebesch\u00e4digende Noxe positiv beeinflussen", "SPECIES", 948, 1117], ["respiratory distress syndrome", "PROBLEM", 92, 121], ["ARDS", "PROBLEM", 124, 128], ["Prostaglandine", "TREATMENT", 343, 357], ["Protein", "TEST", 380, 387], ["einem", "TREATMENT", 410, 415], ["Faktor", "TREATMENT", 425, 431], ["Der gentherapeutische Ansatz zur Behandlung", "TREATMENT", 450, 493], ["Inflammation", "PROBLEM", 505, 517], ["Mehrzahl", "TREATMENT", 552, 560], ["Arthritis", "PROBLEM", 842, 851], ["respiratory", "ANATOMY", 92, 103], ["distress", "OBSERVATION", 104, 112], ["Arthritis", "OBSERVATION", 842, 851]]], ["Mit der stetigen Weiterentwicklung verschiedener Vektorkonstruktionen und neuer nicht-viraler Applikationsformen wird die Gentherapie durch eine verbesserte und zielsichere Steuerbarkeit sowie einer geringeren Immunogenit\u00e4t in den n\u00e4chsten Jahren bald zum klinischen Alltag geh\u00f6ren.", [["Mit der stetigen Weiterentwicklung verschiedener Vektorkonstruktionen und neuer nicht-viraler Applikationsformen wird die Gentherapie durch eine verbesserte und zielsichere Steuerbarkeit sowie einer geringeren Immunogenit\u00e4t in den n\u00e4chsten Jahren bald zum klinischen Alltag geh\u00f6ren", "SPECIES", 0, 281], ["Gentherapie durch eine verbesserte", "TREATMENT", 122, 156]]], ["So k\u00f6nnte die trauma- und/oder sepsisinduzierte Immunparalyse auf Intensivstationen durch eine systemische Reinigung und extrakorporale \u201eBeimpfung\u201c im Sinne einer Dialyse gentherapeutisch unterst\u00fctzt oder sogar behandelt werden.", [["trauma", "DISEASE", 14, 20], ["So k\u00f6nnte die trauma- und/oder sepsisinduzierte Immunparalyse auf Intensivstationen durch eine systemische Reinigung und extrakorporale \u201eBeimpfung\u201c im Sinne einer Dialyse gentherapeutisch unterst\u00fctzt oder sogar behandelt werden", "SPECIES", 0, 227], ["trauma", "PROBLEM", 14, 20]]], ["Immunkompetente Zellen wie dendritische Zellen w\u00fcrden selektiv filtriert, mit dem gew\u00fcnschten Transgen transfiziert und anschlie\u00dfend dem Patienten wieder reinfundiert werden.", [["Immunkompetente Zellen wie dendritische Zellen w\u00fcrden selektiv filtriert, mit dem gew\u00fcnschten Transgen transfiziert und anschlie\u00dfend dem Patienten wieder reinfundiert werden", "SPECIES", 0, 173], ["Immunkompetente", "TEST", 0, 15]]]], "01d772a6a9422d1200ec1511d011fffa4af11f19": [["INTRODUCTIONMycoviruses or fungal viruses are ubiquitous in all major taxa of fungi (1, 2) .", [["fungal viruses", "DISEASE", 27, 41], ["fungal viruses", "ORGANISM", 27, 41], ["INTRODUCTIONMycoviruses", "TREATMENT", 0, 23], ["fungal viruses", "PROBLEM", 27, 41], ["fungal viruses", "OBSERVATION", 27, 41], ["fungi", "OBSERVATION", 78, 83]]], ["According to the latest list of fungal viruses approved by the International Committee on Taxonomy of Viruses (ICTV), mycoviruses have double-stranded (ds) RNA linear genomes, positivesense single-stranded (+ss) RNA linear genomes including reversetranscribing RNA linear genomes, negative-sense ssRNA (\u2212ssRNA) linear genomes, or ssDNA circular genomes (3) .", [["fungal viruses", "DISEASE", 32, 46], ["double-stranded (ds) RNA linear genomes", "DNA", 135, 174], ["positivesense single-stranded (+ss) RNA linear genomes", "DNA", 176, 230], ["reversetranscribing RNA linear genomes", "DNA", 241, 279], ["negative-sense ssRNA (\u2212ssRNA) linear genomes", "DNA", 281, 325], ["ssDNA circular genomes", "DNA", 330, 352], ["ICTV", "SPECIES", 111, 115], ["fungal viruses", "PROBLEM", 32, 46], ["Viruses (ICTV", "TREATMENT", 102, 115], ["mycoviruses", "TREATMENT", 118, 129], ["double-stranded (ds)", "TREATMENT", 135, 155], ["positivesense", "TEST", 176, 189], ["RNA linear genomes", "PROBLEM", 212, 230], ["reversetranscribing RNA linear genomes", "PROBLEM", 241, 279], ["sense ssRNA (\u2212ssRNA) linear genomes", "PROBLEM", 290, 325], ["ssDNA circular genomes", "PROBLEM", 330, 352], ["fungal viruses", "OBSERVATION", 32, 46], ["circular genomes", "OBSERVATION", 336, 352]]], ["The discovery of fungal viruses occurred relatively late compared to the identification and characterization of viruses of animals, plants, and prokaryotes, perhaps due primarily to the cryptic or asymptomatic nature of mycoviruses (4) .", [["fungal viruses", "DISEASE", 17, 31], ["mycoviruses", "DISEASE", 220, 231], ["fungal viruses", "ORGANISM", 17, 31], ["fungal viruses", "PROBLEM", 17, 31], ["the identification", "TEST", 69, 87], ["fungal viruses", "OBSERVATION", 17, 31], ["viruses", "OBSERVATION", 112, 119]]], ["However, the number of known mycoviruses has rapidly increased in the past few decades, and this trend is expected to continue, especially with the development and widespread use of nextgeneration sequencing techniques in the field of virology (3, 5) .", [["mycoviruses", "DISEASE", 29, 40], ["known mycoviruses", "PROBLEM", 23, 40], ["nextgeneration sequencing techniques", "TREATMENT", 182, 218], ["mycoviruses", "OBSERVATION", 29, 40], ["rapidly", "OBSERVATION_MODIFIER", 45, 52], ["increased", "OBSERVATION_MODIFIER", 53, 62]]], ["Studies based on this approach, along with conventional fungal virus hunting, have greatly promoted our understanding of mycovirus diversity and evolution (1) .INTRODUCTIONOur knowledge of circular replication-associated protein-encoding single-stranded (CRESS) DNA virus diversity has increased markedly in recent years due to innovations in molecular techniques and sequencing technologies (6, 7) .", [["fungal virus", "ORGANISM", 56, 68], ["circular replication-associated protein-encoding single-stranded", "GENE_OR_GENE_PRODUCT", 189, 253], ["DNA", "CELLULAR_COMPONENT", 262, 265], ["Studies", "TEST", 0, 7], ["this approach", "TEST", 17, 30], ["conventional fungal virus hunting", "PROBLEM", 43, 76], ["mycovirus diversity", "PROBLEM", 121, 140], ["circular replication", "PROBLEM", 189, 209], ["associated protein", "PROBLEM", 210, 228], ["encoding single-stranded (CRESS", "TREATMENT", 229, 260], ["DNA virus diversity", "PROBLEM", 262, 281], ["sequencing technologies", "TEST", 368, 391], ["fungal virus", "OBSERVATION", 56, 68], ["circular replication", "OBSERVATION", 189, 209], ["increased", "OBSERVATION_MODIFIER", 286, 295], ["markedly", "OBSERVATION_MODIFIER", 296, 304]]], ["CRESS DNA viruses have been identified in environmental, fungal, plant, and animal samples.", [["samples", "ANATOMY", 83, 90], ["CRESS", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["CRESS DNA viruses", "PROBLEM", 0, 17], ["animal samples", "TEST", 76, 90], ["DNA viruses", "OBSERVATION", 6, 17], ["fungal", "OBSERVATION_MODIFIER", 57, 63]]], ["Because of their high diversity, variable genome organizations, and unknown hosts, a large number of the recently identified CRESS DNA viruses cannot be classified into any known viral families, which has resulted in large, novel CRESS DNA viral groups being proposed (8) .", [["CRESS", "ORGANISM", 125, 130], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["DNA", "CELLULAR_COMPONENT", 236, 239], ["their high diversity", "PROBLEM", 11, 31], ["CRESS DNA viruses", "PROBLEM", 125, 142], ["large, novel CRESS DNA viral groups", "PROBLEM", 217, 252], ["high diversity", "OBSERVATION", 17, 31], ["variable", "OBSERVATION_MODIFIER", 33, 41], ["genome organizations", "OBSERVATION", 42, 62], ["large", "OBSERVATION_MODIFIER", 85, 90], ["CRESS DNA viruses", "OBSERVATION", 125, 142], ["large", "OBSERVATION_MODIFIER", 217, 222]]], ["One of the recently proposed groups is the family Genomoviridae (sigil: Ge-for geminivirus-like and nomo-for no movement protein) (9) .", [["Genomoviridae", "GENE_OR_GENE_PRODUCT", 50, 63], ["geminivirus", "PROTEIN", 79, 90], ["nomo", "PROTEIN", 100, 104], ["movement protein", "PROTEIN", 112, 128], ["geminivirus", "PROBLEM", 79, 90]]], ["Currently, there are nine approved genera in this family: Gemycircularvirus, Gemyduguivirus, Gemygorvirus, Gemykibivirus, Gemykolovirus, Gemykrogvirus, Gemykroznavirus, Gemytondvirus, and Gemyvongvirus (10) .", [["Gemycircularvirus", "CHEMICAL", 58, 75], ["Gemycircularvirus", "TEST", 58, 75], ["Gemyduguivirus", "PROBLEM", 77, 91], ["Gemygorvirus", "PROBLEM", 93, 105], ["Gemykibivirus", "PROBLEM", 107, 120], ["Gemykolovirus", "PROBLEM", 122, 135], ["Gemykrogvirus", "PROBLEM", 137, 150], ["Gemykroznavirus", "PROBLEM", 152, 167], ["Gemytondvirus", "PROBLEM", 169, 182], ["Gemytondvirus", "ANATOMY", 169, 182]]], ["These viruses have small (~2 to 2.4 kb), circular ssDNA genomes, and they encode rolling-circle replication initiation proteins (Rep) that are mostly similar to those of geminiviruses, as well as unique capsid proteins (9, 10) .", [["Rep", "GENE_OR_GENE_PRODUCT", 129, 132], ["geminiviruses", "GENE_OR_GENE_PRODUCT", 170, 183], ["circular ssDNA genomes", "DNA", 41, 63], ["rolling-circle replication initiation proteins", "PROTEIN", 81, 127], ["Rep", "PROTEIN", 129, 132], ["geminiviruses", "PROTEIN", 170, 183], ["capsid proteins", "PROTEIN", 203, 218], ["These viruses", "PROBLEM", 0, 13], ["circular ssDNA genomes", "PROBLEM", 41, 63], ["geminiviruses", "PROBLEM", 170, 183], ["unique capsid proteins", "TEST", 196, 218], ["viruses", "OBSERVATION", 6, 13], ["small", "OBSERVATION_MODIFIER", 19, 24], ["circular", "OBSERVATION_MODIFIER", 41, 49], ["ssDNA genomes", "OBSERVATION", 50, 63], ["rolling", "OBSERVATION_MODIFIER", 81, 88], ["geminiviruses", "OBSERVATION", 170, 183]]], ["Of all the identified genomoviruses, only Sclerotinia sclerotiorum hypovirulence-associated DNA virus 1 (SsHADV-1) (species, Sclerotinia gemycircularvirus 1; genus, Gemycircularvirus) has been associated with known hosts, S. sclerotiorum (11) and a mycophagous fly, Lycoriella ingenua (12) .INTRODUCTIONThe vast majority of the viruses and integrated virus-like sequences related to circoviruses, geminiviruses, nanoviruses, genomoviruses, and alphasatellites have been identified on the basis of recognizable DNA sequence of Rep involved in rolling circle replication (RCR) (13, 14) .", [["Sclerotinia sclerotiorum hypovirulence-associated DNA virus 1", "ORGANISM", 42, 103], ["SsHADV-1", "ORGANISM", 105, 113], ["Sclerotinia gemycircularvirus 1", "ORGANISM", 125, 156], ["Gemycircularvirus", "GENE_OR_GENE_PRODUCT", 165, 182], ["S. sclerotiorum", "ORGANISM", 222, 237], ["Lycoriella ingenua", "ORGANISM", 266, 284], ["circoviruses", "GENE_OR_GENE_PRODUCT", 383, 395], ["geminiviruses", "CANCER", 397, 410], ["nanoviruses", "GENE_OR_GENE_PRODUCT", 412, 423], ["genomoviruses", "GENE_OR_GENE_PRODUCT", 425, 438], ["alphasatellites", "GENE_OR_GENE_PRODUCT", 444, 459], ["DNA", "CELLULAR_COMPONENT", 510, 513], ["Rep", "GENE_OR_GENE_PRODUCT", 526, 529], ["virus-like sequences", "DNA", 351, 371], ["circoviruses", "DNA", 383, 395], ["geminiviruses", "DNA", 397, 410], ["nanoviruses", "DNA", 412, 423], ["genomoviruses", "DNA", 425, 438], ["alphasatellites", "DNA", 444, 459], ["DNA sequence", "DNA", 510, 522], ["Rep", "PROTEIN", 526, 529], ["Sclerotinia sclerotiorum", "SPECIES", 42, 66], ["virus 1", "SPECIES", 96, 103], ["Sclerotinia gemycircularvirus", "SPECIES", 125, 154], ["S. sclerotiorum", "SPECIES", 222, 237], ["Lycoriella ingenua", "SPECIES", 266, 284], ["Sclerotinia sclerotiorum", "SPECIES", 42, 66], ["SsHADV-1", "SPECIES", 105, 113], ["Sclerotinia gemycircularvirus 1", "SPECIES", 125, 156], ["S. sclerotiorum", "SPECIES", 222, 237], ["mycophagous fly", "SPECIES", 249, 264], ["Lycoriella ingenua", "SPECIES", 266, 284], ["all the identified genomoviruses", "PROBLEM", 3, 35], ["Sclerotinia sclerotiorum hypovirulence", "PROBLEM", 42, 80], ["DNA virus", "PROBLEM", 92, 101], ["SsHADV", "TEST", 105, 111], ["Sclerotinia gemycircularvirus 1", "PROBLEM", 125, 156], ["a mycophagous fly", "TREATMENT", 247, 264], ["the viruses", "PROBLEM", 324, 335], ["integrated virus-like sequences", "PROBLEM", 340, 371], ["circoviruses", "TREATMENT", 383, 395], ["geminiviruses", "PROBLEM", 397, 410], ["nanoviruses", "TREATMENT", 412, 423], ["genomoviruses", "PROBLEM", 425, 438], ["alphasatellites", "PROBLEM", 444, 459], ["genomoviruses", "OBSERVATION", 22, 35], ["Sclerotinia sclerotiorum", "OBSERVATION", 42, 66], ["viruses", "OBSERVATION", 328, 335]]], ["Compared to the capsid protein, Rep is better conserved across these viruses and satellites (14) .", [["Rep", "GENE_OR_GENE_PRODUCT", 32, 35], ["capsid protein", "PROTEIN", 16, 30], ["Rep", "PROTEIN", 32, 35], ["the capsid protein", "TEST", 12, 30], ["viruses", "OBSERVATION", 69, 76]]], ["Conserved motifs within the Rep are important for these viruses and satellites to replicate through RCR (14) .", [["Rep", "GENE_OR_GENE_PRODUCT", 28, 31], ["Rep", "PROTEIN", 28, 31], ["these viruses", "PROBLEM", 50, 63]]], ["These conserved motifs are divided into two main categories based on their roles: the RCR motifs I, II, and III in the N termini of Reps and the superfamily 3 helicase motifs in the C termini, known as Walker-A, Walker-B, and motif C (14) .", [["II", "GENE_OR_GENE_PRODUCT", 100, 102], ["Reps", "GENE_OR_GENE_PRODUCT", 132, 136], ["Walker-B", "GENE_OR_GENE_PRODUCT", 212, 220], ["RCR motifs I, II, and III", "DNA", 86, 111], ["N termini", "DNA", 119, 128], ["Reps", "DNA", 132, 136], ["superfamily 3 helicase motifs", "DNA", 145, 174], ["C termini", "PROTEIN", 182, 191], ["Walker-A, Walker-B", "DNA", 202, 220], ["the C termini", "TREATMENT", 178, 191]]], ["In addition, a conserved motif [geminivirus Rep sequence (GRS)] located between motifs II and III was initially only found in geminiviruses and later also identified in genomoviruses (10, 15) .", [["geminiviruses", "CANCER", 126, 139], ["geminivirus Rep sequence", "DNA", 32, 56], ["GRS", "DNA", 58, 61], ["motifs II and III", "DNA", 80, 97], ["a conserved motif [geminivirus Rep sequence", "TREATMENT", 13, 56], ["geminiviruses", "PROBLEM", 126, 139], ["geminiviruses", "OBSERVATION", 126, 139]]], ["These CRESS DNA viruses replicate through the RCR mechanism, which is similar to that used by bacterial plasmids (14, 16, 17) .", [["plasmids", "ANATOMY", 104, 112], ["CRESS", "GENE_OR_GENE_PRODUCT", 6, 11], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["bacterial plasmids", "DNA", 94, 112], ["These CRESS DNA viruses", "PROBLEM", 0, 23], ["bacterial plasmids", "TREATMENT", 94, 112], ["DNA viruses", "OBSERVATION", 12, 23], ["bacterial plasmids", "OBSERVATION", 94, 112]]], ["The three conserved RCR motifs are well conserved across CRESS DNA viruses and plasmids (14, 18, 19) .INTRODUCTIONFusarium graminearum is a devastating fungal plant pathogen with worldwide distribution that causes Fusarium head blight (FHB) disease in wheat and barley (20) .", [["head", "ANATOMY", 223, 227], ["fungal plant pathogen", "DISEASE", 152, 173], ["Fusarium head blight (FHB) disease", "DISEASE", 214, 248], ["RCR", "GENE_OR_GENE_PRODUCT", 20, 23], ["CRESS", "GENE_OR_GENE_PRODUCT", 57, 62], ["DNA", "CELLULAR_COMPONENT", 63, 66], [".INTRODUCTIONFusarium graminearum", "ORGANISM", 101, 134], ["Fusarium head blight", "ORGANISM", 214, 234], ["FHB", "ORGANISM_SUBDIVISION", 236, 239], ["wheat", "ORGANISM_SUBDIVISION", 252, 257], ["RCR motifs", "DNA", 20, 30], ["CRESS DNA viruses", "DNA", 57, 74], ["plasmids", "DNA", 79, 87], ["wheat", "SPECIES", 252, 257], ["barley", "SPECIES", 262, 268], [".INTRODUCTIONFusarium graminearum", "SPECIES", 101, 134], ["Fusarium head blight (FHB)", "SPECIES", 214, 240], ["wheat", "SPECIES", 252, 257], ["barley", "SPECIES", 262, 268], ["plasmids", "TEST", 79, 87], ["a devastating fungal plant pathogen", "PROBLEM", 138, 173], ["Fusarium head blight (FHB) disease", "PROBLEM", 214, 248], ["devastating", "OBSERVATION_MODIFIER", 140, 151], ["fungal plant pathogen", "OBSERVATION", 152, 173]]], ["Many mycoviruses have been identified from F. graminearum, including dsRNA, (+)ssRNA, and (\u2212)ssRNA viruses (21) .", [["mycoviruses", "CANCER", 5, 16], ["F. graminearum", "ORGANISM", 43, 57], ["dsRNA", "GENE_OR_GENE_PRODUCT", 69, 74], ["(+)ssRNA", "GENE_OR_GENE_PRODUCT", 76, 84], ["F. graminearum", "SPECIES", 43, 57], ["F. graminearum", "SPECIES", 43, 57], ["Many mycoviruses", "PROBLEM", 0, 16], ["dsRNA", "PROBLEM", 69, 74], ["ssRNA", "PROBLEM", 79, 84], ["ssRNA viruses", "PROBLEM", 93, 106]]], ["In this study, we isolated a tripartite ssDNA virus, named Fusarium graminearum gemytripvirus 1 (FgGMTV1), from F. graminearum, with a unique genome organization.", [["Fusarium graminearum gemytripvirus 1", "ORGANISM", 59, 95], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 97, 104], ["F. graminearum", "ORGANISM", 112, 126], ["Fusarium graminearum", "SPECIES", 59, 79], ["gemytripvirus", "SPECIES", 80, 93], ["F. graminearum", "SPECIES", 112, 126], ["Fusarium graminearum gemytripvirus", "SPECIES", 59, 93], ["F. graminearum", "SPECIES", 112, 126], ["this study", "TEST", 3, 13], ["a tripartite ssDNA virus", "PROBLEM", 27, 51], ["named Fusarium graminearum gemytripvirus", "TEST", 53, 93], ["genome organization", "OBSERVATION", 142, 161]]], ["We constructed infectious clone vectors of these three DNA components and used them to identify essential and symptom-associated components, providing a good system for the study of virus-fungus interactions.", [["DNA", "CELLULAR_COMPONENT", 55, 58], ["infectious clone vectors", "TREATMENT", 15, 39], ["the study", "TEST", 169, 178], ["virus", "PROBLEM", 182, 187], ["fungus interactions", "PROBLEM", 188, 207], ["infectious", "OBSERVATION_MODIFIER", 15, 25]]], ["We also propose that the multipartite genome of FgGMTV1 may represent a natural case of relatively recent multipartition.Observation of viral particles and identification of viral genome sequencesTo explore Fusarium mycovirus diversity, around 200 Fusarium strains, isolated from the diseased seeds or glumes of wheat of seven provinces in China, were conducted for high-throughput RNA sequencing.", [["seeds", "ANATOMY", 293, 298], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 48, 55], ["Fusarium mycovirus", "ORGANISM", 207, 225], ["multipartite genome", "DNA", 25, 44], ["FgGMTV1", "DNA", 48, 55], ["viral genome sequences", "DNA", 174, 196], ["wheat", "SPECIES", 312, 317], ["Fusarium mycovirus", "SPECIES", 207, 225], ["viral particles", "PROBLEM", 136, 151], ["viral genome sequences", "TEST", 174, 196], ["Fusarium mycovirus diversity", "PROBLEM", 207, 235], ["200 Fusarium strains", "PROBLEM", 244, 264], ["the diseased seeds", "PROBLEM", 280, 298], ["viral particles", "OBSERVATION", 136, 151], ["viral genome", "OBSERVATION", 174, 186], ["diseased seeds", "OBSERVATION", 284, 298]]], ["Unexpectedly, SsHADV-1-related sequences were identified in strain HB58 collected in the Hebei province of China.", [["SsHADV-1", "GENE_OR_GENE_PRODUCT", 14, 22], ["SsHADV-1-related sequences", "DNA", 14, 40], ["HB58", "SPECIES", 67, 71], ["SsHADV", "TEST", 14, 20]]], ["The strain HB58 was identified as F. graminearum based on sequencing of polymerase chain reaction (PCR) fragments and subsequent BLASTn searches of translation elongation factor 1\uf061 (EF-1\uf061) ( Fig. 1A and fig. S1 ) (22) .", [["F. graminearum", "ORGANISM", 34, 48], ["translation elongation factor 1\uf061", "GENE_OR_GENE_PRODUCT", 148, 180], ["EF-1", "GENE_OR_GENE_PRODUCT", 182, 186], ["Fig. 1A", "GENE_OR_GENE_PRODUCT", 191, 198], ["polymerase chain reaction (PCR) fragments", "DNA", 72, 113], ["translation elongation factor 1\uf061", "PROTEIN", 148, 180], ["EF", "PROTEIN", 182, 184], ["F. graminearum", "SPECIES", 34, 48], ["HB58", "SPECIES", 11, 15], ["F. graminearum", "SPECIES", 34, 48], ["The strain HB58", "TEST", 0, 15], ["polymerase chain reaction (PCR) fragments", "PROBLEM", 72, 113], ["BLASTn searches", "TEST", 129, 144], ["translation elongation factor", "TEST", 148, 177], ["EF", "TEST", 182, 184]]], ["Electron microscopy observation revealed that the negatively stained virus particles purified from strain HB58 were isometric with a diameter of ~19 to 21 nm (Fig. 1B) , comparable to the 20 to 22 nm in diameter reported for SsHADV-1 (11) .", [["HB58", "CELL", 106, 110], ["SsHADV-1", "GENE_OR_GENE_PRODUCT", 225, 233], ["SsHADV", "PROTEIN", 225, 231], ["SsHADV-1", "SPECIES", 225, 233], ["Electron microscopy observation", "TEST", 0, 31], ["the negatively stained virus particles", "PROBLEM", 46, 84], ["a diameter", "TEST", 131, 141], ["SsHADV", "TEST", 225, 231], ["diameter", "OBSERVATION_MODIFIER", 133, 141]]], ["Nucleic acids extracted from the viral particles appeared as a band at ~1.3 kb in agarose gel electrophoresis (Fig. 1C) .", [["Nucleic acids", "CHEMICAL", 0, 13], ["Nucleic acids", "AMINO_ACID", 0, 13], ["agarose", "SIMPLE_CHEMICAL", 82, 89], ["Nucleic acids", "TEST", 0, 13], ["the viral particles", "PROBLEM", 29, 48], ["a band", "TEST", 61, 67], ["agarose gel electrophoresis", "TEST", 82, 109], ["acids", "OBSERVATION", 8, 13], ["viral particles", "OBSERVATION", 33, 48]]], ["To confirm the properties of the extracted nucleic acids, different nucleases were used.", [["nucleic acids", "CHEMICAL", 43, 56], ["nucleases", "PROTEIN", 68, 77], ["the extracted nucleic acids", "TREATMENT", 29, 56], ["different nucleases", "TREATMENT", 58, 77]]], ["The viral nucleic acids could be digested with both deoxyribonuclease I (DNase I) (active against ssDNA and dsDNA) and S1 nuclease (active against ssDNA or ssRNA), but not with exonuclease III (active against linear dsDNA) or exonuclease I (active against linear ssDNA) (Fig. 1D ).", [["nucleic acids", "CHEMICAL", 10, 23], ["deoxyribonuclease I", "GENE_OR_GENE_PRODUCT", 52, 71], ["DNase I", "GENE_OR_GENE_PRODUCT", 73, 80], ["ssDNA", "CELLULAR_COMPONENT", 98, 103], ["dsDNA", "CELLULAR_COMPONENT", 108, 113], ["S1 nuclease", "GENE_OR_GENE_PRODUCT", 119, 130], ["ssDNA", "CELLULAR_COMPONENT", 147, 152], ["exonuclease III", "GENE_OR_GENE_PRODUCT", 177, 192], ["exonuclease I", "GENE_OR_GENE_PRODUCT", 226, 239], ["deoxyribonuclease I", "PROTEIN", 52, 71], ["DNase I", "PROTEIN", 73, 80], ["ssDNA", "PROTEIN", 98, 103], ["dsDNA", "PROTEIN", 108, 113], ["S1 nuclease", "PROTEIN", 119, 130], ["ssDNA", "PROTEIN", 147, 152], ["ssRNA", "PROTEIN", 156, 161], ["exonuclease III", "PROTEIN", 177, 192], ["linear dsDNA", "PROTEIN", 209, 221], ["exonuclease I", "PROTEIN", 226, 239], ["linear ssDNA", "PROTEIN", 256, 268], ["The viral nucleic acids", "TEST", 0, 23], ["deoxyribonuclease I (DNase I", "TREATMENT", 52, 80], ["ssDNA and dsDNA", "TREATMENT", 98, 113], ["S1 nuclease", "PROBLEM", 119, 130], ["ssDNA", "PROBLEM", 147, 152], ["ssRNA", "PROBLEM", 156, 161], ["linear dsDNA", "TREATMENT", 209, 221], ["viral", "OBSERVATION", 4, 9], ["nucleic acids", "OBSERVATION", 10, 23]]], ["This suggests that the viral nucleic acids are circular ssDNA molecules or linear ssDNA with modified 5\u2032 and 3\u2032 ends similar to that described by Yu et al. (11) .Observation of viral particles and identification of viral genome sequencesNucleic acids from virion preparations purified from mycelia of strain HB58 were subjected to rolling circle amplification (RCA).", [["mycelia", "ANATOMY", 290, 297], ["nucleic acids", "CHEMICAL", 29, 42], ["ssDNA", "CELLULAR_COMPONENT", 82, 87], ["Nucleic acids", "SIMPLE_CHEMICAL", 237, 250], ["HB58", "CELL", 308, 312], ["circular ssDNA molecules", "PROTEIN", 47, 71], ["modified 5\u2032 and 3\u2032 ends", "DNA", 93, 116], ["viral genome sequences", "DNA", 215, 237], ["the viral nucleic acids", "PROBLEM", 19, 42], ["circular ssDNA molecules", "TREATMENT", 47, 71], ["linear ssDNA", "TREATMENT", 75, 87], ["viral particles", "PROBLEM", 177, 192], ["viral genome sequences", "TEST", 215, 237], ["Nucleic acids", "TREATMENT", 237, 250], ["virion preparations", "TREATMENT", 256, 275], ["strain HB58", "PROBLEM", 301, 312], ["viral", "OBSERVATION_MODIFIER", 23, 28], ["nucleic acids", "OBSERVATION", 29, 42], ["viral particles", "OBSERVATION", 177, 192], ["viral genome", "OBSERVATION", 215, 227], ["RCA", "ANATOMY", 361, 364]]], ["Restriction digestion of the RCA products generated a unit-length DNA of ~1.3 kb using five tested restriction enzymes (Bam HI, Eco RI, Sal I, Bgl II, and Kpn I).", [["DNA", "CELLULAR_COMPONENT", 66, 69], ["Bam HI", "GENE_OR_GENE_PRODUCT", 120, 126], ["Eco RI", "GENE_OR_GENE_PRODUCT", 128, 134], ["Sal I", "GENE_OR_GENE_PRODUCT", 136, 141], ["Bgl II", "GENE_OR_GENE_PRODUCT", 143, 149], ["Kpn I", "GENE_OR_GENE_PRODUCT", 155, 160], ["RCA products", "PROTEIN", 29, 41], ["unit-length DNA", "DNA", 54, 69], ["restriction enzymes", "PROTEIN", 99, 118], ["Bam HI", "PROTEIN", 120, 126], ["Eco RI", "PROTEIN", 128, 134], ["Sal I", "PROTEIN", 136, 141], ["Bgl II", "PROTEIN", 143, 149], ["Kpn I", "PROTEIN", 155, 160], ["a unit-length DNA", "TREATMENT", 52, 69], ["enzymes", "TEST", 111, 118], ["Bam HI", "TEST", 120, 126], ["RCA", "ANATOMY", 29, 32]]], ["In addition, using Sal I, a 0.9-kb DNA, and using Kpn I, a 1-kb DNA, were observed upon electrophoresis.", [["Sal I", "GENE_OR_GENE_PRODUCT", 19, 24], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["Kpn I", "GENE_OR_GENE_PRODUCT", 50, 55], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["Sal I", "DNA", 19, 24], ["0.9-kb DNA", "DNA", 28, 38], ["Kpn I", "DNA", 50, 55], ["1-kb DNA", "DNA", 59, 67], ["a 0.9-kb DNA", "TREATMENT", 26, 38], ["a 1-kb DNA", "TREATMENT", 57, 67], ["electrophoresis", "TEST", 88, 103]]], ["The restricted and cloned RCA products were sequenced and analyzed.", [["RCA", "GENE_OR_GENE_PRODUCT", 26, 29], ["RCA products", "PROTEIN", 26, 38], ["The restricted and cloned RCA products", "TREATMENT", 0, 38], ["RCA", "OBSERVATION_MODIFIER", 26, 29]]], ["The full-length sequences were obtained by PCR using specific back-toback primers designed based on the sequences obtained above.", [["full-length sequences", "DNA", 4, 25], ["The full-length sequences", "TEST", 0, 25], ["PCR", "TEST", 43, 46], ["specific back-toback primers", "TEST", 53, 81], ["the sequences", "TEST", 100, 113]]], ["Last, a total of three circular ssDNA components (DNA-A, DNA-B, and DNA-C) associated with the nucleic acids from viral particles were identified, sequenced, and confirmed by Southern blot analyses (Fig. 1, F (9) ; however, the Rep gene of DNA-A lacks an intron similarly to that of SsHADV-1 (11) .", [["nucleic acids", "CHEMICAL", 95, 108], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["-B", "GENE_OR_GENE_PRODUCT", 60, 62], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["-C", "GENE_OR_GENE_PRODUCT", 71, 73], ["Rep", "GENE_OR_GENE_PRODUCT", 228, 231], ["DNA", "CELLULAR_COMPONENT", 240, 243], ["SsHADV-1", "GENE_OR_GENE_PRODUCT", 283, 291], ["circular ssDNA components", "DNA", 23, 48], ["DNA-A, DNA-B", "DNA", 50, 62], ["F (9)", "DNA", 207, 212], ["Rep gene", "DNA", 228, 236], ["DNA-A", "DNA", 240, 245], ["SsHADV", "DNA", 283, 289], ["three circular ssDNA components", "TREATMENT", 17, 48], ["DNA", "TEST", 50, 53], ["DNA", "TEST", 57, 60], ["DNA", "TEST", 68, 71], ["the nucleic acids", "PROBLEM", 91, 108], ["viral particles", "PROBLEM", 114, 129], ["Southern blot analyses", "TEST", 175, 197], ["an intron", "TREATMENT", 252, 261], ["SsHADV", "TEST", 283, 289], ["viral particles", "OBSERVATION", 114, 129]]], ["DNA-B was 1320 nt in length and contained a large ORF with a coding potential for a protein of 215 amino acids (Fig. 1G ).", [["amino acids", "CHEMICAL", 99, 110], ["amino acids", "CHEMICAL", 99, 110], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["amino acids", "AMINO_ACID", 99, 110], ["DNA-B", "DNA", 0, 5], ["ORF", "DNA", 50, 53], ["a large ORF", "PROBLEM", 42, 53], ["a protein", "TEST", 82, 91], ["amino acids", "TREATMENT", 99, 110], ["large", "OBSERVATION_MODIFIER", 44, 49], ["ORF", "OBSERVATION", 50, 53]]], ["The deduced protein shared the highest similarity with the capsid protein (CP) of Finch-associated genomovirus 7 (GenBank accession number QCQ85257.1; 8.0 \u00d7 10 \u221210 , 77% coverage and 21.74% identity), an unpublished virus in the family Genomoviridae.", [["genomovirus 7", "ORGANISM", 99, 112], ["capsid protein", "PROTEIN", 59, 73], ["CP", "PROTEIN", 75, 77], ["Finch", "PROTEIN", 82, 87], ["genomovirus 7", "PROTEIN", 99, 112], ["The deduced protein", "TEST", 0, 19], ["the capsid protein", "TEST", 55, 73], ["genomovirus", "TEST", 99, 110], ["coverage", "TEST", 170, 178], ["an unpublished virus", "PROBLEM", 201, 221], ["protein", "OBSERVATION", 12, 19]]], ["Three bands could be observed in the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of purified virus particles (Fig. 1E) ; unexpectedly, the relative molecular mass estimated by SDS-PAGE for the top band was similar to the deduced size (34.2 kDa) of the DNA-B encoding capsid protein, while the size of another two bands was smaller than the expected 34.2 kDa.", [["SDS-polyacrylamide", "CHEMICAL", 37, 55], ["SDS", "CHEMICAL", 37, 40], ["polyacrylamide", "CHEMICAL", 41, 55], ["DNA-B encoding capsid protein", "GENE_OR_GENE_PRODUCT", 267, 296], ["DNA-B encoding capsid protein", "PROTEIN", 267, 296], ["Three bands", "PROBLEM", 0, 11], ["the SDS", "TEST", 33, 40], ["polyacrylamide gel electrophoresis", "TEST", 41, 75], ["purified virus particles", "PROBLEM", 99, 123], ["the relative molecular mass", "PROBLEM", 150, 177], ["the top band", "TEST", 204, 216], ["the deduced size", "TEST", 232, 248], ["the DNA", "TEST", 263, 270], ["capsid protein", "TEST", 282, 296], ["another two bands", "TEST", 316, 333], ["mass", "OBSERVATION", 173, 177], ["size", "OBSERVATION_MODIFIER", 244, 248], ["capsid protein", "OBSERVATION", 282, 296], ["size", "OBSERVATION_MODIFIER", 308, 312], ["smaller", "OBSERVATION_MODIFIER", 338, 345]]], ["The three bands were unambiguously identified by peptide mass fingerprinting (PMF) as the CP.", [["The three bands", "PROBLEM", 0, 15], ["peptide mass fingerprinting", "PROBLEM", 49, 76], ["the CP", "PROBLEM", 86, 92], ["mass", "OBSERVATION", 57, 61]]], ["This triple-band SDS-PAGE profile might be attributed to partial degradation of CP or to posttranslational modifications of the protein; further studies will be necessary to clarify this point.", [["CP", "SIMPLE_CHEMICAL", 80, 82], ["This triple-band SDS", "TEST", 0, 20], ["partial degradation of CP", "PROBLEM", 57, 82], ["posttranslational modifications of the protein", "PROBLEM", 89, 135], ["further studies", "TEST", 137, 152]]], ["DNA-C (1309 nt) contained a large ORF potentially encoding a protein with a molecular mass of 25.8 kDa (Fig. 1G) , hereafter named p26, which had no obvious similarities to other sequences in the National Center for Biotechnology Information (NCBI) protein database.Observation of viral particles and identification of viral genome sequencesAll three ssDNA segments had two common regions in the untranslated region.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["p26", "GENE_OR_GENE_PRODUCT", 131, 134], ["DNA-C", "DNA", 0, 5], ["ORF", "DNA", 34, 37], ["p26", "PROTEIN", 131, 134], ["National Center for Biotechnology Information (NCBI) protein", "PROTEIN", 196, 256], ["viral genome sequences", "DNA", 319, 341], ["ssDNA segments", "DNA", 351, 365], ["untranslated region", "DNA", 396, 415], ["DNA", "TEST", 0, 3], ["a large ORF", "PROBLEM", 26, 37], ["a molecular mass", "PROBLEM", 74, 90], ["viral particles", "PROBLEM", 281, 296], ["viral genome sequences", "TEST", 319, 341], ["large", "OBSERVATION_MODIFIER", 28, 33], ["mass", "OBSERVATION", 86, 90], ["25.8 kDa", "OBSERVATION_MODIFIER", 94, 102], ["viral particles", "OBSERVATION", 281, 296], ["viral genome", "OBSERVATION", 319, 331], ["three", "OBSERVATION_MODIFIER", 345, 350], ["ssDNA", "OBSERVATION", 351, 356], ["segments", "ANATOMY_MODIFIER", 357, 365], ["two", "OBSERVATION_MODIFIER", 370, 373], ["common regions", "ANATOMY_MODIFIER", 374, 388], ["untranslated", "OBSERVATION", 396, 408]]], ["One was a 105-or 106-nt region that was 98% identical to regions in the three components, termed common region major (CR-M) ( fig. S2) .", [["105-or 106-nt region", "DNA", 10, 30], ["three", "ANATOMY_MODIFIER", 72, 77], ["common", "OBSERVATION_MODIFIER", 97, 103], ["S2", "ANATOMY", 131, 133]]], ["The other was a 77-or 82-nt region, termed common region stem loop (CR-SL), which was 89% identical to the other regions ( fig. S2 ).", [["77-or 82-nt region", "DNA", 16, 34], ["S2", "PROTEIN", 128, 130], ["CR", "TEST", 68, 70], ["common region", "ANATOMY", 43, 56], ["stem loop", "OBSERVATION", 57, 66], ["fig", "OBSERVATION_MODIFIER", 123, 126]]], ["The CR-SL contained a conserved unusual nonanucleotide (TTTAAGATT), which was not found in most reported genomoviruses (10) .", [["nonanucleotide", "GENE_OR_GENE_PRODUCT", 40, 54], ["TTTAAGATT", "GENE_OR_GENE_PRODUCT", 56, 65], ["CR-SL", "DNA", 4, 9], ["The CR", "TEST", 0, 6]]], ["The potential stem-loop structures of DNA-A and DNA-B were the same, but different from that of DNA-C, apart from the aforementioned conserved nonanucleotide.Sequence alignment and phylogenetic classificationWith the exception of motif I, all conserved RCR motifs (motifs II and III) and three helicase motifs known as Walker-A, Walker-B, and motif C were found in the Rep encoded in DNA-A (table S1).", [["stem-loop structures", "ANATOMY", 14, 34], ["DNA-A", "GENE_OR_GENE_PRODUCT", 38, 43], ["DNA-B", "GENE_OR_GENE_PRODUCT", 48, 53], ["DNA-C", "GENE_OR_GENE_PRODUCT", 96, 101], ["nonanucleotide", "SIMPLE_CHEMICAL", 143, 157], ["Walker-A", "GENE_OR_GENE_PRODUCT", 319, 327], ["Walker-B", "GENE_OR_GENE_PRODUCT", 329, 337], ["motif C", "GENE_OR_GENE_PRODUCT", 343, 350], ["Rep", "GENE_OR_GENE_PRODUCT", 369, 372], ["DNA", "CELLULAR_COMPONENT", 384, 387], ["-A (table S1", "GENE_OR_GENE_PRODUCT", 387, 399], ["DNA-A and DNA-B", "DNA", 38, 53], ["DNA-C", "DNA", 96, 101], ["nonanucleotide", "DNA", 143, 157], ["motif I", "DNA", 230, 237], ["RCR motifs", "DNA", 253, 263], ["motifs II and III", "DNA", 265, 282], ["helicase motifs", "DNA", 294, 309], ["Walker-A, Walker-B", "DNA", 319, 337], ["motif C", "DNA", 343, 350], ["Rep", "DNA", 369, 372], ["DNA-A", "DNA", 384, 389], ["table S1", "DNA", 391, 399], ["DNA", "TEST", 38, 41], ["DNA", "TEST", 48, 51], ["DNA", "TEST", 96, 99], ["Sequence alignment", "TEST", 158, 176], ["three helicase motifs", "TREATMENT", 288, 309], ["motif C", "PROBLEM", 343, 350], ["potential", "UNCERTAINTY", 4, 13], ["stem", "OBSERVATION_MODIFIER", 14, 18], ["loop", "OBSERVATION_MODIFIER", 19, 23], ["DNA", "OBSERVATION_MODIFIER", 38, 41]]], ["A fourth conserved motif, GRS, was also found in this Rep (table S1).", [["Rep", "GENE_OR_GENE_PRODUCT", 54, 57], ["GRS", "DNA", 26, 29], ["Rep", "PROTEIN", 54, 57]]], ["Sequence analyses of the full-length amino acid sequence of the putative Rep and CP of this ssDNA virus and selected genomoviruses showed that this novel virus shared higher Rep amino acid sequence identity (24.1 to 33.0%) than CP sequence identity (10.3 to 17.1%) with selected genomoviruses (table S2).", [["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 178, 188], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 178, 188], ["amino acid", "AMINO_ACID", 37, 47], ["Rep", "GENE_OR_GENE_PRODUCT", 73, 76], ["Rep", "GENE_OR_GENE_PRODUCT", 174, 177], ["amino acid", "AMINO_ACID", 178, 188], ["Rep", "PROTEIN", 73, 76], ["CP", "PROTEIN", 81, 83], ["Rep", "PROTEIN", 174, 177], ["genomoviruses", "PROTEIN", 279, 292], ["Sequence analyses", "TEST", 0, 17], ["the full-length amino acid sequence", "TEST", 21, 56], ["this ssDNA virus", "PROBLEM", 87, 103], ["selected genomoviruses", "TEST", 108, 130], ["this novel virus", "PROBLEM", 143, 159], ["Rep amino acid sequence identity", "TEST", 174, 206], ["CP sequence identity", "TEST", 228, 248]]], ["Phylogenetic analysis of the Reps of this virus and selected ssDNA viruses indicated that this ssDNA virus was nested within the family Genomoviridae (Fig. 2) .", [["Reps", "GENE_OR_GENE_PRODUCT", 29, 33], ["ssDNA", "CELLULAR_COMPONENT", 95, 100], ["Reps", "DNA", 29, 33], ["Phylogenetic analysis", "TEST", 0, 21], ["this virus", "PROBLEM", 37, 47], ["selected ssDNA viruses", "PROBLEM", 52, 74], ["this ssDNA virus", "PROBLEM", 90, 106], ["ssDNA viruses", "OBSERVATION", 61, 74]]], ["In many instances, the putative Rep encoded by divergent CRESS DNA viruses is the only protein that has any detectable sequence similarity to other known ssDNA viral Reps (10, 14) .", [["Rep", "GENE_OR_GENE_PRODUCT", 32, 35], ["CRESS", "GENE_OR_GENE_PRODUCT", 57, 62], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["ssDNA", "CELLULAR_COMPONENT", 154, 159], ["Rep", "PROTEIN", 32, 35], ["ssDNA viral Reps", "DNA", 154, 170], ["divergent CRESS DNA viruses", "PROBLEM", 47, 74]]], ["Compared to the Rep amino acid sequences, the CP sequences of this ssDNA virus and the members of nine genera in the family Genomoviridae were all found to be phylogenetically more divergent ( fig. S3 ), possibly because they are involved in interactions with cell surface receptors in the hosts and/ or vectors (10) .", [["cell surface", "ANATOMY", 260, 272], ["amino acid", "CHEMICAL", 20, 30], ["amino acid", "CHEMICAL", 20, 30], ["amino acid", "AMINO_ACID", 20, 30], ["Genomoviridae", "GENE_OR_GENE_PRODUCT", 124, 137], ["S3", "GENE_OR_GENE_PRODUCT", 198, 200], ["cell", "CELL", 260, 264], ["Rep amino acid sequences", "PROTEIN", 16, 40], ["CP sequences", "DNA", 46, 58], ["S3", "PROTEIN", 198, 200], ["cell surface receptors", "PROTEIN", 260, 282], ["the Rep amino acid sequences", "TEST", 12, 40], ["the CP sequences", "TEST", 42, 58], ["this ssDNA virus", "PROBLEM", 62, 78], ["cell surface receptors", "TREATMENT", 260, 282]]], ["In conclusion, we can verify that these three DNA segments are circular ssDNA molecules and tentatively assign this ssDNA virus the name \"Fusarium graminearum gemytripvirus 1 (FgGMTV1).\"", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["Fusarium graminearum gemytripvirus 1", "ORGANISM", 138, 174], ["DNA segments", "DNA", 46, 58], ["circular ssDNA molecules", "PROTEIN", 63, 87], ["Fusarium graminearum gemytripvirus", "SPECIES", 138, 172], ["Fusarium graminearum gemytripvirus 1", "SPECIES", 138, 174], ["circular ssDNA molecules", "PROBLEM", 63, 87], ["circular", "OBSERVATION_MODIFIER", 63, 71], ["ssDNA molecules", "OBSERVATION", 72, 87]]], ["We suggest that the mycovirus FgGMTV1 is a representative member of the new proposed genus Gemytripvirus (Geminilike myco-infecting tripartite virus) in the family Genomoviridae.", [["mycovirus", "ORGANISM", 20, 29], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 30, 37], ["Gemytripvirus", "ORGANISM", 91, 104], ["Geminilike myco-infecting tripartite virus", "ORGANISM", 106, 148], ["mycovirus FgGMTV1", "PROTEIN", 20, 37], ["tripartite virus", "SPECIES", 132, 148], ["Geminilike myco-infecting tripartite virus", "SPECIES", 106, 148], ["the mycovirus FgGMTV1", "TEST", 16, 37]]], ["The GenBank accession numbers for the nucleotide sequence of DNA-A, DNA-B, and DNA-C of FgGMTV1 are MK430076, MK430077, and MK430078, respectively.Infectivity and symptoms induced by DNA-A, DNA-B, and DNA-CTo further test whether DNA-A, DNA-B, and DNA-C identified here represent the FgGMTV1 genome and assess their infectivity and effect on biological properties of the host, we constructed infectious clones of DNA-A (pSK-2A), DNA-B (pSK-2B), and DNA-C (pSK-1.6C), containing a dimer tandem repeat of DNA-A, a dimer tandem repeat of DNA-B, and a 1.6-mer tandem repeat of DNA-C, respectively, following a similar strategy to that used to construct infectious clones of geminiviruses ( fig. S4 ) (23, 24) .", [["clones", "ANATOMY", 660, 666], ["nucleotide", "CHEMICAL", 38, 48], ["MK430076", "CHEMICAL", 100, 108], ["nucleotide", "CHEMICAL", 38, 48], ["MK430076", "CHEMICAL", 100, 108], ["MK430077", "CHEMICAL", 110, 118], ["MK430078", "CHEMICAL", 124, 132], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["-B", "GENE_OR_GENE_PRODUCT", 71, 73], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 88, 95], ["DNA", "CELLULAR_COMPONENT", 183, 186], ["DNA", "CELLULAR_COMPONENT", 190, 193], ["-B", "GENE_OR_GENE_PRODUCT", 193, 195], ["DNA", "CELLULAR_COMPONENT", 201, 204], ["DNA", "CELLULAR_COMPONENT", 230, 233], ["-A", "GENE_OR_GENE_PRODUCT", 233, 235], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["-B", "GENE_OR_GENE_PRODUCT", 240, 242], ["DNA", "CELLULAR_COMPONENT", 248, 251], ["-C", "GENE_OR_GENE_PRODUCT", 251, 253], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 284, 291], ["DNA", "CELLULAR_COMPONENT", 413, 416], ["pSK-2A", "GENE_OR_GENE_PRODUCT", 420, 426], ["DNA-B", "GENE_OR_GENE_PRODUCT", 429, 434], ["pSK-2B", "GENE_OR_GENE_PRODUCT", 436, 442], ["DNA", "CELLULAR_COMPONENT", 449, 452], ["-C", "GENE_OR_GENE_PRODUCT", 452, 454], ["pSK-1.6C", "GENE_OR_GENE_PRODUCT", 456, 464], ["DNA", "CELLULAR_COMPONENT", 503, 506], ["DNA", "CELLULAR_COMPONENT", 535, 538], ["-B", "GENE_OR_GENE_PRODUCT", 538, 540], ["DNA", "CELLULAR_COMPONENT", 573, 576], ["-C", "GENE_OR_GENE_PRODUCT", 576, 578], ["geminiviruses", "CANCER", 670, 683], ["DNA-A, DNA-B, and DNA-C", "DNA", 61, 84], ["FgGMTV1", "DNA", 88, 95], ["DNA-A, DNA-B", "DNA", 183, 195], ["DNA-CTo", "DNA", 201, 208], ["DNA-A", "DNA", 230, 235], ["DNA-B", "DNA", 237, 242], ["DNA-C", "DNA", 248, 253], ["FgGMTV1 genome", "DNA", 284, 298], ["pSK", "DNA", 420, 423], ["DNA-B", "DNA", 429, 434], ["pSK", "DNA", 436, 439], ["DNA-C", "DNA", 449, 454], ["pSK", "DNA", 456, 459], ["1.6C", "DNA", 460, 464], ["dimer tandem repeat", "DNA", 480, 499], ["DNA-A", "DNA", 503, 508], ["dimer tandem repeat", "DNA", 512, 531], ["DNA-B", "DNA", 535, 540], ["1.6-mer tandem repeat", "DNA", 548, 569], ["DNA-C", "DNA", 573, 578], ["the nucleotide sequence", "TEST", 34, 57], ["DNA", "TEST", 61, 64], ["DNA", "TEST", 68, 71], ["DNA", "TEST", 79, 82], ["FgGMTV1", "TEST", 88, 95], ["MK430077", "TEST", 110, 118], ["Infectivity", "PROBLEM", 147, 158], ["symptoms", "PROBLEM", 163, 171], ["DNA", "TEST", 183, 186], ["DNA", "TEST", 190, 193], ["CTo further test", "TEST", 205, 221], ["DNA", "TEST", 230, 233], ["DNA", "TEST", 237, 240], ["DNA", "PROBLEM", 248, 251], ["the FgGMTV1 genome", "PROBLEM", 280, 298], ["their infectivity", "PROBLEM", 310, 327], ["DNA", "TEST", 413, 416], ["A (pSK", "TEST", 417, 423], ["DNA", "TEST", 429, 432], ["DNA", "TEST", 449, 452], ["pSK", "TEST", 456, 459], ["DNA", "TEST", 535, 538], ["DNA", "TEST", 573, 576], ["infectious", "OBSERVATION", 392, 402]]], ["Eight transfectants were generated with different combinations of clones pSK-2A, pSK-2B, and pSK-1.6C and one transfectant using purified viral particles (table S3) , among which strain S was used as a negative control.", [["transfectants", "ANATOMY", 6, 19], ["transfectant", "ANATOMY", 110, 122], ["transfectants", "CELL", 6, 19], ["pSK-2A", "CELL", 73, 79], ["pSK-2B", "CELL", 81, 87], ["pSK-1.6C", "CELL", 93, 101], ["transfectant", "CELL", 110, 122], ["pSK-2A", "CELL_LINE", 73, 79], ["pSK-2B", "CELL_LINE", 81, 87], ["pSK-1.6C", "CELL_LINE", 93, 101], ["Eight transfectants", "TEST", 0, 19], ["clones pSK", "TEST", 66, 76], ["pSK", "TEST", 81, 84], ["pSK", "TEST", 93, 96], ["purified viral particles", "PROBLEM", 129, 153], ["viral particles", "OBSERVATION", 138, 153]]], ["Southern blot analyses of viral DNA extracted from PH-1 and nine transfectants were conducted using probe A, probe B, and probe C (Fig. 3) .", [["transfectants", "ANATOMY", 65, 78], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["transfectants", "CELL", 65, 78], ["viral DNA", "DNA", 26, 35], ["probe B", "DNA", 109, 116], ["probe C", "DNA", 122, 129], ["viral DNA", "PROBLEM", 26, 35], ["PH", "TEST", 51, 53], ["viral DNA", "OBSERVATION", 26, 35]]], ["When using probe A and probe B, viral DNA replicative forms were only present in strain A + B, strain A + B + C, and strain Virion, demonstrating a successful infection, but not in the other seven strains (Fig. 3) .", [["infection", "DISEASE", 159, 168], ["probe B", "GENE_OR_GENE_PRODUCT", 23, 30], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["A + B", "CELL", 88, 93], ["A + B + C", "CELL", 102, 111], ["probe A", "DNA", 11, 18], ["probe B", "DNA", 23, 30], ["probe A and probe B, viral DNA replicative forms", "TEST", 11, 59], ["C", "PROBLEM", 110, 111], ["strain Virion", "PROBLEM", 117, 130], ["a successful infection", "PROBLEM", 146, 168], ["successful", "OBSERVATION_MODIFIER", 148, 158], ["infection", "OBSERVATION", 159, 168]]], ["When using probe C, viral DNA replicative forms were only present in strain A + B + C and strain Virion, but not in the strain A + B or in the other seven strains (Fig. 3) .", [["DNA", "CELLULAR_COMPONENT", 26, 29], ["B + C", "CELL", 80, 85], ["A + B", "CELL", 127, 132], ["probe C", "DNA", 11, 18], ["probe C", "TEST", 11, 18], ["viral DNA replicative forms", "PROBLEM", 20, 47], ["C", "PROBLEM", 84, 85], ["strain Virion", "PROBLEM", 90, 103]]], ["Southern hybridization analyses showed that DNA-A, DNA-B, or DNA-C alone were not infectious; the combination of DNA-A and DNA-C or the combination of DNA-B and DNA-C were also shown not to be infectious, but the combination of DNA-A and DNA-B, the combination of DNA-A, DNA-B, and DNA-C, and viral particles were infectious.", [["DNA-A", "GENE_OR_GENE_PRODUCT", 44, 49], ["DNA-B", "GENE_OR_GENE_PRODUCT", 51, 56], ["DNA-C", "GENE_OR_GENE_PRODUCT", 61, 66], ["DNA-A", "GENE_OR_GENE_PRODUCT", 113, 118], ["DNA-C", "GENE_OR_GENE_PRODUCT", 123, 128], ["DNA-B", "GENE_OR_GENE_PRODUCT", 151, 156], ["DNA-C", "GENE_OR_GENE_PRODUCT", 161, 166], ["DNA-A", "GENE_OR_GENE_PRODUCT", 228, 233], ["DNA-B", "GENE_OR_GENE_PRODUCT", 238, 243], ["DNA-A", "GENE_OR_GENE_PRODUCT", 264, 269], ["DNA-B", "GENE_OR_GENE_PRODUCT", 271, 276], ["DNA-C", "GENE_OR_GENE_PRODUCT", 282, 287], ["DNA-A, DNA-B", "DNA", 44, 56], ["DNA-C", "DNA", 61, 66], ["DNA-A", "DNA", 113, 118], ["DNA-C", "DNA", 123, 128], ["DNA-B and DNA-C", "DNA", 151, 166], ["DNA-A and DNA-B", "DNA", 228, 243], ["DNA-A", "DNA", 264, 269], ["DNA-B", "DNA", 271, 276], ["Southern hybridization analyses", "TEST", 0, 31], ["DNA", "TEST", 44, 47], ["DNA", "TEST", 51, 54], ["DNA", "PROBLEM", 61, 64], ["infectious", "PROBLEM", 82, 92], ["DNA", "TEST", 113, 116], ["DNA", "PROBLEM", 151, 154], ["DNA", "PROBLEM", 161, 164], ["infectious", "PROBLEM", 193, 203], ["DNA", "TEST", 228, 231], ["DNA", "TEST", 238, 241], ["DNA", "TEST", 264, 267], ["DNA", "TEST", 271, 274], ["DNA", "TEST", 282, 285], ["C", "PROBLEM", 286, 287], ["viral particles", "PROBLEM", 293, 308], ["infectious", "PROBLEM", 314, 324], ["infectious", "OBSERVATION", 82, 92], ["infectious", "OBSERVATION", 193, 203], ["viral particles", "OBSERVATION", 293, 308], ["infectious", "OBSERVATION", 314, 324]]], ["These results suggest that DNA-A and DNA-B are mutually interdependent and sufficient for their replication, while DNA-C relies on DNA-A and DNA-B.", [["DNA", "CELLULAR_COMPONENT", 27, 30], ["-A", "GENE_OR_GENE_PRODUCT", 30, 32], ["DNA-B", "GENE_OR_GENE_PRODUCT", 37, 42], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["-C", "GENE_OR_GENE_PRODUCT", 118, 120], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["-A", "GENE_OR_GENE_PRODUCT", 134, 136], ["DNA", "CELLULAR_COMPONENT", 141, 144], ["DNA-A and DNA-B", "DNA", 27, 42], ["DNA-C", "DNA", 115, 120], ["DNA-A", "DNA", 131, 136], ["DNA", "TEST", 131, 134]]], ["In addition, strain A + B + C and strain Virion accumulated more viral DNA than strain A + B, indicating that DNA-C enhances the accumulation level of viral DNA in infected fungi.Infectivity and symptoms induced by DNA-A, DNA-B, and DNA-CTo verify successful infection, viral particles, viral nucleic acids, and structural proteins were extracted from strains S, A + B, A + B + C, and HB58 ( fig. S5 , A to C).", [["infection", "DISEASE", 259, 268], ["A + B + C", "CELL", 20, 29], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["A + B", "CELL", 87, 92], ["DNA-C", "GENE_OR_GENE_PRODUCT", 110, 115], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["DNA", "CELLULAR_COMPONENT", 215, 218], ["DNA", "CELLULAR_COMPONENT", 222, 225], ["-B", "GENE_OR_GENE_PRODUCT", 225, 227], ["DNA", "CELLULAR_COMPONENT", 233, 236], ["A + B", "CELL", 363, 368], ["A + B + C", "CELL", 370, 379], ["HB58", "ORGANISM", 385, 389], ["viral DNA", "DNA", 65, 74], ["viral DNA", "DNA", 151, 160], ["DNA-A, DNA-B", "DNA", 215, 227], ["DNA-CTo", "DNA", 233, 240], ["viral nucleic acids", "PROTEIN", 287, 306], ["structural proteins", "PROTEIN", 312, 331], ["S5", "PROTEIN", 397, 399], ["C", "PROBLEM", 28, 29], ["strain Virion accumulated more viral DNA", "PROBLEM", 34, 74], ["DNA", "TEST", 110, 113], ["the accumulation level", "PROBLEM", 125, 147], ["viral DNA", "PROBLEM", 151, 160], ["infected fungi", "PROBLEM", 164, 178], ["Infectivity", "PROBLEM", 179, 190], ["symptoms", "PROBLEM", 195, 203], ["DNA", "PROBLEM", 233, 236], ["CTo", "TREATMENT", 237, 240], ["successful infection", "PROBLEM", 248, 268], ["viral particles", "PROBLEM", 270, 285], ["viral nucleic acids", "TEST", 287, 306], ["structural proteins", "PROBLEM", 312, 331], ["strains S", "TEST", 352, 361], ["HB58", "TEST", 385, 389], ["viral DNA", "OBSERVATION", 65, 74], ["viral DNA", "OBSERVATION", 151, 160], ["infected fungi", "OBSERVATION", 164, 178], ["infection", "OBSERVATION", 259, 268], ["viral particles", "OBSERVATION", 270, 285], ["nucleic acids", "OBSERVATION", 293, 306]]], ["Viral particles, viral nucleic acids, and structural proteins, similar to those of strain HB58, were observed in strains A + B and A + B + C, not strain S ( fig. S5 , A to C), demonstrating a successful infection.", [["infection", "DISEASE", 203, 212], ["HB58", "GENE_OR_GENE_PRODUCT", 90, 94], ["A + B", "CELL", 121, 126], ["A + B + C", "CELL", 131, 140], ["viral nucleic acids", "PROTEIN", 17, 36], ["structural proteins", "PROTEIN", 42, 61], ["Viral particles", "PROBLEM", 0, 15], ["viral nucleic acids", "PROBLEM", 17, 36], ["structural proteins", "PROBLEM", 42, 61], ["strain HB58", "PROBLEM", 83, 94], ["a successful infection", "PROBLEM", 190, 212], ["viral nucleic acids", "OBSERVATION", 17, 36], ["successful", "OBSERVATION_MODIFIER", 192, 202], ["infection", "OBSERVATION", 203, 212]]], ["Southern blot analyses of nucleic acids extracted from viral particles isolated from these strains were also conducted using probe A, probe B, and probe C ( fig. S5D ).", [["nucleic acids", "CHEMICAL", 26, 39], ["probe B", "DNA", 134, 141], ["probe C", "DNA", 147, 154], ["nucleic acids", "PROBLEM", 26, 39], ["viral particles", "PROBLEM", 55, 70], ["these strains", "PROBLEM", 85, 98], ["nucleic acids", "OBSERVATION", 26, 39], ["viral particles", "OBSERVATION", 55, 70]]], ["Viral DNA was detected in strains A + B, A + B + C, and HB58 using probe A and probe B, while not present in strain A + B using probe C. The results demonstrate that the formation of viral particles does not correlate with the presence of DNA-C, and DNA-A, DNA-B, and DNA-C represent the FgGMTV1 genome.Infectivity and symptoms induced by DNA-A, DNA-B, and DNA-CWe assessed the mycelial growth, conidiation, and virulence on wheat spikes of strains PH-1, S, A + B, A + B + C, Virion, and HB58.", [["A + B", "ANATOMY", 34, 39], ["A + B + C", "ANATOMY", 41, 50], ["mycelial", "ANATOMY", 378, 386], ["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["A + B", "CELL", 34, 39], ["A + B + C", "CELL", 41, 50], ["HB58", "CELL", 56, 60], ["A + B", "CELL", 116, 121], ["DNA", "CELLULAR_COMPONENT", 239, 242], ["-C", "GENE_OR_GENE_PRODUCT", 242, 244], ["DNA", "CELLULAR_COMPONENT", 250, 253], ["-A", "GENE_OR_GENE_PRODUCT", 253, 255], ["DNA", "CELLULAR_COMPONENT", 257, 260], ["-B", "GENE_OR_GENE_PRODUCT", 260, 262], ["DNA", "CELLULAR_COMPONENT", 268, 271], ["-C", "GENE_OR_GENE_PRODUCT", 271, 273], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 288, 295], ["DNA", "CELLULAR_COMPONENT", 339, 342], ["DNA", "CELLULAR_COMPONENT", 346, 349], ["-B", "GENE_OR_GENE_PRODUCT", 349, 351], ["DNA", "CELLULAR_COMPONENT", 357, 360], ["A + B", "CELL", 458, 463], ["A + B + C", "CELL", 465, 474], ["Virion", "SIMPLE_CHEMICAL", 476, 482], ["HB58", "SIMPLE_CHEMICAL", 488, 492], ["Viral DNA", "DNA", 0, 9], ["probe A", "DNA", 67, 74], ["probe B", "DNA", 79, 86], ["DNA-C", "DNA", 239, 244], ["DNA-A", "DNA", 250, 255], ["DNA-B", "DNA", 257, 262], ["DNA-C", "DNA", 268, 273], ["FgGMTV1 genome", "DNA", 288, 302], ["DNA-A, DNA-B, and DNA-CWe", "DNA", 339, 364], ["wheat", "SPECIES", 425, 430], ["wheat", "SPECIES", 425, 430], ["Viral DNA", "TEST", 0, 9], ["viral particles", "PROBLEM", 183, 198], ["DNA", "TEST", 239, 242], ["DNA", "TEST", 250, 253], ["DNA", "TEST", 257, 260], ["DNA", "TEST", 268, 271], ["the FgGMTV1 genome", "PROBLEM", 284, 302], ["Infectivity", "PROBLEM", 303, 314], ["symptoms", "PROBLEM", 319, 327], ["DNA", "PROBLEM", 357, 360], ["the mycelial growth", "PROBLEM", 374, 393], ["virulence", "PROBLEM", 412, 421], ["strains PH", "TEST", 441, 451], ["S", "TEST", 455, 456], ["A", "TEST", 458, 459], ["A", "TEST", 465, 466], ["Virion", "TEST", 476, 482], ["HB58", "TEST", 488, 492], ["viral particles", "OBSERVATION", 183, 198]]], ["Compared to the virus-free strains PH-1 and S, strain A + B showed abnormal colony morphology (Fig. 4A ).", [["colony", "ANATOMY", 76, 82], ["PH-1", "CELL", 35, 39], ["A + B", "CELL", 54, 59], ["PH-1", "SPECIES", 35, 39], ["the virus", "TEST", 12, 21], ["free strains PH", "TEST", 22, 37], ["strain A", "TEST", 47, 55], ["abnormal colony morphology", "PROBLEM", 67, 93], ["abnormal", "OBSERVATION_MODIFIER", 67, 75], ["colony morphology", "OBSERVATION", 76, 93]]], ["Strain A + B grew on potato dextrose agar (PDA) medium at a rate of 9.3 mm/day, whose growth was much slower than that of strain PH-1 (19.0 mm/day) and strain S (18.5 mm/day) (Fig. 4C ).", [["potato dextrose agar", "CHEMICAL", 21, 41], ["PDA", "CHEMICAL", 43, 46], ["A + B", "CELL", 7, 12], ["potato", "SPECIES", 21, 27], ["potato", "SPECIES", 21, 27], ["potato dextrose agar", "TEST", 21, 41], ["a rate", "TEST", 58, 64], ["strain PH", "TEST", 122, 131], ["strain S", "TEST", 152, 160]]], ["In addition, strain A + B had a significant reduction in colony diameter [45.", [["colony", "ANATOMY", 57, 63], ["A + B", "CELL", 20, 25], ["a significant reduction in colony diameter", "PROBLEM", 30, 72], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["reduction", "OBSERVATION_MODIFIER", 44, 53], ["colony diameter", "OBSERVATION", 57, 72]]], ["5% reduction compared to strain PH-1 (P < 0.01) and 44.5% reduction compared to strain S (P < 0.01)] (Fig. 4B ) and conidial production [55.1% reduction compared to strain PH-1 (P < 0.01) and 52.3% reduction compared to strain S (P < 0.01)] (Fig. 4D) .", [["5% reduction", "TREATMENT", 0, 12], ["strain PH", "TEST", 25, 34], ["strain S", "TEST", 80, 88], ["P", "TEST", 90, 91], ["Fig. 4B", "TEST", 102, 109], ["conidial production", "TEST", 116, 135], ["reduction", "TEST", 143, 152], ["strain PH", "TEST", 165, 174], ["P", "TEST", 178, 179], ["reduction", "TEST", 198, 207], ["strain S", "TEST", 220, 228], ["P", "TEST", 230, 231]]], ["Strains A + B + C, Virion, and HB58 showed similar characteristics to the virus-free strains PH-1 and S (Fig. 4) .", [["HB58", "CHEMICAL", 31, 35], ["A + B + C", "CELL", 8, 17], ["HB58", "SIMPLE_CHEMICAL", 31, 35], ["Virion", "TEST", 19, 25], ["HB58", "TEST", 31, 35], ["the virus", "TEST", 70, 79], ["free strains PH", "TEST", 80, 95]]], ["In the virulence assay, 10 \uf06dl of the conidial suspension was inoculated in the glume of a spikelet and cultured in the field for 15 days.", [["spikelet", "ANATOMY", 90, 98], ["the conidial suspension", "TREATMENT", 33, 56]]], ["Before the virulence assay, we tested the probability of the viral horizontal and vertical transmission.", [["viral horizontal and vertical transmission", "DISEASE", 61, 103], ["the virulence assay", "TEST", 7, 26], ["the viral horizontal and vertical transmission", "PROBLEM", 57, 103], ["viral horizontal", "OBSERVATION", 61, 77], ["vertical transmission", "OBSERVATION", 82, 103]]], ["Southern blot analyses showed that the virus from strains A + B or A + B + C could be efficiently transmitted to the strain PH-1 incorporating a hygromycin-resistance gene (hph) (PH-1 hph ), but not from virus-carrying strain HB58 to the vegetative incompatible strain PH-1 hph via hyphal anastomosis ( fig. S6A ).", [["hyphal", "ANATOMY", 282, 288], ["hygromycin", "CHEMICAL", 145, 155], ["hygromycin", "CHEMICAL", 145, 155], ["A + B", "ORGANISM", 58, 63], ["A + B + C", "ORGANISM", 67, 76], ["PH-1", "ORGANISM", 124, 128], ["hygromycin", "SIMPLE_CHEMICAL", 145, 155], ["strain HB58", "ORGANISM", 219, 230], ["hyphal anastomosis", "PATHOLOGICAL_FORMATION", 282, 300], ["S6A", "GENE_OR_GENE_PRODUCT", 308, 311], ["hygromycin-resistance gene", "DNA", 145, 171], ["hph", "DNA", 173, 176], ["PH", "DNA", 179, 181], ["S6A", "PROTEIN", 308, 311], ["Southern blot analyses", "TEST", 0, 22], ["the virus", "PROBLEM", 35, 44], ["the strain PH", "TEST", 113, 126], ["a hygromycin", "TEST", 143, 155], ["PH", "TEST", 179, 181], ["virus", "PROBLEM", 204, 209], ["carrying strain HB58", "PROBLEM", 210, 230], ["PH", "TEST", 269, 271], ["hyphal anastomosis", "TREATMENT", 282, 300], ["hyphal anastomosis", "OBSERVATION", 282, 300]]], ["In addition, the virus in strain A + B + C was vertically transmitted through conidia at a 5 to 10% rate (figs.", [["conidia", "ANATOMY", 78, 85], ["strain A + B + C", "ORGANISM", 26, 42], ["the virus", "PROBLEM", 13, 22], ["vertically transmitted through conidia", "PROBLEM", 47, 85], ["virus", "OBSERVATION", 17, 22]]], ["S6B and S7A), while no virus was detected from single ascospore isolates (0 infected of 150 tested) ( fig. S6C ).", [["S6B", "GENE_OR_GENE_PRODUCT", 0, 3], ["S7A", "GENE_OR_GENE_PRODUCT", 8, 11], ["S6B", "PROTEIN", 0, 3], ["S7A", "PROTEIN", 8, 11], ["virus", "PROBLEM", 23, 28], ["single ascospore isolates", "TEST", 47, 72], ["no", "UNCERTAINTY", 20, 22], ["virus", "OBSERVATION", 23, 28]]], ["As for strain A + B, both the transmission rates through conidia (75 tested) and ascospores (150 tested) were 0% (figs.", [["ascospores", "ANATOMY", 81, 91], ["A + B", "CELL", 14, 19], ["conidia", "TEST", 57, 64], ["ascospores", "TEST", 81, 91]]], ["S6, B and C, and S7A).", [["S6", "GENE_OR_GENE_PRODUCT", 0, 2], ["B", "GENE_OR_GENE_PRODUCT", 4, 5], ["C", "GENE_OR_GENE_PRODUCT", 10, 11], ["S7A", "GENE_OR_GENE_PRODUCT", 17, 20], ["S6", "PROTEIN", 0, 2], ["B", "PROTEIN", 4, 5], ["C", "PROTEIN", 10, 11], ["S7A", "PROTEIN", 17, 20]]], ["When inoculating a conidial suspension into the glume of a spikelet, there was no significant difference in virulence among these six strains ( fig. S7B) .", [["spikelet", "ANATOMY", 59, 67], ["S7B", "GENE_OR_GENE_PRODUCT", 149, 152], ["S7B", "PROTEIN", 149, 152], ["a conidial suspension", "TREATMENT", 17, 38], ["significant difference in virulence", "PROBLEM", 82, 117], ["no", "UNCERTAINTY", 79, 81], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["difference", "OBSERVATION_MODIFIER", 94, 104]]], ["However, when a small equisized mycelial plug was put into the glume of a spikelet, strain A + B spread more slowly from the inoculation sites to nearby spikelets than the other five strains (Fig. 4E ).", [["spikelet", "ANATOMY", 74, 82], ["spikelets", "ANATOMY", 153, 162], ["A + B", "CELL", 91, 96], ["a small equisized mycelial plug", "PROBLEM", 14, 45], ["strain A + B spread", "PROBLEM", 84, 103], ["small", "OBSERVATION_MODIFIER", 16, 21], ["mycelial plug", "OBSERVATION", 32, 45]]], ["At 15 days after inoculation, there was a significant reduction [81.3% reduction compared to strain PH-1 (P < 0.01) and 79.1% reduction compared to strain S (P < 0.01)] in the number of diseased spikelets per invaded wheat head infected with strain A + B (Fig. 4E ).", [["spikelets", "ANATOMY", 195, 204], ["head", "ANATOMY", 223, 227], ["spikelets", "ORGAN", 195, 204], ["wheat", "ORGANISM", 217, 222], ["head", "ORGANISM_SUBDIVISION", 223, 227], ["wheat", "SPECIES", 217, 222], ["wheat", "SPECIES", 217, 222], ["a significant reduction", "PROBLEM", 40, 63], ["strain PH", "TEST", 93, 102], ["strain S", "TEST", 148, 156], ["diseased spikelets", "PROBLEM", 186, 204], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["reduction", "OBSERVATION_MODIFIER", 54, 63], ["diseased spikelets", "OBSERVATION", 186, 204], ["head", "ANATOMY", 223, 227]]], ["The fungi were isolated from the glume of spikelets, and PCR was carried out using DNA-A-, DNA-B-, or DNA-C-specific degenerate primer pairs (table S4) .", [["spikelets", "ANATOMY", 42, 51], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["DNA-A-, DNA-B-, or DNA-C-specific degenerate primer pairs", "DNA", 83, 140], ["The fungi", "TEST", 0, 9], ["PCR", "TEST", 57, 60], ["DNA", "TEST", 83, 86], ["DNA", "TEST", 91, 94], ["B-", "PROBLEM", 95, 97], ["DNA", "TEST", 102, 105], ["fungi", "OBSERVATION", 4, 9]]], ["It was worth mentioning that PCR products of the expected sizes were detected using primer pairs specific for DNA-A or DNA-B in the glumes of spikelets inoculated with mycelial plugs of strain A + B, but not the glumes of spikelets inoculated with a conidial suspension of strain A + B ( fig. S8 ).", [["spikelets", "ANATOMY", 142, 151], ["spikelets", "ANATOMY", 222, 231], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["-A", "GENE_OR_GENE_PRODUCT", 113, 115], ["DNA-B", "GENE_OR_GENE_PRODUCT", 119, 124], ["A + B", "CELL", 193, 198], ["A + B", "CELL", 280, 285], ["primer pairs", "DNA", 84, 96], ["DNA-A", "DNA", 110, 115], ["DNA-B", "DNA", 119, 124], ["PCR products", "TREATMENT", 29, 41], ["primer pairs", "TEST", 84, 96], ["DNA", "TEST", 110, 113], ["DNA", "TEST", 119, 122], ["mycelial plugs", "PROBLEM", 168, 182], ["sizes", "OBSERVATION_MODIFIER", 58, 63], ["mycelial plugs", "OBSERVATION", 168, 182]]], ["Together, these results indicate that DNA-A and/or DNA-B might be related to hypovirulence of the fungal host, which could be countered by DNA-C; in addition, viral transmission through conidia requires DNA-C.DISCUSSIONViruses of the family Genomoviridae are circular ssDNA viruses (~2 to 2.4 kb), encoding a Rep and a capsid protein in the same circular DNA molecule.", [["DNA-A", "GENE_OR_GENE_PRODUCT", 38, 43], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["-B", "GENE_OR_GENE_PRODUCT", 54, 56], ["DNA-C", "GENE_OR_GENE_PRODUCT", 139, 144], ["Genomoviridae", "GENE_OR_GENE_PRODUCT", 241, 254], ["Rep", "GENE_OR_GENE_PRODUCT", 309, 312], ["DNA", "CELLULAR_COMPONENT", 355, 358], ["DNA-A and/or DNA-B", "DNA", 38, 56], ["Rep", "PROTEIN", 309, 312], ["capsid protein", "PROTEIN", 319, 333], ["circular DNA molecule", "PROTEIN", 346, 367], ["DNA", "TEST", 38, 41], ["DNA", "PROBLEM", 51, 54], ["hypovirulence of the fungal host", "PROBLEM", 77, 109], ["viral transmission through conidia", "PROBLEM", 159, 193], ["the family Genomoviridae", "TREATMENT", 230, 254], ["circular ssDNA viruses", "PROBLEM", 259, 281], ["a capsid protein", "TEST", 317, 333], ["fungal host", "OBSERVATION", 98, 109]]], ["Here, we report a novel ssDNA virus in the family Genomoviridae, and its genome comprises three circular ssDNA components of ~1.3 kb in size referred to as DNA-A (encoding the replication protein), DNA-B (encoding the capsid protein), and Bacilladnaviridae, Circoviridae, Geminiviridae, Genomoviridae, Nanoviridae, and Smacoviridae are the only six eukaryotic CRESS DNA viral families currently recognized by the ICTV (7, 13, 25) .", [["Genomoviridae", "GENE_OR_GENE_PRODUCT", 50, 63], ["DNA-A", "GENE_OR_GENE_PRODUCT", 156, 161], ["DNA-B", "GENE_OR_GENE_PRODUCT", 198, 203], ["Bacilladnaviridae", "GENE_OR_GENE_PRODUCT", 239, 256], ["Circoviridae", "GENE_OR_GENE_PRODUCT", 258, 270], ["Geminiviridae", "GENE_OR_GENE_PRODUCT", 272, 285], ["Genomoviridae", "GENE_OR_GENE_PRODUCT", 287, 300], ["Nanoviridae", "GENE_OR_GENE_PRODUCT", 302, 313], ["Smacoviridae", "GENE_OR_GENE_PRODUCT", 319, 331], ["CRESS", "GENE_OR_GENE_PRODUCT", 360, 365], ["DNA", "CELLULAR_COMPONENT", 366, 369], ["DNA-A", "DNA", 156, 161], ["replication protein", "PROTEIN", 176, 195], ["DNA-B", "PROTEIN", 198, 203], ["capsid protein", "PROTEIN", 218, 232], ["Nanoviridae", "PROTEIN", 302, 313], ["Smacoviridae", "PROTEIN", 319, 331], ["eukaryotic CRESS DNA viral families", "PROTEIN", 349, 384], ["a novel ssDNA virus", "PROBLEM", 16, 35], ["the family Genomoviridae", "TREATMENT", 39, 63], ["DNA", "TEST", 198, 201], ["the capsid protein)", "TREATMENT", 214, 233], ["Bacilladnaviridae", "TREATMENT", 239, 256], ["Circoviridae", "TREATMENT", 258, 270], ["Geminiviridae", "TREATMENT", 272, 285], ["Genomoviridae", "TREATMENT", 287, 300], ["Nanoviridae", "TREATMENT", 302, 313], ["Smacoviridae", "TREATMENT", 319, 331]]], ["Among those, members of the Circoviridae, Geminiviridae, Genomoviridae, and Smacoviridae families are circular ssDNA viruses (2 to 3 kb in size) that encode a Rep and a CP in the same circular DNA molecule (9, 13, 25) .", [["Circoviridae", "GENE_OR_GENE_PRODUCT", 28, 40], ["Geminiviridae", "GENE_OR_GENE_PRODUCT", 42, 55], ["Genomoviridae", "GENE_OR_GENE_PRODUCT", 57, 70], ["Smacoviridae", "GENE_OR_GENE_PRODUCT", 76, 88], ["Rep", "GENE_OR_GENE_PRODUCT", 159, 162], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["Rep", "PROTEIN", 159, 162], ["CP", "PROTEIN", 169, 171], ["circular DNA molecule", "PROTEIN", 184, 205], ["the Circoviridae", "TREATMENT", 24, 40], ["Geminiviridae", "TREATMENT", 42, 55], ["Genomoviridae", "TREATMENT", 57, 70], ["Smacoviridae", "TREATMENT", 76, 88], ["circular ssDNA viruses", "PROBLEM", 102, 124], ["a CP", "PROBLEM", 167, 171], ["ssDNA viruses", "OBSERVATION", 111, 124]]], ["Viruses of the family Bacilladnaviridae have larger genome sizes than other eukaryotic CRESS DNA viruses (~4.5 to 6 kb) (7) .", [["Bacilladnaviridae", "GENE_OR_GENE_PRODUCT", 22, 39], ["CRESS", "ORGANISM", 87, 92], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["the family Bacilladnaviridae", "TREATMENT", 11, 39], ["larger genome sizes", "PROBLEM", 45, 64], ["eukaryotic CRESS DNA viruses", "PROBLEM", 76, 104], ["larger", "OBSERVATION_MODIFIER", 45, 51], ["genome", "OBSERVATION_MODIFIER", 52, 58], ["sizes", "OBSERVATION_MODIFIER", 59, 64], ["CRESS DNA viruses", "OBSERVATION", 87, 104]]], ["Viruses of the genus Begomovirus in the family Geminiviridae have either one or two components (13) .", [["Begomovirus", "GENE_OR_GENE_PRODUCT", 21, 32], ["Geminiviridae", "GENE_OR_GENE_PRODUCT", 47, 60], ["the genus Begomovirus", "PROBLEM", 11, 32], ["the family Geminiviridae", "TREATMENT", 36, 60], ["genus Begomovirus", "OBSERVATION", 15, 32]]], ["Members of two genera, Nanovirus and Babuvirus, in the family Nanoviridae encompass viruses with multicomponent genomes, where each component (~1 kb in size) encodes a single protein and is packaged into a separate particle (6, 13) .", [["Babuvirus", "GENE_OR_GENE_PRODUCT", 37, 46], ["Nanoviridae", "GENE_OR_GENE_PRODUCT", 62, 73], ["Nanovirus", "TREATMENT", 23, 32], ["Babuvirus", "TREATMENT", 37, 46], ["viruses", "OBSERVATION", 84, 91], ["multicomponent", "OBSERVATION_MODIFIER", 97, 111], ["genomes", "OBSERVATION", 112, 119], ["size", "OBSERVATION_MODIFIER", 152, 156]]], ["Five homologous DNA components of these two genera (referred to as DNA-R, DNA-S, DNA-C, DNA-M, and DNA-N) encode a replication initiator protein (Rep), a capsid protein (CP), a cell cycle link protein, a movement protein, and a nuclear shuttle protein.", [["cell", "ANATOMY", 177, 181], ["nuclear", "ANATOMY", 228, 235], ["DNA", "CELLULAR_COMPONENT", 16, 19], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["-R", "GENE_OR_GENE_PRODUCT", 70, 72], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["-C", "GENE_OR_GENE_PRODUCT", 84, 86], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["Rep", "GENE_OR_GENE_PRODUCT", 146, 149], ["CP", "GENE_OR_GENE_PRODUCT", 170, 172], ["cell", "CELL", 177, 181], ["nuclear", "CELLULAR_COMPONENT", 228, 235], ["DNA-R, DNA-S", "DNA", 67, 79], ["DNA-C", "DNA", 81, 86], ["DNA-M", "DNA", 88, 93], ["DNA-N", "DNA", 99, 104], ["replication initiator protein", "PROTEIN", 115, 144], ["Rep", "PROTEIN", 146, 149], ["capsid protein", "PROTEIN", 154, 168], ["CP", "PROTEIN", 170, 172], ["cell cycle link protein", "PROTEIN", 177, 200], ["movement protein", "PROTEIN", 204, 220], ["nuclear shuttle protein", "PROTEIN", 228, 251], ["Five homologous DNA components", "PROBLEM", 0, 30], ["DNA", "TEST", 67, 70], ["DNA", "TEST", 74, 77], ["DNA", "TEST", 81, 84], ["DNA", "PROBLEM", 88, 91], ["a replication initiator protein", "TREATMENT", 113, 144], ["a capsid protein (CP", "PROBLEM", 152, 172], ["a cell cycle link protein", "TEST", 175, 200], ["a movement protein", "TEST", 202, 220], ["a nuclear shuttle protein", "PROBLEM", 226, 251]]], ["Another DNA (DNA-U3) from babuviruses and three other DNAs (DNA-U1, DNA-U2, and DNA-U3) from nanoviruses encode potential proteins with presently unknown functions.", [["DNA", "CELLULAR_COMPONENT", 8, 11], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["babuviruses", "CANCER", 26, 37], ["DNAs", "CELLULAR_COMPONENT", 54, 58], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["-U2", "GENE_OR_GENE_PRODUCT", 71, 74], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["DNA (DNA-U3", "DNA", 8, 19], ["babuviruses", "DNA", 26, 37], ["DNAs", "DNA", 54, 58], ["U1", "DNA", 64, 66], ["U2", "DNA", 72, 74], ["U3", "DNA", 84, 86], ["nanoviruses", "DNA", 93, 104], ["Another DNA", "TEST", 0, 11], ["babuviruses", "TREATMENT", 26, 37], ["other DNAs", "TEST", 48, 58], ["DNA", "TEST", 60, 63], ["DNA", "TEST", 68, 71], ["nanoviruses encode potential proteins", "PROBLEM", 93, 130]]], ["All DNA components share two regions of sequence similarity known as the CR-SL and the CR-M (for babuviruses) or CR-II (for nanoviruses) (13) .", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["CR-SL", "GENE_OR_GENE_PRODUCT", 73, 78], ["CR-M", "GENE_OR_GENE_PRODUCT", 87, 91], ["babuviruses", "GENE_OR_GENE_PRODUCT", 97, 108], ["CR-II", "GENE_OR_GENE_PRODUCT", 113, 118], ["CR-SL", "DNA", 73, 78], ["CR-M", "DNA", 87, 91], ["CR-II", "DNA", 113, 118], ["the CR", "TEST", 69, 75], ["the CR", "TEST", 83, 89], ["babuviruses", "TEST", 97, 108], ["CR", "TEST", 113, 115], ["nanoviruses", "TEST", 124, 135]]], ["The DNA-R component encoding the master Rep is capable of self-replication and is required for replication of all other genome components (26, 27) .", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["Rep", "GENE_OR_GENE_PRODUCT", 40, 43], ["DNA-R component", "PROTEIN", 4, 19], ["master Rep", "PROTEIN", 33, 43], ["self-replication", "TREATMENT", 58, 74], ["replication", "TREATMENT", 95, 106]]], ["Similarly, FgGMTV1 DNA-A, DNA-B, and DNA-C also have two common regions named CR-M and CR-SL, and DNA-A is required for replicating the two other genome components.", [["FgGMTV1 DNA-A", "GENE_OR_GENE_PRODUCT", 11, 24], ["DNA-B", "GENE_OR_GENE_PRODUCT", 26, 31], ["DNA-C", "GENE_OR_GENE_PRODUCT", 37, 42], ["CR-M", "GENE_OR_GENE_PRODUCT", 78, 82], ["CR-SL", "GENE_OR_GENE_PRODUCT", 87, 92], ["DNA-A", "GENE_OR_GENE_PRODUCT", 98, 103], ["FgGMTV1 DNA-A", "DNA", 11, 24], ["DNA-B", "DNA", 26, 31], ["DNA-C", "DNA", 37, 42], ["CR", "DNA", 78, 80], ["CR", "DNA", 87, 89], ["SL", "DNA", 90, 92], ["DNA-A", "DNA", 98, 103], ["FgGMTV1 DNA", "TEST", 11, 22], ["DNA", "TEST", 26, 29], ["DNA", "TEST", 37, 40], ["CR", "TEST", 78, 80], ["CR", "TEST", 87, 89], ["DNA", "TEST", 98, 101]]], ["However, in contrast to DNA-R, DNA-A alone could not be detected using Southern blotting analysis, suggesting that this molecule is not sufficient to sustain self-replication.", [["DNA", "CELLULAR_COMPONENT", 24, 27], ["-R", "GENE_OR_GENE_PRODUCT", 27, 29], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["-A", "GENE_OR_GENE_PRODUCT", 34, 36], ["DNA-R", "DNA", 24, 29], ["DNA-A", "DNA", 31, 36], ["DNA", "TEST", 24, 27], ["Southern blotting analysis", "TEST", 71, 97], ["this molecule", "PROBLEM", 115, 128]]], ["A putative circovirus-related multicomponent virus, known as the Pacific flying fox feces-associated multicomponent virus 1 (PfffaMCV-1) that was sequenced from Pacific flying fox feces, harbored three ssDNA molecules of 1143 to 1163 nt that encoded a single ORF (6) .", [["circovirus-related multicomponent virus", "ORGANISM", 11, 50], ["fox feces-associated multicomponent virus 1", "ORGANISM", 80, 123], ["PfffaMCV-1", "GENE_OR_GENE_PRODUCT", 125, 135], ["fox feces", "ORGANISM", 176, 185], ["ssDNA molecules", "PROTEIN", 202, 217], ["ORF", "DNA", 259, 262], ["circovirus", "SPECIES", 11, 21], ["fox feces", "SPECIES", 80, 89], ["multicomponent virus 1", "SPECIES", 101, 123], ["Pacific flying fox", "SPECIES", 65, 83], ["Pacific flying fox", "SPECIES", 161, 179], ["A putative circovirus", "PROBLEM", 0, 21], ["multicomponent virus", "PROBLEM", 30, 50], ["the Pacific flying fox feces", "PROBLEM", 61, 89], ["multicomponent virus", "PROBLEM", 101, 121], ["PfffaMCV", "TEST", 125, 133], ["putative circovirus", "OBSERVATION", 2, 21], ["multicomponent", "OBSERVATION_MODIFIER", 30, 44], ["virus", "OBSERVATION", 45, 50]]], ["In this viral genome, one ORF encoded a Rep, the second encoded a putative CP, and the third one showed no similarities with any sequences in GenBank.", [["Rep", "GENE_OR_GENE_PRODUCT", 40, 43], ["viral genome", "DNA", 8, 20], ["ORF", "DNA", 26, 29], ["Rep", "PROTEIN", 40, 43], ["putative CP", "DNA", 66, 77], ["a putative CP", "PROBLEM", 64, 77], ["viral genome", "OBSERVATION", 8, 20]]], ["The PfffaMCV-1 Rep shared the highest sequence identity (48%) with the Rep of a circovirus and contained the conserved residues seen in the Rep motifs of eukaryotic CRESS DNA viruses.", [["PfffaMCV-1", "GENE_OR_GENE_PRODUCT", 4, 14], ["Rep", "GENE_OR_GENE_PRODUCT", 15, 18], ["Rep", "GENE_OR_GENE_PRODUCT", 71, 74], ["circovirus", "ORGANISM", 80, 90], ["Rep", "GENE_OR_GENE_PRODUCT", 140, 143], ["CRESS", "GENE_OR_GENE_PRODUCT", 165, 170], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["PfffaMCV", "PROTEIN", 4, 12], ["Rep", "PROTEIN", 15, 18], ["Rep", "PROTEIN", 71, 74], ["Rep motifs", "DNA", 140, 150], ["circovirus", "SPECIES", 80, 90], ["The PfffaMCV", "TEST", 0, 12], ["a circovirus", "PROBLEM", 78, 90], ["the conserved residues", "PROBLEM", 105, 127], ["eukaryotic CRESS DNA viruses", "PROBLEM", 154, 182], ["eukaryotic CRESS", "OBSERVATION", 154, 170], ["DNA viruses", "OBSERVATION", 171, 182]]], ["However, the hosts of this virus are not known.", [["this virus", "PROBLEM", 22, 32]]], ["Another two putative multicomponent viruses, referred to as blackfly multicomponent virus (BfMCV) 1 and 2 that were recovered in the New Zealand blackflies, have Reps most similar to the multicomponent virus PfffaMCV-1, sharing 65 and 67% amino acid similarity, respectively (28) .", [["amino acid", "CHEMICAL", 239, 249], ["amino acid", "CHEMICAL", 239, 249], ["blackfly multicomponent virus (BfMCV) 1", "GENE_OR_GENE_PRODUCT", 60, 99], ["2", "GENE_OR_GENE_PRODUCT", 104, 105], ["Reps", "GENE_OR_GENE_PRODUCT", 162, 166], ["PfffaMCV-1", "GENE_OR_GENE_PRODUCT", 208, 218], ["amino acid", "AMINO_ACID", 239, 249], ["Reps", "PROTEIN", 162, 166], ["blackfly multicomponent virus", "SPECIES", 60, 89], ["blackfly multicomponent virus", "SPECIES", 60, 89], ["Another two putative multicomponent viruses", "PROBLEM", 0, 43], ["the multicomponent virus PfffaMCV", "TEST", 183, 216], ["amino acid similarity", "TEST", 239, 260], ["multicomponent", "OBSERVATION_MODIFIER", 21, 35], ["viruses", "OBSERVATION", 36, 43], ["New", "OBSERVATION_MODIFIER", 133, 136], ["Zealand blackflies", "OBSERVATION", 137, 155]]], ["All these factors showed that, in addition to multicomponent viruses in the family Nanoviridae, other multipartite ssDNA viruses that encode a Rep and a CP in separate circular DNA molecule, like FgGMTV1, exist.", [["Nanoviridae", "GENE_OR_GENE_PRODUCT", 83, 94], ["Rep", "GENE_OR_GENE_PRODUCT", 143, 146], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 196, 203], ["Rep", "PROTEIN", 143, 146], ["CP", "PROTEIN", 153, 155], ["circular DNA molecule", "PROTEIN", 168, 189], ["FgGMTV1", "PROTEIN", 196, 203], ["multicomponent viruses", "PROBLEM", 46, 68], ["Nanoviridae", "TREATMENT", 83, 94], ["other multipartite ssDNA viruses", "PROBLEM", 96, 128], ["a CP in separate circular DNA molecule", "PROBLEM", 151, 189], ["viruses", "OBSERVATION", 61, 68], ["ssDNA viruses", "OBSERVATION", 115, 128]]], ["To date, multiparticulate fungal viruses or mycoviruses have been classified into four families and one genus with linear dsRNA virus genomes (Chrysoviridae, Megabirnaviridae, Partitiviridae, Quadriviridae, and Botybirnavirus) (29) .", [["fungal viruses", "DISEASE", 26, 40], ["multiparticulate fungal viruses", "ORGANISM", 9, 40], ["mycoviruses", "CANCER", 44, 55], ["linear dsRNA virus genomes", "DNA", 115, 141], ["multiparticulate fungal viruses", "PROBLEM", 9, 40], ["mycoviruses", "PROBLEM", 44, 55], ["linear dsRNA virus genomes", "TREATMENT", 115, 141], ["Chrysoviridae", "TREATMENT", 143, 156], ["Megabirnaviridae", "TREATMENT", 158, 174], ["Partitiviridae", "TREATMENT", 176, 190], ["Quadriviridae", "TREATMENT", 192, 205], ["fungal viruses", "OBSERVATION", 26, 40]]], ["In addition, no mycoviruses with multipartite DNA genomes have previously been reported.", [["DNA", "CELLULAR_COMPONENT", 46, 49], ["multipartite DNA genomes", "DNA", 33, 57], ["mycoviruses", "PROBLEM", 16, 27], ["multipartite DNA genomes", "PROBLEM", 33, 57], ["no", "UNCERTAINTY", 13, 15]]], ["FgGMTV1 is the first multipartite DNA virus infecting fungi.DISCUSSIONBecause of the RCR mechanism common to geminiviruses infecting plants and to plasmids replicating in bacteria, archaea, and algae, a scenario that geminiviruses, appearing relatively late in viral evolution, have originated from plasmids via the acquisition of capsid protein genes from ssRNA viruses has been proposed (19, (30) (31) (32) (33) .", [["plasmids", "ANATOMY", 147, 155], ["plasmids", "ANATOMY", 299, 307], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["FgGMTV1", "PROTEIN", 0, 7], ["plasmids", "DNA", 147, 155], ["plasmids", "DNA", 299, 307], ["capsid protein genes", "DNA", 331, 351], ["FgGMTV1", "TEST", 0, 7], ["the first multipartite DNA virus infecting fungi", "PROBLEM", 11, 59], ["the RCR mechanism", "PROBLEM", 81, 98], ["geminiviruses infecting plants", "PROBLEM", 109, 139], ["plasmids", "TREATMENT", 147, 155], ["bacteria", "PROBLEM", 171, 179], ["archaea", "PROBLEM", 181, 188], ["geminiviruses", "PROBLEM", 217, 230], ["plasmids", "TREATMENT", 299, 307], ["capsid protein genes", "TREATMENT", 331, 351], ["ssRNA viruses", "PROBLEM", 357, 370], ["DNA virus", "OBSERVATION", 34, 43], ["infecting fungi", "OBSERVATION", 44, 59], ["geminiviruses", "OBSERVATION", 217, 230], ["viral evolution", "OBSERVATION", 261, 276], ["ssRNA viruses", "OBSERVATION", 357, 370]]], ["In this context, the existence of a pre-mastrevirus between plasmids and geminiviruses has been hypothesized (32) .", [["plasmids", "ANATOMY", 60, 68], ["geminiviruses", "CANCER", 73, 86], ["plasmids", "DNA", 60, 68], ["a pre-mastrevirus between plasmids", "TREATMENT", 34, 68], ["geminiviruses", "PROBLEM", 73, 86]]], ["The family Genomoviridae is a geminivirus-like family, in which viruses encode a Rep with similarities to that of the geminiviruses (9).", [["Genomoviridae", "CHEMICAL", 11, 24], ["Genomoviridae", "GENE_OR_GENE_PRODUCT", 11, 24], ["Rep", "GENE_OR_GENE_PRODUCT", 81, 84], ["Rep", "PROTEIN", 81, 84]]], ["As Yu et al. (11) described, SsHADV-1 (from the family Genomoviridae) is likely to resemble a possible precursor of pre-mastreviruses.", [["SsHADV-1", "GENE_OR_GENE_PRODUCT", 29, 37], ["Genomoviridae", "GENE_OR_GENE_PRODUCT", 55, 68], ["pre-mastreviruses", "CANCER", 116, 133], ["SsHADV-1", "DNA", 29, 37], ["pre-mastreviruses", "PROBLEM", 116, 133]]], ["In this study, the phylogenetic analysis of the Reps and CPs of FgGMTV1 and selected ssDNA viruses indicated that FgGMTV1 was lodged within the family Genomoviridae ( Fig. 2 and fig. S3 ). fig. S5 , A to D), which is different from an original genomovirus encoding a Rep and a CP in the same circular DNA molecule (9) .", [["Reps", "GENE_OR_GENE_PRODUCT", 48, 52], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 64, 71], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 114, 121], ["S5", "GENE_OR_GENE_PRODUCT", 194, 196], ["A", "GENE_OR_GENE_PRODUCT", 199, 200], ["D", "GENE_OR_GENE_PRODUCT", 204, 205], ["Rep", "GENE_OR_GENE_PRODUCT", 267, 270], ["DNA", "CELLULAR_COMPONENT", 301, 304], ["Reps", "DNA", 48, 52], ["CPs", "DNA", 57, 60], ["FgGMTV1", "DNA", 64, 71], ["FgGMTV1", "DNA", 114, 121], ["S5", "PROTEIN", 194, 196], ["genomovirus", "PROTEIN", 244, 255], ["Rep", "PROTEIN", 267, 270], ["CP", "PROTEIN", 277, 279], ["circular DNA molecule", "PROTEIN", 292, 313], ["this study", "TEST", 3, 13], ["the phylogenetic analysis", "TEST", 15, 40], ["the Reps", "TEST", 44, 52], ["CPs", "TEST", 57, 60], ["FgGMTV1", "TEST", 64, 71], ["selected ssDNA viruses", "PROBLEM", 76, 98], ["FgGMTV1", "TEST", 114, 121], ["a CP", "PROBLEM", 275, 279]]], ["Some in vitro studies have confirmed that two complementary defective molecules from a complete nonsegmental virus can evolve into two components of a bipartite virus (37) (38) (39) .", [["vitro studies", "TEST", 8, 21], ["two complementary defective molecules", "PROBLEM", 42, 79], ["a complete nonsegmental virus", "PROBLEM", 85, 114], ["a bipartite virus", "PROBLEM", 149, 166], ["defective molecules", "OBSERVATION", 60, 79], ["bipartite virus", "OBSERVATION", 151, 166]]], ["Therefore, the multipartite genome of FgGMTV1 may represent a natural case of relatively recent multipartition.", [["FgGMTV1", "GENE_OR_GENE_PRODUCT", 38, 45], ["multipartite genome", "DNA", 15, 34], ["FgGMTV1", "DNA", 38, 45]]], ["Besides, defective genomic DNA, 236 to 284 nt in length, has been detected in SsHADV-1, which is the first member of the family Genomoviridae (9) .", [["DNA", "CELLULAR_COMPONENT", 27, 30], ["SsHADV-1", "GENE_OR_GENE_PRODUCT", 78, 86], ["defective genomic DNA", "DNA", 9, 30], ["SsHADV-1", "DNA", 78, 86], ["SsHADV-1", "SPECIES", 78, 86], ["defective genomic DNA", "PROBLEM", 9, 30], ["defective", "OBSERVATION_MODIFIER", 9, 18], ["genomic DNA", "OBSERVATION", 19, 30]]], ["However, the origin of the third segment DNA-C of FgGMTV1 and its function on the evolution of FgGMTV1 need to be further investigated.", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 50, 57], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 95, 102], ["third segment DNA-C", "DNA", 27, 46], ["FgGMTV1", "DNA", 50, 57], ["FgGMTV1", "DNA", 95, 102], ["FgGMTV1", "PROBLEM", 50, 57], ["FgGMTV1", "TREATMENT", 95, 102], ["origin", "ANATOMY_MODIFIER", 13, 19], ["third segment", "ANATOMY_MODIFIER", 27, 40]]], ["The development of transformation and transfection techniques [e.g., transformation of fungal spheroplasts using complementary DNA (cDNA) infectious clones (40, 41) , and transfection of fungal spheroplasts with dsRNA (42), in vitro-transcribed RNA transcripts (43) (44) (45) , or purified virions (46, 47) ] has facilitated the identification of viral and/or host factor(s) involved in symptom induction or virus replication for many mycovirus-host systems, especially in the hypovirus-host system (2) .", [["spheroplasts", "ANATOMY", 94, 106], ["spheroplasts", "ANATOMY", 194, 206], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["dsRNA (42)", "GENE_OR_GENE_PRODUCT", 212, 222], ["RNA transcripts (43) (44)", "GENE_OR_GENE_PRODUCT", 245, 270], ["complementary DNA", "DNA", 113, 130], ["cDNA", "DNA", 132, 136], ["host factor", "PROTEIN", 360, 371], ["transformation", "PROBLEM", 19, 33], ["transfection techniques", "TREATMENT", 38, 61], ["fungal spheroplasts", "TREATMENT", 87, 106], ["complementary DNA (cDNA) infectious clones", "PROBLEM", 113, 155], ["fungal spheroplasts", "PROBLEM", 187, 206], ["dsRNA", "PROBLEM", 212, 217], ["viral", "PROBLEM", 347, 352], ["symptom induction", "TREATMENT", 387, 404], ["virus replication", "TREATMENT", 408, 425], ["many mycovirus-host systems", "PROBLEM", 430, 457], ["transformation", "OBSERVATION", 19, 33], ["transfection techniques", "OBSERVATION", 38, 61], ["fungal spheroplasts", "OBSERVATION", 87, 106], ["infectious", "OBSERVATION_MODIFIER", 138, 148], ["fungal spheroplasts", "OBSERVATION", 187, 206]]], ["These techniques can also be used to expand the host ranges of some mycoviruses, without the obstacles of vegetative incompatibility (48) .", [["mycoviruses", "DISEASE", 68, 79], ["some mycoviruses", "PROBLEM", 63, 79], ["vegetative incompatibility", "PROBLEM", 106, 132]]], ["Among CRESS DNA viruses, the infectious DNA clones are mainly available for circoviruses and geminiviruses and are used to explore the properties of these ssDNA viruses and use ssDNA viruses as multifunctional vectors (23, 24, 49, 50) .", [["CRESS", "GENE_OR_GENE_PRODUCT", 6, 11], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["DNA clones", "CELL", 40, 50], ["infectious DNA clones", "DNA", 29, 50], ["Among CRESS DNA viruses", "PROBLEM", 0, 23], ["the infectious DNA clones", "PROBLEM", 25, 50], ["circoviruses", "PROBLEM", 76, 88], ["geminiviruses", "PROBLEM", 93, 106], ["these ssDNA viruses", "PROBLEM", 149, 168], ["ssDNA viruses", "TREATMENT", 177, 190], ["DNA viruses", "OBSERVATION", 12, 23], ["infectious", "OBSERVATION_MODIFIER", 29, 39]]], ["Previous to this work, only infectious cDNA clones of RNA mycoviruses have been constructed.", [["infectious cDNA clones", "DNA", 28, 50], ["RNA mycoviruses", "RNA", 54, 69], ["infectious cDNA clones of RNA mycoviruses", "PROBLEM", 28, 69]]], ["In this study, the first infectious DNA clones of a DNA mycovirus were obtained.", [["DNA", "CELLULAR_COMPONENT", 36, 39], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["infectious DNA clones", "DNA", 25, 46], ["DNA mycovirus", "DNA", 52, 65], ["this study", "TEST", 3, 13], ["a DNA mycovirus", "TEST", 50, 65], ["infectious", "OBSERVATION_MODIFIER", 25, 35]]], ["These clones will allow future further exploration of the interaction between FgGMTV1 and F. graminearum and could be also applicable to effectively extend the infection of FgGMTV1 to other hosts and enable manipulation of FgGMTV1 for both fundamental and practical applications.DISCUSSIONBetasatellites associated with monopartite begomoviruses play important roles in symptom induction and suppression of both transcriptional and posttranscriptional gene silencing (51) .", [["infection", "DISEASE", 160, 169], ["FgGMTV1", "CHEMICAL", 223, 230], ["clones", "CELL", 6, 12], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 78, 85], ["F. graminearum", "ORGANISM", 90, 104], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 173, 180], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 223, 230], ["FgGMTV1", "PROTEIN", 173, 180], ["FgGMTV1", "PROTEIN", 223, 230], ["F. graminearum", "SPECIES", 90, 104], ["F. graminearum", "SPECIES", 90, 104], ["further exploration", "TEST", 31, 50], ["the infection of FgGMTV1", "PROBLEM", 156, 180], ["FgGMTV1", "TREATMENT", 223, 230], ["practical applications", "TREATMENT", 256, 278], ["DISCUSSIONBetasatellites", "PROBLEM", 279, 303], ["monopartite begomoviruses", "PROBLEM", 320, 345], ["symptom induction", "TREATMENT", 370, 387], ["infection", "OBSERVATION", 160, 169]]], ["FgGMTV1 DNA-A and/or DNA-B may cause hypovirulence, but DNA-C can counter this effect, indicating that DNA-A and/or DNA-B and DNA-C probably play important roles in changes of symptoms.", [["hypovirulence", "DISEASE", 37, 50], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 0, 7], ["DNA-A", "GENE_OR_GENE_PRODUCT", 8, 13], ["DNA-B", "GENE_OR_GENE_PRODUCT", 21, 26], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["-C", "SIMPLE_CHEMICAL", 59, 61], ["DNA-A", "GENE_OR_GENE_PRODUCT", 103, 108], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["-B", "GENE_OR_GENE_PRODUCT", 119, 121], ["DNA-C", "GENE_OR_GENE_PRODUCT", 126, 131], ["FgGMTV1 DNA-A and/or DNA-B", "DNA", 0, 26], ["DNA-A and/or DNA-B and DNA-C", "DNA", 103, 131], ["FgGMTV1", "TEST", 0, 7], ["DNA", "TEST", 8, 11], ["DNA", "PROBLEM", 21, 24], ["hypovirulence", "PROBLEM", 37, 50], ["DNA", "PROBLEM", 56, 59], ["DNA", "TEST", 103, 106], ["DNA", "PROBLEM", 116, 119], ["symptoms", "PROBLEM", 176, 184]]], ["FgGMTV1 cannot be transmitted through conidia in the absence of DNA-C, and DNA-C enhances the accumulation level of viral DNA in infected fungi; these observations suggest that DNA-C may be associated with viral movement and transmission and play important roles in the suppression of transcriptional or posttranscriptional gene silencing.", [["conidia", "ANATOMY", 38, 45], ["FgGMTV1", "CHEMICAL", 0, 7], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["-C", "GENE_OR_GENE_PRODUCT", 67, 69], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["-C", "GENE_OR_GENE_PRODUCT", 78, 80], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["DNA-C", "GENE_OR_GENE_PRODUCT", 177, 182], ["FgGMTV1", "PROTEIN", 0, 7], ["viral DNA", "DNA", 116, 125], ["FgGMTV1", "TEST", 0, 7], ["DNA", "TEST", 64, 67], ["DNA", "TEST", 75, 78], ["the accumulation level", "PROBLEM", 90, 112], ["viral DNA", "PROBLEM", 116, 125], ["infected fungi", "PROBLEM", 129, 143], ["these observations", "TEST", 145, 163], ["DNA-C", "PROBLEM", 177, 182], ["viral movement and transmission", "PROBLEM", 206, 237], ["posttranscriptional gene silencing", "TREATMENT", 304, 338], ["viral DNA", "OBSERVATION", 116, 125], ["infected fungi", "OBSERVATION", 129, 143]]], ["However, it is unexpected that DNA-A and DNA-B cause more severe symptoms than the full set of the DNA components, which can replicate more efficiently (Figs.", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["-A", "GENE_OR_GENE_PRODUCT", 34, 36], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["-B", "GENE_OR_GENE_PRODUCT", 44, 46], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["DNA-A and DNA-B", "DNA", 31, 46], ["DNA", "TEST", 31, 34], ["more severe symptoms", "PROBLEM", 53, 73], ["the DNA components", "PROBLEM", 95, 113], ["severe", "OBSERVATION_MODIFIER", 58, 64]]], ["DNA-C can enhance the ecological fitness potential of FgGMTV1 by retaining the growth and conidiation levels of infected strains in comparison with virus-free fungal strains.", [["strains", "ANATOMY", 121, 128], ["FgGMTV1", "CHEMICAL", 54, 61], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 54, 61], ["virus-free fungal strains", "ORGANISM", 148, 173], ["FgGMTV1", "PROTEIN", 54, 61], ["FgGMTV1", "PROBLEM", 54, 61], ["conidiation levels", "TEST", 90, 108], ["infected strains", "PROBLEM", 112, 128], ["virus", "TEST", 148, 153], ["free fungal strains", "PROBLEM", 154, 173], ["infected strains", "OBSERVATION", 112, 128], ["fungal strains", "OBSERVATION", 159, 173]]], ["Collectively, the results obtained here indicate that the combination of F. graminearum-FgGMTV1 will provide an excellent system for examining fungal and viral factors involved in virus-host interactions, although the full characterization of this pathosystem will require further work.MATERIALS AND METHODSFungal strains and culture conditions F. graminearum strain HB58 was isolated from the diseased glumes of wheat infected with Fusarium spp., which were collected in Hebei province, China.", [["HB58", "CHEMICAL", 367, 371], ["F. graminearum", "ORGANISM", 73, 87], ["-FgGMTV1", "ORGANISM", 87, 95], ["F. graminearum", "ORGANISM", 345, 359], ["strain HB58", "ORGANISM", 360, 371], ["wheat", "ORGANISM", 413, 418], ["Fusarium spp.", "ORGANISM", 433, 446], ["fungal and viral factors", "PROTEIN", 143, 167], ["F. graminearum", "SPECIES", 73, 87], ["F. graminearum", "SPECIES", 345, 359], ["wheat", "SPECIES", 413, 418], ["Fusarium spp.", "SPECIES", 433, 446], ["F. graminearum", "SPECIES", 73, 87], ["F. graminearum", "SPECIES", 345, 359], ["HB58", "SPECIES", 367, 371], ["wheat", "SPECIES", 413, 418], ["Fusarium spp.", "SPECIES", 433, 446], ["F. graminearum", "PROBLEM", 73, 87], ["fungal", "PROBLEM", 143, 149], ["viral factors", "PROBLEM", 154, 167], ["this pathosystem", "PROBLEM", 243, 259], ["METHODSFungal strains", "PROBLEM", 300, 321], ["culture conditions", "TEST", 326, 344], ["graminearum strain HB58", "TEST", 348, 371], ["Fusarium spp.", "PROBLEM", 433, 446], ["diseased", "OBSERVATION_MODIFIER", 394, 402], ["infected", "OBSERVATION_MODIFIER", 419, 427]]], ["The PH-1 strain of F. graminearum, a virulent virus-free strain, served as the wide-type and a receptor strain for infectious clones constructed in this study (52) .", [["PH-1 strain", "ORGANISM", 4, 15], ["F. graminearum", "ORGANISM", 19, 33], ["infectious clones", "CELL", 115, 132], ["F. graminearum", "SPECIES", 19, 33], ["F. graminearum", "SPECIES", 19, 33], ["The PH", "TEST", 0, 6], ["a virulent virus", "PROBLEM", 35, 51], ["free strain", "PROBLEM", 52, 63], ["a receptor strain", "PROBLEM", 93, 110], ["infectious clones", "PROBLEM", 115, 132], ["this study", "TEST", 148, 158], ["virulent virus", "OBSERVATION", 37, 51], ["free strain", "OBSERVATION", 52, 63]]], ["PH-1 hph was used for a viral transmission assay.", [["PH", "PROTEIN", 0, 2], ["PH", "TEST", 0, 2], ["a viral transmission assay", "TEST", 22, 48]]], ["All strains, including the transfectants generated here, and the strains arising from PH-1 hph after dual culturing with strains A + B, A + B + C, and HB58, respectively, are listed in table S3 and were cultured at 25\u00b0C on PDA or in potato dextrose broth (PDB) in the dark and kept at 4\u00b0C until they were used.Purification and protein components of virus particlesStrain HB58 of F. graminearum was grown in PDB and incubated on a shaking incubator at 25\u00b0C for 7 days.", [["transfectants", "ANATOMY", 27, 40], ["PDA", "CHEMICAL", 223, 226], ["potato dextrose", "CHEMICAL", 233, 248], ["transfectants", "CELL", 27, 40], ["A + B", "CELL", 129, 134], ["A + B + C", "CELL", 136, 145], ["HB58", "CELL", 151, 155], ["F. graminearum", "ORGANISM", 379, 393], ["PH", "PROTEIN", 86, 88], ["F. graminearum", "SPECIES", 379, 393], ["potato", "SPECIES", 233, 239], ["F. graminearum", "SPECIES", 379, 393], ["All strains", "PROBLEM", 0, 11], ["the transfectants", "TEST", 23, 40], ["the strains", "PROBLEM", 61, 72], ["PH", "TEST", 86, 88], ["dual culturing", "TEST", 101, 115], ["strains", "PROBLEM", 121, 128], ["A", "TEST", 136, 137], ["HB58", "TEST", 151, 155], ["PDA", "TREATMENT", 223, 226], ["potato dextrose broth", "TREATMENT", 233, 254], ["Purification", "TEST", 310, 322], ["protein components of virus particles", "PROBLEM", 327, 364], ["a shaking incubator", "TREATMENT", 428, 447], ["virus particles", "OBSERVATION", 349, 364], ["PDB", "ANATOMY", 407, 410]]], ["Mycelia (~3 g, wet weight) were harvested and ground to a fine powder in liquid nitrogen using a sterilized mortar and pestle.", [["Mycelia", "CHEMICAL", 0, 7], ["nitrogen", "CHEMICAL", 80, 88], ["Mycelia", "TEST", 0, 7], ["a fine powder in liquid nitrogen", "TREATMENT", 56, 88], ["a sterilized mortar and pestle", "TREATMENT", 95, 125]]], ["The powder was transferred to a plastic tube (50 ml) containing 15 ml of 0.1 M sodium phosphate (pH 7.4).", [["sodium phosphate", "CHEMICAL", 79, 95], ["sodium phosphate", "CHEMICAL", 79, 95], ["tube", "TISSUE", 40, 44], ["sodium phosphate", "SIMPLE_CHEMICAL", 79, 95], ["The powder", "TREATMENT", 0, 10], ["a plastic tube", "TREATMENT", 30, 44], ["0.1 M sodium phosphate", "TREATMENT", 73, 95], ["pH", "TEST", 97, 99]]], ["The mixture was stirred on an orbital shaker for 2 hours at 4\u00b0C and then centrifuged at 5000 rpm for 20 min to remove the hyphal cell debris.", [["hyphal cell", "ANATOMY", 122, 133], ["C", "GENE_OR_GENE_PRODUCT", 62, 63], ["hyphal cell", "CELL", 122, 133], ["the hyphal cell debris", "PROBLEM", 118, 140], ["orbital", "ANATOMY", 30, 37], ["hyphal cell debris", "OBSERVATION", 122, 140]]], ["The supernatant was carefully pipetted into another plastic tube containing the same volume of chloroform and stirred for 30 min at 4\u00b0C, followed by centrifugation at 12,000 rpm for 30 min to further remove the hyphal cell debris.", [["supernatant", "ANATOMY", 4, 15], ["hyphal cell", "ANATOMY", 211, 222], ["chloroform", "CHEMICAL", 95, 105], ["tube", "TISSUE", 60, 64], ["chloroform", "SIMPLE_CHEMICAL", 95, 105], ["hyphal cell", "CELL", 211, 222], ["The supernatant", "TREATMENT", 0, 15], ["another plastic tube", "TREATMENT", 44, 64], ["the hyphal cell debris", "PROBLEM", 207, 229], ["tube", "OBSERVATION", 60, 64], ["hyphal cell debris", "OBSERVATION", 211, 229]]], ["The upper aqueous phase was subjected to a 3-hour ultracentrifugation at 35,000 rpm at 4\u00b0C to precipitate all of the particles.", [["C", "SIMPLE_CHEMICAL", 89, 90], ["upper", "ANATOMY_MODIFIER", 4, 9]]], ["The resultant pellet was resuspended in 1 ml of sodium phosphate buffer (0.01 M, pH 7.4) overnight at 4\u00b0C. The suspension was clarified by centrifugation at 12,000 rpm for 20 min at 4\u00b0C. The supernatant was overlaid on a centrifuge tube containing sucrose solutions with a concentration gradient ranging from 10 to 40% (w/v) and centrifuged at 35,000 rpm for 3 hours at 4\u00b0C. Fractions in the middle portion of the tube were individually tested for the presence of the virus particles by detection of nucleic acids using 1% agarose gel electrophoresis.", [["supernatant", "ANATOMY", 191, 202], ["tube", "ANATOMY", 414, 418], ["sodium phosphate", "CHEMICAL", 48, 64], ["sucrose", "CHEMICAL", 248, 255], ["nucleic acids", "CHEMICAL", 500, 513], ["sodium phosphate", "CHEMICAL", 48, 64], ["sucrose", "CHEMICAL", 248, 255], ["sodium phosphate buffer", "SIMPLE_CHEMICAL", 48, 71], ["sucrose", "SIMPLE_CHEMICAL", 248, 255], ["tube", "TISSUE", 414, 418], ["agarose", "SIMPLE_CHEMICAL", 523, 530], ["The resultant pellet", "TREATMENT", 0, 20], ["sodium phosphate buffer", "TREATMENT", 48, 71], ["pH", "TEST", 81, 83], ["The suspension", "TREATMENT", 107, 121], ["a centrifuge tube containing sucrose solutions", "TREATMENT", 219, 265], ["a concentration gradient", "TREATMENT", 271, 295], ["the tube", "TREATMENT", 410, 418], ["the virus particles", "TREATMENT", 464, 483], ["nucleic acids", "TREATMENT", 500, 513], ["1% agarose gel electrophoresis", "TREATMENT", 520, 550], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["pellet", "OBSERVATION_MODIFIER", 14, 20], ["suspension", "OBSERVATION_MODIFIER", 111, 121], ["middle", "ANATOMY_MODIFIER", 392, 398], ["tube", "OBSERVATION", 414, 418], ["virus", "OBSERVATION", 468, 473]]], ["A virus-containing zone located at a sucrose concentration of \u223c25 to 30% was further centrifuged to precipitate particles.", [["sucrose", "CHEMICAL", 37, 44], ["sucrose", "CHEMICAL", 37, 44], ["sucrose", "SIMPLE_CHEMICAL", 37, 44], ["A virus", "TREATMENT", 0, 7], ["a sucrose concentration", "TREATMENT", 35, 58], ["virus", "OBSERVATION", 2, 7], ["zone", "OBSERVATION_MODIFIER", 19, 23]]], ["Last, the pellets were carefully suspended in 1 ml of 0.01 M sodium phosphate buffer (pH 7.4).", [["sodium phosphate", "CHEMICAL", 61, 77], ["sodium phosphate", "CHEMICAL", 61, 77], ["sodium phosphate buffer", "SIMPLE_CHEMICAL", 61, 84], ["the pellets", "TREATMENT", 6, 17], ["0.01 M sodium phosphate buffer", "TREATMENT", 54, 84], ["pH", "TEST", 86, 88]]], ["The virus particles were negatively stained with 1% uranyl acetate on carbon-coated 400-mesh copper grids and observed under transmission electron microscopy.", [["uranyl acetate", "CHEMICAL", 52, 66], ["copper", "CHEMICAL", 93, 99], ["uranyl acetate", "CHEMICAL", 52, 66], ["carbon", "CHEMICAL", 70, 76], ["copper", "CHEMICAL", 93, 99], ["uranyl acetate", "SIMPLE_CHEMICAL", 52, 66], ["carbon", "SIMPLE_CHEMICAL", 70, 76], ["The virus particles", "PROBLEM", 0, 19], ["1% uranyl acetate", "TREATMENT", 49, 66], ["carbon-coated 400-mesh copper grids", "TREATMENT", 70, 105], ["transmission electron microscopy", "TEST", 125, 157], ["virus particles", "OBSERVATION", 4, 19]]], ["Purified virus particles were electrophoresed through PAGE in 12% SDS-PAGE with 25 mM tris-glycine and 0.1% SDS.", [["tris-glycine", "CHEMICAL", 86, 98], ["tris-glycine", "CHEMICAL", 86, 98], ["tris-glycine", "SIMPLE_CHEMICAL", 86, 98], ["Purified virus particles", "PROBLEM", 0, 24], ["SDS", "TEST", 66, 69], ["25 mM tris-glycine", "TREATMENT", 80, 98], ["virus", "OBSERVATION", 9, 14]]], ["Following electrophoresis, the gel was stained using Coomassie brilliant blue R-250 [Sangon Biotech (Shanghai) Co. Ltd.].", [["R-250", "CHEMICAL", 78, 83], ["Coomassie", "SIMPLE_CHEMICAL", 53, 62], ["Coomassie brilliant blue R-250", "SPECIES", 53, 83], ["electrophoresis", "TEST", 10, 25]]], ["PMF of three protein bands were performed by Shanghai Applied Protein Technology Co. Ltd., China.Nucleic acid extraction from viral particles, molecular cloning, and sequencingAbout 200 \uf06dl of purified virus particles was treated with 200 \uf06dl of extraction buffer [20 mM tris-HCl (pH 8.0), 1% SDS, 200 mM NaCl, and 5 mM EDTA] and 400 \uf06dl of phenol/chloroform/isoamyl alcohol (25:24:1) to remove viral proteins.", [["Nucleic acid", "CHEMICAL", 97, 109], ["tris-HCl", "CHEMICAL", 269, 277], ["NaCl", "CHEMICAL", 303, 307], ["phenol/chloroform/isoamyl alcohol", "CHEMICAL", 338, 371], ["tris-HCl", "CHEMICAL", 269, 277], ["NaCl", "CHEMICAL", 303, 307], ["EDTA", "CHEMICAL", 318, 322], ["phenol", "CHEMICAL", 338, 344], ["chloroform", "CHEMICAL", 345, 355], ["isoamyl alcohol", "CHEMICAL", 356, 371], ["Nucleic acid", "SIMPLE_CHEMICAL", 97, 109], ["tris-HCl", "SIMPLE_CHEMICAL", 269, 277], ["EDTA", "SIMPLE_CHEMICAL", 318, 322], ["phenol", "SIMPLE_CHEMICAL", 338, 344], ["chloroform", "SIMPLE_CHEMICAL", 345, 355], ["isoamyl alcohol", "SIMPLE_CHEMICAL", 356, 371], ["25:24:1", "SIMPLE_CHEMICAL", 373, 380], ["viral proteins", "PROTEIN", 392, 406], ["three protein bands", "PROBLEM", 7, 26], ["Nucleic acid extraction", "TREATMENT", 97, 120], ["viral particles", "PROBLEM", 126, 141], ["purified virus particles", "PROBLEM", 192, 216], ["extraction buffer", "TREATMENT", 244, 261], ["pH", "TEST", 279, 281], ["5 mM EDTA", "TREATMENT", 313, 322], ["phenol/chloroform", "TREATMENT", 338, 355], ["isoamyl alcohol", "TREATMENT", 356, 371], ["viral proteins", "PROBLEM", 392, 406], ["viral particles", "OBSERVATION", 126, 141]]], ["The nucleic acids were precipitated with ethanol, dissolved in diethyl pyrocarbonate-treated water, and analyzed using 1% agarose gel electrophoresis.", [["nucleic acids", "CHEMICAL", 4, 17], ["ethanol", "CHEMICAL", 41, 48], ["diethyl pyrocarbonate", "CHEMICAL", 63, 84], ["ethanol", "CHEMICAL", 41, 48], ["diethyl pyrocarbonate", "CHEMICAL", 63, 84], ["nucleic acids", "SIMPLE_CHEMICAL", 4, 17], ["ethanol", "SIMPLE_CHEMICAL", 41, 48], ["diethyl", "SIMPLE_CHEMICAL", 63, 70], ["pyrocarbonate", "SIMPLE_CHEMICAL", 71, 84], ["water", "SIMPLE_CHEMICAL", 93, 98], ["agarose", "SIMPLE_CHEMICAL", 122, 129], ["The nucleic acids", "TEST", 0, 17], ["ethanol", "TREATMENT", 41, 48], ["diethyl pyrocarbonate", "TREATMENT", 63, 84], ["1% agarose gel electrophoresis", "TREATMENT", 119, 149], ["nucleic acids", "OBSERVATION", 4, 17]]], ["Last, the viral nucleic acids were treated with DNase I, exonuclease III, S1 nuclease, or exonuclease I to confirm the properties of the extracted nucleic acids.Nucleic acid extraction from viral particles, molecular cloning, and sequencingRCA was conducted on nucleic acids extracted directly from virion samples using the Illustra TempliPhi Amplification Kit (GE Healthcare, USA).", [["samples", "ANATOMY", 306, 313], ["nucleic acids", "CHEMICAL", 16, 29], ["nucleic acids", "CHEMICAL", 147, 160], ["Nucleic acid", "CHEMICAL", 161, 173], ["nucleic acids", "CHEMICAL", 261, 274], ["DNase I", "GENE_OR_GENE_PRODUCT", 48, 55], ["exonuclease III", "GENE_OR_GENE_PRODUCT", 57, 72], ["S1", "GENE_OR_GENE_PRODUCT", 74, 76], ["exonuclease I", "GENE_OR_GENE_PRODUCT", 90, 103], ["nucleic acids", "SIMPLE_CHEMICAL", 147, 160], ["Nucleic acid", "SIMPLE_CHEMICAL", 161, 173], ["DNase I", "PROTEIN", 48, 55], ["exonuclease III", "PROTEIN", 57, 72], ["S1 nuclease", "PROTEIN", 74, 85], ["exonuclease I", "PROTEIN", 90, 103], ["the viral nucleic acids", "TEST", 6, 29], ["DNase I", "TREATMENT", 48, 55], ["exonuclease III, S1 nuclease", "TREATMENT", 57, 85], ["exonuclease I", "TREATMENT", 90, 103], ["the extracted nucleic acids", "PROBLEM", 133, 160], ["Nucleic acid extraction", "TREATMENT", 161, 184], ["viral particles", "PROBLEM", 190, 205], ["nucleic acids", "TREATMENT", 261, 274], ["virion samples", "TEST", 299, 313], ["nucleic acids", "OBSERVATION", 16, 29], ["nucleic acids", "OBSERVATION", 147, 160], ["acid extraction", "OBSERVATION", 169, 184], ["viral particles", "OBSERVATION", 190, 205]]], ["A volume of 1 \uf06dl of nucleic acids (~100 to 500 ng) was mixed with 5 \uf06dl of sample buffer, denatured at 95\u00b0C for 3 min, and then chilled on ice before adding 5 \uf06dl of reaction buffer and 0.2 \uf06dl of the \u03a629 DNA polymerase, followed by incubation for 20 hours at 30\u00b0C and 10 min at 65\u00b0C. RCA products were digested with various restriction enzymes in appropriate buffers, and the fragments generated by Bam HI, Eco RI, Sal I, Bgl II, and Kpn I were resolved using 1% agarose gels, extracted, and inserted into the pET30a vector (Novagen) restricted with the appropriate restriction enzyme.", [["fragments", "ANATOMY", 374, 383], ["nucleic acids", "CHEMICAL", 20, 33], ["nucleic acids", "SIMPLE_CHEMICAL", 20, 33], ["DNA", "CELLULAR_COMPONENT", 202, 205], ["Bam HI", "GENE_OR_GENE_PRODUCT", 397, 403], ["Eco RI", "GENE_OR_GENE_PRODUCT", 405, 411], ["Sal I", "GENE_OR_GENE_PRODUCT", 413, 418], ["Bgl II", "GENE_OR_GENE_PRODUCT", 420, 426], ["Kpn I", "GENE_OR_GENE_PRODUCT", 432, 437], ["agarose", "SIMPLE_CHEMICAL", 461, 468], ["pET30a", "GENE_OR_GENE_PRODUCT", 508, 514], ["Novagen", "GENE_OR_GENE_PRODUCT", 523, 530], ["\u03a629 DNA polymerase", "PROTEIN", 198, 216], ["RCA products", "PROTEIN", 282, 294], ["restriction enzymes", "PROTEIN", 322, 341], ["Bam HI", "PROTEIN", 397, 403], ["Eco RI", "PROTEIN", 405, 411], ["Sal I", "PROTEIN", 413, 418], ["Bgl II", "PROTEIN", 420, 426], ["Kpn I", "DNA", 432, 437], ["pET30a vector", "DNA", 508, 521], ["Novagen", "DNA", 523, 530], ["restriction enzyme", "PROTEIN", 564, 582], ["nucleic acids", "TEST", 20, 33], ["sample buffer", "TREATMENT", 74, 87], ["reaction buffer", "TREATMENT", 164, 179], ["the \u03a629 DNA polymerase", "TREATMENT", 194, 216], ["RCA products", "TREATMENT", 282, 294], ["various restriction enzymes", "TREATMENT", 314, 341], ["the fragments", "PROBLEM", 370, 383], ["1% agarose gels", "TREATMENT", 458, 473], ["the pET30a vector (Novagen)", "TREATMENT", 504, 531]]], ["The recombinant plasmids were then transformed into Trans5\uf061 chemically competent cells (TransGen) according to the manufacturer's instructions.", [["plasmids", "ANATOMY", 16, 24], ["cells", "ANATOMY", 81, 86], ["cells", "CELL", 81, 86], ["TransGen", "CELL", 88, 96], ["recombinant plasmids", "DNA", 4, 24], ["Trans5\uf061 chemically competent cells", "CELL_LINE", 52, 86], ["TransGen", "CELL_LINE", 88, 96], ["The recombinant plasmids", "TREATMENT", 0, 24], ["plasmids", "OBSERVATION", 16, 24]]], ["Candidate bacteria harboring recombinant plasmids were analyzed to measure the presence of the insert by colony PCRs, and every base was determined by sequencing in at least 10 independent overlapping clones.", [["plasmids", "ANATOMY", 41, 49], ["colony", "ANATOMY", 105, 111], ["clones", "CELL", 201, 207], ["recombinant plasmids", "DNA", 29, 49], ["bacteria harboring recombinant plasmids", "TREATMENT", 10, 49], ["colony PCRs", "TEST", 105, 116], ["recombinant plasmids", "OBSERVATION", 29, 49], ["overlapping", "OBSERVATION_MODIFIER", 189, 200], ["clones", "OBSERVATION", 201, 207]]], ["Positive clones were selected, sequenced, and analyzed via the DNAMAN software (v7) and the BLAST program on the NCBI website (http://blast.st-va.ncbi.nlm.nih.gov/Blast.cgi).Nucleic acid extraction from viral particles, molecular cloning, and sequencingTo obtain a complete DNA sequence representing a complete circular component, specific back-to-back primers were designed on the basis of the sequences obtained above and used in PCR on nucleic acid samples using 2\u00d7 Phanta Max Master Mix (Vazyme Biotech Co. Ltd.).", [["Nucleic acid", "CHEMICAL", 174, 186], ["nucleic acid", "CHEMICAL", 439, 451], ["Nucleic acid", "SIMPLE_CHEMICAL", 174, 186], ["DNA", "CELLULAR_COMPONENT", 274, 277], ["DNAMAN software", "DNA", 63, 78], ["NCBI website", "DNA", 113, 125], ["DNA sequence", "DNA", 274, 286], ["Positive clones", "PROBLEM", 0, 15], ["Nucleic acid extraction", "TREATMENT", 174, 197], ["viral particles", "PROBLEM", 203, 218], ["a complete DNA sequence", "TEST", 263, 286], ["a complete circular component", "PROBLEM", 300, 329], ["the sequences", "TEST", 391, 404], ["nucleic acid samples", "TEST", 439, 459], ["clones", "OBSERVATION", 9, 15], ["viral particles", "OBSERVATION", 203, 218]]], ["PCR primers (DNA-A-1F/1R for DNA-A, DNA-B-1F/1R for DNA-B, and DNA-C-1F/1R for DNA-C) are listed in table S5.", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["DNA-B-1F", "GENE_OR_GENE_PRODUCT", 36, 44], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["-B", "GENE_OR_GENE_PRODUCT", 55, 57], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["PCR primers", "DNA", 0, 11], ["DNA-A", "DNA", 29, 34], ["DNA-B-1F/1R", "DNA", 36, 47], ["DNA-B", "DNA", 52, 57], ["1R", "DNA", 72, 74], ["DNA-C", "DNA", 79, 84], ["PCR primers", "TEST", 0, 11], ["DNA", "TEST", 13, 16], ["DNA", "TEST", 29, 32], ["DNA", "TEST", 36, 39], ["B", "TEST", 40, 41], ["DNA", "TEST", 52, 55], ["DNA", "TEST", 63, 66], ["DNA", "PROBLEM", 79, 82]]], ["All of the PCR products were purified, cloned, and sequenced according to the protocol described above.DNA preparation and Southern blot analysesViral DNA was extracted from mycelia grown in PDB at 25\u00b0C for 7 days according to the manufacturer's instructions of the Fungal DNA Kit (Omega Bio-tek Inc.).", [["mycelia", "ANATOMY", 174, 181], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["Viral", "ORGANISM", 145, 150], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["PCR products", "DNA", 11, 23], ["Viral DNA", "DNA", 145, 154], ["the PCR products", "TREATMENT", 7, 23], ["the protocol", "TEST", 74, 86], ["DNA preparation", "TREATMENT", 103, 118], ["Southern blot analyses", "TEST", 123, 145], ["Viral DNA", "PROBLEM", 145, 154], ["mycelia", "PROBLEM", 174, 181], ["the Fungal DNA Kit (Omega Bio-tek Inc.", "TREATMENT", 262, 300]]], ["Approximately 1 \uf06dg of DNA was separated on 1% agarose gels in tris-acetate-EDTA buffer [40 mM tris-acetate and 1 mM EDTA (pH 8.0)], followed by alkali denaturation and neutralization, and then transferred onto Hybond-N+ membranes (Amersham Biosciences, Buckingham, England) by capillary blotting with 20\u00d7 SSC [3 M NaCl and 0.3 M sodium citrate (pH 7.0)] overnight.", [["capillary", "ANATOMY", 277, 286], ["tris-acetate-EDTA", "CHEMICAL", 62, 79], ["tris-acetate", "CHEMICAL", 94, 106], ["alkali", "CHEMICAL", 144, 150], ["NaCl", "CHEMICAL", 314, 318], ["sodium citrate", "CHEMICAL", 329, 343], ["tris-acetate", "CHEMICAL", 62, 74], ["EDTA", "CHEMICAL", 75, 79], ["tris-acetate", "CHEMICAL", 94, 106], ["EDTA", "CHEMICAL", 116, 120], ["Hybond", "CHEMICAL", 210, 216], ["NaCl", "CHEMICAL", 314, 318], ["sodium citrate", "CHEMICAL", 329, 343], ["DNA", "CELLULAR_COMPONENT", 22, 25], ["agarose", "SIMPLE_CHEMICAL", 46, 53], ["tris-acetate-EDTA", "SIMPLE_CHEMICAL", 62, 79], ["tris-acetate", "SIMPLE_CHEMICAL", 94, 106], ["EDTA", "SIMPLE_CHEMICAL", 116, 120], ["sodium citrate", "SIMPLE_CHEMICAL", 329, 343], ["1% agarose gels in tris-acetate", "TREATMENT", 43, 74], ["EDTA buffer", "TREATMENT", 75, 86], ["40 mM tris-acetate", "TREATMENT", 88, 106], ["1 mM EDTA", "TREATMENT", 111, 120], ["pH", "TEST", 122, 124], ["alkali denaturation", "PROBLEM", 144, 163], ["neutralization", "TREATMENT", 168, 182], ["3 M NaCl", "TREATMENT", 310, 318], ["0.3 M sodium citrate", "TREATMENT", 323, 343], ["pH", "TEST", 345, 347], ["alkali denaturation", "OBSERVATION", 144, 163]]], ["The DNA was cross-linked to the membrane by ultraviolet (UV) irradiation for 10 min.", [["membrane", "ANATOMY", 32, 40], ["ultraviolet (UV", "CHEMICAL", 44, 59], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["membrane", "CELLULAR_COMPONENT", 32, 40], ["ultraviolet (UV) irradiation", "TREATMENT", 44, 72]]], ["Three DNA probes [359 base pair (bp) for probe A, 335 bp for probe B, and 326 bp for probe C, specific for DNA-A, DNA-B, and DNA-C, respectively] were produced by PCR amplification using specific primer pairs (table S6) and labeled with digoxigenin (DIG) using the DIG DNA Labeling and Detection Kit (Roche Diagnostics, Mannheim, Germany).", [["digoxigenin", "CHEMICAL", 237, 248], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["DNA-A", "GENE_OR_GENE_PRODUCT", 107, 112], ["DNA-B", "GENE_OR_GENE_PRODUCT", 114, 119], ["DNA-C", "GENE_OR_GENE_PRODUCT", 125, 130], ["digoxigenin", "SIMPLE_CHEMICAL", 237, 248], ["DIG", "SIMPLE_CHEMICAL", 250, 253], ["DNA", "CELLULAR_COMPONENT", 269, 272], ["DNA probes", "DNA", 6, 16], ["359 base pair", "DNA", 18, 31], ["probe A", "DNA", 41, 48], ["probe B", "DNA", 61, 68], ["probe C", "DNA", 85, 92], ["DNA-A", "DNA", 107, 112], ["DNA-B", "DNA", 114, 119], ["primer pairs", "DNA", 196, 208], ["table S6", "DNA", 210, 218], ["Three DNA probes", "TEST", 0, 16], ["base pair", "TEST", 22, 31], ["bp", "TEST", 33, 35], ["bp", "TEST", 54, 56], ["probe B", "TEST", 61, 68], ["bp", "TEST", 78, 80], ["probe C", "TEST", 85, 92], ["DNA", "TEST", 107, 110], ["DNA", "TEST", 114, 117], ["PCR amplification", "TEST", 163, 180], ["digoxigenin (DIG)", "TREATMENT", 237, 254]]], ["After prehybridization and hybridization were complete, the blots were washed in 1\u00d7 SSC (0.15 M sodium chloride and 0.015 M sodium citrate) and 0.1% SDS at 65\u00b0C for 30 min.", [["sodium chloride", "CHEMICAL", 96, 111], ["sodium citrate", "CHEMICAL", 124, 138], ["sodium chloride", "CHEMICAL", 96, 111], ["sodium citrate", "CHEMICAL", 124, 138], ["sodium chloride", "SIMPLE_CHEMICAL", 96, 111], ["sodium citrate", "SIMPLE_CHEMICAL", 124, 138], ["prehybridization", "TREATMENT", 6, 22], ["hybridization", "TREATMENT", 27, 40], ["sodium chloride", "TREATMENT", 96, 111], ["0.015 M sodium citrate)", "TREATMENT", 116, 139]]], ["Hybridization signals were detected on a Tanon 5200 imaging system (Tanon Science and Technology Co. Ltd.) using the DIG detection kit (Roche Diagnostics, Mannheim, Germany).Sequence and phylogenetic analysesThe assembly and analysis of nucleotide sequences and translation of ORFs were performed using the DNAMAN version 7 software.Sequence and phylogenetic analysesThe sequences of previously reported viruses referenced here were obtained from the NCBI GenBank database (www.ncbi.nlm.nih. gov/genome).", [["nucleotide", "CHEMICAL", 237, 247], ["nucleotide", "CHEMICAL", 237, 247], ["nucleotide sequences", "DNA", 237, 257], ["ORFs", "DNA", 277, 281], ["NCBI GenBank database", "DNA", 451, 472], ["Hybridization signals", "TEST", 0, 21], ["Sequence", "TEST", 174, 182], ["phylogenetic analyses", "TEST", 187, 208], ["nucleotide sequences", "TEST", 237, 257], ["translation of ORFs", "TEST", 262, 281], ["the DNAMAN version", "TREATMENT", 303, 321], ["Sequence", "TEST", 333, 341], ["phylogenetic analyses", "TEST", 346, 367]]], ["Potential ORFs were deduced using DNAMAN and the ORF finder program in the NCBI website (http://ncbi.nlm.nih. gov/projects/gorf).", [["ORFs", "DNA", 10, 14], ["DNAMAN", "DNA", 34, 40], ["ORF", "DNA", 49, 52], ["NCBI website", "DNA", 75, 87], ["Potential ORFs", "PROBLEM", 0, 14]]], ["Sequence similarity searches were performed using the NCBI BLAST program (http://blast.st-va.ncbi.nlm.nih.gov/Blast.cgi).", [["Sequence similarity searches", "TEST", 0, 28]]], ["Multiple alignments of nucleic and amino acid sequences were conducted using DNAMAN with default parameters (53) .", [["amino acid", "CHEMICAL", 35, 45], ["amino acid", "CHEMICAL", 35, 45], ["amino acid", "AMINO_ACID", 35, 45], ["DNAMAN", "PROTEIN", 77, 83], ["Multiple alignments of nucleic and amino acid sequences", "TEST", 0, 55], ["default parameters", "TEST", 89, 107]]], ["The phylogenetic trees were constructed using the maximum-likelihood method based on multiple amino acid sequence alignments in PhyML 3.0 (http://atgc-montpellier.fr/phyml/).", [["amino acid", "CHEMICAL", 94, 104], ["amino acid", "CHEMICAL", 94, 104], ["amino acid", "AMINO_ACID", 94, 104], ["multiple amino acid sequence alignments", "TEST", 85, 124], ["PhyML", "TEST", 128, 133]]], ["See table S7 for all virus names and viral protein accession numbers used for phylogenetic analysis.", [["all virus names", "TEST", 17, 32], ["viral protein accession numbers", "TEST", 37, 68], ["phylogenetic analysis", "TEST", 78, 99]]], ["The best-fit model was selected using the Smart Model Selection technique implemented in PhyML 3.0.", [["the Smart Model Selection technique", "TREATMENT", 38, 73]]], ["Numbers at nodes in the phylogeny represent approximate likelihood ratio test values derived using an Shimodaira-Hasegawa (SH)-like calculation (only values greater than 0.9 are shown).", [["nodes", "ANATOMY", 11, 16], ["nodes", "MULTI-TISSUE_STRUCTURE", 11, 16], ["an Shimodaira", "TEST", 99, 112], ["nodes", "OBSERVATION", 11, 16]]], ["Branch support was determined by bootstrapping (1000 replicates).Construction of infectious clones of FgGMTV1 DNA-A, DNA-B, and DNA-CFor the construction of the infectious clone of FgGMTV1 DNA-A ( fig. S4 ), RCA was conducted on viral DNA extracted from virion samples.", [["samples", "ANATOMY", 261, 268], ["clones", "CELL", 92, 98], ["FgGMTV1 DNA-A", "GENE_OR_GENE_PRODUCT", 102, 115], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["-B", "GENE_OR_GENE_PRODUCT", 120, 122], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["clone", "CELL", 172, 177], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 181, 188], ["DNA", "CELLULAR_COMPONENT", 189, 192], ["DNA", "CELLULAR_COMPONENT", 235, 238], ["FgGMTV1 DNA-A, DNA-B, and DNA-CFor", "DNA", 102, 136], ["FgGMTV1 DNA", "DNA", 181, 192], ["RCA", "PROTEIN", 208, 211], ["viral DNA", "DNA", 229, 238], ["Branch support", "TREATMENT", 0, 14], ["FgGMTV1 DNA", "TEST", 102, 113], ["DNA", "PROBLEM", 128, 131], ["viral DNA", "PROBLEM", 229, 238], ["virion samples", "TEST", 254, 268], ["infectious", "OBSERVATION_MODIFIER", 81, 91], ["infectious", "OBSERVATION", 161, 171], ["RCA", "ANATOMY", 208, 211], ["viral DNA", "OBSERVATION", 229, 238]]], ["RCA products were digested with Eco RI and Kpn I to obtain a full-length unit of DNA-A, and then the fragment obtained, of about 1.3 kb, was inserted into the Eco RI site of the vector pBluescript II SK(+) (pSK) (Stratagene) to produce the clone pSK-1A, containing a 1-mer of DNA-A.", [["Eco RI", "GENE_OR_GENE_PRODUCT", 32, 38], ["Kpn I", "GENE_OR_GENE_PRODUCT", 43, 48], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["pBluescript II SK(+) (pSK)", "GENE_OR_GENE_PRODUCT", 185, 211], ["pSK-1A", "GENE_OR_GENE_PRODUCT", 246, 252], ["DNA", "CELLULAR_COMPONENT", 276, 279], ["RCA products", "PROTEIN", 0, 12], ["Eco RI", "PROTEIN", 32, 38], ["Kpn I", "PROTEIN", 43, 48], ["full-length unit", "DNA", 61, 77], ["DNA-A", "DNA", 81, 86], ["Eco RI site", "DNA", 159, 170], ["vector pBluescript II SK(+) (pSK)", "DNA", 178, 211], ["clone pSK-1A", "DNA", 240, 252], ["Eco RI", "TREATMENT", 32, 38], ["a full-length unit of DNA", "TREATMENT", 59, 84], ["the fragment", "PROBLEM", 97, 109], ["the clone pSK", "TEST", 236, 249], ["clone pSK", "OBSERVATION", 240, 249]]], ["Candidate bacteria harboring the clone pSK-1A were Sanger-sequenced at Sangon Biotech Co. Ltd.", [["pSK-1A", "GENE_OR_GENE_PRODUCT", 39, 45], ["clone pSK-1A", "DNA", 33, 45], ["bacteria", "PROBLEM", 10, 18], ["Sanger", "TEST", 51, 57]]], ["(Shanghai, China) to confirm that no mutations had been introduced by RCA.", [["RCA", "PROTEIN", 70, 73], ["mutations", "PROBLEM", 37, 46], ["RCA", "ANATOMY", 70, 73]]], ["The sequenced pSK-1A clone was digested with Eco RI and inserted into the Eco RI site of plasmid pSK to produce clone pSK-2A, which contained a tandem dimeric repeat of the DNA-A molecule.", [["pSK-1A", "GENE_OR_GENE_PRODUCT", 14, 20], ["clone", "CELL", 21, 26], ["Eco RI", "GENE_OR_GENE_PRODUCT", 45, 51], ["pSK-2A", "GENE_OR_GENE_PRODUCT", 118, 124], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["-A molecule", "GENE_OR_GENE_PRODUCT", 176, 187], ["pSK-1A clone", "DNA", 14, 26], ["Eco RI", "DNA", 45, 51], ["Eco RI site", "DNA", 74, 85], ["plasmid pSK", "DNA", 89, 100], ["clone pSK-2A", "DNA", 112, 124], ["tandem dimeric repeat", "DNA", 144, 165], ["DNA-A molecule", "PROTEIN", 173, 187], ["Eco RI", "TREATMENT", 45, 51], ["plasmid pSK", "TREATMENT", 89, 100], ["clone pSK", "TEST", 112, 121], ["plasmid pSK", "OBSERVATION", 89, 100], ["clone pSK", "OBSERVATION", 112, 121]]], ["The positive recombinant plasmid was verified by restriction enzyme digestion and analyzed via 1% agarose gel electrophoresis.", [["plasmid", "ANATOMY", 25, 32], ["agarose", "SIMPLE_CHEMICAL", 98, 105], ["positive recombinant plasmid", "DNA", 4, 32], ["The positive recombinant plasmid", "TREATMENT", 0, 32], ["restriction enzyme digestion", "PROBLEM", 49, 77], ["1% agarose gel electrophoresis", "TREATMENT", 95, 125], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["recombinant plasmid", "OBSERVATION", 13, 32]]], ["The infectious clone of FgGMTV1 DNA-B (pSK-2B) was constructed following a similar strategy but using different restriction enzymes Eco RI and Spe I to obtain a full-length unit of DNA-B ( fig. S4) .Construction of infectious clones of FgGMTV1 DNA-A, DNA-B, and DNA-CSimilarly, for the construction of the infectious clone of FgGMTV1 DNA-C ( fig. S4 ), RCA products were digested with Xba I to obtain a full-length unit of DNA-C, and then the fragment obtained, of about 1.3 kb, was inserted into the Xba I site of the plasmid pSK to produce the clone pSK-1C, containing a 1-mer of DNA-C.", [["plasmid", "ANATOMY", 519, 526], ["clone", "CELL", 15, 20], ["FgGMTV1 DNA-B", "GENE_OR_GENE_PRODUCT", 24, 37], ["pSK-2B", "GENE_OR_GENE_PRODUCT", 39, 45], ["Eco RI", "GENE_OR_GENE_PRODUCT", 132, 138], ["Spe I", "GENE_OR_GENE_PRODUCT", 143, 148], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["FgGMTV1 DNA-A", "GENE_OR_GENE_PRODUCT", 236, 249], ["DNA", "CELLULAR_COMPONENT", 251, 254], ["-B", "GENE_OR_GENE_PRODUCT", 254, 256], ["DNA", "CELLULAR_COMPONENT", 262, 265], ["clone", "CELL", 317, 322], ["FgGMTV1 DNA-C", "GENE_OR_GENE_PRODUCT", 326, 339], ["Xba I", "GENE_OR_GENE_PRODUCT", 385, 390], ["DNA", "CELLULAR_COMPONENT", 423, 426], ["Xba I", "GENE_OR_GENE_PRODUCT", 501, 506], ["pSK", "GENE_OR_GENE_PRODUCT", 527, 530], ["pSK-1C", "GENE_OR_GENE_PRODUCT", 552, 558], ["DNA", "CELLULAR_COMPONENT", 582, 585], ["FgGMTV1 DNA-B (pSK-2B", "DNA", 24, 45], ["restriction enzymes", "PROTEIN", 112, 131], ["Eco RI", "PROTEIN", 132, 138], ["Spe I", "PROTEIN", 143, 148], ["full-length unit", "DNA", 161, 177], ["FgGMTV1 DNA-A, DNA-B", "DNA", 236, 256], ["DNA-CSimilarly", "DNA", 262, 276], ["FgGMTV1 DNA", "DNA", 326, 337], ["RCA products", "PROTEIN", 353, 365], ["Xba I", "PROTEIN", 385, 390], ["full-length unit", "DNA", 403, 419], ["DNA-C", "DNA", 423, 428], ["Xba I site", "DNA", 501, 511], ["plasmid pSK", "DNA", 519, 530], ["clone pSK-1C", "DNA", 546, 558], ["1-mer of DNA", "DNA", 573, 585], ["The infectious clone", "TEST", 0, 20], ["FgGMTV1 DNA", "TEST", 24, 35], ["a similar strategy", "TREATMENT", 73, 91], ["different restriction enzymes", "TEST", 102, 131], ["DNA", "TEST", 181, 184], ["DNA", "PROBLEM", 262, 265], ["RCA products", "TREATMENT", 353, 365], ["a full-length unit of DNA", "TREATMENT", 401, 426], ["the fragment", "PROBLEM", 439, 451], ["the plasmid pSK", "TREATMENT", 515, 530], ["the clone pSK", "TEST", 542, 555], ["infectious", "OBSERVATION_MODIFIER", 4, 14], ["infectious", "OBSERVATION_MODIFIER", 215, 225], ["infectious", "OBSERVATION", 306, 316], ["RCA", "ANATOMY", 353, 356], ["fragment", "OBSERVATION", 443, 451], ["plasmid pSK", "OBSERVATION", 519, 530]]], ["The sequenced pSK-1C clone was digested with Xba I and Cla I and then inserted into the plasmid pSK to produce the clone pSK-0.6C.", [["plasmid", "ANATOMY", 88, 95], ["pSK-1C clone", "CELL", 14, 26], ["Xba I", "GENE_OR_GENE_PRODUCT", 45, 50], ["Cla I", "GENE_OR_GENE_PRODUCT", 55, 60], ["pSK", "GENE_OR_GENE_PRODUCT", 96, 99], ["pSK-1C clone", "DNA", 14, 26], ["Xba I", "PROTEIN", 45, 50], ["Cla I", "DNA", 55, 60], ["plasmid pSK", "DNA", 88, 99], ["clone pSK", "DNA", 115, 124], ["The sequenced pSK", "TEST", 0, 17], ["1C clone", "TREATMENT", 18, 26], ["Xba I and Cla I", "TREATMENT", 45, 60], ["the plasmid pSK", "TREATMENT", 84, 99], ["the clone pSK", "TEST", 111, 124], ["plasmid pSK", "OBSERVATION", 88, 99]]], ["Clone pSK-1C was digested with Xba I to obtain a full-length unit of DNA-C and inserted into the unique Xba I site of pSK-0.6C to produce pSK-1.6C, containing a 1.6-mer tandem repeat of FgGMTV1 DNA-C.", [["pSK-1C", "GENE_OR_GENE_PRODUCT", 6, 12], ["Xba I", "GENE_OR_GENE_PRODUCT", 31, 36], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["Xba I", "GENE_OR_GENE_PRODUCT", 104, 109], ["pSK-0.6C", "GENE_OR_GENE_PRODUCT", 118, 126], ["pSK-1.6C", "GENE_OR_GENE_PRODUCT", 138, 146], ["Clone pSK-1C", "DNA", 0, 12], ["Xba I", "PROTEIN", 31, 36], ["full-length unit", "DNA", 49, 65], ["DNA-C", "DNA", 69, 74], ["Xba I site", "DNA", 104, 114], ["pSK", "DNA", 118, 121], ["0.6C", "DNA", 122, 126], ["pSK", "DNA", 138, 141], ["1.6C", "DNA", 142, 146], ["1.6-mer tandem repeat", "DNA", 161, 182], ["FgGMTV1 DNA", "DNA", 186, 197], ["Clone pSK", "TEST", 0, 9], ["a full-length unit of DNA", "TREATMENT", 47, 72], ["pSK", "TEST", 118, 121], ["pSK", "TEST", 138, 141], ["FgGMTV1 DNA", "TEST", 186, 197]]], ["The positive recombinant plasmid was also verified through restriction enzyme digestion and analyzed by 1% agarose gel electrophoresis.Protoplast preparation and transfection assaysProtoplast preparation and virus transfection were undertaken following a method described previously (54) with minor modifications.", [["plasmid", "ANATOMY", 25, 32], ["Protoplast", "ANATOMY", 135, 145], ["agarose", "SIMPLE_CHEMICAL", 107, 114], ["positive recombinant plasmid", "DNA", 4, 32], ["The positive recombinant plasmid", "TREATMENT", 0, 32], ["restriction enzyme digestion", "PROBLEM", 59, 87], ["agarose gel electrophoresis", "TEST", 107, 134], ["Protoplast preparation", "TREATMENT", 135, 157], ["transfection assaysProtoplast preparation", "TREATMENT", 162, 203], ["virus transfection", "TREATMENT", 208, 226], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["recombinant plasmid", "OBSERVATION", 13, 32]]], ["Briefly, ~1 \u00d7 10 7 conidia were germinated to produce hyphae overnight in liquid yeast extract peptone dextrose broth [yeast extract (5 g/liter), microbiological peptone (3 g/liter), and dextrose (10 g/liter)].", [["hyphae", "ANATOMY", 54, 60], ["extract", "ANATOMY", 125, 132], ["peptone dextrose", "CHEMICAL", 95, 111], ["dextrose", "CHEMICAL", 187, 195], ["dextrose", "CHEMICAL", 187, 195], ["peptone", "SIMPLE_CHEMICAL", 95, 102], ["dextrose", "SIMPLE_CHEMICAL", 187, 195], ["yeast", "SPECIES", 81, 86], ["yeast", "SPECIES", 119, 124], ["yeast", "SPECIES", 81, 86], ["yeast", "SPECIES", 119, 124], ["hyphae", "PROBLEM", 54, 60], ["liquid yeast extract peptone dextrose broth", "TREATMENT", 74, 117], ["yeast extract", "TREATMENT", 119, 132], ["microbiological peptone", "TREATMENT", 146, 169], ["dextrose", "TREATMENT", 187, 195]]], ["Germinated mycelia were harvested through one layer of Miracloth (Calbiochem) and washed three times with sterile distilled water and twice with 1 M sucrose.", [["mycelia", "ANATOMY", 11, 18], ["sucrose", "CHEMICAL", 149, 156], ["sucrose", "CHEMICAL", 149, 156], ["Germinated mycelia", "PROBLEM", 0, 18], ["Miracloth (Calbiochem", "TREATMENT", 55, 76], ["sterile distilled water", "TREATMENT", 106, 129], ["1 M sucrose", "TREATMENT", 145, 156], ["mycelia", "OBSERVATION", 11, 18], ["harvested", "OBSERVATION_MODIFIER", 24, 33], ["one layer", "OBSERVATION_MODIFIER", 42, 51]]], ["After being filtered on Miracloth, 0.5 g of mycelium was transferred to a 50-ml tube containing 40 ml of 1 M sucrose and 800 mg of cell wall-lysing enzymes (from Trichoderma harzianum; Sigma-Aldrich), followed by incubation for 3 hours at 28\u00b0C in a shaker at 90 rpm to release protoplasts.", [["mycelium", "ANATOMY", 44, 52], ["cell wall", "ANATOMY", 131, 140], ["protoplasts", "ANATOMY", 277, 288], ["sucrose", "CHEMICAL", 109, 116], ["sucrose", "CHEMICAL", 109, 116], ["tube", "TISSUE", 80, 84], ["sucrose", "SIMPLE_CHEMICAL", 109, 116], ["Trichoderma harzianum", "ORGANISM", 162, 183], ["Sigma-Aldrich", "ORGANISM", 185, 198], ["C", "GENE_OR_GENE_PRODUCT", 242, 243], ["protoplasts", "CELL", 277, 288], ["lysing enzymes", "PROTEIN", 141, 155], ["Trichoderma harzianum", "SPECIES", 162, 183], ["Trichoderma harzianum", "SPECIES", 162, 183], ["Miracloth", "TREATMENT", 24, 33], ["mycelium", "TREATMENT", 44, 52], ["1 M sucrose", "TREATMENT", 105, 116]]], ["Protoplasts were filtered into a 50-ml tube and centrifuged at 5000 rpm for 10 min at 4\u00b0C. The protoplast pellet was washed three times with 10 ml of ice-cold sorbitol-tris-calcium chloride (STC) buffer (1 M sorbitol, 50 mM tris with a pH value of 8.0, and 50 mM CaCl 2 \u20222H 2 O), centrifuged at 5000 rpm for 10 min, resuspended in 0.5 ml of STC, and kept on ice.Protoplast preparation and transfection assaysFor transfection, 200 \uf06dl of protoplasts were mixed with 30 \uf06dl of purified virus particles or 30 \uf06dl (about 10 \uf06dg) of infectious clone plasmids and transferred to a 2-ml tube, followed by incubation on ice for 20 min.", [["Protoplasts", "ANATOMY", 0, 11], ["protoplast pellet", "ANATOMY", 95, 112], ["protoplasts", "ANATOMY", 436, 447], ["plasmids", "ANATOMY", 541, 549], ["sorbitol-tris-calcium chloride", "CHEMICAL", 159, 189], ["sorbitol", "CHEMICAL", 208, 216], ["CaCl 2 \u20222H 2 O", "CHEMICAL", 263, 277], ["sorbitol-tris-calcium chloride", "CHEMICAL", 159, 189], ["sorbitol", "CHEMICAL", 208, 216], ["tris", "CHEMICAL", 224, 228], ["CaCl 2 \u20222H 2 O", "CHEMICAL", 263, 277], ["Protoplasts", "CELL", 0, 11], ["tube", "TISSUE", 39, 43], ["sorbitol-tris-calcium chloride", "SIMPLE_CHEMICAL", 159, 189], ["STC", "SIMPLE_CHEMICAL", 191, 194], ["sorbitol", "SIMPLE_CHEMICAL", 208, 216], ["protoplasts", "CELL", 436, 447], ["tube", "TISSUE", 576, 580], ["infectious clone plasmids", "DNA", 524, 549], ["Protoplasts", "TREATMENT", 0, 11], ["a 50-ml tube", "TREATMENT", 31, 43], ["The protoplast pellet", "TREATMENT", 91, 112], ["ice-cold sorbitol-tris-calcium chloride (STC) buffer (1 M sorbitol", "TREATMENT", 150, 216], ["a pH value", "TEST", 234, 244], ["ice", "TREATMENT", 358, 361], ["Protoplast preparation", "TREATMENT", 362, 384], ["transfection assays", "TEST", 389, 408], ["transfection", "TREATMENT", 412, 424], ["protoplasts", "TREATMENT", 436, 447], ["purified virus particles", "TREATMENT", 473, 497], ["infectious clone plasmids", "TREATMENT", 524, 549], ["a 2-ml tube", "TREATMENT", 569, 580], ["protoplast pellet", "OBSERVATION", 95, 112]]], ["Then, 1.25 ml of STC buffer containing 40% polyethylene glycol 3350 was dropwise added into the above 2-ml tube and gently mixed for 15 s before incubation at room temperature for 20 min.", [["polyethylene glycol 3350", "CHEMICAL", 43, 67], ["polyethylene glycol 3350", "CHEMICAL", 43, 67], ["polyethylene glycol 3350", "SIMPLE_CHEMICAL", 43, 67], ["tube", "TISSUE", 107, 111], ["STC buffer containing 40% polyethylene glycol", "TREATMENT", 17, 62]]], ["Following incubation, the protoplast suspension was transferred to a 15-ml tube containing 5 ml of TB3 medium (0.3% yeast extract, 0.3% casamino acids, and 20% sucrose) and incubated for 16 hours at 25\u00b0C in a shaker at 90 rpm.", [["protoplast", "ANATOMY", 26, 36], ["extract", "ANATOMY", 122, 129], ["TB3", "CHEMICAL", 99, 102], ["yeast extract", "CHEMICAL", 116, 129], ["casamino acids", "CHEMICAL", 136, 150], ["sucrose", "CHEMICAL", 160, 167], ["sucrose", "CHEMICAL", 160, 167], ["tube", "TISSUE", 75, 79], ["casamino acids", "SIMPLE_CHEMICAL", 136, 150], ["sucrose", "SIMPLE_CHEMICAL", 160, 167], ["yeast", "SPECIES", 116, 121], ["yeast", "SPECIES", 116, 121], ["the protoplast suspension", "TREATMENT", 22, 47], ["a 15-ml tube", "TREATMENT", 67, 79], ["TB3 medium", "TREATMENT", 99, 109], ["casamino acids", "TREATMENT", 136, 150]]], ["A volume of 200 \uf06dl of aliquots of the mixture was transferred to 9-cm petri dishes, embedded in 20 ml of warm TB3 solid medium containing 0.7% low-melt agarose, and cultured for 2 to 3 days at 25\u00b0C in the dark.", [["agarose", "SIMPLE_CHEMICAL", 152, 159], ["C", "GENE_OR_GENE_PRODUCT", 196, 197], ["the mixture", "TREATMENT", 34, 45], ["warm TB3 solid medium", "TREATMENT", 105, 126], ["melt agarose", "TREATMENT", 147, 159], ["volume", "OBSERVATION_MODIFIER", 2, 8]]], ["Mycelial plugs were randomly cut from the regenerated colonies, individually transferred to fresh PDA plates at one plug per plate, subcultured three times at weekly intervals, and then checked for the presence of the virus by Southern blotting.Biological characterizationWe assessed the mycelial growth, conidiation, and virulence on wheat spikes as previously described (55) .", [["colonies", "ANATOMY", 54, 62], ["mycelial", "ANATOMY", 288, 296], ["wheat", "SPECIES", 335, 340], ["wheat", "SPECIES", 335, 340], ["Mycelial plugs", "PROBLEM", 0, 14], ["fresh PDA plates", "TREATMENT", 92, 108], ["the virus", "PROBLEM", 214, 223], ["virulence on wheat spikes", "PROBLEM", 322, 347], ["plugs", "OBSERVATION", 9, 14], ["regenerated colonies", "OBSERVATION", 42, 62], ["plug", "OBSERVATION", 116, 120], ["plate", "ANATOMY", 125, 130], ["virus", "OBSERVATION", 218, 223]]], ["After fungal isolates were grown on PDA plates for 5 days at 25\u00b0C, agar plugs with a diameter of 7 mm were cut from the actively growing margin and placed in the middle of a PDA plate.", [["fungal isolates", "PROBLEM", 6, 21], ["PDA plates", "TREATMENT", 36, 46], ["agar plugs", "TREATMENT", 67, 77], ["diameter", "OBSERVATION_MODIFIER", 85, 93], ["7 mm", "OBSERVATION_MODIFIER", 97, 101], ["actively", "OBSERVATION_MODIFIER", 120, 128], ["growing", "OBSERVATION_MODIFIER", 129, 136], ["margin", "OBSERVATION_MODIFIER", 137, 143], ["middle", "ANATOMY_MODIFIER", 162, 168], ["PDA plate", "OBSERVATION", 174, 183]]], ["The growth rate of fungi was calculated by measuring colonial diameters daily after culturing for 4 days at 25\u00b0C. Three agar plugs were added to O-carboxymethylcellulose broth and cultured for 5 days, and conidial production was determined on blood count plates.", [["blood", "ANATOMY", 243, 248], ["O-carboxymethylcellulose", "CHEMICAL", 145, 169], ["O-carboxymethylcellulose", "CHEMICAL", 145, 169], ["O-carboxymethylcellulose", "SIMPLE_CHEMICAL", 145, 169], ["blood", "ORGANISM_SUBSTANCE", 243, 248], ["fungi", "PROBLEM", 19, 24], ["culturing", "TEST", 84, 93], ["Three agar plugs", "TREATMENT", 114, 130], ["O-carboxymethylcellulose broth", "TREATMENT", 145, 175], ["conidial production", "PROBLEM", 205, 224], ["blood count plates", "TEST", 243, 261], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["fungi", "OBSERVATION", 19, 24], ["diameters", "OBSERVATION_MODIFIER", 62, 71], ["agar plugs", "OBSERVATION", 120, 130]]], ["For the virulence assay, 10 \uf06dl of conidial suspension (3 \u00d7 10 5 conidia/ml) or a small equisized mycelial plug was inoculated in the glume of a spikelet and cultured in the field for 15 days.", [["mycelial plug", "ANATOMY", 97, 110], ["spikelet", "ANATOMY", 144, 152], ["the virulence assay", "TEST", 4, 23], ["conidial suspension", "TREATMENT", 34, 53], ["a small equisized mycelial plug", "PROBLEM", 79, 110], ["small", "OBSERVATION_MODIFIER", 81, 86], ["mycelial plug", "OBSERVATION", 97, 110]]], ["At the end of the cultivation period, virulence was assessed by measuring the numbers of diseased spikelets per wheat head invaded.", [["spikelets", "ANATOMY", 98, 107], ["head", "ANATOMY", 118, 122], ["head", "ORGANISM_SUBDIVISION", 118, 122], ["wheat", "SPECIES", 112, 117], ["wheat", "SPECIES", 112, 117], ["virulence", "PROBLEM", 38, 47], ["diseased spikelets", "OBSERVATION", 89, 107]]], ["The infected glume was plucked from the spikelet, placed onto a PDA plate, and incubated for 3 to 5 days at 25\u00b0C. The generated fungi were transferred to PDA for subculture.", [["glume", "ANATOMY", 13, 18], ["spikelet", "ANATOMY", 40, 48], ["spikelet", "ORGAN", 40, 48], ["The infected glume", "PROBLEM", 0, 18], ["a PDA plate", "TREATMENT", 62, 73], ["subculture", "PROBLEM", 162, 172], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["glume", "OBSERVATION", 13, 18], ["spikelet", "OBSERVATION_MODIFIER", 40, 48], ["PDA plate", "OBSERVATION", 64, 73], ["fungi", "OBSERVATION", 128, 133]]], ["Subsequently, the mycelial mass was collected for DNA extraction, followed by PCR using the indicated primer pairs (DNA-A-2F/2R for DNA-A, DNA-B-2F/2R for DNA-B, and DNA-C-2F/2R for DNA-C) (table S4) .Viral horizontal transmission via hyphal anastomosis and vertical transmission through conidia and ascosporesTo assess the possibility of horizontal transmission of FgGMTV1 between strains of F. graminearum, fresh mycelial agar discs from strains A + B and PH-1 hph , A + B + C and PH-1 hph , or HB58 and PH-1 hph were dual-cultured on PDA plates.", [["mycelial mass", "ANATOMY", 18, 31], ["hyphal", "ANATOMY", 235, 241], ["conidia", "ANATOMY", 288, 295], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 366, 373], ["F. graminearum", "ORGANISM", 393, 407], ["A + B", "CELL", 448, 453], ["PH-1 hph", "CELL", 458, 466], ["A + B + C", "CELL", 469, 478], ["PH-1 hph", "CELL", 483, 491], ["HB58", "CELL", 497, 501], ["primer pairs", "DNA", 102, 114], ["DNA-A-2F/2R", "DNA", 116, 127], ["DNA-A", "DNA", 132, 137], ["DNA-B-2F/2R", "DNA", 139, 150], ["DNA-B", "DNA", 155, 160], ["2R", "DNA", 175, 177], ["DNA-C", "DNA", 182, 187], ["F. graminearum", "SPECIES", 393, 407], ["F. graminearum", "SPECIES", 393, 407], ["the mycelial mass", "PROBLEM", 14, 31], ["DNA extraction", "TREATMENT", 50, 64], ["PCR", "TEST", 78, 81], ["DNA", "TEST", 116, 119], ["DNA", "TEST", 132, 135], ["DNA", "TEST", 139, 142], ["B", "TEST", 143, 144], ["DNA", "TEST", 155, 158], ["B", "TEST", 159, 160], ["DNA", "TEST", 166, 169], ["C", "TEST", 170, 171], ["DNA", "PROBLEM", 182, 185], ["Viral horizontal transmission", "TREATMENT", 201, 230], ["hyphal anastomosis", "TREATMENT", 235, 253], ["vertical transmission through conidia", "TREATMENT", 258, 295], ["horizontal transmission of FgGMTV1", "PROBLEM", 339, 373], ["fresh mycelial agar discs", "TEST", 409, 434], ["strains", "TEST", 440, 447], ["PH", "TEST", 458, 460], ["hph", "TEST", 463, 466], ["A", "TEST", 469, 470], ["C", "TEST", 477, 478], ["PH", "TEST", 483, 485], ["hph", "TEST", 488, 491], ["HB58", "TEST", 497, 501], ["PH", "TEST", 506, 508], ["hph", "TEST", 511, 514], ["dual", "TEST", 520, 524], ["PDA plates", "TREATMENT", 537, 547], ["mass", "OBSERVATION", 27, 31], ["hyphal anastomosis", "OBSERVATION", 235, 253], ["vertical", "OBSERVATION_MODIFIER", 258, 266]]], ["In the contact culture in each dish (9 cm in diameter), strains A + B, A + B + C, and HB58 served as donors, whereas strain PH-1 hph served as the recipient.", [["A + B", "ANATOMY", 64, 69], ["A + B + C", "ANATOMY", 71, 80], ["HB58", "ANATOMY", 86, 90], ["A + B", "CELL", 64, 69], ["A + B + C", "CELL", 71, 80], ["HB58", "CELL", 86, 90], ["donors", "ORGANISM", 101, 107], ["the contact culture", "TEST", 3, 22], ["C", "PROBLEM", 79, 80], ["HB58", "TEST", 86, 90], ["donors", "TEST", 101, 107], ["strain PH", "TEST", 117, 126], ["9 cm", "OBSERVATION_MODIFIER", 37, 41]]], ["After 4 days of dual culture, six mycelial derivative isolates were obtained from the growth side of six recipients and transferred to a fresh PDA plate containing hygromycin (200 \uf06dg/ml).", [["hygromycin", "CHEMICAL", 164, 174], ["hygromycin", "CHEMICAL", 164, 174], ["recipients", "ORGANISM", 105, 115], ["hygromycin", "SIMPLE_CHEMICAL", 164, 174], ["dual culture", "TEST", 16, 28], ["six mycelial derivative isolates", "TEST", 30, 62], ["a fresh PDA plate containing hygromycin", "TREATMENT", 135, 174]]], ["New colonies were subcultured two times on hygromycin-containing PDA plates and then transferred onto fresh PDA plates overlaid with cellophane for further incubation for 3 days before viral detection.", [["colonies", "ANATOMY", 4, 12], ["hygromycin", "CHEMICAL", 43, 53], ["cellophane", "CHEMICAL", 133, 143], ["hygromycin", "CHEMICAL", 43, 53], ["hygromycin", "SIMPLE_CHEMICAL", 43, 53], ["New colonies", "PROBLEM", 0, 12], ["hygromycin", "TREATMENT", 43, 53], ["PDA plates", "TREATMENT", 65, 75], ["fresh PDA plates", "TREATMENT", 102, 118], ["cellophane", "TREATMENT", 133, 143], ["further incubation", "TREATMENT", 148, 166], ["viral detection", "TEST", 185, 200], ["colonies", "OBSERVATION", 4, 12]]], ["Subcultures of PH-1 hph after dual culturing and contacting with strains A + B, A + B + C, and HB58, respectively, were analyzed for the presence of the mycovirus by performing total DNA extraction and Southern dot blot.Viral horizontal transmission via hyphal anastomosis and vertical transmission through conidia and ascosporesTo test whether FgGMTV1 can be vertically transmitted through conidia, five aliquots (200 \uf06dl) of the conidial suspensions containing approximately 3 \u00d7 10 5 conidia/ml were inoculated in 50 ml of PDB broth and cultured for 5 days at 25\u00b0C on a rotary shaker.", [["hyphal", "ANATOMY", 254, 260], ["conidia", "ANATOMY", 307, 314], ["conidia", "ANATOMY", 391, 398], ["FgGMTV1", "CHEMICAL", 345, 352], ["A + B", "CELL", 73, 78], ["A + B + C", "CELL", 80, 89], ["HB58", "CELL", 95, 99], ["DNA", "CELLULAR_COMPONENT", 183, 186], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 345, 352], ["PH", "PROTEIN", 15, 17], ["FgGMTV1", "PROTEIN", 345, 352], ["Subcultures of PH", "TEST", 0, 17], ["dual culturing", "TEST", 30, 44], ["HB58", "TEST", 95, 99], ["the mycovirus", "PROBLEM", 149, 162], ["total DNA extraction", "TREATMENT", 177, 197], ["Southern dot blot", "PROBLEM", 202, 219], ["Viral horizontal transmission", "TREATMENT", 220, 249], ["hyphal anastomosis", "TREATMENT", 254, 272], ["vertical transmission through conidia", "TREATMENT", 277, 314], ["FgGMTV1", "TEST", 345, 352], ["the conidial suspensions", "TREATMENT", 426, 450], ["PDB broth", "TREATMENT", 524, 533], ["a rotary shaker", "TREATMENT", 569, 584], ["hyphal anastomosis", "OBSERVATION", 254, 272], ["vertical", "OBSERVATION_MODIFIER", 277, 285]]], ["Germinated mycelia were harvested, dried, and ground to a fine powder.", [["mycelia", "ANATOMY", 11, 18], ["Germinated mycelia", "PROBLEM", 0, 18], ["a fine powder", "TREATMENT", 56, 69], ["mycelia", "OBSERVATION_MODIFIER", 11, 18], ["harvested", "OBSERVATION_MODIFIER", 24, 33]]], ["Viral DNA extraction and Southern blotting were conducted as described above.Viral horizontal transmission via hyphal anastomosis and vertical transmission through conidia and ascosporesTo assess the frequency of vertical transmission of FgGMTV1, 75 single conidia of strains A + B and A + B + C, respectively, were obtained, and the resultant monoconidial cultures were analyzed for the presence of the mycovirus by performing total DNA purification and Southern dot blot.Viral horizontal transmission via hyphal anastomosis and vertical transmission through conidia and ascosporesTo test the possible transmission of FgGMTV1 through ascospores, mycelia plugs were inoculated onto carrot agar plates [carrots (400 g/liter) and agar (20 g/liter)] at 25\u00b0C for 5 days.", [["hyphal", "ANATOMY", 111, 117], ["conidia", "ANATOMY", 164, 171], ["conidia", "ANATOMY", 257, 264], ["hyphal", "ANATOMY", 507, 513], ["conidia", "ANATOMY", 560, 567], ["mycelia plugs", "ANATOMY", 647, 660], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["FgGMTV1", "GENE_OR_GENE_PRODUCT", 238, 245], ["A + B", "CELL", 276, 281], ["A + B + C", "CELL", 286, 295], ["monoconidial cultures", "CELL", 344, 365], ["DNA", "CELLULAR_COMPONENT", 434, 437], ["FgGMTV1", "SIMPLE_CHEMICAL", 619, 626], ["mycelia plugs", "ORGANISM_SUBSTANCE", 647, 660], ["carrots", "ORGANISM_SUBDIVISION", 702, 709], ["monoconidial cultures", "CELL_LINE", 344, 365], ["carrot", "SPECIES", 682, 688], ["Viral DNA extraction", "TREATMENT", 0, 20], ["Southern blotting", "PROBLEM", 25, 42], ["Viral horizontal transmission", "TREATMENT", 77, 106], ["hyphal anastomosis", "TREATMENT", 111, 129], ["vertical transmission through conidia", "TREATMENT", 134, 171], ["FgGMTV1", "TEST", 238, 245], ["the resultant monoconidial cultures", "TEST", 330, 365], ["the mycovirus", "PROBLEM", 400, 413], ["total DNA purification", "TREATMENT", 428, 450], ["Southern dot blot", "PROBLEM", 455, 472], ["Viral horizontal transmission", "TREATMENT", 473, 502], ["hyphal anastomosis", "TREATMENT", 507, 525], ["vertical transmission through conidia", "TREATMENT", 530, 567], ["FgGMTV1 through ascospores", "TREATMENT", 619, 645], ["mycelia plugs", "TREATMENT", 647, 660], ["agar", "TEST", 728, 732], ["hyphal anastomosis", "OBSERVATION", 111, 129], ["vertical", "OBSERVATION_MODIFIER", 134, 142], ["hyphal anastomosis", "OBSERVATION", 507, 525], ["vertical", "OBSERVATION_MODIFIER", 530, 538]]], ["Aerial hyphae were gently removed with a sterile toothpick and pressed down with 1 ml of sterile 0.2% Tween-20 solution to induce sexual development.", [["hyphae", "ANATOMY", 7, 13], ["Tween-20", "CHEMICAL", 102, 110], ["Tween-20", "CHEMICAL", 102, 110], ["Aerial hyphae", "CELL", 0, 13], ["Tween-20", "SIMPLE_CHEMICAL", 102, 110], ["Aerial hyphae", "PROBLEM", 0, 13], ["a sterile toothpick", "TREATMENT", 39, 58], ["sterile 0.2% Tween", "TREATMENT", 89, 107], ["hyphae", "OBSERVATION", 7, 13]]], ["The plates were continuously incubated under near-UV light at 23\u00b0C. After induction for 7 days, perithecia were observed under a dissecting microscope.", [["perithecia", "ANATOMY", 96, 106], ["The plates", "TREATMENT", 0, 10], ["perithecia", "TREATMENT", 96, 106], ["a dissecting microscope", "TEST", 127, 150], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["At least 10 perithecia were collected with a needle and crushed on a microscope slide and examined for ascospores with a light microscope.", [["perithecia", "ANATOMY", 12, 22], ["ascospores", "ANATOMY", 103, 113], ["a needle", "TREATMENT", 43, 51], ["a microscope slide", "TEST", 67, 85], ["a light microscope", "TEST", 119, 137]]], ["The ascospores were washed off the slide with sterile water and quantified.", [["ascospores", "ANATOMY", 4, 14], ["The ascospores", "TREATMENT", 0, 14], ["sterile water", "TREATMENT", 46, 59]]], ["Fifty single ascospores of strains A + B and A + B + C, respectively, were obtained, and the resultant single ascospore cultures were analyzed for the presence of the mycovirus by performing total DNA extraction and Southern dot blot.", [["ascospores", "ANATOMY", 13, 23], ["A + B", "CELL", 35, 40], ["A + B + C", "CELL", 45, 54], ["ascospore cultures", "CELL", 110, 128], ["DNA", "CELLULAR_COMPONENT", 197, 200], ["resultant single ascospore cultures", "CELL_LINE", 93, 128], ["strains", "PROBLEM", 27, 34], ["the resultant single ascospore cultures", "TEST", 89, 128], ["the mycovirus", "PROBLEM", 163, 176], ["total DNA extraction", "TREATMENT", 191, 211], ["Southern dot blot", "PROBLEM", 216, 233]]], ["The experiment was repeated three times.Statistical analysisStatistical analysis was performed using GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA, USA).", [["Statistical analysisStatistical analysis", "TEST", 40, 80], ["GraphPad Prism version", "TEST", 101, 123], ["GraphPad", "TEST", 129, 137]]], ["Significant differences between the control and treatment groups were analyzed using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test.", [["treatment groups", "TREATMENT", 48, 64], ["Tukey's post hoc test", "TEST", 134, 155]]], ["Significant differences occurred when P < 0.05.SUPPLEMENTARY MATERIALSSupplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/6/14/eaay9634/DC1 View/request a protocol for this paper from Bio-protocol.", [["SUPPLEMENTARY", "DISEASE", 47, 60], ["Significant differences", "PROBLEM", 0, 23], ["P", "TEST", 38, 39], ["SUPPLEMENTARY MATERIALSSupplementary material", "TREATMENT", 47, 92]]]], "PMC7151846": [["MANAGEMENT OF PATIENTS AND RATIONAL USE OF ANTIBIOTICSThere are a number of cardinal features of acute virus infections which need to be emphasized.", [["acute virus infections", "DISEASE", 97, 119], ["ANTIBIOTICSThere", "TREATMENT", 43, 59], ["acute virus infections", "PROBLEM", 97, 119], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["virus infections", "OBSERVATION", 103, 119]]], ["The presence of viruses at the site of illness usually means that the virus is associated with that illness and is almost certainly causal.", [["illness", "DISEASE", 100, 107], ["viruses", "PROBLEM", 16, 23], ["illness", "PROBLEM", 39, 46], ["the virus", "PROBLEM", 66, 75], ["viruses", "OBSERVATION", 16, 23], ["illness", "OBSERVATION", 39, 46], ["virus", "OBSERVATION", 70, 75], ["illness", "OBSERVATION", 100, 107]]], ["There are exceptions to this, such as enteroviruses in stools and adenoviruses both in stools and the respiratory tract, but even here they have caused infection and, because they have the property of being excreted for a long time, may be found at the site after the acute phase has passed.", [["stools", "ANATOMY", 87, 93], ["respiratory tract", "ANATOMY", 102, 119], ["enteroviruses", "DISEASE", 38, 51], ["infection", "DISEASE", 152, 161], ["enteroviruses", "ORGANISM", 38, 51], ["adenoviruses", "ORGANISM", 66, 78], ["stools", "ORGANISM_SUBDIVISION", 87, 93], ["respiratory tract", "ORGANISM_SUBDIVISION", 102, 119], ["enteroviruses in stools", "PROBLEM", 38, 61], ["adenoviruses", "PROBLEM", 66, 78], ["stools and the respiratory tract", "PROBLEM", 87, 119], ["infection", "PROBLEM", 152, 161], ["enteroviruses", "OBSERVATION", 38, 51], ["stools", "OBSERVATION", 87, 93], ["respiratory tract", "ANATOMY", 102, 119], ["infection", "OBSERVATION", 152, 161]]], ["However, in lesions of the skin, central nervous system and respiratory tract, viruses found in the presence of symptoms should be taken as causal.", [["lesions", "ANATOMY", 12, 19], ["skin", "ANATOMY", 27, 31], ["central nervous system", "ANATOMY", 33, 55], ["respiratory tract", "ANATOMY", 60, 77], ["lesions", "PATHOLOGICAL_FORMATION", 12, 19], ["skin", "ORGAN", 27, 31], ["central nervous system", "ANATOMICAL_SYSTEM", 33, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["lesions of the skin, central nervous system and respiratory tract", "PROBLEM", 12, 77], ["viruses", "PROBLEM", 79, 86], ["symptoms", "PROBLEM", 112, 120], ["lesions", "OBSERVATION", 12, 19], ["skin", "ANATOMY", 27, 31], ["central", "ANATOMY_MODIFIER", 33, 40], ["nervous system", "ANATOMY", 41, 55], ["respiratory tract", "ANATOMY", 60, 77], ["viruses", "OBSERVATION", 79, 86]]], ["In the respiratory tract, influenza virus, respiratory syncytial virus and the parainfluenza viruses are seldom if ever found without illness.", [["respiratory tract", "ANATOMY", 7, 24], ["respiratory tract", "DISEASE", 7, 24], ["influenza virus", "DISEASE", 26, 41], ["respiratory syncytial virus", "DISEASE", 43, 70], ["parainfluenza viruses", "DISEASE", 79, 100], ["respiratory tract", "ORGANISM_SUBDIVISION", 7, 24], ["influenza virus", "ORGANISM", 26, 41], ["respiratory syncytial virus", "ORGANISM", 43, 70], ["parainfluenza viruses", "ORGANISM", 79, 100], ["influenza virus", "SPECIES", 26, 41], ["respiratory syncytial virus", "SPECIES", 43, 70], ["parainfluenza", "SPECIES", 79, 92], ["influenza virus", "SPECIES", 26, 41], ["respiratory syncytial virus", "SPECIES", 43, 70], ["the respiratory tract", "PROBLEM", 3, 24], ["influenza virus", "PROBLEM", 26, 41], ["respiratory syncytial virus", "PROBLEM", 43, 70], ["the parainfluenza viruses", "PROBLEM", 75, 100], ["illness", "PROBLEM", 134, 141], ["respiratory tract", "ANATOMY", 7, 24], ["influenza virus", "OBSERVATION", 26, 41], ["syncytial virus", "OBSERVATION", 55, 70], ["parainfluenza viruses", "OBSERVATION", 79, 100]]], ["The rapid diagnosis of a virus infection in 2-3 hours after admission to hospital revolutionizes the attitude of physicians.", [["infection", "DISEASE", 31, 40], ["a virus infection", "PROBLEM", 23, 40], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["virus", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40]]], ["They are no longer dealing with a disease of unknown aetiology for most, if not all, of the patient's stay in hospital but with one which is a precise entity immediately known.MANAGEMENT OF PATIENTS AND RATIONAL USE OF ANTIBIOTICSA basic tenet in virology is that a virus is completely insensitive to antibiotics and that virus-infected patients, particularly children, do not as a rule acquire secondary bacterial infections.", [["virus-infected", "DISEASE", 322, 336], ["bacterial infections", "DISEASE", 405, 425], ["patient", "ORGANISM", 92, 99], ["patients", "ORGANISM", 337, 345], ["children", "ORGANISM", 360, 368], ["patient", "SPECIES", 92, 99], ["patients", "SPECIES", 337, 345], ["children", "SPECIES", 360, 368], ["a disease", "PROBLEM", 32, 41], ["a virus", "PROBLEM", 264, 271], ["antibiotics", "TREATMENT", 301, 312], ["secondary bacterial infections", "PROBLEM", 395, 425], ["no longer", "UNCERTAINTY", 9, 18], ["bacterial", "OBSERVATION_MODIFIER", 405, 414], ["infections", "OBSERVATION", 415, 425]]], ["The main exception to this rule is influenza infections in a previously damaged lung.", [["lung", "ANATOMY", 80, 84], ["influenza infections", "DISEASE", 35, 55], ["influenza", "ORGANISM", 35, 44], ["lung", "ORGAN", 80, 84], ["influenza infections", "PROBLEM", 35, 55], ["a previously damaged lung", "PROBLEM", 59, 84], ["main", "OBSERVATION_MODIFIER", 4, 8], ["influenza", "OBSERVATION_MODIFIER", 35, 44], ["infections", "OBSERVATION", 45, 55], ["lung", "ANATOMY", 80, 84]]], ["This knowledge and confidence has been acquired over a number of years of investigation in joint virological and clinical studies (Elderkin et al., 1965; Holdaway, Romer and Gardner, 1967; Gardners et al., 1967; Aherne et al, 1970).MANAGEMENT OF PATIENTS AND RATIONAL USE OF ANTIBIOTICSA physician can now manage his patients with, in most cases, sure knowledge of the aetiology.", [["patients", "ORGANISM", 317, 325], ["patients", "SPECIES", 317, 325], ["investigation in joint virological", "TEST", 74, 108], ["clinical studies", "TEST", 113, 129], ["joint", "ANATOMY", 91, 96]]], ["This should give him confidence that in respiratory viral infections antibiotics will not benefit the patient, and that nursing and general support therapy should form the treatment.", [["respiratory viral infections", "DISEASE", 40, 68], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["respiratory viral infections antibiotics", "TREATMENT", 40, 80], ["general support therapy", "TREATMENT", 132, 155], ["the treatment", "TREATMENT", 168, 181], ["respiratory", "ANATOMY", 40, 51], ["viral infections", "OBSERVATION", 52, 68]]], ["In other infections antiviral agents are now becoming available and even in respiratory infections the future holds promise as will be seen presently.", [["respiratory", "ANATOMY", 76, 87], ["infections", "DISEASE", 9, 19], ["respiratory infections", "DISEASE", 76, 98], ["antiviral agents", "TREATMENT", 20, 36], ["respiratory infections", "PROBLEM", 76, 98], ["infections", "OBSERVATION", 9, 19]]], ["The clinician should be well satisfied with this rapid progress which will at worst at least satisfy his curiosity during the acute phase of illness and not retrospectively, and at best indicate a line of specific therapy to pursue.THE USE OF ANTIVIRAL DRUGSThere is now a vast literature on the use of antiviral drugs; amongst recent books is Gallasso, Merigan and Buchanan (1979).", [["specific therapy", "TREATMENT", 205, 221], ["ANTIVIRAL DRUGSThere", "TREATMENT", 243, 263], ["antiviral drugs", "TREATMENT", 303, 318]]], ["Drugs may be used in two ways: pro- phylactically or therapeutically.", [["Drugs", "TREATMENT", 0, 5]]], ["Rapid virus diagnosis may determine quickly the presence of a virus in a community, for instance a school, factory, family, etc. Should a drug be available for prophylactic use then treatment of the uninfected members of the community may prevent the development and spread of an outbreak.", [["Rapid virus diagnosis", "PROBLEM", 0, 21], ["prophylactic use", "TREATMENT", 160, 176], ["treatment", "TREATMENT", 182, 191], ["virus", "OBSERVATION", 6, 11], ["virus", "OBSERVATION", 62, 67]]], ["One such drug is amantadine hydrochloride which has been used effectively in the prevention of influenza A.THE USE OF ANTIVIRAL DRUGSInfections with the herpesvirus group are those which have, at this time, been the most effectively treated with antiviral drugs.", [["amantadine hydrochloride", "CHEMICAL", 17, 41], ["influenza", "DISEASE", 95, 104], ["amantadine hydrochloride", "CHEMICAL", 17, 41], ["amantadine", "SIMPLE_CHEMICAL", 17, 27], ["herpesvirus", "ORGANISM", 153, 164], ["amantadine hydrochloride", "TREATMENT", 17, 41], ["influenza", "PROBLEM", 95, 104], ["ANTIVIRAL DRUGSInfections", "TREATMENT", 118, 143], ["the herpesvirus group", "TREATMENT", 149, 170], ["antiviral drugs", "TREATMENT", 246, 261], ["influenza", "OBSERVATION", 95, 104], ["most effectively", "OBSERVATION_MODIFIER", 216, 232]]], ["Most studies have been undertaken with herpesvirus hominis, which more often than not, causes just minor skin lesions such as \u2018cold\u2019 sores.", [["skin lesions", "ANATOMY", 105, 117], ["herpesvirus hominis", "DISEASE", 39, 58], ["sores", "DISEASE", 133, 138], ["herpesvirus hominis", "ORGANISM", 39, 58], ["skin lesions", "PATHOLOGICAL_FORMATION", 105, 117], ["herpesvirus hominis", "SPECIES", 39, 58], ["herpesvirus hominis", "SPECIES", 39, 58], ["Most studies", "TEST", 0, 12], ["herpesvirus hominis", "PROBLEM", 39, 58], ["minor skin lesions", "PROBLEM", 99, 117], ["\u2018cold\u2019 sores", "PROBLEM", 126, 138], ["minor", "OBSERVATION_MODIFIER", 99, 104], ["skin", "ANATOMY", 105, 109], ["lesions", "OBSERVATION", 110, 117]]], ["However, herpesvirus hominis eye infections are not infrequent and those of the brain, though rare, are often fatal.", [["eye", "ANATOMY", 29, 32], ["brain", "ANATOMY", 80, 85], ["herpesvirus hominis eye infections", "DISEASE", 9, 43], ["herpesvirus hominis", "ORGANISM", 9, 28], ["eye", "ORGAN", 29, 32], ["brain", "ORGAN", 80, 85], ["herpesvirus hominis", "SPECIES", 9, 28], ["herpesvirus hominis", "SPECIES", 9, 28], ["herpesvirus hominis eye infections", "PROBLEM", 9, 43], ["eye", "ANATOMY", 29, 32], ["infections", "OBSERVATION", 33, 43], ["brain", "ANATOMY", 80, 85]]], ["Both these conditions need immediate diagnosis and treatment with one of the antiherpetic drugs now available.", [["treatment", "TREATMENT", 51, 60], ["the antiherpetic drugs", "TREATMENT", 73, 95]]], ["Amongst these drugs with antiherpetic action are idoxuridine, cytarabine, vidarabine and acycloguanosine (Collins and Bauer, 1977).", [["idoxuridine", "CHEMICAL", 49, 60], ["cytarabine", "CHEMICAL", 62, 72], ["vidarabine", "CHEMICAL", 74, 84], ["acycloguanosine", "CHEMICAL", 89, 104], ["idoxuridine", "CHEMICAL", 49, 60], ["cytarabine", "CHEMICAL", 62, 72], ["vidarabine", "CHEMICAL", 74, 84], ["acycloguanosine", "CHEMICAL", 89, 104], ["idoxuridine", "SIMPLE_CHEMICAL", 49, 60], ["cytarabine", "SIMPLE_CHEMICAL", 62, 72], ["vidarabine", "SIMPLE_CHEMICAL", 74, 84], ["acycloguanosine", "SIMPLE_CHEMICAL", 89, 104], ["these drugs", "TREATMENT", 8, 19], ["antiherpetic action", "TREATMENT", 25, 44], ["idoxuridine", "TREATMENT", 49, 60], ["cytarabine", "TREATMENT", 62, 72], ["vidarabine", "TREATMENT", 74, 84], ["acycloguanosine", "TREATMENT", 89, 104]]], ["The first has been effective when locally applied but is toxic when administered systemically; cytarabine and vidarabine are less toxic but trial evidence of their effectiveness in herpes encephalitis is still equivocal.", [["cytarabine", "CHEMICAL", 95, 105], ["vidarabine", "CHEMICAL", 110, 120], ["herpes encephalitis", "DISEASE", 181, 200], ["cytarabine", "CHEMICAL", 95, 105], ["vidarabine", "CHEMICAL", 110, 120], ["cytarabine", "SIMPLE_CHEMICAL", 95, 105], ["vidarabine", "SIMPLE_CHEMICAL", 110, 120], ["herpes encephalitis", "ORGANISM", 181, 200], ["cytarabine", "TREATMENT", 95, 105], ["vidarabine", "TREATMENT", 110, 120], ["less toxic", "PROBLEM", 125, 135], ["herpes encephalitis", "PROBLEM", 181, 200], ["effective", "OBSERVATION_MODIFIER", 19, 28]]], ["Acycloguanosine is reputed to be non-toxic and with a very powerful antiherpetic action; its action is directed against viral enzyme only.", [["Acycloguanosine", "CHEMICAL", 0, 15], ["Acycloguanosine", "CHEMICAL", 0, 15], ["Acycloguanosine", "SIMPLE_CHEMICAL", 0, 15], ["viral enzyme", "PROTEIN", 120, 132], ["Acycloguanosine", "TREATMENT", 0, 15], ["a very powerful antiherpetic action", "TREATMENT", 52, 87], ["viral enzyme", "TEST", 120, 132]]], ["It could indicate the lines along which certain antiviral drugs may develop.", [["the lines", "PROBLEM", 18, 27], ["antiviral drugs", "TREATMENT", 48, 63], ["lines", "OBSERVATION", 22, 27]]], ["The results of the clinical trials which are proceeding at the moment must be awaited with reasonable optimism (Schaeffer et al., 1978).THE USE OF ANTIVIRAL DRUGSA naturally occurring substance which has wide application as an antiviral agent in vitro is interferon.", [["interferon", "GENE_OR_GENE_PRODUCT", 255, 265], ["interferon", "PROTEIN", 255, 265], ["ANTIVIRAL DRUGSA", "TREATMENT", 147, 163], ["an antiviral agent", "TREATMENT", 224, 242], ["vitro is interferon", "TREATMENT", 246, 265]]], ["Difficulties in manufacture and standardization have prevented early practical use but successes have now been claimed for clinical use especially in eye infections with herpes zoster (Merigan et al., 1978).", [["eye", "ANATOMY", 150, 153], ["eye infections", "DISEASE", 150, 164], ["herpes zoster", "DISEASE", 170, 183], ["eye", "ORGAN", 150, 153], ["herpes zoster", "ORGANISM", 170, 183], ["herpes zoster", "SPECIES", 170, 183], ["eye infections", "PROBLEM", 150, 164], ["herpes zoster", "PROBLEM", 170, 183], ["eye", "ANATOMY", 150, 153]]], ["Its use in the immunosuppressed patient is discussed on page 292.THE USE OF ANTIVIRAL DRUGSBy the time a patient manifests the signs and symptoms of illness, virus infection of cells at the site of infection is widespread.", [["cells", "ANATOMY", 177, 182], ["infection", "DISEASE", 164, 173], ["infection", "DISEASE", 198, 207], ["patient", "ORGANISM", 32, 39], ["patient", "ORGANISM", 105, 112], ["cells", "CELL", 177, 182], ["patient", "SPECIES", 32, 39], ["patient", "SPECIES", 105, 112], ["ANTIVIRAL DRUGSBy", "TREATMENT", 76, 93], ["the signs and symptoms", "PROBLEM", 123, 145], ["illness", "PROBLEM", 149, 156], ["virus infection of cells", "PROBLEM", 158, 182], ["infection", "PROBLEM", 198, 207], ["infection", "OBSERVATION", 198, 207], ["widespread", "OBSERVATION_MODIFIER", 211, 221]]], ["Therefore, if antiviral therapy is to stand any chance of success a diagnosis must be made as near to the time of onset of symptoms as possible.", [["antiviral therapy", "TREATMENT", 14, 31], ["symptoms", "PROBLEM", 123, 131]]], ["It is only at this stage that antiviral drugs can do good by preventing the infection of further cells and thus further replication of virus.", [["cells", "ANATOMY", 97, 102], ["infection", "DISEASE", 76, 85], ["cells", "CELL", 97, 102], ["antiviral drugs", "TREATMENT", 30, 45], ["the infection of further cells", "PROBLEM", 72, 102], ["further replication of virus", "PROBLEM", 112, 140], ["infection", "OBSERVATION", 76, 85]]], ["This delaying process will allow the normal immunological defences of the body to respond fully and thus terminate what might be an overwhelming virus infection.", [["body", "ANATOMY", 74, 78], ["infection", "DISEASE", 151, 160], ["body", "ORGANISM_SUBDIVISION", 74, 78], ["an overwhelming virus infection", "PROBLEM", 129, 160], ["overwhelming", "OBSERVATION_MODIFIER", 132, 144], ["virus", "OBSERVATION", 145, 150]]], ["The most vulnerable groups are therefore the young, perhaps the very old and those who are immunosuppressed.", [["most vulnerable", "OBSERVATION_MODIFIER", 4, 19], ["immunosuppressed", "OBSERVATION", 91, 107]]], ["Even when efficient antiviral agents become available their use will still be dependent on accurate rapid virus diagnosis in order to start treatment sufficiently early to contain the infection.VIRUS INFECTION OUTSIDE ACUTE STAGE OF ILLNESSSome patients do not come into hospital at the onset of their virus illness but may have been ineffectively treated at home with antibiotics.", [["infection", "DISEASE", 184, 193], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["efficient antiviral agents", "TREATMENT", 10, 36], ["treatment", "TREATMENT", 140, 149], ["the infection", "PROBLEM", 180, 193], ["VIRUS INFECTION", "PROBLEM", 194, 209], ["their virus illness", "PROBLEM", 296, 315], ["antibiotics", "TREATMENT", 369, 380], ["infection", "OBSERVATION", 184, 193], ["ACUTE", "OBSERVATION_MODIFIER", 218, 223]]], ["These patients can still be diagnosed rapidly on admission to hospital by immunofluorescence.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["It has already been pointed out in Chapter 6 that respiratory syncytial virus may be identified in many patients late in their illness, frequently as late as the seventh day and occasionally as late as the fourteenth day.", [["respiratory syncytial virus", "DISEASE", 50, 77], ["respiratory syncytial virus", "ORGANISM", 50, 77], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["respiratory syncytial virus", "SPECIES", 50, 77], ["respiratory syncytial virus", "PROBLEM", 50, 77], ["syncytial virus", "OBSERVATION", 62, 77]]], ["In the later stages of the illness infected cells have an altered appearance which was illustrated in Figure 41(seepage 115), the fluorescent green colour being dull and the outline of the cell hazy.", [["cells", "ANATOMY", 44, 49], ["cell", "ANATOMY", 189, 193], ["illness", "DISEASE", 27, 34], ["cells", "CELL", 44, 49], ["cell", "CELL", 189, 193], ["the illness infected cells", "PROBLEM", 23, 49], ["an altered appearance", "PROBLEM", 55, 76], ["seepage", "TEST", 112, 119], ["the fluorescent green colour", "PROBLEM", 126, 154], ["dull", "PROBLEM", 161, 165], ["the cell hazy", "PROBLEM", 185, 198], ["altered", "OBSERVATION_MODIFIER", 58, 65], ["green colour", "OBSERVATION", 142, 154], ["dull", "OBSERVATION_MODIFIER", 161, 165], ["cell hazy", "OBSERVATION", 189, 198]]], ["This is due to a coating of local antibody acquired by infected cells in the respiratory tract during the course of the illness (Gardner and McQuillin, 1978).", [["cells", "ANATOMY", 64, 69], ["respiratory tract", "ANATOMY", 77, 94], ["illness", "DISEASE", 120, 127], ["cells", "CELL", 64, 69], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["local antibody", "PROTEIN", 28, 42], ["infected cells", "CELL_TYPE", 55, 69], ["local antibody", "TEST", 28, 42], ["infected cells in the respiratory tract", "PROBLEM", 55, 94], ["infected cells", "OBSERVATION", 55, 69], ["respiratory tract", "ANATOMY", 77, 94]]], ["The number of infected cells in the secretions is also greatly reduced as the patient progresses to convalescence.VIRUS INFECTION OUTSIDE ACUTE STAGE OF ILLNESSAt this stage of illness virus is difficult to isolate and in the majority of cases the diagnosis can only be made by immunofluorescence.", [["cells", "ANATOMY", 23, 28], ["secretions", "ANATOMY", 36, 46], ["illness", "DISEASE", 177, 184], ["cells", "CELL", 23, 28], ["secretions", "ORGANISM_SUBSTANCE", 36, 46], ["patient", "ORGANISM", 78, 85], ["infected cells", "CELL_TYPE", 14, 28], ["patient", "SPECIES", 78, 85], ["infected cells in the secretions", "PROBLEM", 14, 46], ["VIRUS INFECTION", "PROBLEM", 114, 129], ["illness virus", "PROBLEM", 177, 190], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infected cells", "OBSERVATION", 14, 28], ["secretions", "OBSERVATION", 36, 46], ["greatly", "OBSERVATION_MODIFIER", 55, 62], ["reduced", "OBSERVATION_MODIFIER", 63, 70], ["ACUTE STAGE", "OBSERVATION_MODIFIER", 138, 149], ["illness", "OBSERVATION", 177, 184], ["difficult to isolate", "OBSERVATION_MODIFIER", 194, 214]]], ["Table 2 in Chapter 6 (page 115) illustrates clearly the difficulty of isolating virus after the early days of the illness have passed.", [["isolating virus", "PROBLEM", 70, 85], ["the illness", "PROBLEM", 110, 121]]], ["The coating of cells by antibody, with the subsequent difficulty of virus isolation, does not occur solely with respiratory syncytial virus but with many other respiratory viruses: the parainfluenza viruses and probably influenza A and B viruses.", [["cells", "ANATOMY", 15, 20], ["respiratory syncytial virus", "DISEASE", 112, 139], ["respiratory viruses", "DISEASE", 160, 179], ["parainfluenza viruses", "DISEASE", 185, 206], ["influenza A and B viruses", "DISEASE", 220, 245], ["cells", "CELL", 15, 20], ["respiratory syncytial virus", "ORGANISM", 112, 139], ["parainfluenza viruses", "ORGANISM", 185, 206], ["influenza A and B viruses", "ORGANISM", 220, 245], ["parainfluenza", "SPECIES", 185, 198], ["respiratory syncytial virus", "SPECIES", 112, 139], ["virus isolation", "TREATMENT", 68, 83], ["respiratory syncytial virus", "PROBLEM", 112, 139], ["many other respiratory viruses", "PROBLEM", 149, 179], ["the parainfluenza viruses", "PROBLEM", 181, 206], ["influenza A and B viruses", "PROBLEM", 220, 245], ["cells", "OBSERVATION", 15, 20], ["syncytial virus", "OBSERVATION", 124, 139], ["respiratory viruses", "OBSERVATION", 160, 179], ["parainfluenza viruses", "OBSERVATION", 185, 206], ["probably", "UNCERTAINTY", 211, 219], ["influenza", "OBSERVATION", 220, 229]]], ["Armed with a knowledge of this phenomenon and with a developing experience of the appearance of these coated cells, all these respiratory virus infections can be rapidly diagnosed, in many cases late in the illness.THE USE OF RAPID DIAGNOSTIC TECHNIQUES IN FATAL INFECTIONSIn the UK there are still approximately 2500 deaths per year from respiratory infections, mainly in those under 1 year of age.", [["cells", "ANATOMY", 109, 114], ["respiratory", "ANATOMY", 339, 350], ["respiratory virus infections", "DISEASE", 126, 154], ["deaths", "DISEASE", 318, 324], ["respiratory infections", "DISEASE", 339, 361], ["cells", "CELL", 109, 114], ["this phenomenon", "PROBLEM", 26, 41], ["these coated cells", "PROBLEM", 96, 114], ["all these respiratory virus infections", "PROBLEM", 116, 154], ["respiratory infections", "PROBLEM", 339, 361], ["coated cells", "OBSERVATION", 102, 114], ["respiratory virus", "OBSERVATION", 126, 143], ["respiratory", "ANATOMY", 339, 350], ["infections", "OBSERVATION", 351, 361]]], ["It would appear from various studies that the majority of these are of viral aetiology (Gardner et al., 1967; Aherne et al., 1970; Scott et al., 1978).", [["various studies", "TEST", 21, 36]]], ["The viruses most frequently associated with infant deaths are respiratory syncytial virus, influenza A virus, parainfluenza virus type 3 and various adenoviruses, but recently others such as parainfluenza virus type 1, 4a and 4b have also been incriminated.", [["deaths", "DISEASE", 51, 57], ["respiratory syncytial virus", "DISEASE", 62, 89], ["influenza A virus", "DISEASE", 91, 108], ["parainfluenza virus", "DISEASE", 110, 129], ["parainfluenza virus type 1, 4a and 4b", "CHEMICAL", 191, 228], ["respiratory syncytial virus", "ORGANISM", 62, 89], ["influenza A virus", "ORGANISM", 91, 108], ["parainfluenza virus type 3", "ORGANISM", 110, 136], ["adenoviruses", "ORGANISM", 149, 161], ["parainfluenza virus type 1", "ORGANISM", 191, 217], ["4a", "GENE_OR_GENE_PRODUCT", 219, 221], ["4b", "GENE_OR_GENE_PRODUCT", 226, 228], ["infant", "SPECIES", 44, 50], ["respiratory syncytial virus", "SPECIES", 62, 89], ["influenza A virus", "SPECIES", 91, 108], ["parainfluenza virus", "SPECIES", 110, 129], ["parainfluenza virus type 1", "SPECIES", 191, 217], ["respiratory syncytial virus", "SPECIES", 62, 89], ["influenza A virus", "SPECIES", 91, 108], ["parainfluenza virus type 1", "SPECIES", 191, 217], ["The viruses", "PROBLEM", 0, 11], ["infant deaths", "PROBLEM", 44, 57], ["respiratory syncytial virus", "PROBLEM", 62, 89], ["influenza A virus", "PROBLEM", 91, 108], ["parainfluenza virus type 3", "PROBLEM", 110, 136], ["various adenoviruses", "PROBLEM", 141, 161], ["parainfluenza virus type", "PROBLEM", 191, 215], ["viruses", "OBSERVATION", 4, 11], ["respiratory", "ANATOMY", 62, 73], ["syncytial virus", "OBSERVATION", 74, 89], ["parainfluenza virus", "OBSERVATION", 110, 129]]], ["Measles, too, occasionally causes death in the normal child but is a major cause of death in the immunosuppressed child, who is usually undergoing antitumour therapy (seepage 292).", [["Measles", "DISEASE", 0, 7], ["death", "DISEASE", 34, 39], ["death", "DISEASE", 84, 89], ["child", "ORGANISM", 114, 119], ["antitumour", "CANCER", 147, 157], ["Measles", "PROBLEM", 0, 7], ["death", "PROBLEM", 34, 39], ["death", "PROBLEM", 84, 89], ["antitumour therapy", "TREATMENT", 147, 165], ["immunosuppressed", "OBSERVATION", 97, 113]]], ["The majority of respiratory viruses are labile and by necessity most autopsies need to be delayed at least 18 hours, often much longer, in order to obtain the consent of relatives.", [["respiratory viruses", "DISEASE", 16, 35], ["respiratory viruses", "PROBLEM", 16, 35], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["respiratory viruses", "OBSERVATION", 16, 35], ["labile", "OBSERVATION_MODIFIER", 40, 46]]], ["It has already been pointed out that the ability to demonstrate the presence of virus antigen persists for longer than the ability to detect virus infectivity.", [["virus antigen", "PROTEIN", 80, 93], ["virus antigen", "PROBLEM", 80, 93], ["virus infectivity", "PROBLEM", 141, 158], ["virus", "OBSERVATION", 80, 85], ["virus", "OBSERVATION", 141, 146]]], ["Immunofluorescence has therefore become a key tool in the examination of autopsy material for the demonstration of viruses.THE USE OF RAPID DIAGNOSTIC TECHNIQUES IN FATAL INFECTIONSVirus deaths in infancy are usually due to bronchiolitis or pneumonia, the latter often being associated with a congenital abnormality.", [["deaths", "DISEASE", 187, 193], ["bronchiolitis", "DISEASE", 224, 237], ["pneumonia", "DISEASE", 241, 250], ["congenital abnormality", "DISEASE", 293, 315], ["Immunofluorescence", "TEST", 0, 18], ["the examination", "TEST", 54, 69], ["autopsy material", "TEST", 73, 89], ["viruses", "PROBLEM", 115, 122], ["bronchiolitis", "PROBLEM", 224, 237], ["pneumonia", "PROBLEM", 241, 250], ["a congenital abnormality", "PROBLEM", 291, 315], ["viruses", "OBSERVATION", 115, 122], ["FATAL", "OBSERVATION_MODIFIER", 165, 170], ["usually due to", "UNCERTAINTY", 209, 223], ["bronchiolitis", "OBSERVATION", 224, 237], ["pneumonia", "OBSERVATION", 241, 250], ["congenital", "OBSERVATION_MODIFIER", 293, 303], ["abnormality", "OBSERVATION", 304, 315]]], ["Recently, the presence of viruses has been clearly demonstrated in about 20-25 percent of \u2018cot deaths\u2019 or the sudden infant death syndrome (SIDS) (Ferris et al., 1973; Scott et al., 1978).", [["deaths", "DISEASE", 95, 101], ["sudden infant death syndrome", "DISEASE", 110, 138], ["SIDS", "DISEASE", 140, 144], ["viruses", "PROBLEM", 26, 33], ["the sudden infant death syndrome", "PROBLEM", 106, 138], ["viruses", "OBSERVATION", 26, 33]]], ["In adults influenza A is still the main virus pathogen but, here, especially in those with previously damaged lungs, bacteria may be associated.THE USE OF RAPID DIAGNOSTIC TECHNIQUES IN FATAL INFECTIONSThe presence of a virus in the lungs at autopsy does not necessarily mean that the virus was the cause of death.", [["lungs", "ANATOMY", 110, 115], ["lungs", "ANATOMY", 233, 238], ["influenza A", "DISEASE", 10, 21], ["death", "DISEASE", 308, 313], ["adults influenza A", "ORGANISM", 3, 21], ["lungs", "ORGAN", 110, 115], ["lungs", "ORGAN", 233, 238], ["adults influenza A", "PROBLEM", 3, 21], ["the main virus pathogen", "PROBLEM", 31, 54], ["previously damaged lungs", "PROBLEM", 91, 115], ["bacteria", "PROBLEM", 117, 125], ["FATAL INFECTIONS", "PROBLEM", 186, 202], ["a virus in the lungs", "PROBLEM", 218, 238], ["the virus", "PROBLEM", 281, 290], ["death", "PROBLEM", 308, 313], ["influenza", "OBSERVATION", 10, 19], ["lungs", "ANATOMY", 110, 115], ["bacteria", "OBSERVATION", 117, 125], ["FATAL", "OBSERVATION_MODIFIER", 186, 191], ["INFECTIONS", "OBSERVATION", 192, 202], ["virus", "OBSERVATION", 220, 225], ["lungs", "ANATOMY", 233, 238], ["virus", "OBSERVATION", 285, 290]]], ["It could be present because of contamination from an unrelated infection of the upper respiratory tract.", [["upper respiratory tract", "ANATOMY", 80, 103], ["infection of the upper respiratory tract", "DISEASE", 63, 103], ["upper respiratory", "ORGANISM_SUBDIVISION", 80, 97], ["tract", "ORGANISM_SUBDIVISION", 98, 103], ["contamination", "PROBLEM", 31, 44], ["an unrelated infection of the upper respiratory tract", "PROBLEM", 50, 103], ["contamination", "OBSERVATION", 31, 44], ["unrelated", "OBSERVATION_MODIFIER", 53, 62], ["infection", "OBSERVATION", 63, 72], ["upper", "ANATOMY_MODIFIER", 80, 85], ["respiratory tract", "ANATOMY", 86, 103]]], ["It is therefore essential for all deaths to be investigated by methods other than the isolation of virus in order to substantiate the aetiological role of any virus found.", [["deaths", "DISEASE", 34, 40], ["all deaths", "PROBLEM", 30, 40], ["the isolation of virus", "TREATMENT", 82, 104], ["any virus", "PROBLEM", 155, 164]]], ["In the studies already quoted pains were taken to use conventional histological investigations of the respiratory tract and supporting evidence was looked for and found in all those autopsies in which virus was identified.", [["respiratory tract", "ANATOMY", 102, 119], ["pains", "DISEASE", 30, 35], ["respiratory tract", "ORGANISM_SUBDIVISION", 102, 119], ["quoted pains", "PROBLEM", 23, 35], ["conventional histological investigations", "TEST", 54, 94], ["the respiratory tract", "PROBLEM", 98, 119], ["virus", "PROBLEM", 201, 206], ["respiratory tract", "ANATOMY", 102, 119]]], ["Immunofluorescence, too, supplies a second confirmatory tool, for by its use virus antigen can be actually seen in the alveolar and bronchiolar epithelial cells.THE USE OF RAPID DIAGNOSTIC TECHNIQUES IN FATAL INFECTIONSImmunofluorescence can therefore be used to investigate all respiratory deaths where the prospect of virus isolation is small.", [["alveolar", "ANATOMY", 119, 127], ["bronchiolar epithelial cells", "ANATOMY", 132, 160], ["respiratory deaths", "DISEASE", 279, 297], ["alveolar", "CELL", 119, 127], ["bronchiolar epithelial cells", "CELL", 132, 160], ["alveolar and bronchiolar epithelial cells", "CELL_TYPE", 119, 160], ["Immunofluorescence", "TEST", 0, 18], ["a second confirmatory tool", "TEST", 34, 60], ["virus antigen", "PROBLEM", 77, 90], ["all respiratory deaths", "PROBLEM", 275, 297], ["virus isolation", "TREATMENT", 320, 335], ["alveolar", "ANATOMY_MODIFIER", 119, 127], ["bronchiolar epithelial cells", "OBSERVATION", 132, 160], ["respiratory deaths", "OBSERVATION", 279, 297], ["virus", "OBSERVATION", 320, 325], ["small", "OBSERVATION_MODIFIER", 339, 344]]], ["Respiratory deaths in infancy and occasionally in adults can be sudden and here too immunofluorescence has an important role to play.", [["Respiratory deaths", "DISEASE", 0, 18], ["Respiratory deaths", "PROBLEM", 0, 18]]], ["Many a coroner, faced with unexpected deaths, is grateful for a report within 3-4 hours of autopsy so that other more sinister causes can be quickly eliminated, while the parents of an SIDS may be relieved of the inevitable feeling of guilt that they have experienced.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTThe immunosuppression of children and adults as part of specific therapy is now commonplace and on occasions it may be produced as an unwanted side-effect of many current drug regimens.", [["deaths", "DISEASE", 38, 44], ["SIDS", "DISEASE", 185, 189], ["children", "ORGANISM", 359, 367], ["children", "SPECIES", 359, 367], ["VIRUS INFECTION", "PROBLEM", 268, 283], ["ITS MANAGEMENT", "TREATMENT", 320, 334], ["specific therapy", "TREATMENT", 390, 406], ["many current drug regimens", "TREATMENT", 492, 518], ["INFECTION", "OBSERVATION", 274, 283], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 291, 307]]], ["Included among the drugs frequently used are vincristine, cyclophosphamide, methotrexate, 6-mercaptopurine, prednisone and azothioprine.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTIn adults these immunosuppressive measures often lead to greater risk of reinfection or reactivation with the herpes group of viruses.", [["vincristine", "CHEMICAL", 45, 56], ["cyclophosphamide", "CHEMICAL", 58, 74], ["methotrexate", "CHEMICAL", 76, 88], ["6-mercaptopurine", "CHEMICAL", 90, 106], ["prednisone", "CHEMICAL", 108, 118], ["azothioprine", "CHEMICAL", 123, 135], ["reinfection", "DISEASE", 275, 286], ["vincristine", "CHEMICAL", 45, 56], ["cyclophosphamide", "CHEMICAL", 58, 74], ["methotrexate", "CHEMICAL", 76, 88], ["6-mercaptopurine", "CHEMICAL", 90, 106], ["prednisone", "CHEMICAL", 108, 118], ["azothioprine", "CHEMICAL", 123, 135], ["vincristine", "SIMPLE_CHEMICAL", 45, 56], ["cyclophosphamide", "SIMPLE_CHEMICAL", 58, 74], ["methotrexate", "SIMPLE_CHEMICAL", 76, 88], ["6-mercaptopurine", "SIMPLE_CHEMICAL", 90, 106], ["prednisone", "SIMPLE_CHEMICAL", 108, 118], ["azothioprine", "SIMPLE_CHEMICAL", 123, 135], ["herpes", "ORGANISM", 312, 318], ["the drugs", "TREATMENT", 15, 24], ["vincristine", "TREATMENT", 45, 56], ["cyclophosphamide", "TREATMENT", 58, 74], ["methotrexate", "TREATMENT", 76, 88], ["mercaptopurine", "TREATMENT", 92, 106], ["prednisone", "TREATMENT", 108, 118], ["azothioprine", "TREATMENT", 123, 135], ["VIRUS INFECTION", "PROBLEM", 136, 151], ["ITS MANAGEMENTIn adults", "TREATMENT", 188, 211], ["these immunosuppressive measures", "TREATMENT", 212, 244], ["reinfection", "PROBLEM", 275, 286], ["reactivation", "PROBLEM", 290, 302], ["the herpes group of viruses", "PROBLEM", 308, 335], ["INFECTION", "OBSERVATION", 142, 151], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 159, 175], ["reinfection", "OBSERVATION", 275, 286]]], ["They cause a wide variety of bizarre clinical conditions ranging from ocular complications to death (Porter et al., 1972).", [["ocular", "ANATOMY", 70, 76], ["ocular complications", "DISEASE", 70, 90], ["death", "DISEASE", 94, 99], ["ocular", "ORGAN", 70, 76], ["bizarre clinical conditions", "PROBLEM", 29, 56], ["ocular complications", "PROBLEM", 70, 90], ["wide", "OBSERVATION_MODIFIER", 13, 17]]], ["Cytomegalovirus is the principal culprit but herpesvirus hominis and varicella-zoster are also frequently involved.", [["Cytomegalovirus", "DISEASE", 0, 15], ["herpesvirus hominis", "DISEASE", 45, 64], ["varicella-zoster", "DISEASE", 69, 85], ["Cytomegalovirus", "ORGANISM", 0, 15], ["herpesvirus hominis", "ORGANISM", 45, 64], ["varicella-zoster", "ORGANISM", 69, 85], ["herpesvirus hominis", "SPECIES", 45, 64], ["varicella-zoster", "SPECIES", 69, 85], ["herpesvirus hominis", "SPECIES", 45, 64], ["Cytomegalovirus", "PROBLEM", 0, 15], ["herpesvirus hominis", "PROBLEM", 45, 64], ["varicella", "PROBLEM", 69, 78], ["zoster", "PROBLEM", 79, 85], ["herpesvirus hominis", "OBSERVATION", 45, 64], ["varicella", "OBSERVATION_MODIFIER", 69, 78], ["zoster", "OBSERVATION", 79, 85]]], ["A rapid diagnosis is urgently required as survival of graft, retina or life itself depends on achieving a fine balance between the treatment and the virus infection.", [["graft", "ANATOMY", 54, 59], ["retina", "ANATOMY", 61, 67], ["infection", "DISEASE", 155, 164], ["graft", "TISSUE", 54, 59], ["retina", "MULTI-TISSUE_STRUCTURE", 61, 67], ["graft", "TREATMENT", 54, 59], ["the treatment", "TREATMENT", 127, 140], ["the virus infection", "PROBLEM", 145, 164], ["graft", "OBSERVATION", 54, 59]]], ["Moreover the increasing efficiency of the antiherpes drugs and the possible availability of interferon for clinical use in the future makes early diagnosis essential.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTThe major reason for children becoming immunosuppressed is the intensive and prolonged therapy required for the treatment of acute lymphatic leukaemia.", [["lymphatic leukaemia", "ANATOMY", 363, 382], ["acute lymphatic leukaemia", "DISEASE", 357, 382], ["interferon", "GENE_OR_GENE_PRODUCT", 92, 102], ["children", "ORGANISM", 253, 261], ["acute lymphatic leukaemia", "CANCER", 357, 382], ["interferon", "PROTEIN", 92, 102], ["children", "SPECIES", 253, 261], ["the antiherpes drugs", "TREATMENT", 38, 58], ["interferon", "TREATMENT", 92, 102], ["VIRUS INFECTION", "PROBLEM", 166, 181], ["ITS MANAGEMENT", "TREATMENT", 218, 232], ["immunosuppressed", "PROBLEM", 271, 287], ["prolonged therapy", "TREATMENT", 309, 326], ["acute lymphatic leukaemia", "PROBLEM", 357, 382], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["efficiency", "OBSERVATION_MODIFIER", 24, 34], ["INFECTION", "OBSERVATION", 172, 181], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 189, 205], ["immunosuppressed", "OBSERVATION", 271, 287], ["acute", "OBSERVATION_MODIFIER", 357, 362], ["lymphatic leukaemia", "OBSERVATION", 363, 382]]], ["Therapy not only includes the above-mentioned drugs but also radiation.", [["Therapy", "TREATMENT", 0, 7], ["drugs", "TREATMENT", 46, 51]]], ["Recent months have seen the development of techniques for the grafting of bone marrow transplants after whole-body irradiation.", [["bone marrow", "ANATOMY", 74, 85], ["body", "ANATOMY", 110, 114], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 74, 85], ["body", "ORGANISM_SUBDIVISION", 110, 114], ["the grafting", "TREATMENT", 58, 70], ["bone marrow transplants", "TREATMENT", 74, 97], ["whole-body irradiation", "TREATMENT", 104, 126], ["grafting", "OBSERVATION", 62, 70], ["bone", "ANATOMY", 74, 78], ["marrow transplants", "OBSERVATION", 79, 97]]], ["However, during the treatment the child is center highly vulnerable and susceptible to infection.", [["infection", "DISEASE", 87, 96], ["child", "ORGANISM", 34, 39], ["infection", "PROBLEM", 87, 96], ["infection", "OBSERVATION", 87, 96]]], ["Infection has therefore become the major cause of death in acute lymphatic leukaemia, the majority of these infections being associated with viruses.", [["lymphatic leukaemia", "ANATOMY", 65, 84], ["Infection", "DISEASE", 0, 9], ["death", "DISEASE", 50, 55], ["acute lymphatic leukaemia", "DISEASE", 59, 84], ["infections", "DISEASE", 108, 118], ["acute lymphatic leukaemia", "CANCER", 59, 84], ["Infection", "PROBLEM", 0, 9], ["death", "PROBLEM", 50, 55], ["acute lymphatic leukaemia", "PROBLEM", 59, 84], ["these infections", "PROBLEM", 102, 118], ["viruses", "PROBLEM", 141, 148], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["lymphatic leukaemia", "OBSERVATION", 65, 84], ["majority", "OBSERVATION_MODIFIER", 90, 98], ["infections", "OBSERVATION", 108, 118], ["viruses", "OBSERVATION", 141, 148]]], ["The viruses involved are rhinoviruses, measles, mumps, influenza, respiratory syncytial virus and the other everyday viruses which normal children easily combat.", [["measles", "DISEASE", 39, 46], ["mumps", "DISEASE", 48, 53], ["influenza", "DISEASE", 55, 64], ["respiratory syncytial virus", "DISEASE", 66, 93], ["rhinoviruses", "ORGANISM", 25, 37], ["respiratory syncytial virus", "ORGANISM", 66, 93], ["children", "ORGANISM", 138, 146], ["respiratory syncytial virus", "SPECIES", 66, 93], ["children", "SPECIES", 138, 146], ["respiratory syncytial virus", "SPECIES", 66, 93], ["rhinoviruses", "PROBLEM", 25, 37], ["measles", "PROBLEM", 39, 46], ["mumps", "PROBLEM", 48, 53], ["influenza", "PROBLEM", 55, 64], ["respiratory syncytial virus", "PROBLEM", 66, 93], ["viruses", "OBSERVATION", 4, 11], ["rhinoviruses", "OBSERVATION", 25, 37], ["respiratory syncytial virus", "OBSERVATION", 66, 93]]], ["However, children with leukaemia and under therapy can die of rhinovirus pneumonia, and most children who are infected with measles during the course of their leukaemia also die.", [["leukaemia", "ANATOMY", 23, 32], ["leukaemia", "ANATOMY", 159, 168], ["leukaemia", "DISEASE", 23, 32], ["rhinovirus pneumonia", "DISEASE", 62, 82], ["measles", "DISEASE", 124, 131], ["leukaemia", "DISEASE", 159, 168], ["children", "ORGANISM", 9, 17], ["leukaemia", "CANCER", 23, 32], ["rhinovirus", "ORGANISM", 62, 72], ["children", "ORGANISM", 93, 101], ["leukaemia", "CANCER", 159, 168], ["children", "SPECIES", 9, 17], ["children", "SPECIES", 93, 101], ["leukaemia", "PROBLEM", 23, 32], ["therapy", "TREATMENT", 43, 50], ["rhinovirus pneumonia", "PROBLEM", 62, 82], ["leukaemia", "OBSERVATION", 23, 32], ["rhinovirus", "OBSERVATION", 62, 72]]], ["In a defined study of virus infections in childhood leukaemias, their importance in morbidity and mortality has been clearly demonstrated (Craft et al., 1977, 1978, 1979).", [["childhood leukaemias", "ANATOMY", 42, 62], ["infections", "DISEASE", 28, 38], ["leukaemias", "DISEASE", 52, 62], ["childhood leukaemias", "CANCER", 42, 62], ["virus infections", "PROBLEM", 22, 38], ["childhood leukaemias", "PROBLEM", 42, 62], ["virus infections", "OBSERVATION", 22, 38], ["leukaemias", "OBSERVATION", 52, 62]]], ["The numbers of patients both in remission and relapse in whom viruses were associated with death are indicated in Table 15.", [["death", "DISEASE", 91, 96], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["death", "PROBLEM", 91, 96], ["numbers", "OBSERVATION_MODIFIER", 4, 11]]], ["A distinct feature of infectious illness in the immunosuppressed child is its unusual symptomology.", [["infectious illness", "DISEASE", 22, 40], ["child", "ORGANISM", 65, 70], ["infectious illness", "PROBLEM", 22, 40], ["distinct feature of", "UNCERTAINTY", 2, 21], ["infectious", "OBSERVATION_MODIFIER", 22, 32], ["illness", "OBSERVATION", 33, 40], ["immunosuppressed", "OBSERVATION", 48, 64]]], ["Measles is especially severe, often fatal, but seldom has a rash; respiratory syncytial virus, less often seen in childhood after 1-2 years of age, causes severe and prolonged symptoms in the older immunosuppressed child.", [["Measles", "DISEASE", 0, 7], ["rash", "DISEASE", 60, 64], ["respiratory syncytial virus", "DISEASE", 66, 93], ["respiratory syncytial virus", "ORGANISM", 66, 93], ["child", "ORGANISM", 215, 220], ["respiratory syncytial virus", "SPECIES", 66, 93], ["respiratory syncytial virus", "SPECIES", 66, 93], ["Measles", "PROBLEM", 0, 7], ["a rash", "PROBLEM", 58, 64], ["respiratory syncytial virus", "PROBLEM", 66, 93], ["severe and prolonged symptoms", "PROBLEM", 155, 184], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["fatal", "OBSERVATION_MODIFIER", 36, 41], ["rash", "OBSERVATION", 60, 64], ["respiratory", "ANATOMY", 66, 77], ["syncytial virus", "OBSERVATION", 78, 93], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["prolonged", "OBSERVATION_MODIFIER", 166, 175]]], ["On many occasions, onset of a virus infection can be sudden and severe, with death rapidly intervening.", [["infection", "DISEASE", 36, 45], ["death", "DISEASE", 77, 82], ["a virus infection", "PROBLEM", 28, 45], ["death", "PROBLEM", 77, 82], ["virus", "OBSERVATION", 30, 35], ["severe", "OBSERVATION_MODIFIER", 64, 70]]], ["Rapid diagnosis in these circumstances has become a vital procedure; it is a guide both to the amount of immunosuppressive therapy which should be given at this time and to specific antiviral treatment needed.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTThe coating of infected epithelial cells by locally produced antibody in the normal infected child has already been discussed but the position is often very different in the immunosuppressed child.", [["epithelial cells", "ANATOMY", 299, 315], ["epithelial cells", "CELL", 299, 315], ["child", "ORGANISM", 368, 373], ["child", "ORGANISM", 466, 471], ["infected epithelial cells", "CELL_TYPE", 290, 315], ["child", "SPECIES", 368, 373], ["a vital procedure", "TREATMENT", 50, 67], ["immunosuppressive therapy", "TREATMENT", 105, 130], ["antiviral treatment", "TREATMENT", 182, 201], ["VIRUS INFECTION", "PROBLEM", 209, 224], ["ITS MANAGEMENT", "TREATMENT", 261, 275], ["infected epithelial cells", "PROBLEM", 290, 315], ["immunosuppressive therapy", "OBSERVATION", 105, 130], ["INFECTION", "OBSERVATION", 215, 224], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 232, 248], ["coating", "OBSERVATION_MODIFIER", 279, 286], ["infected epithelial cells", "OBSERVATION", 290, 315], ["antibody", "OBSERVATION_MODIFIER", 336, 344], ["normal", "OBSERVATION_MODIFIER", 352, 358], ["infected", "OBSERVATION", 359, 367], ["immunosuppressed", "OBSERVATION", 449, 465]]], ["Depending on the stage of the illness and the treatment regimen, many of these children are incapable of producing an antibody response either locally in the respiratory tract or humorally.", [["respiratory tract", "ANATOMY", 158, 175], ["children", "ORGANISM", 79, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 158, 175], ["children", "SPECIES", 79, 87], ["the illness", "PROBLEM", 26, 37], ["the treatment regimen", "TREATMENT", 42, 63], ["an antibody response", "PROBLEM", 115, 135], ["illness", "OBSERVATION", 30, 37], ["respiratory tract", "ANATOMY", 158, 175]]], ["Infected cells therefore continue to be excreted for long periods of time and their appearance, when stained by immunofluorescence, is indistinguishable from that of a normal child's cells in the first day or two of an acute illness.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 183, 188], ["cells", "CELL", 9, 14], ["cells", "CELL", 183, 188], ["normal child's cells", "CELL_TYPE", 168, 188], ["Infected cells", "PROBLEM", 0, 14], ["immunofluorescence", "TEST", 112, 130], ["an acute illness", "PROBLEM", 216, 232], ["acute", "OBSERVATION_MODIFIER", 219, 224], ["illness", "OBSERVATION", 225, 232]]], ["Figure 77illustrates respiratory syncytial virus-infected cells in the secretions of a child aged 4 years with acute lymphatic leukaemia and a severe bronchitis which lasted for 64 days.", [["cells", "ANATOMY", 58, 63], ["secretions", "ANATOMY", 71, 81], ["lymphatic leukaemia", "ANATOMY", 117, 136], ["respiratory syncytial virus-infected", "DISEASE", 21, 57], ["acute lymphatic leukaemia", "DISEASE", 111, 136], ["bronchitis", "DISEASE", 150, 160], ["77illustrates respiratory syncytial virus", "ORGANISM", 7, 48], ["cells", "CELL", 58, 63], ["lymphatic leukaemia", "CANCER", 117, 136], ["infected cells", "CELL_TYPE", 49, 63], ["respiratory syncytial virus", "SPECIES", 21, 48], ["child", "SPECIES", 87, 92], ["Figure 77illustrates respiratory syncytial virus", "PROBLEM", 0, 48], ["infected cells", "PROBLEM", 49, 63], ["acute lymphatic leukaemia", "PROBLEM", 111, 136], ["a severe bronchitis", "PROBLEM", 141, 160], ["respiratory syncytial virus", "OBSERVATION", 21, 48], ["infected cells", "OBSERVATION", 49, 63], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["lymphatic leukaemia", "OBSERVATION", 117, 136], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["bronchitis", "OBSERVATION", 150, 160]]], ["It shows the number and brightness of respiratory syncytial virus-infected cells at the thirty-fifth day of illness\u2014there is no evidence whatsoever of coating.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTImmunofluorescence has also become an essential tool for diagnosing an infection which is not resolving, for controlling chemotherapy and for determining prognosis.", [["cells", "ANATOMY", 75, 80], ["respiratory syncytial virus-infected", "DISEASE", 38, 74], ["infection", "DISEASE", 296, 305], ["respiratory syncytial virus", "ORGANISM", 38, 65], ["cells", "CELL", 75, 80], ["infected cells", "CELL_TYPE", 66, 80], ["respiratory syncytial virus", "SPECIES", 38, 65], ["respiratory syncytial virus", "PROBLEM", 38, 65], ["infected cells", "PROBLEM", 66, 80], ["VIRUS INFECTION", "PROBLEM", 159, 174], ["an infection", "PROBLEM", 293, 305], ["chemotherapy", "TREATMENT", 346, 358], ["respiratory syncytial virus", "OBSERVATION", 38, 65], ["infected cells", "OBSERVATION", 66, 80], ["no evidence whatsoever", "UNCERTAINTY", 125, 147], ["coating", "OBSERVATION", 151, 158], ["INFECTION", "OBSERVATION", 165, 174], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 182, 198], ["infection", "OBSERVATION", 296, 305]]], ["Measles is particularly difficult to diagnose in the immunosuppressed child because of its very varied picture.", [["Measles", "DISEASE", 0, 7], ["Measles", "PROBLEM", 0, 7], ["immunosuppressed", "OBSERVATION", 53, 69]]], ["It is possible that early treatment with interferon might alter what has, up till now, been a very gloomy prognosis; the use of rapid diagnosis and interferon therapy in measles is currently being investigated in a multicentred study.", [["measles", "DISEASE", 170, 177], ["interferon", "GENE_OR_GENE_PRODUCT", 41, 51], ["interferon", "PROTEIN", 41, 51], ["interferon", "PROTEIN", 148, 158], ["interferon", "TREATMENT", 41, 51], ["rapid diagnosis", "TREATMENT", 128, 143], ["interferon therapy", "TREATMENT", 148, 166], ["a multicentred study", "TEST", 213, 233]]], ["However, the key to any successful chemotherapy must lie in early diagnosis, and the screening of secretions for respiratory viruses even in mild infections should include a test for measles.", [["secretions", "ANATOMY", 98, 108], ["respiratory", "ANATOMY", 113, 124], ["respiratory viruses", "DISEASE", 113, 132], ["infections", "DISEASE", 146, 156], ["measles", "DISEASE", 183, 190], ["secretions", "ORGANISM_SUBDIVISION", 98, 108], ["any successful chemotherapy", "TREATMENT", 20, 47], ["the screening", "TEST", 81, 94], ["secretions", "PROBLEM", 98, 108], ["respiratory viruses", "PROBLEM", 113, 132], ["mild infections", "PROBLEM", 141, 156], ["a test", "TEST", 172, 178], ["measles", "PROBLEM", 183, 190], ["mild", "OBSERVATION_MODIFIER", 141, 145], ["infections", "OBSERVATION", 146, 156]]], ["Immunofluorescence enables this to be done.", [["Immunofluorescence", "TEST", 0, 18]]], ["In the normal child with measles, infected cells, including giant cells, are rarely seen after the third day of rash (McQuillin et al., 1976).", [["cells", "ANATOMY", 43, 48], ["giant cells", "ANATOMY", 60, 71], ["measles, infected", "DISEASE", 25, 42], ["rash", "DISEASE", 112, 116], ["child", "ORGANISM", 14, 19], ["cells", "CELL", 43, 48], ["giant cells", "CELL", 60, 71], ["infected cells", "CELL_TYPE", 34, 48], ["giant cells", "CELL_TYPE", 60, 71], ["child", "SPECIES", 14, 19], ["measles", "PROBLEM", 25, 32], ["infected cells", "PROBLEM", 34, 48], ["giant cells", "PROBLEM", 60, 71], ["rash", "PROBLEM", 112, 116], ["normal", "OBSERVATION", 7, 13], ["infected cells", "OBSERVATION", 34, 48], ["giant cells", "OBSERVATION", 60, 71]]], ["The picture is totally different in the immunosuppressed child with measles.", [["measles", "DISEASE", 68, 75], ["child", "ORGANISM", 57, 62], ["child", "SPECIES", 57, 62], ["measles", "PROBLEM", 68, 75], ["totally different", "OBSERVATION_MODIFIER", 15, 32], ["immunosuppressed", "OBSERVATION", 40, 56]]], ["In these circumstances the secretions are loaded with giant cells which continue to be excreted, usually until the child dies (Pullan et al., 1976).", [["secretions", "ANATOMY", 27, 37], ["giant cells", "ANATOMY", 54, 65], ["secretions", "ORGANISM_SUBSTANCE", 27, 37], ["giant cells", "CELL", 54, 65], ["giant cells", "CELL_TYPE", 54, 65], ["giant cells", "PROBLEM", 54, 65], ["secretions", "OBSERVATION", 27, 37], ["giant cells", "OBSERVATION", 54, 65]]], ["These virus- loaded giant cells are far more numerous and observed for a far longer period than those which occur in the normal child even at the height of his rash.", [["giant cells", "ANATOMY", 20, 31], ["rash", "DISEASE", 160, 164], ["giant cells", "CELL", 20, 31], ["child", "ORGANISM", 128, 133], ["virus- loaded giant cells", "CELL_TYPE", 6, 31], ["These virus- loaded giant cells", "PROBLEM", 0, 31], ["his rash", "PROBLEM", 156, 164], ["giant cells", "OBSERVATION", 20, 31], ["more numerous", "OBSERVATION_MODIFIER", 40, 53], ["normal", "OBSERVATION", 121, 127], ["rash", "OBSERVATION", 160, 164]]], ["Figure 78illustrates the appearance of such a giant cell on the twenty- first day of a measles illness that had become complicated by the development of an interstitial pneumonia.", [["giant cell", "ANATOMY", 46, 56], ["interstitial", "ANATOMY", 156, 168], ["measles illness", "DISEASE", 87, 102], ["interstitial pneumonia", "DISEASE", 156, 178], ["giant cell", "CELL", 46, 56], ["a giant cell", "PROBLEM", 44, 56], ["a measles illness", "PROBLEM", 85, 102], ["an interstitial pneumonia", "PROBLEM", 153, 178], ["giant cell", "OBSERVATION", 46, 56], ["interstitial", "ANATOMY_MODIFIER", 156, 168], ["pneumonia", "OBSERVATION", 169, 178]]], ["Plate 18 illustrates a giant cell in a lung impression smear of a leukaemic child who died with measles pneumonitis.", [["giant cell", "ANATOMY", 23, 33], ["lung", "ANATOMY", 39, 43], ["leukaemic", "ANATOMY", 66, 75], ["leukaemic", "DISEASE", 66, 75], ["measles pneumonitis", "DISEASE", 96, 115], ["giant cell", "CELL", 23, 33], ["lung", "ORGAN", 39, 43], ["leukaemic", "CANCER", 66, 75], ["child", "ORGANISM", 76, 81], ["Plate", "TEST", 0, 5], ["a giant cell", "PROBLEM", 21, 33], ["measles pneumonitis", "PROBLEM", 96, 115], ["giant cell", "OBSERVATION", 23, 33], ["lung", "ANATOMY", 39, 43], ["leukaemic", "OBSERVATION_MODIFIER", 66, 75], ["pneumonitis", "OBSERVATION", 104, 115]]], ["There is every hope that the immunofluorescent techniques will not only simplify the diagnosis of these cases but be a guide to the effect of interferon in the ongoing coded trials.VIRUS INFECTION IN THE IMMUNOSUPPRESSED PATIENT AND ITS MANAGEMENTAs long as immunosuppressive therapy remains an integral part of medical treatment, rapid virus diagnosis must be relied upon as the method of controlling the devastating illnesses caused by relatively innocuous viruses which now prevent the full realization of the improving prognoses in childhood malignancy.FREQUENTLY OCCURRING VIRUSES PRODUCING UNUSUAL SYMPTOMSIn the previous section it was emphasized that ordinary virus infections may, in the immunosuppressed patient, present with unusual clinical features which may make diagnosis difficult.", [["malignancy", "DISEASE", 546, 556], ["infections", "DISEASE", 674, 684], ["interferon", "GENE_OR_GENE_PRODUCT", 142, 152], ["malignancy", "CANCER", 546, 556], ["patient", "ORGANISM", 714, 721], ["interferon", "PROTEIN", 142, 152], ["patient", "SPECIES", 714, 721], ["the immunofluorescent techniques", "TEST", 25, 57], ["interferon", "TREATMENT", 142, 152], ["VIRUS INFECTION", "PROBLEM", 181, 196], ["ITS MANAGEMENTAs", "TREATMENT", 233, 249], ["immunosuppressive therapy", "TREATMENT", 258, 283], ["medical treatment", "TREATMENT", 312, 329], ["rapid virus diagnosis", "PROBLEM", 331, 352], ["the devastating illnesses", "PROBLEM", 402, 427], ["relatively innocuous viruses", "PROBLEM", 438, 466], ["childhood malignancy", "PROBLEM", 536, 556], ["ordinary virus infections", "PROBLEM", 659, 684], ["INFECTION", "OBSERVATION", 187, 196], ["IMMUNOSUPPRESSED", "OBSERVATION_MODIFIER", 204, 220], ["improving", "OBSERVATION_MODIFIER", 513, 522], ["malignancy", "OBSERVATION", 546, 556], ["VIRUSES", "OBSERVATION", 578, 585]]], ["Frequently occurring viruses in normal children may produce unusual symptoms and therefore be difficult to identify; rapid diagnostic methods in these circumstances may be invaluable.", [["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["unusual symptoms", "PROBLEM", 60, 76], ["viruses", "OBSERVATION", 21, 28]]], ["Three of these viruses will serve to illustrate this problem.FREQUENTLY OCCURRING VIRUSES PRODUCING UNUSUAL SYMPTOMSMeasles usually commences with a severe coryza although the rash may not appear for a few days.", [["coryza", "DISEASE", 156, 162], ["rash", "DISEASE", 176, 180], ["these viruses", "PROBLEM", 9, 22], ["a severe coryza", "PROBLEM", 147, 162], ["the rash", "PROBLEM", 172, 180], ["viruses", "OBSERVATION", 15, 22], ["VIRUSES", "OBSERVATION", 82, 89]]], ["It is important to exclude these children from the community at this highly infectious stage.", [["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["infectious", "OBSERVATION", 76, 86]]], ["Measles rashes may be modified by prophylactic vaccines and, moreover, be difficult to recognize in the coloured child.", [["Measles rashes", "DISEASE", 0, 14], ["child", "ORGANISM", 113, 118], ["Measles rashes", "PROBLEM", 0, 14], ["prophylactic vaccines", "TREATMENT", 34, 55]]], ["The latter point is of great importance in developing countries where measles can be a devastating illness and in the UK where there has been a substantial increase in the coloured child population.FREQUENTLY OCCURRING VIRUSES PRODUCING UNUSUAL SYMPTOMSInfluenza A is present in the community most winters and frequently reaches epidemic proportions.", [["measles", "DISEASE", 70, 77], ["measles", "ORGANISM", 70, 77], ["a devastating illness", "PROBLEM", 85, 106], ["the coloured child population", "PROBLEM", 168, 197], ["great", "OBSERVATION_MODIFIER", 23, 28], ["substantial", "OBSERVATION_MODIFIER", 144, 155], ["increase", "OBSERVATION_MODIFIER", 156, 164], ["coloured", "OBSERVATION_MODIFIER", 172, 180], ["VIRUSES", "OBSERVATION", 219, 226], ["UNUSUAL", "OBSERVATION_MODIFIER", 237, 244], ["SYMPTOMSInfluenza", "OBSERVATION", 245, 262]]], ["Normally the diagnosis of influenza A is self-evident with a symptomatology which all have experienced.", [["influenza", "DISEASE", 26, 35], ["influenza A", "PROBLEM", 26, 37], ["a symptomatology", "PROBLEM", 59, 75], ["influenza", "OBSERVATION", 26, 35]]], ["The child cannot usually complain in a succinct manner though it is now known that he is frequently infected by the virus.", [["child", "ORGANISM", 4, 9], ["child", "SPECIES", 4, 9], ["the virus", "PROBLEM", 112, 121]]], ["The most frequent form of presentation for influenza A in the young child is a febrile convulsion, a symptom still not considered of viral origin by many physicians because respiratory symptoms and signs are often minimal or absent.", [["respiratory", "ANATOMY", 173, 184], ["influenza A", "DISEASE", 43, 54], ["febrile convulsion", "DISEASE", 79, 97], ["child", "SPECIES", 68, 73], ["influenza", "PROBLEM", 43, 52], ["a febrile convulsion", "PROBLEM", 77, 97], ["a symptom", "PROBLEM", 99, 108], ["respiratory symptoms", "PROBLEM", 173, 193], ["most frequent", "OBSERVATION_MODIFIER", 4, 17]]], ["Immunofluorescence can diagnose influenza A in the cells of these childrens\u2019 secretions very readily (Brocklebank et al., 1972).FREQUENTLY OCCURRING VIRUSES PRODUCING UNUSUAL SYMPTOMSSimilarly, abdominal pain in childhood may be of viral origin.", [["cells", "ANATOMY", 51, 56], ["abdominal", "ANATOMY", 194, 203], ["abdominal pain", "DISEASE", 194, 208], ["cells", "CELL", 51, 56], ["abdominal", "ORGANISM_SUBDIVISION", 194, 203], ["Immunofluorescence", "TEST", 0, 18], ["influenza", "PROBLEM", 32, 41], ["UNUSUAL SYMPTOMSSimilarly", "PROBLEM", 167, 192], ["abdominal pain", "PROBLEM", 194, 208], ["viral origin", "PROBLEM", 232, 244], ["VIRUSES", "OBSERVATION", 149, 156], ["abdominal", "ANATOMY", 194, 203], ["pain", "OBSERVATION", 204, 208], ["may be of", "UNCERTAINTY", 222, 231], ["viral origin", "OBSERVATION", 232, 244]]], ["The association of this symptom with influenza B infection was originally noted by Kerr et al. (1975).", [["influenza B infection", "DISEASE", 37, 58], ["influenza B", "ORGANISM", 37, 48], ["this symptom", "PROBLEM", 19, 31], ["influenza B infection", "PROBLEM", 37, 58], ["infection", "OBSERVATION", 49, 58]]], ["In a similar manner to influenza A in febrile convulsions, respiratory symptoms may be minimal.", [["respiratory", "ANATOMY", 59, 70], ["influenza A", "DISEASE", 23, 34], ["febrile convulsions", "DISEASE", 38, 57], ["respiratory symptoms", "DISEASE", 59, 79], ["influenza", "PROBLEM", 23, 32], ["febrile convulsions", "PROBLEM", 38, 57], ["respiratory symptoms", "PROBLEM", 59, 79], ["influenza", "OBSERVATION", 23, 32], ["minimal", "OBSERVATION_MODIFIER", 87, 94]]], ["When it is known that influenza B is prevalent rapid immunofluorescence diagnostic techniques could prevent unnecessary appendicectomies.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYMany viruses are difficult to culture in the laboratory and one example\u2014measles\u2014has been considered already.", [["influenza B", "DISEASE", 22, 33], ["influenza B", "ORGANISM", 22, 33], ["influenza", "PROBLEM", 22, 31], ["unnecessary appendicectomies", "TREATMENT", 108, 136], ["VIRUSES", "PROBLEM", 137, 144], ["THE LABORATORYMany viruses", "PROBLEM", 171, 197], ["culture", "TEST", 215, 222], ["viruses", "OBSERVATION", 190, 197]]], ["In measles, rapid immunofluorescent diagnosis is simple and highly sensitive from 2-3 days before the eruption to 2-3 days afterwards; this technique has therefore become the method of choice.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYParainfluenza virus types 4a and 4b are slow growing and the conditions for the haemadsorption technique, necessary for their screening, variable.", [["measles", "DISEASE", 3, 10], ["rapid immunofluorescent diagnosis", "TEST", 12, 45], ["the eruption", "PROBLEM", 98, 110], ["this technique", "TREATMENT", 135, 149], ["VIRUSES", "PROBLEM", 192, 199], ["slow growing", "PROBLEM", 280, 292], ["the haemadsorption technique", "TEST", 316, 344], ["their screening", "TEST", 360, 375], ["slow", "OBSERVATION_MODIFIER", 280, 284], ["growing", "OBSERVATION_MODIFIER", 285, 292]]], ["Their diagnosis by directly staining virus-infected nasopharyngeal cells by immunofluorescence is easily accomplished, provided suitable reagents are available, and should prove to be the method of choice.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYSimilarly, coronaviruses probably play an important role in human respiratory infection but their cultivation and identification at this stage can only be considered a research procedure because of the cumbersome and insensitive techniques available.", [["nasopharyngeal cells", "ANATOMY", 52, 72], ["respiratory", "ANATOMY", 319, 330], ["respiratory infection", "DISEASE", 319, 340], ["nasopharyngeal cells", "CELL", 52, 72], ["coronaviruses", "ORGANISM", 264, 277], ["human", "ORGANISM", 313, 318], ["infected nasopharyngeal cells", "CELL_TYPE", 43, 72], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 313, 318], ["directly staining virus", "PROBLEM", 19, 42], ["infected nasopharyngeal cells", "PROBLEM", 43, 72], ["immunofluorescence", "TEST", 76, 94], ["coronaviruses", "PROBLEM", 264, 277], ["human respiratory infection", "PROBLEM", 313, 340], ["their cultivation", "TEST", 345, 362], ["a research procedure", "TREATMENT", 419, 439], ["infected", "OBSERVATION_MODIFIER", 43, 51], ["nasopharyngeal cells", "OBSERVATION", 52, 72], ["respiratory", "ANATOMY", 319, 330], ["infection", "OBSERVATION", 331, 340]]], ["Antisera were prepared against two of these viruses known to be associated with human illness, OC38 and 229E, and used to identify these agents in cells shed from the respiratory tract of human volunteers who had been previously inoculated with them.", [["cells", "ANATOMY", 147, 152], ["respiratory tract", "ANATOMY", 167, 184], ["human illness", "DISEASE", 80, 93], ["Antisera", "ORGANISM_SUBSTANCE", 0, 8], ["human", "ORGANISM", 80, 85], ["cells", "CELL", 147, 152], ["respiratory tract", "ORGANISM_SUBDIVISION", 167, 184], ["human", "ORGANISM", 188, 193], ["volunteers", "ORGANISM", 194, 204], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 188, 193], ["Antisera", "TREATMENT", 0, 8], ["these viruses", "PROBLEM", 38, 51], ["human illness", "PROBLEM", 80, 93], ["viruses", "OBSERVATION", 44, 51], ["respiratory tract", "ANATOMY", 167, 184]]], ["Figure 79shows the appearance of a cell infected with OC38 in an NPS.", [["cell", "ANATOMY", 35, 39], ["cell", "CELL", 35, 39], ["a cell infected", "PROBLEM", 33, 48], ["an NPS", "TREATMENT", 62, 68], ["cell", "OBSERVATION", 35, 39], ["infected", "OBSERVATION_MODIFIER", 40, 48], ["NPS", "OBSERVATION_MODIFIER", 65, 68]]], ["Virus- infected cells were only found in those volunteers with symptoms (McIntosh et al., 1978).", [["cells", "ANATOMY", 16, 21], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 16, 21], ["volunteers", "ORGANISM", 47, 57], ["Virus- infected cells", "CELL_TYPE", 0, 21], ["Virus", "PROBLEM", 0, 5], ["infected cells", "PROBLEM", 7, 21], ["symptoms", "PROBLEM", 63, 71], ["infected cells", "OBSERVATION", 7, 21]]], ["These experiments clearly demonstrate that the now routine method of identifying respiratory viruses by immunofluorescence in cells shed into the respiratory tract would be suitable for coronaviruses and is at this stage the only effective method for their rapid diagnosis.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYThe new group, rotaviruses, is now known to be responsible for 40 per cent of acute diarrhoea in infants and children (Birch et al., 1977).VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYThe diagnosis of infection by this virus is usually made at present by electron microscopy, enzyme-linked immunosorbent assay (ELISA) or immunofluorescence.", [["cells", "ANATOMY", 126, 131], ["respiratory tract", "ANATOMY", 146, 163], ["diarrhoea", "DISEASE", 405, 414], ["infection", "DISEASE", 525, 534], ["cells", "CELL", 126, 131], ["respiratory tract", "ORGANISM_SUBDIVISION", 146, 163], ["coronaviruses", "ORGANISM", 186, 199], ["rotaviruses", "ORGANISM", 336, 347], ["infants", "ORGANISM", 418, 425], ["children", "ORGANISM", 430, 438], ["infants", "SPECIES", 418, 425], ["children", "SPECIES", 430, 438], ["respiratory viruses", "PROBLEM", 81, 100], ["immunofluorescence in cells", "PROBLEM", 104, 131], ["coronaviruses", "PROBLEM", 186, 199], ["rotaviruses", "PROBLEM", 336, 347], ["acute diarrhoea", "PROBLEM", 399, 414], ["infection", "PROBLEM", 525, 534], ["this virus", "PROBLEM", 538, 548], ["electron microscopy", "TEST", 579, 598], ["enzyme", "TEST", 600, 606], ["immunosorbent assay", "TEST", 614, 633], ["ELISA", "TEST", 635, 640], ["immunofluorescence", "PROBLEM", 645, 663], ["respiratory viruses", "OBSERVATION", 81, 100], ["respiratory tract", "ANATOMY", 146, 163], ["rotaviruses", "OBSERVATION", 336, 347], ["acute", "OBSERVATION_MODIFIER", 399, 404], ["diarrhoea", "OBSERVATION", 405, 414], ["infection", "OBSERVATION", 525, 534]]], ["However, the first method enables the virus to be identified within an hour but an electron microscope is not available to all nor is it particularly suitable for handling large numbers of specimens.", [["specimens", "ANATOMY", 189, 198], ["specimens", "CANCER", 189, 198], ["the virus", "PROBLEM", 34, 43], ["an electron microscope", "TEST", 80, 102]]], ["Although the virus has not as yet been cultured it is known to penetrate tissue culture cells and give one abortive cycle.", [["tissue culture cells", "ANATOMY", 73, 93], ["tissue culture cells", "CELL", 73, 93], ["tissue culture cells", "CELL_TYPE", 73, 93], ["the virus", "PROBLEM", 9, 18], ["tissue culture cells", "TEST", 73, 93], ["virus", "OBSERVATION", 13, 18]]], ["Tissue cultures may be so infected and examined the following day by immunofluorescence.", [["Tissue cultures", "ANATOMY", 0, 15], ["Tissue cultures", "CELL", 0, 15], ["Tissue cultures", "TEST", 0, 15], ["infected", "PROBLEM", 26, 34], ["infected", "OBSERVATION", 26, 34]]], ["The sensitivity of the method may be enhanced by centrifugation of faecalsupernatant on to the tissue culture cells at low speeds (Banatvala et al., 1975); the presence of trypsin has also made the method more sensitive by increasing the number of infective centres in the first cycle (Moosai et al., 1979).VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYThe diagnosis of hepatitis B can now be made rapidly and effectively by many techniques and immunofluorescence has no part to play at this stage.", [["tissue culture cells", "ANATOMY", 95, 115], ["hepatitis B", "DISEASE", 372, 383], ["faecalsupernatant", "SIMPLE_CHEMICAL", 67, 84], ["tissue culture cells", "CELL", 95, 115], ["trypsin", "GENE_OR_GENE_PRODUCT", 172, 179], ["hepatitis B", "ORGANISM", 372, 383], ["tissue culture cells", "CELL_LINE", 95, 115], ["trypsin", "PROTEIN", 172, 179], ["the tissue culture cells", "TEST", 91, 115], ["trypsin", "PROBLEM", 172, 179], ["hepatitis B", "PROBLEM", 372, 383], ["immunofluorescence", "TEST", 447, 465], ["infective", "OBSERVATION", 248, 257], ["hepatitis", "OBSERVATION", 372, 381]]], ["However, though rarely a matter of rapid diagnosis, liver biopsy material can be effectively examined by immunofluorescence (Brzosko et al., 1973).", [["liver biopsy", "ANATOMY", 52, 64], ["liver biopsy material", "MULTI-TISSUE_STRUCTURE", 52, 73], ["liver biopsy material", "TEST", 52, 73], ["liver", "ANATOMY", 52, 57], ["biopsy", "OBSERVATION", 58, 64]]], ["Until the viruses of hepatitis A, non-A and non-B are more clearly defined it is difficult to see a role for immunofluorescence in their diagnosis.VIRUSES DIFFICULT TO CULTIVATE IN THE LABORATORYThe examples only serve to illustrate how immunofluorescence may be used to identify viruses for which current culture techniques are inefficient and at the same time provide the clinician with a rapid aetiological diagnosis.Influenza A ::: PREVENTION OF WARD CROSS-INFECTION WITH VIRUSESInfluenza A also plays an important role in cross-infection.", [["hepatitis A", "DISEASE", 21, 32], ["Influenza", "DISEASE", 420, 429], ["hepatitis A", "ORGANISM", 21, 32], ["non-A", "CANCER", 34, 39], ["non-B", "CELL", 44, 49], ["hepatitis A", "SPECIES", 21, 32], ["hepatitis A", "PROBLEM", 21, 32], ["immunofluorescence", "TEST", 109, 127], ["viruses", "PROBLEM", 280, 287], ["current culture techniques", "TEST", 298, 324], ["Influenza", "PROBLEM", 420, 429], ["viruses", "OBSERVATION", 10, 17], ["hepatitis", "OBSERVATION", 21, 30], ["INFECTION", "OBSERVATION", 461, 470], ["cross-infection", "OBSERVATION", 527, 542]]], ["It would appear from Table 16 that it is relatively unimportant with fewer severe lower respiratory tract infections.", [["lower respiratory tract", "ANATOMY", 82, 105], ["respiratory tract infections", "DISEASE", 88, 116], ["lower", "ORGANISM_SUBDIVISION", 82, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 88, 105], ["fewer severe lower respiratory tract infections", "PROBLEM", 69, 116], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["lower", "ANATOMY_MODIFIER", 82, 87], ["respiratory tract", "ANATOMY", 88, 105], ["infections", "OBSERVATION", 106, 116]]], ["In fact, the latter illnesses were all pneumonias and a number of these patients died.", [["pneumonias", "DISEASE", 39, 49], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["the latter illnesses", "PROBLEM", 9, 29], ["all pneumonias", "PROBLEM", 35, 49], ["all", "OBSERVATION_MODIFIER", 35, 38], ["pneumonias", "OBSERVATION", 39, 49]]], ["The patients with influenza A infection admitted to hospital are usually older than those admitted with respiratory syncytial virus infection.", [["influenza A infection", "DISEASE", 18, 39], ["respiratory syncytial virus infection", "DISEASE", 104, 141], ["patients", "ORGANISM", 4, 12], ["influenza A", "ORGANISM", 18, 29], ["respiratory syncytial virus", "ORGANISM", 104, 131], ["patients", "SPECIES", 4, 12], ["respiratory syncytial virus", "SPECIES", 104, 131], ["influenza A infection", "PROBLEM", 18, 39], ["respiratory syncytial virus infection", "PROBLEM", 104, 141], ["influenza", "OBSERVATION", 18, 27], ["infection", "OBSERVATION", 30, 39], ["respiratory", "ANATOMY", 104, 115], ["syncytial virus", "OBSERVATION", 116, 131]]], ["The usual reason for admission is a febrile convulsion.", [["febrile convulsion", "DISEASE", 36, 54], ["a febrile convulsion", "PROBLEM", 34, 54]]], ["Frequently by the time they have been admitted to hospital they have recovered from their convulsion and have lost their fever.", [["convulsion", "DISEASE", 90, 100], ["fever", "DISEASE", 121, 126], ["their convulsion", "PROBLEM", 84, 100], ["their fever", "PROBLEM", 115, 126]]], ["Being relatively well at this stage, they run around the ward coughing and secreting virus over patients who can ill afford to acquire infections, such as patients with mucoviscidosis, congenital heart disease or leukaemia or on immunosuppressive therapy.", [["heart", "ANATOMY", 196, 201], ["leukaemia", "ANATOMY", 213, 222], ["infections", "DISEASE", 135, 145], ["mucoviscidosis", "DISEASE", 169, 183], ["congenital heart disease", "DISEASE", 185, 209], ["leukaemia", "DISEASE", 213, 222], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 155, 163], ["heart", "ORGAN", 196, 201], ["leukaemia", "CANCER", 213, 222], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 155, 163], ["the ward coughing", "PROBLEM", 53, 70], ["secreting virus", "PROBLEM", 75, 90], ["infections", "PROBLEM", 135, 145], ["mucoviscidosis", "PROBLEM", 169, 183], ["congenital heart disease", "PROBLEM", 185, 209], ["leukaemia", "PROBLEM", 213, 222], ["immunosuppressive therapy", "TREATMENT", 229, 254], ["infections", "OBSERVATION", 135, 145], ["heart", "ANATOMY", 196, 201], ["disease", "OBSERVATION", 202, 209], ["leukaemia", "OBSERVATION", 213, 222]]], ["It is the latter group of patients who fare badly when acquiring influenza A. Unfortunately, toddlers are not respecters of cubicles, which to them are no barrier.", [["influenza", "DISEASE", 65, 74], ["patients", "ORGANISM", 26, 34], ["cubicles", "CANCER", 124, 132], ["patients", "SPECIES", 26, 34]]], ["It is essential that ward staff realize that febrile convulsions in 50 per cent of cases can be of viral origin and when influenza A is prevalent the percentage of febrile convulsions due to this cause and admitted to hospital rises to very much higher than average (Stokes et al., 1976).", [["febrile convulsions", "DISEASE", 45, 64], ["influenza A", "DISEASE", 121, 132], ["convulsions", "DISEASE", 172, 183], ["febrile convulsions", "PROBLEM", 45, 64], ["viral origin", "PROBLEM", 99, 111], ["influenza", "PROBLEM", 121, 130], ["febrile convulsions", "PROBLEM", 164, 183]]], ["They must also realize the serious consequences of cross-infection in debilitated children.", [["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90]]], ["Rapid diagnosis by immunofluorescence has provided a method for identifying influenza A within 3 hours of admission to hospital.", [["influenza A", "DISEASE", 76, 87], ["influenza A", "SPECIES", 76, 87], ["immunofluorescence", "TEST", 19, 37], ["influenza", "PROBLEM", 76, 85]]], ["Now that the risks of influenza A cross-infections are known, every child with a febrile convulsion admitted to hospital when influenza A is prevalent must be examined and also confined to a cubicle until the result of the rapid diagnostic test is available.", [["febrile convulsion", "DISEASE", 81, 99], ["influenza A", "DISEASE", 126, 137], ["cubicle", "CANCER", 191, 198], ["influenza A cross-infections", "PROBLEM", 22, 50], ["a febrile convulsion", "PROBLEM", 79, 99], ["influenza A", "PROBLEM", 126, 137], ["the rapid diagnostic test", "TEST", 219, 244], ["influenza", "OBSERVATION", 22, 31]]], ["It is only in this way that tragic deaths from influenza in debilitated children can be avoided.Influenza A ::: PREVENTION OF WARD CROSS-INFECTION WITH VIRUSESParainfluenza virus is also spread easily and may cause severe lower respiratory tract infection; once again the severest infections are in debilitated children.", [["lower respiratory tract", "ANATOMY", 222, 245], ["deaths", "DISEASE", 35, 41], ["influenza", "DISEASE", 47, 56], ["Influenza", "DISEASE", 96, 105], ["lower respiratory tract infection", "DISEASE", 222, 255], ["infections", "DISEASE", 281, 291], ["children", "ORGANISM", 72, 80], ["VIRUSESParainfluenza virus", "ORGANISM", 152, 178], ["tract", "ORGANISM_SUBDIVISION", 240, 245], ["children", "ORGANISM", 311, 319], ["children", "SPECIES", 72, 80], ["children", "SPECIES", 311, 319], ["VIRUSESParainfluenza virus", "SPECIES", 152, 178], ["tragic deaths", "PROBLEM", 28, 41], ["influenza", "PROBLEM", 47, 56], ["Influenza", "PROBLEM", 96, 105], ["WARD CROSS-INFECTION", "PROBLEM", 126, 146], ["VIRUSESParainfluenza virus", "PROBLEM", 152, 178], ["severe lower respiratory tract infection", "PROBLEM", 215, 255], ["the severest infections", "PROBLEM", 268, 291], ["INFECTION", "OBSERVATION", 137, 146], ["may cause", "UNCERTAINTY", 205, 214], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["lower", "ANATOMY_MODIFIER", 222, 227], ["respiratory tract", "ANATOMY", 228, 245], ["infection", "OBSERVATION", 246, 255], ["severest", "OBSERVATION_MODIFIER", 272, 280], ["infections", "OBSERVATION", 281, 291]]], ["The toddler will again cause the problems though he is not usually as well on admission as the child following febrile convulsion; the predominant cause of admission with this group of viruses will be croup.VIRUS DIAGNOSIS IN AREAS DISTANT FROM A VIRUS LABORATORYSlides dried and fixed for staining by the fluorescent antibody technique are suitable for transporting over long distances.", [["febrile convulsion", "DISEASE", 111, 129], ["croup", "DISEASE", 201, 206], ["the problems", "PROBLEM", 29, 41], ["febrile convulsion", "PROBLEM", 111, 129], ["viruses", "PROBLEM", 185, 192], ["croup", "PROBLEM", 201, 206], ["A VIRUS LABORATORYSlides", "TREATMENT", 245, 269], ["the fluorescent antibody technique", "TREATMENT", 302, 336], ["VIRUS", "OBSERVATION", 247, 252]]], ["If preparations of secretions, scrapings, biopsies and post-mortem material, etc. are dried and fixed on slides in the usual way they can be sent to a virus laboratory to be diagnosed by immunofluorescence.", [["secretions", "ANATOMY", 19, 29], ["scrapings", "ANATOMY", 31, 40], ["biopsies", "ANATOMY", 42, 50], ["secretions", "ORGANISM_SUBSTANCE", 19, 29], ["scrapings", "TISSUE", 31, 40], ["biopsies", "TISSUE", 42, 50], ["secretions", "PROBLEM", 19, 29], ["scrapings", "TEST", 31, 40], ["biopsies", "TEST", 42, 50], ["post-mortem material", "TEST", 55, 75]]], ["Minimal resources are required at the originating centre where staff can readily be trained in the production of satisfactory slide preparations.VIRUS DIAGNOSIS IN AREAS DISTANT FROM A VIRUS LABORATORYA scheme was initiated some years ago with the Medical Research Council Nutritional Unit in Uganda.", [["A VIRUS LABORATORYA scheme", "TREATMENT", 183, 209], ["resources", "OBSERVATION", 8, 17], ["VIRUS", "OBSERVATION", 185, 190]]], ["A small batch of slides arrived by air within 18 hours and 1 child with pneumonia was shown to have a parainfluenza virus type 3 infection.", [["pneumonia", "DISEASE", 72, 81], ["parainfluenza virus type 3 infection", "DISEASE", 102, 138], ["parainfluenza virus type 3", "ORGANISM", 102, 128], ["parainfluenza virus", "SPECIES", 102, 121], ["A small batch of slides", "PROBLEM", 0, 23], ["pneumonia", "PROBLEM", 72, 81], ["a parainfluenza virus type 3 infection", "PROBLEM", 100, 138], ["small", "OBSERVATION_MODIFIER", 2, 7], ["pneumonia", "OBSERVATION", 72, 81], ["parainfluenza virus", "OBSERVATION", 102, 121], ["infection", "OBSERVATION", 129, 138]]], ["Figure 81shows how a slide of a specimen which has been well prepared and well fixed can be stained satisfactorily by immunofluorescence after having travelled a long distance.", [["specimen", "ANATOMY", 32, 40]]], ["For obvious reasons this planned investigation came to an abrupt end in Uganda but occasional specimens still arrive from tropical countries for diagnosis, for example 5 out of 8 specimens from children with pneumonia in Kenya proved to be influenza A.VIRUS DIAGNOSIS IN AREAS DISTANT FROM A VIRUS LABORATORYThese successes inspired us to attempt a similar study in an area closer to home without a virus diagnostic service (Downham et al., 1974).", [["specimens", "ANATOMY", 94, 103], ["specimens", "ANATOMY", 179, 188], ["pneumonia", "DISEASE", 208, 217], ["influenza", "DISEASE", 240, 249], ["specimens", "CANCER", 94, 103], ["specimens", "CANCER", 179, 188], ["children", "ORGANISM", 194, 202], ["children", "SPECIES", 194, 202], ["occasional specimens", "PROBLEM", 83, 103], ["pneumonia", "PROBLEM", 208, 217], ["influenza", "PROBLEM", 240, 249], ["a similar study", "TEST", 347, 362], ["pneumonia", "OBSERVATION", 208, 217]]], ["West Cumbria, a rural area, has a single hospital admitting all children from that region of the country.", [["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72]]], ["All children admitted with respiratory illness were examined and specimens taken by ward staff and sent to the local pathology laboratory which had no virus facilities.", [["respiratory", "ANATOMY", 27, 38], ["specimens", "ANATOMY", 65, 74], ["respiratory illness", "DISEASE", 27, 46], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["respiratory illness", "PROBLEM", 27, 46], ["respiratory", "ANATOMY", 27, 38], ["illness", "OBSERVATION", 39, 46]]], ["Table 17shows the results of the study.", [["the study", "TEST", 29, 38]]], ["All the respiratory viruses found in conurbations were also found in West Cumbria causing the same illnesses.VIRUS DIAGNOSIS IN AREAS DISTANT FROM A VIRUS LABORATORYHowever, their incidence was 2-3 times less.", [["respiratory viruses", "DISEASE", 8, 27], ["All the respiratory viruses", "PROBLEM", 0, 27], ["the same illnesses", "PROBLEM", 90, 108], ["A VIRUS LABORATORYHowever", "TEST", 147, 172], ["respiratory", "ANATOMY", 8, 19], ["viruses", "OBSERVATION", 20, 27]]], ["Specimens were sent by post and always reached Newcastle within 24 hours of dispatch.", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9]]], ["This proved very satisfactory for an area which previously had no virus diagnostic service and indeed under the circumstances could still be considered as rapid virus diagnosis.RAPID DIAGNOSIS IN EPIDEMIOLOGYVirus epidemiological studies in the community are difficult and expensive to perform.", [["rapid virus diagnosis", "PROBLEM", 155, 176], ["epidemiological studies", "TEST", 214, 237]]], ["Collection of specimens, their transportation under suitable conditions to the laboratory for virus isolation and the sampling of all illnesses from the most trivial to the most severe in all age groups and both sexes have proved to be the chief stumbling blocks.", [["specimens", "ANATOMY", 14, 23], ["specimens", "CANCER", 14, 23], ["Collection of specimens", "TEST", 0, 23], ["virus isolation", "TREATMENT", 94, 109], ["all illnesses", "PROBLEM", 130, 143], ["most severe", "OBSERVATION_MODIFIER", 173, 184]]], ["To obtain some idea of the virus epidemiology of an area, the total admission of patients to the hospital covering that area can be investigated.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89]]], ["Hospital admissions, however, can only reflect the viruses present in the community as only the most severely ill patients are admitted, but nevertheless much useful information can be obtained.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["the viruses", "PROBLEM", 47, 58], ["viruses", "OBSERVATION", 51, 58]]], ["Many such surveys have been carried out both in Newcastle and in various parts of the country (Report by the Medical Research Council, 1978); the most recent report gave valuable information on the occurrence of epidemics of respiratory syncytial virus, influenza A and B and parainfluenza viruses over a 6-year period, the interrelationships of these viruses and the effect of climatic conditions, and admission rates to hospital (Martin, Gardner and McQuillin, 1978).", [["respiratory syncytial virus", "DISEASE", 225, 252], ["influenza A and B and parainfluenza viruses", "DISEASE", 254, 297], ["respiratory syncytial virus", "ORGANISM", 225, 252], ["influenza A", "ORGANISM", 254, 265], ["B", "GENE_OR_GENE_PRODUCT", 270, 271], ["parainfluenza viruses", "ORGANISM", 276, 297], ["parainfluenza", "SPECIES", 276, 289], ["respiratory syncytial virus", "SPECIES", 225, 252], ["respiratory syncytial virus", "PROBLEM", 225, 252], ["influenza A", "PROBLEM", 254, 265], ["parainfluenza viruses", "PROBLEM", 276, 297], ["these viruses", "PROBLEM", 346, 359], ["respiratory syncytial virus", "OBSERVATION", 225, 252], ["parainfluenza viruses", "OBSERVATION", 276, 297], ["viruses", "OBSERVATION", 352, 359]]], ["The use of immunofluorescence for rapid virus diagnosis made possible the investigation of a greater number of patients and the diagnosis of a wider range of viruses than could be achieved by routine methods.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["immunofluorescence", "TEST", 11, 29], ["rapid virus diagnosis", "TEST", 34, 55], ["a wider range of viruses", "PROBLEM", 141, 165]]], ["The study was based on total hospital admissions and included 2311 identifications by immunofluorescence of respiratory syncytial virus, parainfluenza viruses 1, 2 and 3 and influenza A alone.RAPID DIAGNOSIS IN EPIDEMIOLOGYFurther knowledge of community virus epidemiology might well be obtained by using the immunofluorescence technique of collection and transportation as outlined for specimens coming from a distance.", [["specimens", "ANATOMY", 387, 396], ["respiratory syncytial virus", "DISEASE", 108, 135], ["parainfluenza viruses", "DISEASE", 137, 158], ["respiratory syncytial virus", "ORGANISM", 108, 135], ["parainfluenza viruses 1", "ORGANISM", 137, 160], ["3", "GENE_OR_GENE_PRODUCT", 168, 169], ["respiratory syncytial virus", "SPECIES", 108, 135], ["parainfluenza", "SPECIES", 137, 150], ["respiratory syncytial virus", "SPECIES", 108, 135], ["The study", "TEST", 0, 9], ["immunofluorescence", "TEST", 86, 104], ["respiratory syncytial virus", "PROBLEM", 108, 135], ["parainfluenza viruses", "PROBLEM", 137, 158], ["influenza", "PROBLEM", 174, 183], ["community virus epidemiology", "PROBLEM", 244, 272], ["the immunofluorescence technique", "TEST", 305, 337], ["specimens", "TEST", 387, 396], ["respiratory", "ANATOMY", 108, 119], ["syncytial virus", "OBSERVATION", 120, 135], ["parainfluenza viruses", "OBSERVATION", 137, 158]]], ["The specimens could be prepared in a small side room in the general practitioner's surgery with a nurse or health visitor collecting the specimens.", [["specimens", "ANATOMY", 4, 13], ["specimens", "ANATOMY", 137, 146]]], ["If the general practice is near the hospital the secretion itself, transported on melting ice, could be taken to the laboratory\u2014the time scale here is less critical if isolation of viruses is not attempted and only specific antigen is being identified.RAPID DIAGNOSIS IN EPIDEMIOLOGYA further epidemiological use of the fluorescent antibody technique can be confidently anticipated for assessment of live respiratory vaccines.", [["respiratory", "ANATOMY", 405, 416], ["melting ice", "TREATMENT", 82, 93], ["viruses", "PROBLEM", 181, 188], ["the fluorescent antibody technique", "TREATMENT", 316, 350], ["assessment", "TEST", 386, 396], ["live respiratory vaccines", "TREATMENT", 400, 425], ["viruses", "OBSERVATION", 181, 188]]], ["Great difficulties have been experienced in making a live respiratory syncytial virus vaccine so urgently needed for infant protection.", [["respiratory syncytial virus", "DISEASE", 58, 85], ["respiratory syncytial virus", "ORGANISM", 58, 85], ["Great difficulties", "PROBLEM", 0, 18], ["a live respiratory syncytial virus vaccine", "TREATMENT", 51, 93], ["infant protection", "TREATMENT", 117, 134]]], ["Control of such a vaccine, when produced both in the investigational stage and the practical stage as regards infectivity, spread and length of time of excretion, will prove to be invaluable.RAPID DIAGNOSIS IN EPIDEMIOLOGYOther respiratory vaccines such as influenza A are already available and their control will similarly be simplified by these techniques.RAPID DIAGNOSIS IN EPIDEMIOLOGYThe next few years may see the development of a new class of highly specific monoclonal viral antibodies.", [["monoclonal viral antibodies", "PROTEIN", 466, 493], ["a vaccine", "TREATMENT", 16, 25], ["infectivity", "PROBLEM", 110, 121], ["EPIDEMIOLOGYOther respiratory vaccines", "TREATMENT", 210, 248], ["influenza A", "PROBLEM", 257, 268], ["highly specific monoclonal viral antibodies", "PROBLEM", 450, 493], ["respiratory vaccines", "OBSERVATION", 228, 248], ["monoclonal viral antibodies", "OBSERVATION", 466, 493]]], ["Minor degrees of antigenic variation might be detected directly for viruses in patients\u2019 secretions when changes occur in current antigen types.", [["secretions", "ANATOMY", 89, 99], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["antigenic variation", "PROBLEM", 17, 36], ["viruses", "PROBLEM", 68, 75], ["degrees", "OBSERVATION_MODIFIER", 6, 13], ["antigenic variation", "OBSERVATION", 17, 36]]], ["The method might also be adapted to differentiate between vaccine and wild virus strains.", [["wild virus strains", "ORGANISM", 70, 88], ["vaccine", "TREATMENT", 58, 65], ["wild virus strains", "PROBLEM", 70, 88]]], ["The future is alive with many exciting epidemiological developments employing these newer methods.IMMUNOFLUORESCENCE AS A LABORATORY AIDIt has already been stated that wide-scale epidemiological studies on respiratory virus infections would have been almost impossible if every virus needed to be cultured and identified by conventional means.", [["respiratory virus infections", "DISEASE", 206, 234], ["respiratory virus", "ORGANISM", 206, 223], ["respiratory virus", "SPECIES", 206, 223], ["respiratory virus infections", "PROBLEM", 206, 234], ["every virus", "PROBLEM", 272, 283]]], ["Virus culture, however, still takes place mainly when the specimen submitted is unsuitable for immunofluorescence, for example when there are too few cells in the secretion or a throat swab has been submitted instead of a secretion.", [["specimen", "ANATOMY", 58, 66], ["cells", "ANATOMY", 150, 155], ["throat swab", "ANATOMY", 178, 189], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 150, 155], ["Virus culture", "TEST", 0, 13], ["the specimen", "TEST", 54, 66], ["immunofluorescence", "TEST", 95, 113], ["too few cells", "PROBLEM", 142, 155], ["the secretion", "PROBLEM", 159, 172], ["a throat swab", "TEST", 176, 189], ["throat", "ANATOMY", 178, 184]]], ["Under these circumstances, an agent causing a suspicious cytopathic effect can be immediately identified6 by immunofluorescence by scraping the cells off the culture tube, placing them on to a slide and staining in the usual way.", [["cells", "ANATOMY", 144, 149], ["culture tube", "ANATOMY", 158, 170], ["cells", "CELL", 144, 149], ["tube", "TISSUE", 166, 170], ["an agent", "TREATMENT", 27, 35], ["a suspicious cytopathic effect", "PROBLEM", 44, 74], ["immunofluorescence", "TEST", 109, 127], ["the culture tube", "TREATMENT", 154, 170], ["suspicious", "OBSERVATION_MODIFIER", 46, 56], ["cytopathic", "OBSERVATION", 57, 67], ["culture tube", "OBSERVATION", 158, 170]]], ["This identifies the agent immediately without the necessity for a long and unsatisfactory neutralization test such as for respiratory syncytial virus or for a fastidious haemadsorption inhibition test for the identification of a haemadsorption virus.IMMUNOFLUORESCENCE AS A LABORATORY AIDSince the initial description of immunofluorescence by Coons, Creech and Jones in 1941 the method has evolved from an academic technique of unreliable clinical value to a routine bedside investigation.", [["respiratory syncytial virus", "DISEASE", 122, 149], ["haemadsorption", "DISEASE", 229, 243], ["respiratory syncytial virus", "ORGANISM", 122, 149], ["respiratory syncytial virus", "SPECIES", 122, 149], ["a long and unsatisfactory neutralization test", "TEST", 64, 109], ["respiratory syncytial virus", "PROBLEM", 122, 149], ["a fastidious haemadsorption inhibition test", "TEST", 157, 200], ["a haemadsorption virus", "PROBLEM", 227, 249], ["a routine bedside investigation", "TEST", 457, 488]]]], "f994d7e4dda4fe71ec829ae1700f1c51b0d9e3dc": [["IntroductionEmerging infectious diseases are a major challenge in the 21st century.", [["infectious diseases", "DISEASE", 21, 40], ["IntroductionEmerging infectious diseases", "PROBLEM", 0, 40]]], ["In recent years, worldwide outbreaks of Ebola and Middle East Respiratory Syndrome caused great health and economic losses.", [["Ebola", "DISEASE", 40, 45], ["Middle East Respiratory Syndrome", "DISEASE", 50, 82], ["Ebola", "ORGANISM", 40, 45], ["Ebola", "SPECIES", 40, 45], ["Ebola", "PROBLEM", 40, 45], ["Middle East Respiratory Syndrome", "PROBLEM", 50, 82], ["economic losses", "PROBLEM", 107, 122], ["worldwide", "OBSERVATION_MODIFIER", 17, 26], ["outbreaks", "OBSERVATION_MODIFIER", 27, 36], ["Ebola", "OBSERVATION", 40, 45], ["Middle", "ANATOMY_MODIFIER", 50, 56], ["Respiratory Syndrome", "OBSERVATION", 62, 82], ["great", "OBSERVATION_MODIFIER", 90, 95], ["economic losses", "OBSERVATION", 107, 122]]], ["[1, 2] The ongoing new coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) outbreak is becoming a global public health problem.", [["coronavirus pneumonia", "DISEASE", 23, 44], ["Corona Virus Disease", "DISEASE", 46, 66], ["COVID-19", "CHEMICAL", 73, 81], ["coronavirus", "ORGANISM", 23, 34], ["Corona Virus", "ORGANISM", 46, 58], ["coronavirus", "SPECIES", 23, 34], ["Corona Virus Disease 2019, COVID-19", "SPECIES", 46, 81], ["The ongoing new coronavirus pneumonia", "PROBLEM", 7, 44], ["Corona Virus Disease", "PROBLEM", 46, 66], ["COVID", "TEST", 73, 78], ["a global public health problem", "PROBLEM", 104, 134], ["new", "OBSERVATION_MODIFIER", 19, 22], ["coronavirus", "OBSERVATION_MODIFIER", 23, 34], ["pneumonia", "OBSERVATION", 35, 44], ["Corona", "OBSERVATION_MODIFIER", 46, 52], ["global", "OBSERVATION_MODIFIER", 106, 112]]], ["The COVID-19 outbreak is highly similar to the severe acute respiratory syndrome (SARS) outbreak that occurred in 2003; both outbreaks were caused by new coronaviruses during time periods overlapping with the Chinese Spring Festival.", [["acute respiratory syndrome", "DISEASE", 54, 80], ["SARS", "DISEASE", 82, 86], ["The COVID", "TEST", 0, 9], ["the severe acute respiratory syndrome", "PROBLEM", 43, 80], ["SARS) outbreak", "PROBLEM", 82, 96], ["new coronaviruses", "PROBLEM", 150, 167], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["respiratory syndrome", "OBSERVATION", 60, 80], ["new", "OBSERVATION_MODIFIER", 150, 153], ["coronaviruses", "OBSERVATION", 154, 167]]], ["[3] On December 31, 2019, the Wuhan Municipal Health Committee reported 27 cases of pneumonia with an unknown cause, and many cases were traced to the Wuhan Southern China Seafood Market, which was subsequently closed on January 1, 2020.", [["pneumonia", "DISEASE", 84, 93], ["pneumonia", "PROBLEM", 84, 93], ["pneumonia", "OBSERVATION", 84, 93]]], ["[4] On January 7, 2020, laboratory tests showed that the pathogen causing the previously unexplained pneumonia was a new type of coronavirus; this pneumonia was then officially named COVID-19 by the World Health Organization.", [["pneumonia", "DISEASE", 101, 110], ["coronavirus", "DISEASE", 129, 140], ["pneumonia", "DISEASE", 147, 156], ["coronavirus", "ORGANISM", 129, 140], ["laboratory tests", "TEST", 24, 40], ["the pathogen", "PROBLEM", 53, 65], ["the previously unexplained pneumonia", "PROBLEM", 74, 110], ["coronavirus", "PROBLEM", 129, 140], ["this pneumonia", "PROBLEM", 142, 156], ["pneumonia", "OBSERVATION", 101, 110], ["new", "OBSERVATION_MODIFIER", 117, 120], ["coronavirus", "OBSERVATION", 129, 140], ["pneumonia", "OBSERVATION", 147, 156]]], ["[5, 6] The COVID-19 outbreak started in Wuhan and spread rapidly to other provinces and countries.", [["The COVID", "TEST", 7, 16]]], ["[9, 10] COVID-19 has been defined as a class B infectious disease but has been managed as a class A infectious disease by the Chinese government.", [["[9, 10] COVID-19", "CHEMICAL", 0, 16], ["infectious disease", "DISEASE", 47, 65], ["infectious disease", "DISEASE", 100, 118], ["infectious", "OBSERVATION", 47, 57], ["infectious", "OBSERVATION", 100, 110]]], ["Currently, the number of cases is still increasing, and the epidemic has not yet reached its peak; however, the situation differs from province to province.", [["increasing", "OBSERVATION_MODIFIER", 40, 50]]], ["Information on the temporal and spatial distributions of cases is important for developing targeted treatment and prevention strategies.", [["targeted treatment", "TREATMENT", 91, 109], ["prevention strategies", "TREATMENT", 114, 135]]], ["Because the return peak of Spring Festival travel is approaching, information on the possible changes in the incidence of COVID-19 in different cities will help in better preparation for disease prevention and management.", [["COVID", "TEST", 122, 127], ["disease prevention", "TREATMENT", 187, 205], ["management", "TREATMENT", 210, 220]]], ["Therefore, in this study, we investigated the temporal and spatial distributions of the early COVID-19 epidemic to reveal the dynamic changes and trends in reported cases.", [["this study", "TEST", 14, 24], ["the early COVID", "TEST", 84, 99], ["epidemic", "PROBLEM", 103, 111], ["the dynamic changes", "PROBLEM", 122, 141], ["temporal", "OBSERVATION_MODIFIER", 46, 54]]], ["These results will provide valuable information for disease prevention at both the individual and organization levels.Collection of case dataAll officially reported confirmed and suspected cases of COVID-19 and related deaths were collected from the official website of health departments or articles citing their reports.", [["COVID", "DISEASE", 198, 203], ["deaths", "DISEASE", 219, 225], ["disease prevention", "TREATMENT", 52, 70], ["case data", "TEST", 132, 141], ["COVID", "TEST", 198, 203]]], ["Case data were imported into Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and analyzed.Temporal and spatial distribution and risk analysisThe national and Hubei province shapefiles were used for ArcGIS (Environmental Systems Research Institute, Redlands, WA, USA) analysis.", [["risk analysis", "TEST", 138, 151], ["Hubei province shapefiles", "TREATMENT", 168, 193], ["spatial distribution", "OBSERVATION", 113, 133]]], ["Location data were available for 34 provinces of China and 17 prefecture level cities of Hubei province.", [["Location data", "TEST", 0, 13]]], ["The COVID-19 risk analysis was based on the Bayesian space-time model of the WinBUGS (Microsoft Corporation) software.", [["COVID-19", "DNA", 4, 12], ["WinBUGS", "DNA", 77, 84], ["The COVID-19 risk analysis", "TEST", 0, 26]]], ["[11, 12] The model was divided into three levels:Temporal and spatial distribution and risk analysis(1) Data modelTemporal and spatial distribution and risk analysisThe statistical data on low incidence were assumed to follow a Poisson distribution for the parameters n i and m it : y it \u223c Poisson (n i m it ), where the Hubei province y it was i (1, ..., 17) cities with t (1, ..., 15) days number of cases occurring during the day, and the nationwide y it was the number of cases occurring in t (1, ..., 15) days in i (1, ..., 34) provinces.", [["risk analysis", "TEST", 87, 100], ["Data modelTemporal", "TEST", 104, 122], ["risk analysis", "TEST", 152, 165], ["Temporal", "OBSERVATION_MODIFIER", 49, 57]]], ["We assumed that there was no change in the number of people at risk in each city during the study period, such that n i was the number of people at risk in the town (i), and m it was the corresponding disease risk in the city (t) per day (i).Temporal and spatial distribution and risk analysis(2) Process model m it 's logarithmic transformation of disease risk allows the relative risk to be expressed as a linear combination of spatial, temporal, and spatiotemporal interaction components.", [["people", "ORGANISM", 53, 59], ["people", "ORGANISM", 138, 144], ["people", "SPECIES", 53, 59], ["people", "SPECIES", 138, 144], ["the study", "TEST", 88, 97], ["Temporal and spatial distribution and risk analysis", "PROBLEM", 242, 293], ["disease risk", "PROBLEM", 349, 361], ["spatial, temporal, and spatiotemporal interaction components", "PROBLEM", 430, 490], ["no", "UNCERTAINTY", 26, 28], ["change", "OBSERVATION_MODIFIER", 29, 35], ["spatial", "OBSERVATION_MODIFIER", 255, 262], ["distribution", "OBSERVATION_MODIFIER", 263, 275], ["disease", "OBSERVATION", 349, 356], ["temporal", "ANATOMY_MODIFIER", 439, 447], ["spatiotemporal interaction", "OBSERVATION", 453, 479]]], ["The mathematical expression is shown in Equation (1).Temporal and spatial distribution and risk analysiswhere a is the fixed effect of the overall relative risk in the entire study area within 11 days, and t * = t -5.5 is the time span relative to the intermediate time point.", [["t", "TEST", 212, 213], ["spatial", "OBSERVATION_MODIFIER", 66, 73], ["distribution", "OBSERVATION_MODIFIER", 74, 86], ["risk analysiswhere", "OBSERVATION", 91, 109]]], ["In this model, the risk of disease is broken down into three parts: spatial change, temporal change, and space-time interaction; s i is a component of spatial variability, describing the urban disease risk relative to the risk in the entire study region over an 11-day observation period; b 0t * + y t is the change over time, which represents the overall trend of disease risk in the entire study area relative to that on the medium-term observation day, including the linear trend b 0t * and the time random effect y t ; b 0 is the time coefficient, representing the time trend in the study area; and b 1i t * allows each city to have different time-varying trends and is part of the spatiotemporal interaction.", [["disease", "PROBLEM", 27, 34], ["spatial change", "PROBLEM", 68, 82], ["temporal change", "PROBLEM", 84, 99], ["spatial variability", "PROBLEM", 151, 170], ["the urban disease risk", "PROBLEM", 183, 205], ["disease risk", "PROBLEM", 365, 377], ["disease", "OBSERVATION", 27, 34], ["temporal", "OBSERVATION_MODIFIER", 84, 92], ["change", "OBSERVATION", 93, 99], ["spatial variability", "OBSERVATION", 151, 170]]], ["Relative to b 0 , it represents the trend of local change in each city based on b 0 ; e it is used to explain local changes that cannot be explained by spatiotemporal random effects.", [["cannot be explained", "UNCERTAINTY", 129, 148]]], ["[13] (3) Parametric modelTemporal and spatial distribution and risk analysisAccording to the Besag York and Molli\u00e8 (BYM) model, [14] a spatial structure effect is defined by a prior conditional autoregressive (CAR) structure.", [["a spatial structure effect", "PROBLEM", 133, 159], ["a prior conditional autoregressive (CAR) structure", "PROBLEM", 174, 224], ["spatial distribution", "OBSERVATION", 38, 58]]], ["In this process, a spatial adjacency weight matrix needs to be defined.", [["matrix", "CELLULAR_COMPONENT", 44, 50], ["a spatial adjacency weight matrix", "TREATMENT", 17, 50]]], ["If adjacent, the weight w ij = 1; otherwise the weight w ij = 0, and the special w ij = 0.", [["the weight w ij", "TEST", 13, 28], ["the weight w ij", "TEST", 44, 59], ["the special w ij", "TREATMENT", 69, 85]]], ["Similarly, b 1i is also assumed to follow BYM characteristics.", [["b 1i", "GENE_OR_GENE_PRODUCT", 11, 15], ["b 1i", "PROTEIN", 11, 15], ["BYM", "PROTEIN", 42, 45]]], ["For the time structure effect y t , a CAR process is used, and the adjacency weight matrix in time is defined.", [["matrix", "CELLULAR_COMPONENT", 84, 90], ["CAR", "PROTEIN", 38, 41], ["a CAR process", "PROBLEM", 36, 49]]], ["For the over-discrete parameter e it , according to Gelman, the normal distribution with a mean value of 0 and a variance of s 2 e, is generally assumed and the variance of each parameter obeys Gamma (a, b).", [["a mean value", "TEST", 89, 101], ["normal", "OBSERVATION", 64, 70], ["distribution", "OBSERVATION_MODIFIER", 71, 83]]], ["[15] Based on this model, through the spatial component s i and its posterior probability, high-or low-risk cities (identified based on the average risk [a] in the entire study area) can be identified.", [["high-or low-risk cities", "PROBLEM", 91, 114], ["posterior", "ANATOMY_MODIFIER", 68, 77], ["high", "OBSERVATION_MODIFIER", 91, 95]]], ["By calculating the probability that spatial relative risk exp(s i ) is greater than 1, regions can be divided into five categories: those with probability >0.8, 0.6-0.8, 0.4-0.6, 0.2-0.4, and <0.2 are defined as hot spots, secondary hot spots, warm-spots, subcold spots, and cold-spots, respectively.", [["spatial relative risk exp", "PROBLEM", 36, 61], ["probability", "TEST", 143, 154], ["hot spots", "PROBLEM", 212, 221], ["secondary hot spots", "PROBLEM", 223, 242], ["subcold spots", "PROBLEM", 256, 269], ["hot spots", "OBSERVATION_MODIFIER", 212, 221], ["hot spots", "OBSERVATION_MODIFIER", 233, 242], ["warm", "OBSERVATION_MODIFIER", 244, 248], ["subcold spots", "OBSERVATION", 256, 269]]], ["Further, based on the probability that exp (b 1i ) is greater than 1, regions can be divided into five categories: cities with an incidence risk probability greater than 0.8 show a trend for a rapid change in risk relative to the overall change, and those with an incidence risk probability between 0.6 and 0.8 show a trend for a greater change in the incidence risk than the overall change.", [["exp (b 1i )", "TEST", 39, 50], ["an incidence risk probability", "PROBLEM", 127, 156], ["a rapid change", "PROBLEM", 191, 205], ["a greater change", "PROBLEM", 328, 344], ["greater", "OBSERVATION_MODIFIER", 330, 337], ["change", "OBSERVATION_MODIFIER", 338, 344]]], ["A value between 0.4 and 0.6 indicates that the change in the occurrence risk is the same as the overall risk change; 0.2 to 0.4, that the trend of change in disease risk is lower than the overall risk change; and less than 0.2, that the trend of change in disease risk is much lower than the overall risk.Correlation between number of cases and population migrationPopulation migration data were collected from the Baidu website (http://qianxi.baidu.com/).", [["A value", "TEST", 0, 7], ["the change in the occurrence risk", "PROBLEM", 43, 76], ["change in disease risk", "PROBLEM", 147, 169], ["change in disease risk", "PROBLEM", 246, 268], ["population migrationPopulation migration data", "TEST", 345, 390], ["disease", "OBSERVATION", 157, 164], ["lower", "OBSERVATION_MODIFIER", 173, 178], ["disease", "OBSERVATION", 256, 263]]], ["Emigration intensity was calculated using the migration index multiplied by the migration proportion in the province or city.", [["Emigration intensity", "TEST", 0, 20], ["the migration index", "TEST", 42, 61], ["migration", "OBSERVATION_MODIFIER", 46, 55], ["migration", "OBSERVATION_MODIFIER", 80, 89], ["proportion", "OBSERVATION_MODIFIER", 90, 100]]], ["Correlation analysis was performed using IBM SPSS Statistics software (version 22; International Business Machines Corporation, Armonk, NY, USA).", [["Correlation analysis", "TEST", 0, 20]]], ["P values less than 0.05 were considered statistically significant.", [["P values", "TEST", 0, 8]]], ["Pearson correlation coefficients greater than 0.2 were considered indicators of a positive correlation.ResultsTo obtain a general profile of the case distribution, we first analyzed all the available cases during this COVID-19 outbreak.", [["Pearson correlation coefficients", "TEST", 0, 32], ["this COVID", "TEST", 213, 223]]], ["[16] As shown in Figure 1A , the number of cases remained stable from January 11 to 15, 2020, and the number of new and cumulative cases increased rapidly after January 16.", [["[16] As", "CHEMICAL", 0, 7], ["stable", "OBSERVATION_MODIFIER", 58, 64], ["new", "OBSERVATION_MODIFIER", 112, 115]]], ["The first death was reported on January 10, and the number of deaths began to increase rapidly from January 17 onwards, with the cumulative number of deaths reaching 213 on January 30 [ Figure 1B ].", [["death", "DISEASE", 10, 15], ["deaths", "DISEASE", 62, 68], ["deaths", "DISEASE", 150, 156], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["rapidly", "OBSERVATION_MODIFIER", 87, 94]]], ["[6] After the nucleic acid assay became available, suspected cases waiting for laboratory confirmation could be diagnosed rapidly.", [["nucleic acid", "CHEMICAL", 14, 26], ["the nucleic acid assay", "TEST", 10, 32], ["laboratory confirmation", "TEST", 79, 102]]], ["[17] After January 19, the number of suspected cases increased rapidly, and about 40% to 50% of these suspected cases were then confirmed [ Figure 1C ].", [["increased", "OBSERVATION_MODIFIER", 53, 62], ["rapidly", "OBSERVATION_MODIFIER", 63, 70]]], ["Before January 19, the number of severe cases remained low, but they increased steadily from January 20 onwards [ Figure 1D ].", [["severe cases", "PROBLEM", 33, 45], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["low", "OBSERVATION", 55, 58]]], ["Because Wuhan is the capital city of Hubei province and the virus spread throughout the province quickly, we also analyzed the changes in number of cases in Hubei province.", [["the virus spread", "PROBLEM", 56, 72]]], ["These data indicated that both the incidence and mortality of COVID-19 disease were the highest in Hubei province.", [["COVID-19 disease", "PROBLEM", 62, 78]]], ["In general, the core outbreak area, Wuhan, and its surrounding cities had the highest number of cases, followed by cities with a high population which are transportation hubs.", [["a high population", "PROBLEM", 127, 144], ["highest", "OBSERVATION_MODIFIER", 78, 85], ["number", "OBSERVATION_MODIFIER", 86, 92]]], ["After the model converged, it was iterated another 110,000 times to obtain parameter estimations.", [["parameter estimations", "TEST", 75, 96]]], ["Generally, a ratio close to 1 indicates that the two chain iterative sequences are close, and that the model has a good convergence and is stable [ Figure 2A ].", [["good", "OBSERVATION_MODIFIER", 115, 119], ["stable", "OBSERVATION_MODIFIER", 139, 145]]], ["Using the established model and parameters, hot and cold spots were identified.", [["hot and cold spots", "PROBLEM", 44, 62]]], ["The results showed that Sichuan, Yunnan, Guizhou, Hainan, and Taiwan were hot spots, and Inner Mongolia, Gansu, Ningxia, Qinghai, Xinjiang, Chongqing, Hunan, and Guangxi were secondary hot spots.", [["hot spots", "PROBLEM", 74, 83], ["Guangxi", "TREATMENT", 162, 169], ["hot spots", "PROBLEM", 185, 194], ["Inner Mongolia", "ANATOMY", 89, 103]]], ["Through the analysis, b 0 was estimated to be 0.4604, that is, the disease risk on the following day was found to be approximately 1.585 times higher than that on the previous day.", [["the analysis", "TEST", 8, 20], ["the disease risk", "PROBLEM", 63, 79], ["disease", "OBSERVATION", 67, 74]]], ["As shown in Figure 2D , Heilongjiang, Hebei, Beijing, Tianjin, Xinjiang, Ningxia, Jiangsu, Hunan, Taiwan, and Hainan showed a faster increase in the number of cases than was observed overall in the country.", [["a faster increase", "PROBLEM", 124, 141], ["faster", "OBSERVATION_MODIFIER", 126, 132], ["increase", "OBSERVATION_MODIFIER", 133, 141]]], ["The increase in the number of cases in Jilin, Liaoning, Shaanxi, Guangxi, and Fujian provinces also occurred relatively fast [Supplementary Table 1 , http://links.lww.com/CM9/A210].", [["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["The increase in other provinces was consistent with or lower than the overall national trend [ Figure 2D ].ResultsSince Hubei province had the highest number of cases, we analyzed the temporal and spatial distribution in different cities of Hubei province.", [["increase", "OBSERVATION_MODIFIER", 4, 12], ["consistent with", "UNCERTAINTY", 36, 51], ["temporal", "OBSERVATION_MODIFIER", 184, 192], ["spatial", "OBSERVATION_MODIFIER", 197, 204], ["distribution", "OBSERVATION_MODIFIER", 205, 217]]], ["The spatial convergence analysis had 100,000 iterations [ Figure 3A ].", [["The spatial convergence analysis", "TEST", 0, 32]]], ["Hot spots were identified in the east regions and cold spots were identified in the west regions [ Figure 3B ].", [["Hot spots", "PROBLEM", 0, 9], ["cold spots", "PROBLEM", 50, 60], ["spots", "OBSERVATION", 4, 9], ["east", "ANATOMY_MODIFIER", 33, 37], ["regions", "ANATOMY_MODIFIER", 38, 45], ["cold spots", "OBSERVATION", 50, 60]]], ["The overall temporal trend in the change in the number of cases was calculated using the model.", [["overall", "OBSERVATION_MODIFIER", 4, 11], ["temporal", "OBSERVATION_MODIFIER", 12, 20], ["trend", "OBSERVATION_MODIFIER", 21, 26], ["change", "OBSERVATION_MODIFIER", 34, 40]]], ["Other cities had a growth slower than the overall growth in the province [Supplementary Table 2 , http://links.lww.com/CM9/ A210].", [["growth", "OBSERVATION_MODIFIER", 19, 25], ["slower", "OBSERVATION_MODIFIER", 26, 32], ["growth", "OBSERVATION_MODIFIER", 50, 56]]], ["The increase rate in Hubei province (1.960) was higher than that in the whole country (1.585), indicating that the rate of increase in Hubei province was significantly higher than that in other provinces in China.ResultsThe outbreak started from Wuhan, and nearly all early cases were derived from this city, which is located in Hubei province.", [["The increase rate", "PROBLEM", 0, 17], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["rate", "OBSERVATION_MODIFIER", 13, 17], ["increase", "OBSERVATION_MODIFIER", 123, 131], ["significantly", "OBSERVATION_MODIFIER", 154, 167], ["higher", "OBSERVATION_MODIFIER", 168, 174]]], ["Because the outbreak occurred just before the Spring Festival, large-scale population migration during this period influenced the subsequent epidemic.", [["the outbreak", "PROBLEM", 8, 20], ["large-scale population migration", "TREATMENT", 63, 95], ["large", "OBSERVATION_MODIFIER", 63, 68], ["epidemic", "OBSERVATION_MODIFIER", 141, 149]]], ["Wuhan city was under lockdown on January 23, and after that, population migration was greatly inhibited.", [["population migration", "PROBLEM", 61, 81]]], ["As observed in 2019, high population migration occurred on January 31; the timely city lockdown prevented a subsequent outbreak burst.", [["high population migration", "PROBLEM", 21, 46], ["a subsequent outbreak burst", "PROBLEM", 106, 133], ["high", "OBSERVATION_MODIFIER", 21, 25], ["population", "OBSERVATION_MODIFIER", 26, 36], ["migration", "OBSERVATION_MODIFIER", 37, 46], ["outbreak burst", "OBSERVATION", 119, 133]]], ["We analyzed the migration into and out of Wuhan city and Hubei province.", [["migration", "OBSERVATION_MODIFIER", 16, 25]]], ["More people migrated out of Wuhan than into the city [ Figure 4C ].", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["To analyze the correlation between the number of cases and the emigration in Wuhan city and Hubei province, population migration data were collected from Baidu Qianxi.", [["population migration data", "TEST", 108, 133]]], ["Although we do not know the exact number of people emigrating from Wuhan, 5 million is an astonishing number, considering that each individual may be a potential virus carrier.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["a potential virus carrier", "PROBLEM", 150, 175]]], ["If no control measures were implemented, the number of cases would exponentially increase.", [["control measures", "TREATMENT", 6, 22], ["increase", "OBSERVATION_MODIFIER", 81, 89]]], ["Of the 5 million emigrants, 74.22% emigrated to other cities of Hubei province [Supplementary Because the outbreak duration overlaps with the Spring Festival transport waves, large-scale migration will be a strong determinant of the characteristics of this outbreak.", [["large-scale migration", "TREATMENT", 175, 196], ["this outbreak", "PROBLEM", 252, 265], ["large", "OBSERVATION_MODIFIER", 175, 180]]], ["We analyzed the migration in the 3 days before the Spring cities with high immigration were relatively scattered.", [["migration", "OBSERVATION_MODIFIER", 16, 25], ["high immigration", "OBSERVATION", 70, 86], ["scattered", "OBSERVATION_MODIFIER", 103, 112]]], ["Chongqing experienced the highest immigration, accounting for 1.50% of the total number of immigrants [ Figure 4 ].", [["highest", "OBSERVATION_MODIFIER", 26, 33], ["immigration", "OBSERVATION", 34, 45]]], ["As immigrants will be traveling back to work after the Spring Festival, the cities showing high \"emigration\" may be at a high risk of another wave of new cases owing to the return of the migrants.DiscussionCOVID-19 is causing great public health and economic losses in China.", [["economic losses in China", "PROBLEM", 250, 274]]], ["The number of cases has increased rapidly, with over 70% coming from Hubei province.", [["increased", "OBSERVATION_MODIFIER", 24, 33], ["rapidly", "OBSERVATION_MODIFIER", 34, 41]]], ["[16, 19] As of January 30, the number of cases has exceeded the total number of cases of the SARS-CoV outbreak.", [["SARS", "DISEASE", 93, 97], ["SARS-CoV", "SPECIES", 93, 101], ["the SARS", "PROBLEM", 89, 97]]], ["[20] Until February 15, 2020, the cumulative number of confirmed cases was 70,533, nearly ten times that noted during the SARS outbreak.", [["SARS", "DISEASE", 122, 126], ["the SARS outbreak", "PROBLEM", 118, 135]]], ["Prevention and control of the outbreak has required concerted action from the whole population of China.", [["the outbreak", "PROBLEM", 26, 38]]], ["Although all individuals have participated in the campaign against the outbreak, people in areas with a low number of cases assumed that they were safe from the disease.", [["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["the disease", "PROBLEM", 157, 168], ["disease", "OBSERVATION", 161, 168]]], ["Therefore, awareness of high-risk regions is important for preparing individuals, particularly in regions with low incidence.", [["high-risk regions", "PROBLEM", 24, 41], ["low incidence", "OBSERVATION_MODIFIER", 111, 124]]], ["Further, it must be noted that 5 million persons emigrated from Wuhan to all over the country.", [["persons", "ORGANISM", 41, 48], ["persons", "SPECIES", 41, 48]]], ["Evidence from previous cases showed that asymptomatic patients in the incubation period are also infectious, making it a greater challenge to track virus carriers.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["previous cases", "TEST", 14, 28], ["asymptomatic", "PROBLEM", 41, 53], ["infectious", "PROBLEM", 97, 107], ["asymptomatic", "OBSERVATION_MODIFIER", 41, 53], ["infectious", "OBSERVATION", 97, 107]]], ["Therefore, isolation at home and less contact with others is the most efficient measure to prevent infection and transmission.", [["infection", "DISEASE", 99, 108], ["isolation", "TREATMENT", 11, 20], ["infection", "PROBLEM", 99, 108], ["infection", "OBSERVATION", 99, 108]]], ["Factories have been required to delay resumption or allow work from home.DiscussionWe analyzed the temporal and spatial distribution of reported cases.", [["temporal", "OBSERVATION_MODIFIER", 99, 107]]], ["For Hubei province, which has the highest number of cases and deaths, the growth trend is relatively stable.", [["deaths", "DISEASE", 62, 68], ["the growth trend", "TEST", 70, 86], ["relatively", "OBSERVATION_MODIFIER", 90, 100], ["stable", "OBSERVATION_MODIFIER", 101, 107]]], ["Conversely, in other hot spots, the number of cases was not very high, but the growth continued.", [["very high", "PROBLEM", 60, 69], ["the growth", "PROBLEM", 75, 85]]], ["[22] It is particularly noteworthy that the cities with the fastest change in temporal risk, such as Chongqing, have large population movements and rapid temporal risk.", [["large population movements", "PROBLEM", 117, 143], ["rapid temporal risk", "PROBLEM", 148, 167], ["temporal risk", "OBSERVATION", 78, 91], ["large", "OBSERVATION_MODIFIER", 117, 122], ["population movements", "OBSERVATION", 123, 143], ["rapid", "OBSERVATION_MODIFIER", 148, 153], ["temporal risk", "OBSERVATION", 154, 167]]], ["If they are not strictly monitored, there may be more outbreaks.", [["may be", "UNCERTAINTY", 42, 48], ["more", "OBSERVATION_MODIFIER", 49, 53], ["outbreaks", "OBSERVATION", 54, 63]]], ["To prevent disease outbreaks caused by the return travel wave after the Spring Festival, the country has extended the Spring Festival holiday.DiscussionCorrelation analysis showed that early incidence was closely related to the emigration waves from Wuhan, that is, the higher the migrating population index, the larger Chinese Medical Journal 2020;Vol(No) www.cmj.org was the number of cases.", [["disease outbreaks", "PROBLEM", 11, 28], ["Correlation analysis", "TEST", 152, 172], ["disease", "OBSERVATION", 11, 18], ["larger", "OBSERVATION_MODIFIER", 313, 319]]], ["However, with the progress of the epidemic, migrants are spreading the virus to other people and are becoming an important source of local community transmission.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["Therefore, it is necessary to strictly implement isolation and related control measures in accordance with the guidelines.", [["isolation", "TREATMENT", 49, 58], ["related control measures", "TREATMENT", 63, 87]]], ["Particularly, control measures must be taken to prevent the spread of diseases in communities, which is crucial to prevent a large-scale outbreak.DiscussionVery soon, many company staff will return to their workplaces.", [["diseases", "PROBLEM", 70, 78], ["a large-scale outbreak", "PROBLEM", 123, 145], ["diseases", "OBSERVATION", 70, 78], ["large", "OBSERVATION_MODIFIER", 125, 130]]], ["Because many enterprises in China are labor intensive, with large populations, human-to-human transmission is extremely easy.", [["human", "ORGANISM", 79, 84], ["human", "ORGANISM", 88, 93], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 88, 93], ["labor", "PROBLEM", 38, 43], ["large", "OBSERVATION_MODIFIER", 60, 65], ["populations", "OBSERVATION", 66, 77]]], ["Therefore, workers need to meet requirements for isolation after returning to the city and use personal protection at work to prevent clustered outbreaks.", [["isolation", "TREATMENT", 49, 58], ["personal protection", "TREATMENT", 95, 114]]], ["At present, there have been several reports of employee infections caused by resumption of work; these represent a warning for all enterprises.", [["infections", "DISEASE", 56, 66], ["employee infections", "PROBLEM", 47, 66], ["infections", "OBSERVATION", 56, 66]]], ["Super megacities such as Guangzhou, Shenzhen, and Shanghai, which have the largest number of migrant workers, need to be prepared for this.DiscussionFrom February 16, the number of new cases began to decrease, but the epidemic did not stop completely.", [["largest", "OBSERVATION_MODIFIER", 75, 82]]], ["Therefore, we must act together to stop the spread of the disease.", [["the disease", "PROBLEM", 54, 65], ["disease", "OBSERVATION", 58, 65]]], ["At present, the state has adopted mobility control measures to encourage people to avoid going to public places and wear masks when going out to reduce the risk of human-to-human transmission.", [["people", "ORGANISM", 73, 79], ["human", "ORGANISM", 164, 169], ["human", "ORGANISM", 173, 178], ["people", "SPECIES", 73, 79], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 173, 178], ["mobility control measures", "TREATMENT", 34, 59], ["masks", "TREATMENT", 121, 126]]], ["We believe that with the joint efforts made by everyone, the number of cases and losses will be kept to a minimum.", [["joint", "ANATOMY", 25, 30]]]], "PMC7522000": [["The immediate impact of Covid-19 has stalled educational development on all levels worldwide and has generated cross-sectoral challenges in ways that could not have been anticipated in the first two months at the start of the decade.", [["Covid-19", "CHEMICAL", 24, 32], ["Covid", "TEST", 24, 29], ["cross-sectoral challenges", "TREATMENT", 111, 136]]], ["As the International Journal of Educational Development (IJED) recognises its 40th Anniversary these and other contemporary global challenges have complex implications for future scholarly priorities, be they academic, professional or methodological, that are greater in magnitude and reach than ever before.", [["greater", "OBSERVATION_MODIFIER", 260, 267]]], ["It is in this exceptional global context that we reflect upon the history of the journal, its evolving nature and rationale and, most fundamentally, upon possibilities and priorities for IJED\u2019s future in what are now uncertain times for all.A niche rationale: IJED foundationsThe origins of IJED have been documented in several articles over the years by Taylor (1988), Vulliam, (1988), Watson (1990) and McGrath (2010).", [["IJED", "DISEASE", 291, 295], ["IJED", "CANCER", 291, 295], ["origins", "ANATOMY_MODIFIER", 280, 287], ["several", "OBSERVATION_MODIFIER", 320, 327], ["articles", "OBSERVATION_MODIFIER", 328, 336]]], ["This not only helps to set the scene for our analysis, but it also explains the rationale behind establishing the new journal in 1980:A niche rationale: IJED foundationsInshing.", [["our analysis", "TEST", 41, 53]]], ["The initial focus on matters of educational policy and practice in international development continues to be at the heart of IJED, and can be seen in the themes and topics for the articles published in each volume and in the Journal\u2019s now clearly established niche positioning.A niche rationale: IJED foundationsThe first two issues of Volume 1 were published by William I. Ozanne and Associates Ltd in 1981 but by 1983 William Ozanne had negotiated a promising move to Pergamon Press in Oxford.", [["heart", "ANATOMY", 116, 121], ["heart", "ORGAN", 116, 121], ["educational policy", "TREATMENT", 32, 50], ["heart", "ANATOMY", 116, 121]]], ["This combination of academic interests, policy engagement and development expertise added greatly to the distinctive positioning for the new Journal, focussing on education in the \u2018developing world\u2019 and purposefully bridging, theory, policy and practice.", [["policy engagement", "TREATMENT", 40, 57]]], ["This was held in September 1989 on the theme of \u2018Development Through Education\u2019 and the resulting papers became available in Volume 10 (2-3) 1990 of IJED (See also Watson, 1990).Engaging with the Post-Jomtien Era1990 was a benchmark year for the field of education and international development with the convening of the first truly global agenda setting conference to be held in Jomtien, Thailand (World Conference on Education for All (WCEFA, 1990).", [["Volume", "TEST", 125, 131]]], ["This gave added impetus for the Journal that was reflected both in its growing influence in policy circles worldwide and in terms of academic standing.", [["growing", "OBSERVATION_MODIFIER", 71, 78]]], ["Strengthening the responsiveness of the operational structure, from the first issue of Volume 11 in 1991 there was to be an Editor-in-Chief who would also act as Chairman of the Editorial Board.", [["responsiveness", "OBSERVATION_MODIFIER", 18, 32]]], ["Keith Watson was appointed and held the position with distinction for 16 years, generating wider international input, leading the ongoing development of an active International Editorial Board, and establishing new roles for two International Regional Editors, representing Asia and North America, respectively.", [["active", "OBSERVATION_MODIFIER", 156, 162], ["Regional Editors", "OBSERVATION", 243, 259]]], ["The original pattern of the three issues per volume lasted until Volume 12 in 1992 when it was changed to six issues as the number of readers and subscribers increased and as the Journal\u2019s reputation continued to grow.", [["Volume", "TEST", 65, 71], ["pattern", "OBSERVATION_MODIFIER", 13, 20], ["three", "OBSERVATION_MODIFIER", 28, 33], ["issues", "OBSERVATION", 34, 40]]], ["The concern behind this initiative was that while the UK clearly had pertinent experience and considerable expertise, it was at that time a rather fragmented constituency.", [["a rather fragmented constituency", "PROBLEM", 138, 170], ["fragmented", "OBSERVATION_MODIFIER", 147, 157], ["constituency", "OBSERVATION", 158, 170]]], ["It was also felt that this resource should be able to play a more active role in contributing to the shaping, monitoring and evaluating of policies in education, in both multilateral and bilateral arenas.", [["both", "ANATOMY_MODIFIER", 165, 169], ["multilateral", "ANATOMY_MODIFIER", 170, 182], ["bilateral", "ANATOMY_MODIFIER", 187, 196], ["arenas", "ANATOMY", 197, 203]]], ["A month before Jomtien, Beverley Young, Director of the British Council\u2019s Education Department wrote to others of an \u2018Informal Group\u2019 about the need to bring together the rich, diverse but scattered British resource.", [["scattered", "OBSERVATION_MODIFIER", 189, 198]]]]}